|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]
|
CTD |
PMID:8647108 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Drd2
|
dopamine receptor D2
|
affects binding
|
EXP
|
Benzimidazoles analog binds to DRD2 protein
|
CTD |
PMID:21509803 |
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339
|
|
G
|
Htr2a
|
5-hydroxytryptamine receptor 2A
|
affects binding
|
EXP
|
Benzimidazoles analog binds to HTR2A protein
|
CTD |
PMID:21509803 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619
|
|
G
|
Igf2
|
insulin-like growth factor 2
|
multiple interactions decreases response to substance
|
ISO
|
Benzimidazoles inhibits the reaction [IGF2 protein results in increased expression of STS mRNA] Benzimidazoles results in decreased susceptibility to IGF2 protein
|
CTD |
PMID:24055520 |
|
NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667
|
|
G
|
Kcnq2
|
potassium voltage-gated channel subfamily Q member 2
|
multiple interactions
|
ISO
|
[Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; [Benzimidazoles analog results in increased activity of KCNQ2 protein] which results in increased import of Thallium; Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]
|
CTD |
PMID:21723881 |
|
NCBI chr 3:188,572,345...188,631,391
Ensembl chr 3:188,572,926...188,631,302
|
|
G
|
Kcnq3
|
potassium voltage-gated channel subfamily Q member 3
|
multiple interactions
|
ISO
|
[Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]
|
CTD |
PMID:21723881 |
|
NCBI chr 7:99,614,089...99,914,736
Ensembl chr 7:99,619,544...99,914,610
|
|
G
|
Mtr
|
5-methyltetrahydrofolate-homocysteine methyltransferase
|
decreases activity
|
EXP
|
Benzimidazoles results in decreased activity of MTR protein
|
CTD |
PMID:17222188 |
|
NCBI chr17:62,911,705...62,996,544
Ensembl chr17:62,911,771...62,996,541
|
|
G
|
Sts
|
steroid sulfatase
|
multiple interactions
|
ISO
|
Benzimidazoles inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]
|
CTD |
PMID:24055520 |
|
NCBI chr X:46,102,524...46,110,868
Ensembl chr X:46,102,548...46,111,104
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
decreases activity
|
ISO
|
Benzimidazoles results in decreased activity of TOP2A protein
|
CTD |
PMID:20884089 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
|
G
|
Epas1
|
endothelial PAS domain protein 1
|
increases stability
|
EXP
|
benzimidazole results in increased stability of EPAS1 protein
|
CTD |
PMID:23545307 |
|
NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729
|
|
G
|
Trpv1
|
transient receptor potential cation channel, subfamily V, member 1
|
multiple interactions
|
EXP
|
benzimidazole analog inhibits the reaction [Capsaicin results in increased activity of TRPV1 protein]; benzimidazole analog inhibits the reaction [Protons results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [benzimidazole analog inhibits the reaction [Protons results in increased activity of TRPV1 protein]]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [benzimidazole analog inhibits the reaction [Protons results in increased activity of TRPV1 protein]]
|
CTD |
PMID:16135784 |
|
NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021
|
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression
|
EXP
|
2-mercaptobenzimidazole analog results in increased expression of CYP1A1 protein; 2-mercaptobenzimidazole results in increased expression of CYP1A1 protein
|
CTD |
PMID:10103034 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions decreases activity
|
ISO
|
bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] bisbenzimide ethoxide trihydrochloride results in decreased activity of ABCB11 protein
|
CTD |
PMID:24014644 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
increases transport multiple interactions
|
ISO
|
ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride abamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride] [zosuquidar trihydrochloride results in decreased activity of ABCB1 protein] which results in decreased export of bisbenzimide ethoxide trihydrochloride; abamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]
|
CTD |
PMID:25865432 PMID:34896433 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions increases transport
|
ISO
|
abamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]
|
CTD |
PMID:25865432 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
decreases abundance decreases export decreases activity multiple interactions increases export increases transport
|
ISO
|
ABCG2 protein results in decreased abundance of bisbenzimide ethoxide trihydrochloride ABCG2 protein polymorphism results in decreased export of bisbenzimide ethoxide trihydrochloride bisbenzimide ethoxide trihydrochloride results in decreased activity of ABCG2 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; [3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester results in decreased activity of ABCG2 protein] which results in decreased export of bisbenzimide ethoxide trihydrochloride; [bisphenol A results in decreased activity of ABCG2 protein] which results in decreased transport of bisbenzimide ethoxide trihydrochloride; [MLN 8237 affects the activity of ABCG2 protein] which affects the export of bisbenzimide ethoxide trihydrochloride; [MYC protein results in increased expression of ABCG2 protein] which results in increased export of bisbenzimide ethoxide trihydrochloride; Cimetidine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Cyclosporine inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; danofloxacin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Genistein inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Genistein promotes the reaction [ABCG2 protein polymorphism results in decreased export of bisbenzimide ethoxide trihydrochloride]; Methotrexate inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Nitrofurantoin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Porphyrins inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Reserpine inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Tobacco Smoke Pollution inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; tryptoquivaline inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; verlukast inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]
|
CTD |
PMID:12869632 PMID:19239227 PMID:26850786 PMID:26907376 PMID:27450509 PMID:27475308 PMID:34073890 PMID:34717915 PMID:34896433 More...
|
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
decreases export
|
ISO
|
KEAP1 protein results in decreased export of bisbenzimide ethoxide trihydrochloride
|
CTD |
PMID:25841332 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions
|
ISO
|
[MYC protein results in increased expression of ABCG2 protein] which results in increased export of bisbenzimide ethoxide trihydrochloride
|
CTD |
PMID:19239227 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression
|
EXP
|
2-aminobenzimidazole results in increased expression of CYP1A1 protein
|
CTD |
PMID:10103034 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression
|
EXP
|
5-hydroxymethylomeprazole results in increased expression of CYP1A1 protein
|
CTD |
PMID:10103034 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [mangiferin results in increased expression of ABCB1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [sodium arsenite results in increased expression of ABCB1 protein]
|
CTD |
PMID:16121039 PMID:20513373 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abl1
|
ABL proto-oncogene 1, non-receptor tyrosine kinase
|
decreases expression multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein]
|
CTD |
PMID:15039284 |
|
NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]
|
CTD |
PMID:12917420 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions increases expression
|
ISO
|
Dexamethasone inhibits the reaction [Dichlororibofuranosylbenzimidazole results in increased expression of BCL2L1 protein]
|
CTD |
PMID:9326359 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]
|
CTD |
PMID:17295206 PMID:18636177 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]
|
CTD |
PMID:15014036 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Ces2h
|
carboxylesterase 2H
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Methoxsalen results in increased expression of CES2 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]
|
CTD |
PMID:17003103 |
|
NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [sodium arsenite results in decreased expression of CFTR protein]
|
CTD |
PMID:16121039 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:15962303 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Csf1
|
colony stimulating factor 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]
|
CTD |
PMID:17295206 PMID:18636177 |
|
NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]
|
CTD |
PMID:12917420 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
multiple interactions
|
EXP
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 protein]]
|
CTD |
PMID:25233930 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Methoxsalen results in increased expression of CYP3A4 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
|
CTD |
PMID:17003103 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Fbl
|
fibrillarin
|
affects localization
|
ISO
|
Dichlororibofuranosylbenzimidazole analog affects the localization of FBL protein
|
CTD |
PMID:10942594 |
|
NCBI chr 1:92,597,407...92,606,507
Ensembl chr 1:92,597,258...92,606,506
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [TNF protein results in increased expression of HIF1A protein]
|
CTD |
PMID:12479793 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]
|
CTD |
PMID:16109301 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hnrnpa1
|
heterogeneous nuclear ribonucleoprotein A1
|
multiple interactions affects localization
|
ISO
|
Dichlororibofuranosylbenzimidazole affects the reaction [HNRNPA1 protein binds to CYP2A5 mRNA] Dichlororibofuranosylbenzimidazole affects the localization of HNRNPA1 protein
|
CTD |
PMID:12754101 |
|
NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085
|
|
G
|
Hnrnpk
|
heterogeneous nuclear ribonucleoprotein K
|
multiple interactions
|
EXP
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Glycine results in increased expression of HNRNPK mRNA]
|
CTD |
PMID:24990929 |
|
NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,268,385...6,280,565
|
|
G
|
Ifnb1
|
interferon beta 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]
|
CTD |
PMID:23589332 |
|
NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]
|
CTD |
PMID:11295263 PMID:12185005 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Isg15
|
ISG15 ubiquitin-like modifier
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]
|
CTD |
PMID:23589332 |
|
NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:172,066,369...172,067,656
|
|
G
|
Mt1
|
metallothionein 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Cadmium Chloride results in increased expression of MT1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of MT1 mRNA]
|
CTD |
PMID:15142038 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200 Ensembl chr X:79,695,809...79,696,200 Ensembl chr19:79,695,809...79,696,200
|
|
G
|
Mx1
|
MX dynamin like GTPase 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]
|
CTD |
PMID:23589332 |
|
NCBI chr11:50,269,056...50,294,699
Ensembl chr11:50,269,057...50,292,904
|
|
G
|
Nelfa
|
negative elongation factor complex member A
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]
|
CTD |
PMID:23589332 |
|
NCBI chr14:81,033,470...81,057,546
Ensembl chr14:81,033,514...81,058,719
|
|
G
|
Nr3c1
|
nuclear receptor subfamily 3, group C, member 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]
|
CTD |
PMID:21569845 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
[Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein
|
CTD |
PMID:15039284 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Polr2a
|
RNA polymerase II subunit A
|
decreases phosphorylation multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein]; sodium arsenite inhibits the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein]
|
CTD |
PMID:8126066 PMID:15039284 PMID:24102143 |
|
NCBI chr10:54,951,162...54,977,179
Ensembl chr10:54,951,162...54,977,179
|
|
G
|
Rgn
|
regucalcin
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA]
|
CTD |
PMID:18327666 |
|
NCBI chr X:4,172,537...4,190,112
Ensembl chr X:4,172,537...4,190,251
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]
|
CTD |
PMID:15962303 PMID:18327666 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Slc30a1
|
solute carrier family 30 member 1
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Cadmium Chloride results in increased expression of SLC30A1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA]
|
CTD |
PMID:15142038 |
|
NCBI chr13:106,022,019...106,025,892
Ensembl chr13:106,022,019...106,025,892
|
|
G
|
Slc38a2
|
solute carrier family 38, member 2
|
affects expression
|
ISO
|
Dichlororibofuranosylbenzimidazole affects the expression of SLC38A2 protein
|
CTD |
PMID:15581851 |
|
NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:129,730,450...129,742,619
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
Dichlororibofuranosylbenzimidazole affects the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]] Dichlororibofuranosylbenzimidazole inhibits the reaction [TNF protein results in increased expression of HIF1A protein] Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 protein]]
|
CTD |
PMID:11295263 PMID:12185005 PMID:12479793 PMID:25233930 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfsf11
|
TNF superfamily member 11
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA]
|
CTD |
PMID:17295206 PMID:18327666 PMID:18636177 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
G
|
Tp53
|
tumor protein p53
|
increases phosphorylation
|
ISO
|
Dichlororibofuranosylbenzimidazole results in increased phosphorylation of TP53 protein
|
CTD |
PMID:24102143 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tyms
|
thymidylate synthetase
|
multiple interactions
|
ISO
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Fluorouracil results in increased expression of TYMS protein]
|
CTD |
PMID:23056627 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
multiple interactions
|
EXP
|
Dichlororibofuranosylbenzimidazole inhibits the reaction [Oxygen deficiency results in increased phosphorylation of and results in increased activity of XDH protein]
|
CTD |
PMID:11278616 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
|
G
|
Abca1
|
ATP binding cassette subfamily A member 1
|
increases expression
|
ISO
|
Omeprazole results in increased expression of ABCA1 mRNA
|
CTD |
PMID:20060385 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
decreases activity
|
ISO
|
Omeprazole results in decreased activity of ABCB11 protein
|
CTD |
PMID:20829430 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
affects expression multiple interactions
|
EXP ISO
|
Omeprazole affects the expression of ABCB1A mRNA Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1A protein] Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1 protein]
|
CTD |
PMID:19483382 PMID:30452898 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
decreases expression
|
ISO
|
Omeprazole results in decreased expression of ABCB4 mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
ISO
|
[Omeprazole results in increased susceptibility to Cisplatin] which results in decreased expression of ABCC2 protein
|
CTD |
PMID:35447140 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
increases expression
|
EXP
|
Omeprazole results in increased expression of ABCC3 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Abcc6
|
ATP binding cassette subfamily C member 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABCC6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
increases expression multiple interactions
|
ISO
|
Omeprazole results in increased expression of ABCG2 mRNA alternative form; Omeprazole results in increased expression of ABCG2 protein Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow]
|
CTD |
PMID:20804740 PMID:31348918 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Abcg5
|
ATP binding cassette subfamily G member 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABCG5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376
|
|
G
|
Abhd1
|
abhydrolase domain containing 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABHD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:31,142,476...31,147,464
Ensembl chr 6:31,142,476...31,147,464
|
|
G
|
Abhd14b
|
abhydrolase domain containing 14b
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABHD14B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:115,966,792...115,970,829
Ensembl chr 8:115,965,932...115,970,833
|
|
G
|
Abhd17a
|
abhydrolase domain containing 17A, depalmitoylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABHD17A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:9,775,016...9,781,447
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACACA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Acadl
|
acyl-CoA dehydrogenase, long chain
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACADL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:75,783,689...75,822,077
Ensembl chr 9:75,783,689...75,822,164
|
|
G
|
Ace2
|
angiotensin converting enzyme 2
|
decreases expression
|
ISO EXP
|
Omeprazole results in decreased expression of ACE2 mRNA
|
CTD |
PMID:32808185 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596
|
|
G
|
Aco1
|
aconitase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:60,055,895...60,111,920
Ensembl chr 5:60,055,866...60,112,600
|
|
G
|
Aco2
|
aconitase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACO2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:115,265,816...115,308,931
Ensembl chr 7:115,265,791...115,308,892
|
|
G
|
Acot12
|
acyl-CoA thioesterase 12
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACOT12 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:24,721,648...24,763,686
Ensembl chr 2:24,721,910...24,765,298
|
|
G
|
Acot4
|
acyl-CoA thioesterase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACOT4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138
|
|
G
|
Adam15
|
ADAM metallopeptidase domain 15
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADAM15 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:177,052,363...177,062,879
Ensembl chr 2:177,052,363...177,062,849
|
|
G
|
Add1
|
adducin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:80,333,242...80,401,641
Ensembl chr14:80,333,244...80,391,732
|
|
G
|
Adh1c
|
alcohol dehydrogenase 1C (class I), gamma polypeptide
|
decreases expression
|
ISO
|
Omeprazole results in decreased expression of ADH1C mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291
|
|
G
|
Adh4
|
alcohol dehydrogenase 4 (class II), pi polypeptide
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADH4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:229,622,092...229,640,120
Ensembl chr 2:229,622,095...229,641,879
|
|
G
|
Adtrp
|
androgen-dependent TFPI-regulating protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADTRP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:23,113,578...23,199,616
Ensembl chr17:23,135,809...23,216,622
|
|
G
|
Afm
|
afamin
|
affects expression
|
EXP
|
Omeprazole affects the expression of AFM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:17,815,194...17,848,042
Ensembl chr14:17,815,194...17,848,039
|
|
G
|
Agt
|
angiotensinogen
|
affects expression
|
EXP
|
Omeprazole affects the expression of AGT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
affects expression
|
EXP
|
Omeprazole affects the expression of AGTR1A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions decreases activity increases activity increases expression decreases expression affects localization increases response to substance
|
EXP ISO
|
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Omeprazole affects the localization of [ARNT protein co-treated with AHR protein] Omeprazole results in decreased activity of AHR protein Omeprazole results in increased activity of AHR protein Omeprazole results in increased expression of AHR protein Omeprazole results in decreased expression of AHR mRNA AG-879 inhibits the reaction [Omeprazole results in increased activity of AHR protein]; AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of AHR mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]; Omeprazole binds to and results in increased activity of AHR protein; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; omeprazole sulfide inhibits the reaction [Omeprazole results in increased activity of AHR protein]; Puromycin inhibits the reaction [Omeprazole results in increased expression of AHR protein] Omeprazole affects the localization of AHR protein AHR protein results in increased susceptibility to Omeprazole
|
CTD |
PMID:9139728 PMID:9395520 PMID:14742684 PMID:16109480 PMID:20171196 PMID:21703235 PMID:21861773 PMID:21924250 PMID:22687989 PMID:23850985 PMID:25797602 PMID:25826687 PMID:26187274 PMID:26272953 PMID:31669099 More...
|
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Akr1a1
|
aldo-keto reductase family 1 member A1
|
affects expression
|
EXP
|
Omeprazole affects the expression of AKR1A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035
|
|
G
|
Akr7a2
|
aldo-keto reductase family 7, member A2
|
affects expression
|
EXP
|
Omeprazole affects the expression of AKR7A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:156,835,551...156,844,109
|
|
G
|
Akr7a3
|
aldo-keto reductase family 7 member A3
|
affects expression multiple interactions
|
EXP
|
Omeprazole affects the expression of AKR7A3 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA
|
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
affects expression multiple interactions
|
EXP
|
Omeprazole affects the expression of ALDH1A1 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ALDH1A1 mRNA
|
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
G
|
Aldh1a3
|
aldehyde dehydrogenase 1 family, member A3
|
increases expression
|
ISO
|
Omeprazole results in increased expression of ALDH1A3 mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777
|
|
G
|
Aldh1a7
|
aldehyde dehydrogenase family 1, subfamily A7
|
affects expression
|
EXP
|
Omeprazole affects the expression of ALDH1A7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:227,627,977...227,667,877
Ensembl chr 1:227,627,448...227,672,523
|
|
G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
affects expression
|
EXP
|
Omeprazole affects the expression of ALDH2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219
|
|
G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
increases expression
|
ISO
|
Omeprazole results in increased expression of ALDH3A1 mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
G
|
Alkbh7
|
alkB homolog 7
|
affects expression
|
EXP
|
Omeprazole affects the expression of ALKBH7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:1,925,896...1,928,048
Ensembl chr 9:1,925,743...1,928,048
|
|
G
|
Ap2m1
|
adaptor related protein complex 2 subunit mu 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of AP2M1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:93,859,690...93,868,600
Ensembl chr11:93,859,690...93,868,480
|
|
G
|
Apcs
|
amyloid P component, serum
|
affects expression
|
EXP
|
Omeprazole affects the expression of APCS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:87,905,532...87,906,508
Ensembl chr13:87,905,532...87,928,824
|
|
G
|
Apoa4
|
apolipoprotein A4
|
affects expression
|
EXP
|
Omeprazole affects the expression of APOA4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164
|
|
G
|
Apoh
|
apolipoprotein H
|
affects expression
|
EXP
|
Omeprazole affects the expression of APOH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:93,841,992...93,855,897
Ensembl chr10:93,841,966...93,857,127
|
|
G
|
Apool
|
apolipoprotein O-like
|
affects expression
|
EXP
|
Omeprazole affects the expression of APOOL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:81,569,960...81,635,906
Ensembl chr X:81,570,053...81,640,036
|
|
G
|
Arg1
|
arginase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ARG1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Arl6ip1
|
ARL6 interacting reticulophagy regulator 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ARL6IP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:181,864,717...181,874,232
Ensembl chr 1:181,864,746...181,874,232
|
|
G
|
Arnt
|
aryl hydrocarbon receptor nuclear translocator
|
multiple interactions affects localization
|
ISO EXP
|
Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter] Omeprazole affects the localization of ARNT protein Omeprazole affects the localization of [ARNT protein co-treated with AHR protein]
|
CTD |
PMID:9395520 PMID:21703235 PMID:25826687 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546
|
|
G
|
Asgr2
|
asialoglycoprotein receptor 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ASGR2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:55,320,082...55,333,294
Ensembl chr10:55,320,091...55,333,263
|
|
G
|
Atf5
|
activating transcription factor 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATF5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183
|
|
G
|
Atp5f1e
|
ATP synthase F1 subunit epsilon
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP5F1E mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:183,677,270...183,680,172
Ensembl chr 3:183,677,273...183,680,214
|
|
G
|
Atp6ap2
|
ATPase H+ transporting accessory protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP6AP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:12,856,708...12,883,670
Ensembl chr X:12,855,859...12,905,875
|
|
G
|
Atp6v1a
|
ATPase H+ transporting V1 subunit A
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP6V1A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:70,066,800...70,120,603
Ensembl chr11:70,035,134...70,120,603
|
|
G
|
Atp6v1f
|
ATPase H+ transporting V1 subunit F
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP6V1F mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:59,033,020...59,035,980
|
|
G
|
Atp7a
|
ATPase copper transporting alpha
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein] Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein]; Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein]
|
CTD |
PMID:25337692 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093
|
|
G
|
Baat
|
bile acid CoA:amino acid N-acyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of BAAT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:68,647,166...68,656,137
Ensembl chr 5:68,646,203...68,656,181
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of BAX protein]
|
CTD |
PMID:30452898 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]
|
CTD |
PMID:30452898 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl6b
|
BCL6B, transcription repressor
|
affects expression
|
EXP
|
Omeprazole affects the expression of BCL6B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:55,439,566...55,444,631
Ensembl chr10:55,432,382...55,444,631
|
|
G
|
Bltp3b
|
bridge-like lipid transfer protein family member 3B
|
affects expression
|
EXP
|
Omeprazole affects the expression of BLTP3B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:26,068,948...26,149,033
Ensembl chr 7:26,068,955...26,149,083
|
|
G
|
Bmf
|
Bcl2 modifying factor
|
affects expression
|
EXP
|
Omeprazole affects the expression of BMF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258
|
|
G
|
Bmx
|
BMX non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]
|
CTD |
PMID:21861773 |
|
NCBI chr X:33,859,128...33,921,876
Ensembl chr X:33,859,129...33,921,874
|
|
G
|
Bnip3
|
BCL2 interacting protein 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of BNIP3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962
|
|
G
|
Btf3
|
basic transcription factor 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of BTF3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:31,394,010...31,401,138
Ensembl chr 2:31,394,011...31,401,125 Ensembl chr13:31,394,011...31,401,125
|
|
G
|
C1qa
|
complement C1q A chain
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of C1QA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732
|
|
G
|
C1qbp
|
complement C1q binding protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of C1QBP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:56,198,534...56,203,185
Ensembl chr10:56,198,540...56,203,235
|
|
G
|
C1qc
|
complement C1q C chain
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of C1QC mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468
|
|
G
|
C1s
|
complement C1s
|
affects expression
|
EXP
|
Omeprazole affects the expression of C1S mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736
|
|
G
|
C2cd2
|
C2 calcium-dependent domain containing 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of C2CD2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016
|
|
G
|
C4bpa
|
complement component 4 binding protein, alpha
|
affects expression decreases expression
|
EXP
|
Omeprazole affects the expression of C4BPA mRNA Omeprazole results in decreased expression of C4BPA mRNA
|
CTD |
PMID:19483382 PMID:25626140 |
|
NCBI chr13:44,627,959...44,663,552
Ensembl chr13:44,627,982...44,663,471
|
|
G
|
C4bpb
|
complement component 4 binding protein, beta
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of C4BPB mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,673,064...44,683,781
Ensembl chr13:44,673,065...44,683,793
|
|
G
|
C7
|
complement C7
|
affects expression
|
EXP
|
Omeprazole affects the expression of C7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:55,815,687...55,892,605
Ensembl chr 2:55,816,807...55,892,672
|
|
G
|
C8b
|
complement C8 beta chain
|
affects expression
|
EXP
|
Omeprazole affects the expression of C8B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:124,763,974...124,801,522
Ensembl chr 5:124,761,790...124,801,516
|
|
G
|
Ca3
|
carbonic anhydrase 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of CAR3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524
|
|
G
|
Cadps2
|
calcium dependent secretion activator 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of CADPS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:52,746,054...53,275,252
Ensembl chr 4:52,746,065...53,275,004
|
|
G
|
Caprin1
|
cell cycle associated protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CAPRIN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:110,606,489...110,685,408
Ensembl chr 3:110,606,489...110,685,562
|
|
G
|
Car2
|
carbonic anhydrase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of CA2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064
|
|
G
|
Casp3
|
caspase 3
|
increases activity multiple interactions affects expression increases cleavage
|
ISO EXP
|
Omeprazole analog results in increased activity of CASP3 protein; Omeprazole results in increased activity of CASP3 protein Omeprazole inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] Omeprazole inhibits the reaction [Ethanol results in increased activity of CASP3 protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of CASP3 mRNA]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of CASP3 protein] Omeprazole affects the expression of CASP3 mRNA Omeprazole results in increased cleavage of CASP3 protein
|
CTD |
PMID:15461867 PMID:18336733 PMID:19251492 PMID:19483382 PMID:25637687 PMID:30452898 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases cleavage
|
ISO
|
Omeprazole analog results in increased cleavage of CASP8 protein
|
CTD |
PMID:18336733 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Cat
|
catalase
|
increases activity multiple interactions
|
EXP ISO
|
Omeprazole results in increased activity of CAT protein Omeprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein] Omeprazole inhibits the reaction [Acetic Acid results in increased activity of CAT protein]
|
CTD |
PMID:18547560 PMID:28849987 PMID:33245926 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cbr1
|
carbonyl reductase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CBR1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104 Ensembl chr11:46,378,411...46,381,104
|
|
G
|
Cckbr
|
cholecystokinin B receptor
|
multiple interactions
|
ISO
|
[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3
|
CTD |
PMID:17704804 |
|
NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of CCND1 mRNA
|
CTD |
PMID:17202759 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Omeprazole results in increased expression of CDKN1A protein
|
CTD |
PMID:27358234 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdo1
|
cysteine dioxygenase type 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CDO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:41,619,076...41,633,719
Ensembl chr18:41,619,070...41,633,891
|
|
G
|
Cept1
|
choline/ethanolamine phosphotransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CEPT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:196,682,455...196,724,430
Ensembl chr 2:196,681,681...196,723,812
|
|
G
|
Ces2h
|
carboxylesterase 2H
|
affects expression
|
EXP
|
Omeprazole affects the expression of CES2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752
|
|
G
|
Cfi
|
complement factor I
|
affects expression decreases expression
|
EXP
|
Omeprazole affects the expression of CFI mRNA Omeprazole results in decreased expression of CFI mRNA
|
CTD |
PMID:19483382 PMID:25626140 |
|
NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
affects metabolic processing
|
ISO
|
CFTR protein affects the metabolism of Omeprazole
|
CTD |
PMID:15319328 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Chp1
|
calcineurin-like EF-hand protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CHP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:126,989,579...127,042,443
|
|
G
|
Cisd1
|
CDGSH iron sulfur domain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CISD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:17,254,462...17,267,843
Ensembl chr20:17,254,187...17,271,042
|
|
G
|
Clcn4
|
chloride voltage-gated channel 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of CLCN4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:27,290,769...27,356,967
Ensembl chr X:27,290,868...27,356,939
|
|
G
|
Clpp
|
caseinolytic mitochondrial matrix peptidase proteolytic subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of CLPP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:1,917,305...1,924,706
Ensembl chr 9:1,918,682...1,924,705
|
|
G
|
Clptm1l
|
CLPTM1-like
|
affects expression
|
EXP
|
Omeprazole affects the expression of CLPTM1L mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:31,496,094...31,512,148
Ensembl chr 1:31,496,094...31,512,077
|
|
G
|
Cmbl
|
carboxymethylenebutenolidase homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of CMBL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880
|
|
G
|
Cmpk1
|
cytidine/uridine monophosphate kinase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CMPK1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:133,717,073...133,744,623
Ensembl chr 5:133,717,086...133,744,596
|
|
G
|
Copg1
|
COPI coat complex subunit gamma 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of COPG1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:121,923,644...121,949,819
Ensembl chr 4:121,923,873...121,949,812
|
|
G
|
Cops4
|
COP9 signalosome subunit 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of COPS4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:9,382,897...9,413,216
Ensembl chr14:9,382,900...9,413,107
|
|
G
|
Coq3
|
coenzyme Q3 methyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of COQ3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:40,226,313...40,257,383
Ensembl chr 5:40,226,368...40,257,617
|
|
G
|
Cox4i1
|
cytochrome c oxidase subunit 4i1
|
affects expression
|
EXP
|
Omeprazole affects the expression of COX4I1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:65,630,383...65,636,623
Ensembl chr19:65,630,432...65,636,624
|
|
G
|
Cpn1
|
carboxypeptidase N subunit 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CPN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:252,793,786...252,822,675
Ensembl chr 1:252,793,423...252,822,664
|
|
G
|
Cpq
|
carboxypeptidase Q
|
affects expression
|
EXP
|
Omeprazole affects the expression of CPQ mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:66,148,973...66,719,189
Ensembl chr 7:66,149,377...66,716,137
|
|
G
|
Crem
|
cAMP responsive element modulator
|
affects expression
|
EXP
|
Omeprazole affects the expression of CREM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160
|
|
G
|
Csnk2b
|
casein kinase 2 beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of CSNK2B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525
|
|
G
|
Csrp1
|
cysteine and glycine-rich protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CSRP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139
|
|
G
|
Ctnna1
|
catenin alpha 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CTNNA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:27,002,330...27,135,009
Ensembl chr18:26,999,820...27,135,007
|
|
G
|
Ctsb
|
cathepsin B
|
decreases activity
|
ISO
|
Omeprazole results in decreased activity of CTSB protein
|
CTD |
PMID:34871754 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478
|
|
G
|
Ctsd
|
cathepsin D
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Cysteamine results in increased expression of CTSD protein]
|
CTD |
PMID:20165931 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821
|
|
G
|
Ctse
|
cathepsin E
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of CTSE
|
CTD |
PMID:7575556 |
|
NCBI chr13:45,644,168...45,666,722
Ensembl chr13:45,644,147...45,666,722
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
decreases expression multiple interactions
|
ISO
|
Omeprazole results in decreased expression of CXCR4 mRNA AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]
|
CTD |
PMID:25826687 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions increases expression increases activity decreases activity
|
ISO EXP
|
AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter] Omeprazole inhibits the reaction [Oxygen results in increased expression of CYP1A1 protein]; Omeprazole promotes the reaction [Oxygen results in decreased expression of CYP1A1 mRNA] Omeprazole results in increased expression of CYP1A1 mRNA; Omeprazole results in increased expression of CYP1A1 protein Omeprazole results in increased activity of CYP1A1 protein [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; lavendustin A inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Staurosporine inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA] Omeprazole results in decreased activity of CYP1A1 protein Omeprazole results in increased activity of CYP1A1 promoter
|
CTD |
PMID:8647108 PMID:8900397 PMID:9041675 PMID:9139728 PMID:9152597 PMID:9395520 PMID:9860486 PMID:10103034 PMID:10859152 PMID:11454723 PMID:11849738 PMID:12040753 PMID:12623754 PMID:12841937 PMID:14742684 PMID:14987951 PMID:15681896 PMID:15860653 PMID:17202759 PMID:17954527 PMID:18420780 PMID:18502397 PMID:19118567 PMID:20171196 PMID:21666223 PMID:21703235 PMID:21784029 PMID:22687989 PMID:25626140 PMID:25826687 PMID:26187180 PMID:26272953 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
decreases activity multiple interactions increases expression increases activity
|
ISO EXP
|
Omeprazole results in decreased activity of CYP1A2 protein [Omeprazole results in increased expression of CYP1A2 protein] which results in decreased alkylation of Phenacetin; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; Omeprazole results in increased expression of and results in increased activity of CYP1A2 protein Omeprazole results in increased expression of CYP1A2 mRNA; Omeprazole results in increased expression of CYP1A2 protein [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA Omeprazole results in increased activity of CYP1A2 promoter; Omeprazole results in increased activity of CYP1A2 protein
|
CTD |
PMID:9152597 PMID:9744552 PMID:12040753 PMID:12623754 PMID:12841937 PMID:15681896 PMID:15802389 PMID:16035375 PMID:17954527 PMID:18332078 PMID:18420780 PMID:18502397 PMID:19118567 PMID:19230594 PMID:20171196 PMID:21784029 PMID:21924250 PMID:22524704 PMID:22687989 PMID:23274770 PMID:23850985 PMID:24752503 PMID:25626140 PMID:26204831 PMID:27794450 PMID:30044681 PMID:31863871 PMID:36288780 More...
|
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
multiple interactions affects expression increases expression decreases activity
|
ISO
|
Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter] Omeprazole affects the expression of CYP1B1 mRNA Omeprazole results in increased expression of CYP1B1 mRNA Omeprazole results in decreased activity of CYP1B1 protein
|
CTD |
PMID:12040753 PMID:12623754 PMID:18420780 PMID:21703235 PMID:25826687 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp2a1
|
cytochrome P450, family 2, subfamily a, polypeptide 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:91,359,272...91,389,730
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of CYP2B1 mRNA; Omeprazole results in increased expression of CYP2B1 protein
|
CTD |
PMID:9152597 PMID:19118567 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
affects expression increases expression
|
EXP
|
Omeprazole affects the expression of CYP2B2 mRNA Omeprazole results in increased expression of CYP2B2 protein
|
CTD |
PMID:9152597 PMID:19483382 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
affects expression decreases activity increases expression increases activity
|
EXP ISO
|
Omeprazole affects the expression of CYP2B3 mRNA Omeprazole results in decreased activity of CYP2B10 protein Omeprazole results in increased expression of CYP2B6 mRNA Omeprazole results in increased activity of CYP2B6 protein
|
CTD |
PMID:17954527 PMID:18420780 PMID:19118567 PMID:19483382 PMID:22524704 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
affects metabolic processing decreases activity multiple interactions increases metabolic processing decreases metabolic processing increases hydroxylation
|
ISO
|
CYP2C19 protein affects the metabolism of Omeprazole Omeprazole results in decreased activity of CYP2C19 protein [5-bromotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-chlorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [7-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Chloramphenicol results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [indopan results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Tryptamines analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin]; Omeprazole inhibits the reaction [CYP2C19 protein results in decreased methylation of adinazolam]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of auriculasin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of Clopidogrel] CYP2C19 protein results in increased metabolism of Omeprazole CYP2C19 gene alternative form results in decreased metabolism of Omeprazole CYP2C19 protein results in increased hydroxylation of Omeprazole
|
CTD |
PMID:8930576 PMID:9600717 PMID:11752104 PMID:12464242 PMID:12467917 PMID:12485723 PMID:12637241 PMID:14586384 PMID:15258107 PMID:15286053 PMID:15306208 PMID:15626586 PMID:16035375 PMID:17565714 PMID:17702393 PMID:18511451 PMID:18520598 PMID:19812348 PMID:20573087 PMID:21277363 PMID:21795468 PMID:21915887 PMID:22634058 PMID:26599973 PMID:31515991 More...
|
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2d1
|
cytochrome P450, family 2, subfamily d, polypeptide 1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of CYP2D9 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 7:115,789,026...115,793,430
Ensembl chr 7:115,789,023...115,793,479
|
|
G
|
Cyp2d3
|
cytochrome P450, family 2, subfamily d, polypeptide 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2D3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:115,797,785...115,802,142
Ensembl chr 7:115,797,789...115,802,158
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
affects expression decreases activity
|
EXP ISO
|
Omeprazole affects the expression of CYP2D4 mRNA Omeprazole results in decreased activity of CYP2D6 protein
|
CTD |
PMID:18420780 PMID:19483382 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
ISO
|
Omeprazole results in increased expression of and results in increased activity of CYP2E1 protein
|
CTD |
PMID:15802389 PMID:36243147 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp2f4
|
cytochrome P450, family 2, subfamily f, polypeptide 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2F4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553
|
|
G
|
Cyp2j4
|
cytochrome P450, family 2, subfamily j, polypeptide 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2J4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042
|
|
G
|
Cyp2t1
|
cytochrome P450, family 2, subfamily t, polypeptide 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2T1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:91,573,923...91,579,215
Ensembl chr 1:91,574,572...91,579,215
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions increases expression increases metabolic processing affects metabolic processing
|
ISO
|
[Omeprazole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein affects the reaction [Omeprazole results in increased expression of CYP3A4 mRNA]; Omeprazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Omeprazole results in increased expression of and results in increased activity of CYP3A4 protein Omeprazole results in increased expression of CYP3A4 mRNA; Omeprazole results in increased expression of CYP3A4 protein CYP3A4 protein results in increased metabolism of Omeprazole CYP3A4 protein affects the metabolism of Omeprazole
|
CTD |
PMID:7870052 PMID:8930576 PMID:9744552 PMID:12235278 PMID:12485723 PMID:12695340 PMID:15286053 PMID:15466163 PMID:15626586 PMID:15802389 PMID:17041008 PMID:17565714 PMID:17954527 PMID:19118567 PMID:19299527 PMID:22634058 More...
|
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
affects expression increases expression
|
EXP
|
Omeprazole affects the expression of CYP3A23-3A1 mRNA Omeprazole results in increased expression of CYP3A23-3A1 mRNA
|
CTD |
PMID:19118567 PMID:19483382 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
affects expression increases expression
|
EXP ISO
|
Omeprazole affects the expression of CYP3A9 mRNA Omeprazole results in increased expression of CYP3A5 mRNA
|
CTD |
PMID:19118567 PMID:19483382 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Cyp4a8
|
cytochrome P450, family 4, subfamily a, polypeptide 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP4A8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:133,938,882...133,970,226
Ensembl chr 5:133,938,883...133,970,226
|
|
G
|
Cyp4f6
|
cytochrome P450, family 4, subfamily f, polypeptide 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP4F6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:12,680,799...12,708,378
Ensembl chr 7:12,680,806...12,708,402
|
|
G
|
Dbi
|
diazepam binding inhibitor
|
affects expression
|
EXP
|
Omeprazole affects the expression of DBI mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450
|
|
G
|
Dcaf11
|
DDB1 and CUL4 associated factor 11
|
affects expression
|
EXP
|
Omeprazole affects the expression of DCAF11 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:33,015,370...33,027,407
Ensembl chr15:33,016,762...33,027,672
|
|
G
|
Dcxr
|
dicarbonyl and L-xylulose reductase
|
affects expression
|
EXP
|
Omeprazole affects the expression of DCXR mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:106,504,730...106,506,619
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
Omeprazole results in increased expression of DDIT3 protein
|
CTD |
PMID:27358234 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Decr1
|
2,4-dienoyl-CoA reductase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of DECR1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033
|
|
G
|
Dexi
|
Dexi homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of DEXI mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:5,632,400...5,645,653
Ensembl chr10:5,632,961...5,645,648
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of DGAT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Dhcr24
|
24-dehydrocholesterol reductase
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHCR24 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936
|
|
G
|
Dhrs4
|
dehydrogenase/reductase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHRS4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:32,924,482...32,948,103
Ensembl chr15:32,936,522...32,948,101
|
|
G
|
Dhrs7b
|
dehydrogenase/reductase 7B
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHRS7B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:46,003,845...46,036,498
Ensembl chr10:46,003,845...46,036,499
|
|
G
|
Dhx16
|
DEAH-box helicase 16
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHX16 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:2,866,804...2,879,790
Ensembl chr20:2,866,804...2,879,751
|
|
G
|
Dmac2l
|
distal membrane arm assembly component 2 like
|
affects expression
|
EXP
|
Omeprazole affects the expression of DMAC2L mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:93,941,690...93,960,662
|
|
G
|
Dnajc3
|
DnaJ heat shock protein family (Hsp40) member C3
|
affects expression
|
EXP
|
Omeprazole affects the expression of DNAJC3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:102,432,667...102,475,643
Ensembl chr15:102,432,663...102,475,643
|
|
G
|
Dpp4
|
dipeptidylpeptidase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of DPP4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422
|
|
G
|
Dpyd
|
dihydropyrimidine dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of DPYD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:209,293,929...210,159,778
|
|
G
|
Ears2
|
glutamyl-tRNA synthetase 2, mitochondrial
|
affects expression
|
EXP
|
Omeprazole affects the expression of EARS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:186,025,740...186,057,165
|
|
G
|
Echs1
|
enoyl-CoA hydratase, short chain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ECHS1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506
|
|
G
|
Eci1
|
enoyl-CoA delta isomerase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ECI1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:13,961,250...13,974,595
Ensembl chr10:13,961,218...13,974,773
|
|
G
|
Eci2
|
enoyl-CoA delta isomerase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ECI2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:30,056,274...30,092,169
Ensembl chr17:30,076,524...30,092,161
|
|
G
|
Eef1g
|
eukaryotic translation elongation factor 1 gamma
|
affects expression
|
EXP
|
Omeprazole affects the expression of EEF1G mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:215,289,815...215,300,421
Ensembl chr 1:215,277,860...215,301,479
|
|
G
|
Egf
|
epidermal growth factor
|
multiple interactions
|
ISO
|
Omeprazole promotes the reaction [Indomethacin results in increased expression of EGF protein]
|
CTD |
PMID:18431645 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
G
|
Ehhadh
|
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of EHHADH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662
|
|
G
|
Eif4a2
|
eukaryotic translation initiation factor 4A2
|
affects expression
|
EXP
|
Omeprazole affects the expression of EIF4A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:91,268,730...91,276,738
Ensembl chr11:91,268,731...91,275,323
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of EIF4EBP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Eif4h
|
eukaryotic translation initiation factor 4H
|
affects expression
|
EXP
|
Omeprazole affects the expression of EIF4H mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:27,719,527...27,736,350
Ensembl chr12:27,719,321...27,736,346
|
|
G
|
Enc1
|
ectodermal-neural cortex 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENC1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721
|
|
G
|
Eno1
|
enolase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:166,002,867...166,014,252
Ensembl chr 3:77,946,261...77,986,003 Ensembl chr 5:77,946,261...77,986,003
|
|
G
|
Enpep
|
glutamyl aminopeptidase
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENPEP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:220,456,258...220,526,218
Ensembl chr 2:220,456,278...220,526,218
|
|
G
|
Enpp1
|
ectonucleotide pyrophosphatase/phosphodiesterase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENPP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044
|
|
G
|
Ep300
|
E1A binding protein p300
|
multiple interactions
|
ISO
|
Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]
|
CTD |
PMID:21703235 |
|
NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574
|
|
G
|
Epcam
|
epithelial cell adhesion molecule
|
affects expression
|
EXP
|
Omeprazole affects the expression of EPCAM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702
|
|
G
|
Erp29
|
endoplasmic reticulum protein 29
|
affects expression
|
EXP
|
Omeprazole affects the expression of ERP29 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:40,750,177...40,756,607
Ensembl chr12:40,750,314...40,757,010
|
|
G
|
Esd
|
esterase D
|
affects expression
|
EXP
|
Omeprazole affects the expression of ESD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508
|
|
G
|
Etfb
|
electron transfer flavoprotein subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of ETFB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:102,988,499...103,002,663
Ensembl chr 1:102,988,499...103,002,659
|
|
G
|
Faah
|
fatty acid amide hydrolase
|
affects expression
|
EXP
|
Omeprazole affects the expression of FAAH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:134,716,545...134,735,396
Ensembl chr 5:134,716,545...134,735,396
|
|
G
|
Fads2
|
fatty acid desaturase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of FADS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066
|
|
G
|
Fbp1
|
fructose-bisphosphatase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of FBP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746
|
|
G
|
Fdft1
|
farnesyl diphosphate farnesyl transferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of FDFT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168
|
|
G
|
Fdps
|
farnesyl diphosphate synthase
|
affects expression
|
EXP
|
Omeprazole affects the expression of FDPS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:176,795,192...176,807,136
|
|
G
|
Fdx2
|
ferredoxin 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of FDX2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:27,881,091...27,886,230
Ensembl chr 8:27,881,091...27,886,015
|
|
G
|
Fmo1
|
flavin containing dimethylaniline monoxygenase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of FMO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874
|
|
G
|
Gamt
|
guanidinoacetate N-methyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GAMT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:10,099,267...10,102,083
Ensembl chr 7:10,098,571...10,102,083
|
|
G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GAPDH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
G
|
Gast
|
gastrin
|
increases expression
|
ISO EXP
|
Omeprazole results in increased expression of GAST protein
|
CTD |
PMID:11422300 PMID:12189558 PMID:12763636 PMID:15223672 PMID:16618411 PMID:17652263 More...
|
|
NCBI chr10:85,765,216...85,767,881
Ensembl chr10:85,765,216...85,767,880
|
|
G
|
Gbe1
|
1,4-alpha-glucan branching enzyme 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GBE1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:22,181,194...22,446,640
Ensembl chr11:22,181,103...22,446,638
|
|
G
|
Gchfr
|
GTP cyclohydrolase I feedback regulator
|
affects expression
|
EXP
|
Omeprazole affects the expression of GCHFR mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926
|
|
G
|
Ggh
|
gamma-glutamyl hydrolase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GGH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:38,326,747...38,349,655
Ensembl chr 5:38,326,594...38,349,647
|
|
G
|
Ggt1
|
gamma-glutamyltransferase 1
|
multiple interactions
|
EXP
|
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GGT1 mRNA
|
CTD |
PMID:22687989 |
|
NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050
|
|
G
|
Gjb1
|
gap junction protein, beta 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GJB1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:70,541,845...70,549,776
Ensembl chr X:70,541,862...70,549,843
|
|
G
|
Gpld1
|
glycosylphosphatidylinositol specific phospholipase D1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GPLD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:40,512,659...40,560,483
Ensembl chr17:40,512,660...40,554,975
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GPX1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions
|
EXP
|
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA
|
CTD |
PMID:22687989 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862
|
|
G
|
Gpx4
|
glutathione peroxidase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of GPX4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
G
|
Grina
|
glutamate ionotropic receptor NMDA type subunit associated protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GRINA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:109,842,870...109,846,048
Ensembl chr 7:109,843,196...109,846,042
|
|
G
|
Grpel1
|
GrpE-like 1, mitochondrial
|
affects expression
|
EXP
|
Omeprazole affects the expression of GRPEL1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:78,517,049...78,522,868
Ensembl chr14:78,517,052...78,522,861
|
|
G
|
Gsta5
|
glutathione S-transferase alpha 5
|
multiple interactions increases expression
|
EXP
|
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA Omeprazole results in increased expression of GSTA5 mRNA
|
CTD |
PMID:17202759 PMID:22687989 |
|
NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of GSTP1 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
Gstt1
|
glutathione S-transferase theta 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GSTT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019
|
|
G
|
Gtf2h5
|
general transcription factor IIH subunit 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of GTF2H5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:49,061,904...49,068,612
Ensembl chr 1:49,061,959...49,070,039
|
|
G
|
Gulo
|
gulonolactone (L-) oxidase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GULO mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:44,381,226...44,403,314
Ensembl chr15:44,381,214...44,403,422
|
|
G
|
Gzma
|
granzyme A
|
affects expression
|
EXP
|
Omeprazole affects the expression of GZMA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:46,473,763...46,485,696
Ensembl chr 2:46,473,763...46,485,696
|
|
G
|
H3f3b
|
H3.3 histone B
|
affects expression
|
EXP
|
Omeprazole affects the expression of H3F3B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:101,755,404...101,764,616
Ensembl chr10:101,755,404...101,757,636
|
|
G
|
Hal
|
histidine ammonia lyase
|
affects expression
|
EXP
|
Omeprazole affects the expression of HAL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:29,894,495...29,924,744
Ensembl chr 7:29,893,855...29,924,744
|
|
G
|
Hamp
|
hepcidin antimicrobial peptide
|
increases secretion multiple interactions increases expression
|
ISO
|
Omeprazole results in increased secretion of HAMP protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA] Omeprazole results in increased expression of HAMP mRNA; Omeprazole results in increased expression of HAMP protein
|
CTD |
PMID:31669099 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
G
|
Hao2
|
hydroxyacid oxidase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HAO2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:188,888,848...188,921,567
Ensembl chr 2:188,889,212...188,913,133
|
|
G
|
Hba-a2
|
hemoglobin alpha, adult chain 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HBA-A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,828,377...15,829,141
|
|
G
|
Hbb
|
hemoglobin subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of HBB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:167,630,245...167,663,873
|
|
G
|
Hdc
|
histidine decarboxylase
|
affects expression increases expression increases stability multiple interactions
|
EXP
|
Omeprazole affects the expression of HDC mRNA Omeprazole results in increased expression of HDC mRNA Omeprazole results in increased stability of HDC protein Omeprazole results in increased expression of and results in increased activity of HDC protein
|
CTD |
PMID:12763636 PMID:19483382 |
|
NCBI chr 3:134,300,628...134,318,704
Ensembl chr 3:134,300,632...134,318,711
|
|
G
|
Hgd
|
homogentisate 1, 2-dioxygenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of HGD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:76,592,202...76,643,776
Ensembl chr11:76,592,204...76,643,767
|
|
G
|
Hmgn1
|
high mobility group nucleosome binding domain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of HMGN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:48,891,813...48,897,732
Ensembl chr11:48,891,814...48,897,771
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression multiple interactions
|
ISO
|
Omeprazole results in increased expression of HMOX1 mRNA; Omeprazole results in increased expression of HMOX1 protein Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]; Omeprazole results in increased expression of and results in increased activity of HMOX1 protein
|
CTD |
PMID:16712795 PMID:27725188 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hprt1
|
hypoxanthine phosphoribosyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of HPRT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:137,655,744...137,687,718
Ensembl chr X:137,655,680...137,687,712
|
|
G
|
Hps5
|
HPS5, biogenesis of lysosomal organelles complex 2 subunit 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HPS5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:106,417,902...106,457,220
Ensembl chr 1:106,417,902...106,452,859
|
|
G
|
Hsd17b4
|
hydroxysteroid (17-beta) dehydrogenase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of HSD17B4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467
|
|
G
|
Hsdl2
|
hydroxysteroid dehydrogenase like 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HSDL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
multiple interactions decreases expression
|
EXP
|
Zinc Compounds analog inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein] Omeprazole results in decreased expression of HSPA1A mRNA; Omeprazole results in decreased expression of HSPA1A protein
|
CTD |
PMID:15223672 PMID:16945336 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa1l
|
heat shock protein family A (Hsp70) member 1 like
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA]
|
CTD |
PMID:25637687 |
|
NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877
|
|
G
|
Htra1
|
HtrA serine peptidase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of HTRA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:194,927,687...194,977,620
|
|
G
|
Ier3
|
immediate early response 3
|
multiple interactions
|
ISO
|
[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3
|
CTD |
PMID:17704804 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]
|
CTD |
PMID:19232345 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Igf1
|
insulin-like growth factor 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of IGF1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
G
|
Igfals
|
insulin-like growth factor binding protein, acid labile subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of IGFALS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:14,397,076...14,408,439
Ensembl chr10:14,403,399...14,407,138
|
|
G
|
Igfbp2
|
insulin-like growth factor binding protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of IGFBP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:81,864,783...81,892,171
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
ISO EXP
|
Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein]
|
CTD |
PMID:26970604 PMID:38341112 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il16
|
interleukin 16
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Ethanol results in increased expression of IL16 protein]
|
CTD |
PMID:38341112 |
|
NCBI chr 1:147,026,852...147,127,177
Ensembl chr 1:147,027,097...147,127,023
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
|
CTD |
PMID:32418911 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP ISO
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL6 protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL6 protein] Omeprazole inhibits the reaction [Ethanol results in increased expression of IL6 protein]
|
CTD |
PMID:25637687 PMID:32418911 PMID:38341112 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Impa1
|
inositol monophosphatase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of IMPA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:93,370,200...93,391,474
Ensembl chr 2:93,370,299...93,391,468
|
|
G
|
Inhbe
|
inhibin subunit beta E
|
affects expression
|
EXP
|
Omeprazole affects the expression of INHBE mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519
|
|
G
|
Isyna1
|
inositol-3-phosphate synthase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ISYNA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:18,873,119...18,876,116
Ensembl chr16:18,873,121...18,875,955
|
|
G
|
Itih4
|
inter-alpha-trypsin inhibitor heavy chain 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of ITIH4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:6,086,985...6,102,162
Ensembl chr16:6,086,973...6,102,160
|
|
G
|
Jak1
|
Janus kinase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of JAK1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758
|
|
G
|
Kdelr2
|
KDEL endoplasmic reticulum protein retention receptor 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of KDELR2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:16,252,424...16,270,737
Ensembl chr12:16,252,424...16,270,719
|
|
G
|
Kdr
|
kinase insert domain receptor
|
affects expression multiple interactions
|
EXP ISO
|
Omeprazole affects the expression of KDR mRNA Omeprazole promotes the reaction [Oxygen results in decreased expression of KDR protein]
|
CTD |
PMID:19483382 PMID:26272953 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192
|
|
G
|
Krt8
|
keratin 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of KRT8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403
|
|
G
|
Lcat
|
lecithin cholesterol acyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of LCAT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:50,744,598...50,748,064
Ensembl chr19:50,744,601...50,748,081
|
|
G
|
Lcmt1
|
leucine carboxyl methyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of LCMT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:187,335,173...187,391,195
Ensembl chr 1:187,327,706...187,391,516
|
|
G
|
Lipc
|
lipase C, hepatic type
|
affects expression
|
EXP
|
Omeprazole affects the expression of LIPC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:80,390,471...80,516,285
|
|
G
|
Lox
|
lysyl oxidase
|
affects expression
|
EXP
|
Omeprazole affects the expression of LOX mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:48,162,889...48,175,640
Ensembl chr18:48,165,688...48,239,810
|
|
G
|
Lrp3
|
LDL receptor related protein 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of LRP3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:96,980,762...96,996,157
Ensembl chr 1:96,981,815...96,996,057
|
|
G
|
Man2b1
|
mannosidase, alpha, class 2B, member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of MAN2B1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:39,959,964...39,979,299
Ensembl chr19:39,959,965...39,979,246
|
|
G
|
Map2k2
|
mitogen activated protein kinase kinase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MAP2K2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK14 protein]
|
CTD |
PMID:17406807 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
G
|
Masp2
|
MBL associated serine protease 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MASP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:164,319,017...164,332,686
Ensembl chr 5:164,308,991...164,332,705
|
|
G
|
Me1
|
malic enzyme 1
|
affects expression multiple interactions
|
EXP
|
Omeprazole affects the expression of ME1 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ME1 mRNA
|
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275
|
|
G
|
Mmp14
|
matrix metallopeptidase 14
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Indomethacin results in decreased expression of MMP14 protein]
|
CTD |
PMID:16934674 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Hydrogen Peroxide results in decreased activity of MMP2 protein]
|
CTD |
PMID:16934674 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmut
|
methylmalonyl-CoA mutase
|
affects expression
|
EXP
|
Omeprazole affects the expression of MMUT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:27,425,935...27,454,202
Ensembl chr 9:27,425,935...27,454,342
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions decreases activity
|
ISO EXP
|
Omeprazole inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Acids results in increased activity of MPO protein] Omeprazole results in decreased activity of MPO protein Omeprazole inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Cysteamine results in increased expression of MPO protein]; Omeprazole inhibits the reaction [Ethanol results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein]
|
CTD |
PMID:16091555 PMID:17151854 PMID:20165931 PMID:25637687 PMID:27780710 PMID:29770154 PMID:31095933 PMID:33245926 More...
|
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mro
|
maestro
|
affects expression
|
EXP
|
Omeprazole affects the expression of MRO mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:69,723,764...69,742,815
Ensembl chr18:69,725,798...69,743,031
|
|
G
|
Mrpl2
|
mitochondrial ribosomal protein L2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MRPL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:21,830,834...21,834,607
Ensembl chr 9:21,830,835...21,834,641
|
|
G
|
Mrpl9
|
mitochondrial ribosomal protein L9
|
affects expression
|
EXP
|
Omeprazole affects the expression of MRPL9 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:184,768,837...184,775,787
Ensembl chr 2:184,763,529...184,775,777
|
|
G
|
Mug2
|
murinoglobulin 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of PZP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:156,836,140...156,908,972
|
|
G
|
Myadm
|
myeloid-associated differentiation marker
|
affects expression
|
EXP
|
Omeprazole affects the expression of MYADM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:74,779,616...74,796,752
Ensembl chr 1:74,775,698...74,789,710
|
|
G
|
Mycbp2
|
MYC binding protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MYCBP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325
|
|
G
|
Myo1d
|
myosin ID
|
affects expression
|
EXP
|
Omeprazole affects the expression of MYO1D mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958
|
|
G
|
Naa38
|
N(alpha)-acetyltransferase 38, NatC auxiliary subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of NAA38 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:54,588,304...54,617,715
Ensembl chr10:54,592,990...54,617,715
|
|
G
|
Nap1l1
|
nucleosome assembly protein 1-like 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NAP1L1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:48,819,464...48,844,108
Ensembl chr 7:48,819,477...48,844,104
|
|
G
|
Nat8
|
N-acetyltransferase 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of NAT8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:119,836,986...119,837,764
Ensembl chr 4:119,835,645...119,843,159
|
|
G
|
Ncoa1
|
nuclear receptor coactivator 1
|
multiple interactions
|
ISO
|
Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter]
|
CTD |
PMID:21703235 |
|
NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924
|
|
G
|
Ndrg2
|
NDRG family member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NDRG2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:27,074,481...27,087,376
Ensembl chr15:27,074,481...27,083,125
|
|
G
|
Ndufs5
|
NADH:ubiquinone oxidoreductase subunit S5
|
affects expression
|
EXP
|
Omeprazole affects the expression of NDUFS5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:141,258,828...141,264,552
Ensembl chr 2:184,849,197...185,028,909 Ensembl chr 5:184,849,197...185,028,909 Ensembl chr14:184,849,197...185,028,909
|
|
G
|
Ndufv3
|
NADH:ubiquinone oxidoreductase subunit V3
|
affects expression
|
EXP
|
Omeprazole affects the expression of NDUFV3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:9,613,786...9,622,941
Ensembl chr13:48,468,224...48,488,847 Ensembl chr20:48,468,224...48,488,847
|
|
G
|
Neu2
|
neuraminidase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NEU2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:95,666,338...95,715,209
Ensembl chr 9:95,696,507...95,715,208
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]
|
CTD |
PMID:27725188 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Cisplatin results in decreased expression of NFKBIA protein]
|
CTD |
PMID:32418911 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nfx1
|
nuclear transcription factor, X-box binding 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NFX1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:60,900,140...60,958,889
Ensembl chr 5:60,901,217...60,958,889
|
|
G
|
Nipal2
|
NIPA-like domain containing 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NIPAL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:67,659,628...67,771,105
Ensembl chr 7:67,659,628...67,769,959
|
|
G
|
Nit1
|
nitrilase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NIT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:86,302,334...86,305,770
Ensembl chr13:86,298,387...86,305,770
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
EXP
|
Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]
|
CTD |
PMID:32418911 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nme2
|
NME/NM23 nucleoside diphosphate kinase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NME2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:79,394,999...79,400,418
Ensembl chr20:11,179,066...11,179,497 Ensembl chr10:11,179,066...11,179,497
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
increases expression multiple interactions
|
EXP ISO
|
Omeprazole results in increased expression of NQO1 mRNA Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 mRNA]; Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 protein] [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of NQO1 mRNA
|
CTD |
PMID:17202759 PMID:22687989 PMID:26272953 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions increases activity
|
ISO EXP
|
[Omeprazole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein affects the reaction [Omeprazole results in increased expression of CYP3A4 mRNA]
|
CTD |
PMID:12695340 PMID:17041008 PMID:25680588 PMID:26187274 PMID:27732639 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
affects expression decreases metabolic processing increases expression
|
EXP ISO
|
Omeprazole affects the expression of NR1I3 mRNA NR1I3 gene mutant form results in decreased metabolism of Omeprazole Omeprazole results in increased expression of NR1I3 mRNA
|
CTD |
PMID:19118567 PMID:19483382 PMID:27434302 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370
|
|
G
|
Nr3c1
|
nuclear receptor subfamily 3, group C, member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NR3C1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843
|
|
G
|
Oaf
|
out at first homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of OAF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:52,491,314...52,509,285
Ensembl chr 8:52,491,315...52,509,285
|
|
G
|
Obp3
|
alpha-2u globulin PGCL4
|
affects expression
|
EXP
|
Omeprazole affects the expression of OBP3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:79,637,234...79,640,810
Ensembl chr 5:79,637,234...79,640,675
|
|
G
|
Ogdh
|
oxoglutarate dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of OGDH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:85,363,949...85,431,405
Ensembl chr14:85,364,014...85,432,271
|
|
G
|
Olr59
|
olfactory receptor 59
|
affects expression
|
EXP
|
Omeprazole affects the expression of OLR59 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:166,604,972...166,639,634
Ensembl chr 1:166,604,141...166,623,265
|
|
G
|
Ostc
|
oligosaccharyltransferase complex non-catalytic subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of OSTC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:221,924,727...221,940,253
Ensembl chr 2:221,874,948...221,940,267
|
|
G
|
Otc
|
ornithine transcarbamylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of OTC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:15,126,358...15,202,473
Ensembl chr X:15,126,358...15,239,555
|
|
G
|
Pabpc4
|
poly(A) binding protein, cytoplasmic 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of PABPC4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:140,847,835...140,864,089
Ensembl chr 5:140,848,225...140,864,087
|
|
G
|
Paics
|
phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase
|
affects expression
|
EXP
|
Omeprazole affects the expression of PAICS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:31,553,355...31,586,843
Ensembl chr14:31,553,357...31,587,027
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage
|
ISO
|
Omeprazole results in increased cleavage of PARP1 protein
|
CTD |
PMID:15461867 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pc
|
pyruvate carboxylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCX mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:211,228,708...211,327,792
Ensembl chr 1:211,228,731...211,329,940
|
|
G
|
Pccb
|
propionyl-CoA carboxylase subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCCB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:110,470,197...110,520,222
Ensembl chr 8:110,469,934...110,520,187
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
EXP ISO
|
[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; Omeprazole promotes the reaction [Acetic Acid results in increased expression of PCNA protein] Omeprazole inhibits the reaction [Ethanol results in decreased expression of PCNA protein]
|
CTD |
PMID:19251492 PMID:26970604 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pcsk6
|
proprotein convertase subtilisin/kexin type 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCSK6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:128,839,742...129,038,087
Ensembl chr 1:128,839,232...129,052,128
|
|
G
|
Pctp
|
phosphatidylcholine transfer protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCTP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:75,305,999...75,351,919
Ensembl chr10:75,305,999...75,326,432
|
|
G
|
Pdcl3
|
phosducin-like 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PDCL3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:48,730,083...48,738,554
Ensembl chr 9:48,723,767...48,739,529
|
|
G
|
Pdia3
|
protein disulfide isomerase family A, member 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PDIA3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:128,841,917...128,867,327
|
|
G
|
Pdia6
|
protein disulfide isomerase family A, member 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PDIA6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:45,791,678...45,810,091
|
|
G
|
Pex19
|
peroxisomal biogenesis factor 19
|
affects expression
|
EXP
|
Omeprazole affects the expression of PEX19 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:87,124,654...87,141,170
Ensembl chr13:87,124,698...87,141,757
|
|
G
|
Pgam1
|
phosphoglycerate mutase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PGAM1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:250,673,049...250,690,203
|
|
G
|
Pgrmc1
|
progesterone receptor membrane component 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PGRMC1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:120,698,610...120,706,805
Ensembl chr X:120,698,610...120,706,805
|
|
G
|
Phyh
|
phytanoyl-CoA 2-hydroxylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of PHYH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:78,238,747...78,255,645
Ensembl chr17:78,238,747...78,255,645
|
|
G
|
Pigp
|
phosphatidylinositol glycan anchor biosynthesis, class P
|
affects expression
|
EXP
|
Omeprazole affects the expression of PIGP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:47,152,601...47,158,766
Ensembl chr11:47,148,465...47,160,082
|
|
G
|
Pklr
|
pyruvate kinase L/R
|
affects expression
|
EXP
|
Omeprazole affects the expression of PKLR mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:176,840,764...176,849,644
|
|
G
|
Pla2g4a
|
phospholipase A2 group 4A
|
increases phosphorylation multiple interactions
|
ISO
|
Omeprazole results in increased phosphorylation of PLA2G4A protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Omeprazole results in increased phosphorylation of PLA2G4A protein]
|
CTD |
PMID:25797602 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641
|
|
G
|
Plbd1
|
phospholipase B domain containing 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PLBD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:171,204,198...171,260,488
Ensembl chr 4:171,204,198...171,260,488
|
|
G
|
Plg
|
plasminogen
|
affects expression
|
EXP
|
Omeprazole affects the expression of PLG mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:50,872,926...50,917,320
|
|
G
|
Pls3
|
plastin 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PLS3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:116,401,247...116,495,898
Ensembl chr X:116,401,293...116,495,893
|
|
G
|
Pon2
|
paraoxonase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of PON2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:34,356,270...34,391,684
Ensembl chr 4:34,356,274...34,391,996
|
|
G
|
Pou2f2
|
POU class 2 homeobox 2
|
multiple interactions
|
ISO EXP
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of POU2F2 protein]
|
CTD |
PMID:30452898 |
|
NCBI chr 1:89,810,153...89,897,560
Ensembl chr 1:89,812,093...89,897,564
|
|
G
|
Ppdpf
|
pancreatic progenitor cell differentiation and proliferation factor
|
affects expression
|
EXP
|
Omeprazole affects the expression of PPDPF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:188,676,821...188,678,599
Ensembl chr 3:188,676,965...188,678,599
|
|
G
|
Prdx2
|
peroxiredoxin 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of PRDX2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006
|
|
G
|
Prdx6
|
peroxiredoxin 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PRDX6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:76,062,082...76,072,631
Ensembl chr13:76,061,554...76,072,657
|
|
G
|
Prl
|
prolactin
|
increases expression
|
ISO
|
Omeprazole results in increased expression of PRL protein
|
CTD |
PMID:20726208 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
G
|
Proc
|
protein C, inactivator of coagulation factors Va and VIIIa
|
affects expression
|
EXP
|
Omeprazole affects the expression of PROC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:24,038,596...24,049,061
Ensembl chr18:24,038,597...24,048,964
|
|
G
|
Prpsap1
|
phosphoribosyl pyrophosphate synthetase-associated protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PRPSAP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:102,199,949...102,221,642
Ensembl chr10:102,199,950...102,221,642
|
|
G
|
Psma6
|
proteasome 20S subunit alpha 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMA6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:78,500,676...78,531,693
Ensembl chr 6:78,500,736...78,531,717
|
|
G
|
Psmb1
|
proteasome 20S subunit beta 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMB1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:65,115,770...65,136,516
Ensembl chr 1:65,114,724...65,136,640
|
|
G
|
Psmb3
|
proteasome 20S subunit beta 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMB3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:83,193,787...83,200,883
Ensembl chr10:83,193,787...83,200,883
|
|
G
|
Psmc1
|
proteasome 26S subunit, ATPase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMC1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:125,122,497...125,134,859
Ensembl chr 6:125,122,490...125,134,858
|
|
G
|
Psmc3
|
proteasome 26S subunit, ATPase 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMC3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:97,487,643...97,493,025
Ensembl chr 3:97,487,632...97,499,176
|
|
G
|
Psmc5
|
proteasome 26S subunit, ATPase 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMC5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:91,687,553...91,693,487
Ensembl chr10:91,686,295...91,695,921
|
|
G
|
Psmd1
|
proteasome 26S subunit, non-ATPase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:94,157,971...94,233,218
Ensembl chr 9:94,157,971...94,233,218
|
|
G
|
Psmd4
|
proteasome 26S subunit ubiquitin receptor, non-ATPase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMD4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:185,287,941...185,297,238
Ensembl chr 2:185,286,868...185,297,201
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
EXP ISO
|
[Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA; [Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein Omeprazole inhibits the reaction [Ethanol results in increased expression of PTGS2 protein]
|
CTD |
PMID:23038005 PMID:26970604 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptms
|
parathymosin
|
affects expression
|
EXP
|
Omeprazole affects the expression of PTMS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:159,408,647...159,412,837
Ensembl chr 4:159,408,649...159,415,212
|
|
G
|
Ptprf
|
protein tyrosine phosphatase, receptor type, F
|
affects expression
|
EXP
|
Omeprazole affects the expression of PTPRF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426
|
|
G
|
Pttg1ip
|
PTTG1 interacting protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of PTTG1IP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:11,029,608...11,047,395
Ensembl chr20:11,029,608...11,046,909
|
|
G
|
Pygl
|
glycogen phosphorylase L
|
affects expression
|
EXP
|
Omeprazole affects the expression of PYGL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:94,426,346...94,476,269
|
|
G
|
Rab5if
|
RAB5 interacting factor
|
affects expression
|
EXP
|
Omeprazole affects the expression of RAB5IF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:165,818,060...165,828,071
Ensembl chr 3:165,816,588...165,828,067
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP ISO
|
[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of RELA protein]; Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] Omeprazole inhibits the reaction [Cisplatin affects the localization of RELA protein]
|
CTD |
PMID:19251492 PMID:30452898 PMID:32418911 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Retsat
|
retinol saturase
|
increases expression
|
EXP
|
Omeprazole results in increased expression of RETSAT mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:106,211,436...106,229,552
|
|
G
|
Rida
|
reactive intermediate imine deaminase A homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of RIDA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:67,576,586...67,590,493
Ensembl chr 7:67,576,586...67,590,692
|
|
G
|
Rnase4
|
ribonuclease A family member 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of RNASE4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:26,786,287...26,803,634
Ensembl chr15:26,786,079...26,803,639
|
|
G
|
Rnf103
|
ring finger protein 103
|
affects expression
|
EXP
|
Omeprazole affects the expression of RNF103 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:105,084,762...105,100,839
Ensembl chr 4:105,084,686...105,106,809
|
|
G
|
Rnps1
|
RNA binding protein with serine rich domain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of RNPS1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:13,950,151...13,960,396
Ensembl chr10:13,950,184...13,960,393
|
|
G
|
Rpl11
|
ribosomal protein L11
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL11 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:153,557,592...153,561,230
Ensembl chr 5:153,557,597...153,561,127
|
|
G
|
Rpl13
|
ribosomal protein L13
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL13 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:68,062,442...68,065,065
Ensembl chr19:68,062,493...68,065,059
|
|
G
|
Rpl15
|
ribosomal protein L15
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL15 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:9,934,663...9,937,946
Ensembl chr15:9,934,679...9,938,308
|
|
G
|
Rpl17
|
ribosomal protein L17
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL17 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:70,856,275...70,859,388
Ensembl chr 3:111,722,010...111,722,638 Ensembl chr18:111,722,010...111,722,638
|
|
G
|
Rpl23
|
ribosomal protein L23
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL23 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:83,268,223...83,272,184
Ensembl chr10:83,262,592...83,272,214
|
|
G
|
Rpl3
|
ribosomal protein L3
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:113,491,943...113,508,115
Ensembl chr 7:113,501,960...113,507,990
|
|
G
|
Rpl32
|
ribosomal protein L32
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL32 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:150,536,650...150,540,214
Ensembl chr 4:150,536,646...150,540,214
|
|
G
|
Rpl4
|
ribosomal protein L4
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:73,566,477...73,571,600
Ensembl chr 8:73,566,466...73,571,788
|
|
G
|
Rpn2
|
ribophorin II
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPN2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:166,361,955...166,409,272
Ensembl chr 3:166,362,049...166,409,922
|
|
G
|
Rps14
|
ribosomal protein S14
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS14 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:56,492,010...56,503,092
Ensembl chr18:56,498,245...56,503,091
|
|
G
|
Rps18
|
ribosomal protein S18
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS18 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:4,933,741...4,937,423
Ensembl chr20:4,917,095...4,937,423
|
|
G
|
Rps19
|
ribosomal protein S19
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS19 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:89,608,408...89,614,390
Ensembl chr 7:104,324,520...104,325,132 Ensembl chr 1:104,324,520...104,325,132
|
|
G
|
Rps20
|
ribosomal protein S20
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS20 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:21,616,687...21,618,068
Ensembl chr 3:42,839,965...43,095,621 Ensembl chr 9:42,839,965...43,095,621 Ensembl chr 5:42,839,965...43,095,621
|
|
G
|
Rps3a
|
ribosomal protein S3a
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS3A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:173,822,673...173,827,042
Ensembl chr 2:173,822,488...173,827,043
|
|
G
|
Rps6
|
ribosomal protein S6
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566
|
|
G
|
Rps8
|
ribosomal protein S8
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:135,866,941...135,869,511
Ensembl chr 5:135,866,941...135,869,548
|
|
G
|
Rras2
|
RAS related 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of RRAS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:177,668,143...177,737,551
Ensembl chr 1:177,668,144...177,737,551
|
|
G
|
RT1-DMa
|
RT1 class II, locus DMa
|
affects expression
|
ISO
|
Omeprazole affects the expression of HLA-DMA mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,708,933...4,712,335
|
|
G
|
RT1-M3-1
|
RT1 class Ib, locus M3, gene 1
|
affects expression
|
ISO
|
Omeprazole affects the expression of HLA-G mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366
|
|
G
|
RT1-S3
|
RT1 class Ib, locus S3
|
affects expression
|
EXP
|
Omeprazole affects the expression of RT1-S3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:2,675,463...2,680,229
|
|
G
|
S1pr1
|
sphingosine-1-phosphate receptor 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of S1PR1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:206,309,715...206,314,070
Ensembl chr 2:205,900,836...206,328,689
|
|
G
|
Sbspon
|
somatomedin B and thrombospondin, type 1 domain containing
|
affects expression
|
EXP
|
Omeprazole affects the expression of SBSPON mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:8,186,004...8,216,576
Ensembl chr 5:8,185,985...8,218,898
|
|
G
|
Sdc2
|
syndecan 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SDC2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:66,012,405...66,125,101
Ensembl chr 7:66,108,853...66,126,294
|
|
G
|
Sdhc
|
succinate dehydrogenase complex subunit C
|
affects expression
|
EXP
|
Omeprazole affects the expression of SDHC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044
|
|
G
|
Sdhd
|
succinate dehydrogenase complex subunit D
|
affects expression
|
EXP
|
Omeprazole affects the expression of SDHD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:59,841,090...59,850,641
Ensembl chr 8:59,841,090...59,850,641
|
|
G
|
Sell
|
selectin L
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of SELL protein
|
CTD |
PMID:17652263 |
|
NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600
|
|
G
|
Serinc3
|
serine incorporator 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERINC3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:172,721,208...172,749,853
Ensembl chr 3:172,721,321...172,740,765
|
|
G
|
Serpina1
|
serpin family A member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:128,631,101...128,653,125
Ensembl chr 6:128,619,382...128,660,703
|
|
G
|
Serpina10
|
serpin family A member 10
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINA10 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:128,520,894...128,529,332
Ensembl chr 6:128,520,896...128,529,332
|
|
G
|
Serpina4
|
serpin family A member 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINA4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:128,764,738...128,773,858
Ensembl chr 6:128,764,769...128,776,028
|
|
G
|
Serpinf2
|
serpin family F member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINF2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:60,770,698...60,778,782
Ensembl chr10:60,770,698...60,778,996
|
|
G
|
Serping1
|
serpin family G member 1
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of SERPING1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:90,249,423...90,258,717
|
|
G
|
Sfxn1
|
sideroflexin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SFXN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:10,491,315...10,527,793
Ensembl chr17:10,491,344...10,527,456
|
|
G
|
Shmt2
|
serine hydroxymethyltransferase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SHMT2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:65,244,247...65,249,580
Ensembl chr 7:65,244,247...65,249,567
|
|
G
|
Slc22a1
|
solute carrier family 22 member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC22A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Slc22a5
|
solute carrier family 22 member 5
|
multiple interactions
|
EXP
|
Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]
|
CTD |
PMID:19041296 |
|
NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077
|
|
G
|
Slc22a8
|
solute carrier family 22 member 8
|
multiple interactions
|
ISO
|
[Omeprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican
|
CTD |
PMID:36243147 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588
|
|
G
|
Slc23a1
|
solute carrier family 23 member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC23A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:27,490,549...27,504,563
Ensembl chr18:27,490,374...27,504,702
|
|
G
|
Slc25a13
|
solute carrier family 25 member 13
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC25A13 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:35,145,721...35,328,403
Ensembl chr 4:35,145,721...35,328,360
|
|
G
|
Slc25a3
|
solute carrier family 25 member 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC25A3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:27,499,164...27,506,685
Ensembl chr 7:27,499,165...27,506,309
|
|
G
|
Slc27a2
|
solute carrier family 27 member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC27A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581
|
|
G
|
Slc39a8
|
solute carrier family 39 member 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC39A8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:226,929,644...226,992,667
|
|
G
|
Slc40a1
|
solute carrier family 40 member 1
|
decreases expression
|
ISO
|
Omeprazole results in decreased expression of SLC40A1 protein
|
CTD |
PMID:31669099 |
|
NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460
|
|
G
|
Slc46a1
|
solute carrier family 46 member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC46A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869
|
|
G
|
Slc66a2
|
solute carrier family 66 member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC66A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:75,976,000...76,014,651
Ensembl chr18:75,977,458...76,014,651
|
|
G
|
Slc6a6
|
solute carrier family 6 member 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC6A6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:125,752,340...125,826,033
Ensembl chr 4:125,752,372...125,826,032
|
|
G
|
Slco1a1
|
solute carrier organic anion transporter family, member 1a1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLCO1A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:176,606,924...176,682,027
Ensembl chr 4:176,607,687...176,681,992
|
|
G
|
Slco1a4
|
solute carrier organic anion transporter family, member 1a4
|
increases expression
|
ISO
|
Omeprazole results in increased expression of SLCO1A2 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Ethanol results in decreased activity of SOD1 protein]
|
CTD |
PMID:28849987 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sppl2a
|
signal peptide peptidase-like 2A
|
affects expression
|
EXP
|
Omeprazole affects the expression of SPPL2A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:134,602,684...134,646,752
Ensembl chr 3:134,605,750...134,646,752
|
|
G
|
Srm
|
spermidine synthase
|
affects expression
|
EXP
|
Omeprazole affects the expression of SRM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705
|
|
G
|
Srprb
|
SRP receptor subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of SRPRB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:112,647,577...112,661,524
|
|
G
|
Ssx2ip
|
SSX family member 2 interacting protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of SSX2IP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:237,958,286...237,991,026
Ensembl chr 2:237,958,465...237,991,017
|
|
G
|
St3gal6
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of ST3GAL6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:55,530,120...55,590,950
Ensembl chr11:55,530,248...55,598,720
|
|
G
|
St6gal1
|
ST6 beta-galactoside alpha-2,6-sialyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ST6GAL1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:91,031,481...91,158,111
Ensembl chr11:91,032,450...91,040,415
|
|
G
|
Suclg1
|
succinate-CoA ligase GDP/ADP-forming subunit alpha
|
affects expression
|
EXP
|
Omeprazole affects the expression of SUCLG1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:106,866,329...106,895,686
Ensembl chr 4:106,866,114...106,895,689
|
|
G
|
Surf4
|
surfeit 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of SURF4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:30,646,435...30,659,641
Ensembl chr 3:30,638,299...30,661,390
|
|
G
|
Synj2bp
|
synaptojanin 2 binding protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of SYNJ2BP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:106,920,970...106,958,653
Ensembl chr 6:106,920,970...106,966,543
|
|
G
|
Tacr1
|
tachykinin receptor 1
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Acids affects the localization of TACR1 protein]
|
CTD |
PMID:16091555 |
|
NCBI chr 4:116,478,617...116,647,492
Ensembl chr 4:116,478,617...116,647,492
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression
|
ISO
|
Omeprazole results in increased expression of TGFB1 protein
|
CTD |
PMID:36243147 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfbi
|
transforming growth factor, beta induced
|
affects expression
|
EXP
|
Omeprazole affects the expression of TGFBI mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471
|
|
G
|
Thnsl2
|
threonine synthase-like 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of THNSL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:104,671,305...104,691,084
Ensembl chr 4:104,670,925...104,691,959
|
|
G
|
Timm21
|
translocase of inner mitochondrial membrane 21
|
affects expression
|
EXP
|
Omeprazole affects the expression of TIMM21 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:80,589,775...80,594,237
Ensembl chr18:80,589,783...80,594,237
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Indomethacin results in increased expression of TIMP2 protein]
|
CTD |
PMID:16934674 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Tkfc
|
triokinase and FMN cyclase
|
affects expression
|
EXP
|
Omeprazole affects the expression of TKFC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:216,664,446...216,677,815
Ensembl chr 1:216,661,477...216,677,928
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
EXP
|
Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]
|
CTD |
PMID:32418911 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tmbim1
|
transmembrane BAX inhibitor motif containing 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMBIM1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:83,320,972...83,338,469
Ensembl chr 9:83,320,979...83,338,657
|
|
G
|
Tmbim6
|
transmembrane BAX inhibitor motif containing 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of TEGT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:132,405,217...132,422,492
Ensembl chr 7:132,386,134...132,422,492
|
|
G
|
Tmco1
|
transmembrane and coiled-coil domains 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMCO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:81,993,172...82,016,496
Ensembl chr13:81,993,097...82,017,201
|
|
G
|
Tmed2
|
transmembrane p24 trafficking protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMED2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:37,713,522...37,722,606
Ensembl chr12:37,713,529...37,722,606
|
|
G
|
Tmed7
|
transmembrane p24 trafficking protein 7
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMED7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:41,505,167...41,512,243
Ensembl chr18:41,478,539...41,512,243
|
|
G
|
Tmem123
|
transmembrane protein 123
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMEM123 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:13,206,907...13,237,069
Ensembl chr 8:13,206,403...13,257,427
|
|
G
|
Tmem97
|
transmembrane protein 97
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMEM97 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818
|
|
G
|
Tmprss2
|
transmembrane serine protease 2
|
increases expression
|
EXP
|
Omeprazole results in increased expression of TMPRSS2 mRNA
|
CTD |
PMID:32808185 |
|
NCBI chr11:50,403,707...50,443,224
Ensembl chr11:50,398,349...50,443,114
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of TNF protein] Omeprazole inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of TNF protein]
|
CTD |
PMID:19232345 PMID:25637687 PMID:26970604 PMID:30452898 PMID:32418911 PMID:38341112 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Txn1
|
thioredoxin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TXN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Txnl1
|
thioredoxin-like 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TXNL1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:59,397,275...59,428,072
Ensembl chr18:59,398,535...59,435,518
|
|
G
|
Tyr
|
tyrosinase
|
multiple interactions decreases expression
|
ISO
|
Omeprazole affects the N-linked glycosylation of and results in increased degradation of TYR protein; Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein] Omeprazole results in decreased expression of TYR protein
|
CTD |
PMID:25337692 |
|
NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857
|
|
G
|
Uba52
|
ubiquitin A-52 residue ribosomal protein fusion product 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of UBA52 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:18,952,583...18,954,780
|
|
G
|
Ube2n
|
ubiquitin-conjugating enzyme E2N
|
affects expression
|
EXP
|
Omeprazole affects the expression of UBE2N mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:32,041,190...32,071,252
|
|
G
|
Ufd1
|
ubiquitin recognition factor in ER associated degradation 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of UFD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:95,665,971...95,689,423
Ensembl chr11:95,665,972...95,689,434
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression affects expression
|
ISO EXP
|
Omeprazole results in increased expression of UGT1A1 mRNA Omeprazole affects the expression of UGT1A1 mRNA
|
CTD |
PMID:19118567 PMID:19483382 PMID:25626140 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a2
|
UDP glucuronosyltransferase 1 family, polypeptide A2
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A2 mRNA; Omeprazole results in increased expression of UGT1A3 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a3
|
UDP glycosyltransferase 1 family, polypeptide A3
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A5 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,228,134...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a5
|
UDP glucuronosyltransferase family 1 member A5
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A4 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,210,053...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a6
|
UDP glucuronosyltransferase family 1 member A6
|
multiple interactions increases expression
|
EXP ISO
|
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of UGT1A6 mRNA Omeprazole results in increased expression of UGT1A6 mRNA
|
CTD |
PMID:19118567 PMID:22687989 |
|
NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a9
|
UDP glucuronosyltransferase family 1 member A9
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A9 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt2b1
|
UDP glucuronosyltransferase 2 family, polypeptide B1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of UGT2B1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331
|
|
G
|
Uqcr11
|
ubiquinol-cytochrome c reductase, complex III subunit XI
|
affects expression
|
EXP
|
Omeprazole affects the expression of UQCR11 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:9,955,717...9,960,432
Ensembl chr 7:9,955,764...9,959,047
|
|
G
|
Vnn1
|
vanin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of VNN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:23,356,324...23,366,629
Ensembl chr 1:23,356,330...23,366,629
|
|
G
|
Wdr26
|
WD repeat domain 26
|
affects expression
|
EXP
|
Omeprazole affects the expression of WDR26 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:95,462,017...95,503,826
Ensembl chr13:95,462,020...95,503,738
|
|
G
|
Ywhag
|
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma
|
affects expression
|
EXP
|
Omeprazole affects the expression of YWHAG mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:26,381,106...26,409,466
Ensembl chr12:26,380,816...26,409,465
|
|
G
|
Zdhhc23
|
zinc finger DHHC-type palmitoyltransferase 23
|
affects expression
|
EXP
|
Omeprazole affects the expression of ZDHHC23 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:70,224,581...70,240,971
Ensembl chr11:70,225,045...70,240,102
|
|
G
|
Zwint
|
ZW10 interacting kinetochore protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of ZWINT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:15,502,559...15,953,701
Ensembl chr20:15,937,396...15,953,203
|
|
|
G
|
Adcy7
|
adenylate cyclase 7
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of ADCY7 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743
|
|
G
|
Arl4c
|
ARF like GTPase 4C
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of ARL4C mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 9:96,748,075...96,751,510
Ensembl chr 9:96,745,069...96,752,772
|
|
G
|
Bag3
|
BAG cochaperone 3
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of BAG3 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Albendazole results in increased expression of CCL2 protein
|
CTD |
PMID:20116850 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccl3
|
C-C motif chemokine ligand 3
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of CCL3 protein
|
CTD |
PMID:16861626 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
G
|
Ccr7
|
C-C motif chemokine receptor 7
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of CCR7 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501
|
|
G
|
Cct3
|
chaperonin containing TCP1 subunit 3
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of CCT3 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 2:176,063,529...176,088,180
Ensembl chr 2:176,063,526...176,089,925
|
|
G
|
Cd86
|
CD86 molecule
|
multiple interactions
|
ISO
|
[Albendazole co-treated with CYP3A4 protein] results in increased expression of CD86 protein
|
CTD |
PMID:22785256 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361
|
|
G
|
Ctsl
|
cathepsin L
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of CTSL mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr17:770,104...776,266
Ensembl chr17:770,093...777,113
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases activity decreases activity increases expression
|
ISO
|
Albendazole results in increased activity of CYP1A1 promoter; Albendazole results in increased activity of CYP1A1 protein Albendazole results in decreased activity of CYP1A1 protein Albendazole results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:12451431 PMID:16714371 PMID:18502397 PMID:33814510 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases expression affects metabolic processing
|
ISO
|
Albendazole results in increased expression of CYP1A2 mRNA CYP1A2 protein affects the metabolism of Albendazole
|
CTD |
PMID:12451431 PMID:12920490 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
decreases activity
|
ISO
|
Albendazole results in decreased activity of CYP1B1 protein
|
CTD |
PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
EXP ISO
|
[SOD2 co-treated with CYP3A4] affects the susceptibility to Albendazole [Albendazole co-treated with CYP3A4 protein] results in increased expression of CD86 protein; [Albendazole co-treated with CYP3A4 protein] results in increased expression of ICAM1 protein
|
CTD |
PMID:19501153 PMID:22785256 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Dnajb1
|
DnaJ heat shock protein family (Hsp40) member B1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of DNAJB1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416
|
|
G
|
Dpysl2
|
dihydropyrimidinase-like 2
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of DPYSL2 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr15:45,181,041...45,287,065
Ensembl chr15:45,181,041...45,287,065
|
|
G
|
Gem
|
GTP binding protein overexpressed in skeletal muscle
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of GEM mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 5:30,011,641...30,022,554
Ensembl chr 5:30,011,592...30,022,542
|
|
G
|
Gpr183
|
G protein-coupled receptor 183
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr15:105,445,129...105,457,192
Ensembl chr15:105,437,561...105,466,977
|
|
G
|
Hsf1
|
heat shock transcription factor 1
|
increases activity
|
ISO
|
Albendazole results in increased activity of HSF1 protein
|
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AA1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
G
|
Hsp90ab1
|
heat shock protein 90 alpha family class B member 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AB1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926
|
|
G
|
Hspa4
|
heat shock protein family A (Hsp70) member 4
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of HSPA4 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr10:37,908,866...37,951,994
Ensembl chr10:37,908,866...37,949,835
|
|
G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of HSPA8 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372
|
|
G
|
Hspd1
|
heat shock protein family D (Hsp60) member 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of HSPD1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037
|
|
G
|
Hspe1
|
heat shock protein family E (Hsp10) member 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of HSPE1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502
|
|
G
|
Hsph1
|
heat shock protein family H (Hsp110) member 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of HSPH1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO
|
[Albendazole co-treated with CYP3A4 protein] results in increased expression of ICAM1 protein
|
CTD |
PMID:22785256 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of IL10 protein
|
CTD |
PMID:16861626 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il1a
|
interleukin 1 alpha
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of IL1A protein
|
CTD |
PMID:16861626 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
G
|
Il1r1
|
interleukin 1 receptor type 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of IL1R1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579
|
|
G
|
Il6r
|
interleukin 6 receptor
|
increases expression
|
ISO
|
Albendazole results in increased expression of IL6R protein modified form
|
CTD |
PMID:20116850 |
|
NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221
|
|
G
|
Map3k8
|
mitogen-activated protein kinase kinase kinase 8
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of MAP3K8 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr17:58,078,175...58,098,455
Ensembl chr17:58,078,320...58,098,452
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
decreases expression
|
ISO
|
Albendazole results in decreased expression of MAPT mRNA; Albendazole results in decreased expression of MAPT protein
|
CTD |
PMID:16930453 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
Albendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Ppid
|
peptidylprolyl isomerase D
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of PPID mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 2:167,025,985...167,037,998
Ensembl chr 2:167,025,931...167,054,493
|
|
G
|
Ppif
|
peptidylprolyl isomerase F
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of PPIF mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954
|
|
G
|
Ptges3
|
prostaglandin E synthase 3
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of PTGES3 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 7:1,075,230...1,092,363
Ensembl chr 7:1,075,227...1,092,695
|
|
G
|
RT1-DMb
|
RT1 class II, locus DMb
|
affects expression
|
ISO
|
Albendazole affects the expression of HLA-DMB mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:4,695,009...4,702,560
Ensembl chr20:4,695,010...4,702,246
|
|
G
|
Skap2
|
src kinase associated phosphoprotein 2
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of SKAP2 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 4:82,281,221...82,431,664
Ensembl chr 4:82,263,709...82,432,886
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
EXP
|
[SOD2 co-treated with CYP3A4] affects the susceptibility to Albendazole
|
CTD |
PMID:19501153 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sphk1
|
sphingosine kinase 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of SPHK1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082
|
|
G
|
St13
|
ST13, Hsp70 interacting protein
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of ST13 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 7:114,769,758...114,805,877
Ensembl chr 7:114,769,759...114,805,941
|
|
G
|
Tcp1
|
t-complex 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in increased expression of TCP1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 1:50,376,848...50,384,527
Ensembl chr 1:50,376,848...50,384,527
|
|
G
|
Tgif1
|
TGFB-induced factor homeobox 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of TGIF1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr 9:118,194,735...118,204,354
Ensembl chr 9:118,194,444...118,204,442
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases secretion
|
ISO
|
U 0126 inhibits the reaction [Albendazole results in increased secretion of TNF protein]
|
CTD |
PMID:20848085 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
affects activity
|
ISO
|
Albendazole affects the activity of TP53 protein
|
CTD |
PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tsc22d1
|
TSC22 domain family, member 1
|
multiple interactions
|
ISO
|
[Ivermectin co-treated with Albendazole] results in decreased expression of TSC22D1 mRNA
|
CTD |
PMID:16861626 |
|
NCBI chr15:58,159,612...58,260,244
Ensembl chr15:58,159,952...58,183,322
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
ISO
|
Albendazole results in increased expression of VEGFA protein
|
CTD |
PMID:20116850 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
affects transport
|
ISO
|
ABCG2 protein affects the transport of albendazole sulfoxide
|
CTD |
PMID:15703302 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
albendazole sulfoxide inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Tp53
|
tumor protein p53
|
affects activity
|
ISO
|
albendazole sulfoxide affects the activity of TP53 protein
|
CTD |
PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions decreases activity
|
ISO
|
Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Astemizole results in decreased activity of ABCB11 protein
|
CTD |
PMID:24014644 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Ak3
|
adenylate kinase 3
|
increases expression
|
EXP
|
Astemizole results in increased expression of AK3 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:236,151,012...236,178,689
Ensembl chr 1:236,151,012...236,178,183
|
|
G
|
Alas2
|
5'-aminolevulinate synthase 2
|
increases expression
|
EXP
|
Astemizole results in increased expression of ALAS2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr X:22,890,650...22,914,046
Ensembl chr X:22,890,689...22,914,043
|
|
G
|
Angpt2
|
angiopoietin 2
|
increases expression
|
EXP
|
Astemizole results in increased expression of ANGPT2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239
|
|
G
|
Atf3
|
activating transcription factor 3
|
increases expression
|
ISO
|
Astemizole results in increased expression of ATF3 mRNA
|
CTD |
PMID:32661532 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750
|
|
G
|
Atp1b1
|
ATPase Na+/K+ transporting subunit beta 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of ATP1B1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr13:79,319,708...79,340,226
Ensembl chr13:79,319,706...79,340,549
|
|
G
|
Atp1b2
|
ATPase Na+/K+ transporting subunit beta 2
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of ATP1B2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr10:54,817,473...54,823,708
Ensembl chr10:54,817,476...54,823,708
|
|
G
|
Atp5f1e
|
ATP synthase F1 subunit epsilon
|
increases expression
|
EXP
|
Astemizole results in increased expression of ATP5F1E mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 3:183,677,270...183,680,172
Ensembl chr 3:183,677,273...183,680,214
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of BCL2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bmp1
|
bone morphogenetic protein 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of BMP1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr15:51,961,310...52,005,597
Ensembl chr15:51,961,310...52,005,485
|
|
G
|
Camk2d
|
calcium/calmodulin-dependent protein kinase II delta
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of CAMK2D mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 2:217,698,324...217,961,898
Ensembl chr 2:217,698,551...217,960,276
|
|
G
|
Cat
|
catalase
|
increases expression
|
EXP
|
Astemizole results in increased expression of CAT mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccl7
|
C-C motif chemokine ligand 7
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of CCL7 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
increases expression
|
EXP
|
Astemizole results in increased expression of CEBPB mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Cebpg
|
CCAAT/enhancer binding protein gamma
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of CEBPG mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:96,820,981...96,829,736
Ensembl chr 1:96,810,214...96,830,283
|
|
G
|
Cfh
|
complement factor H
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of CFH mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr13:54,063,079...54,164,523
Ensembl chr13:54,062,531...54,164,532
|
|
G
|
Colec12
|
collectin sub-family member 12
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of COLEC12 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297
|
|
G
|
Cox6c-ps1
|
cytochrome c oxidase subunit VIc, pseudogene
|
increases expression
|
EXP
|
Astemizole results in increased expression of COX6C-PS1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr19:69,090,047...69,090,905
Ensembl chr19:69,090,047...69,090,905
|
|
G
|
Crh
|
corticotropin releasing hormone
|
multiple interactions
|
EXP
|
Astemizole inhibits the reaction [Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]]
|
CTD |
PMID:18835572 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of CXCL3 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
G
|
Cxcl9
|
C-X-C motif chemokine ligand 9
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of CXCL9 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299
|
|
G
|
Cyp2j4
|
cytochrome P450, family 2, subfamily j, polypeptide 4
|
multiple interactions increases metabolic processing decreases methylation
|
ISO
|
Arachidonic Acid inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole]; ebastine inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole] CYP2J2 protein results in increased metabolism of Astemizole
|
CTD |
PMID:12386130 PMID:15861034 PMID:17162467 |
|
NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases degradation
|
ISO
|
CYP3A4 protein results in increased degradation of Astemizole
|
CTD |
PMID:15684493 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Eaf1
|
ELL associated factor 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of EAF1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr16:6,704,727...6,719,476
Ensembl chr16:6,704,727...6,719,476
|
|
G
|
Egln1
|
egl-9 family hypoxia-inducible factor 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of EGLN1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr19:69,765,276...69,804,681
|
|
G
|
Eif4a1
|
eukaryotic translation initiation factor 4A1
|
increases expression
|
EXP
|
Astemizole results in increased expression of EIF4A1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr10:54,883,093...54,888,602
Ensembl chr10:54,883,093...54,888,602
|
|
G
|
Errfi1
|
ERBB receptor feedback inhibitor 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of ERRFI1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432
|
|
G
|
Etv5
|
ETS variant transcription factor 5
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of ETV5 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr11:92,113,171...92,170,758
Ensembl chr11:92,113,224...92,170,767
|
|
G
|
Fam124a
|
family with sequence similarity 124 member A
|
increases expression
|
EXP
|
Astemizole results in increased expression of FAM124A mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr15:40,975,789...41,031,069
Ensembl chr15:40,975,877...41,029,628
|
|
G
|
Fcer1a
|
Fc epsilon receptor Ia
|
multiple interactions
|
EXP
|
Astemizole inhibits the reaction [FCER1A protein results in increased secretion of HEXB protein]
|
CTD |
PMID:9088877 |
|
NCBI chr13:88,218,427...88,224,723
Ensembl chr13:88,218,420...88,224,681
|
|
G
|
Gdf10
|
growth differentiation factor 10
|
increases expression
|
EXP
|
Astemizole results in increased expression of GDF10 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr16:9,243,434...9,256,788
Ensembl chr16:9,243,317...9,256,794
|
|
G
|
Gimap1
|
GTPase, IMAP family member 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of GIMAP1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 4:79,018,473...79,022,360
Ensembl chr 4:79,018,202...79,022,525
|
|
G
|
Gpm6b
|
glycoprotein m6b
|
increases expression
|
EXP
|
Astemizole results in increased expression of GPM6B mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr X:31,689,485...31,836,199
Ensembl chr X:31,690,359...31,733,272
|
|
G
|
Gpx4
|
glutathione peroxidase 4
|
increases expression
|
EXP
|
Astemizole results in increased expression of GPX4 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
G
|
Hexb
|
hexosaminidase subunit beta
|
increases secretion multiple interactions
|
EXP
|
Astemizole results in increased secretion of HEXB protein Astemizole inhibits the reaction [FCER1A protein results in increased secretion of HEXB protein]
|
CTD |
PMID:9088877 |
|
NCBI chr 2:30,218,608...30,238,771
Ensembl chr 2:30,218,608...30,238,771
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression
|
ISO
|
Astemizole results in increased expression of HMOX1 mRNA
|
CTD |
PMID:32661532 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hrh1
|
histamine receptor H 1
|
multiple interactions
|
ISO
|
[Astemizole binds to and results in decreased activity of HRH1 protein] which affects the susceptibility to Aminophylline Astemizole inhibits the reaction [Histamine results in decreased activity of [KCNQ2 protein co-treated with KCNQ3 protein co-treated with HRH1 protein]]
|
CTD |
PMID:12147327 PMID:16129921 |
|
NCBI chr 4:149,120,511...149,204,267
Ensembl chr 4:149,120,039...149,208,248
|
|
G
|
Hsp90ab1
|
heat shock protein 90 alpha family class B member 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of HSP90AB1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926
|
|
G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
increases expression
|
EXP
|
Astemizole results in increased expression of HSPA8 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372
|
|
G
|
Hspb8
|
heat shock protein family B (small) member 8
|
increases expression
|
EXP
|
Astemizole results in increased expression of HSPB8 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr12:45,835,899...45,866,449
Ensembl chr12:45,837,066...45,851,937
|
|
G
|
Hsph1
|
heat shock protein family H (Hsp110) member 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of HSPH1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO
|
Astemizole inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]
|
CTD |
PMID:17517105 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Ifit3
|
interferon-induced protein with tetratricopeptide repeats 3
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of IFIT3 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521
|
|
G
|
Igf1
|
insulin-like growth factor 1
|
multiple interactions
|
ISO
|
Astemizole inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein]
|
CTD |
PMID:17520698 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
G
|
Igsf6
|
immunoglobulin superfamily, member 6
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of IGSF6 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:185,041,462...185,051,956
Ensembl chr 1:185,041,462...185,052,245
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
Astemizole inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Astemizole inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]
|
CTD |
PMID:17517105 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il36rn
|
interleukin 36 receptor antagonist
|
increases expression
|
EXP
|
Astemizole results in increased expression of IL36RN mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 3:27,442,679...27,449,306
Ensembl chr 3:27,442,709...27,449,306
|
|
G
|
Il7r
|
interleukin 7 receptor
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of IL7R mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027
|
|
G
|
Itga8
|
integrin subunit alpha 8
|
increases expression
|
EXP
|
Astemizole results in increased expression of ITGA8 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr17:80,213,139...80,410,633
Ensembl chr17:80,213,143...80,410,633
|
|
G
|
Kcnh1
|
potassium voltage-gated channel subfamily H member 1
|
multiple interactions decreases activity affects binding
|
ISO
|
Astemizole binds to and results in decreased activity of KCNH1 protein; Astemizole inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein] Astemizole results in decreased activity of KCNH1 protein Astemizole binds to KCNH1 protein
|
CTD |
PMID:14985237 PMID:16816845 PMID:17520698 PMID:18471075 PMID:18497958 PMID:20050851 PMID:32533968 More...
|
|
NCBI chr13:106,253,101...106,555,712
Ensembl chr13:106,253,213...106,555,710
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
multiple interactions affects binding decreases activity affects localization
|
ISO EXP
|
Astemizole binds to and results in decreased activity of KCNH2 protein; Astemizole inhibits the reaction [arsenic trioxide results in increased degradation of KCNH2 protein]; Astemizole inhibits the reaction [Digoxin results in decreased activity of KCNH2 protein]; Astemizole inhibits the reaction [Digoxin results in decreased metabolism of KCNH2 protein modified form]; Astemizole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; dofetilide analog inhibits the reaction [Astemizole binds to KCNH2 protein]; Hydrogen Peroxide inhibits the reaction [Astemizole results in decreased activity of KCNH2 protein mutant form]; Potassium promotes the reaction [Astemizole binds to KCNH2 protein] Astemizole binds to KCNH2 gene polymorphism; Astemizole binds to KCNH2 protein Astemizole affects the localization of KCNH2 protein mutant form
|
CTD |
PMID:8641472 PMID:9658196 PMID:10376921 PMID:10422790 PMID:10531299 PMID:10828461 PMID:11040061 PMID:11082114 PMID:11705456 PMID:11741928 PMID:12388285 PMID:15272206 PMID:15671647 PMID:15740727 PMID:16723379 PMID:18701618 PMID:19139152 PMID:19583963 PMID:21158687 PMID:24052561 PMID:24200993 PMID:28521025 More...
|
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Kcnq2
|
potassium voltage-gated channel subfamily Q member 2
|
multiple interactions
|
ISO
|
Astemizole inhibits the reaction [Histamine results in decreased activity of [KCNQ2 protein co-treated with KCNQ3 protein co-treated with HRH1 protein]]
|
CTD |
PMID:12147327 |
|
NCBI chr 3:188,572,345...188,631,391
Ensembl chr 3:188,572,926...188,631,302
|
|
G
|
Kcnq3
|
potassium voltage-gated channel subfamily Q member 3
|
multiple interactions
|
ISO
|
Astemizole inhibits the reaction [Histamine results in decreased activity of [KCNQ2 protein co-treated with KCNQ3 protein co-treated with HRH1 protein]]
|
CTD |
PMID:12147327 |
|
NCBI chr 7:99,614,089...99,914,736
Ensembl chr 7:99,619,544...99,914,610
|
|
G
|
Maoa
|
monoamine oxidase A
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of MAOA mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
affects binding
|
ISO
|
Astemizole binds to MAPT protein alternative form
|
CTD |
PMID:20110603 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of MMP2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Ms4a6a
|
membrane spanning 4-domains A6A
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of MS4A6A mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:217,826,261...217,839,606
Ensembl chr 1:217,826,261...217,850,013
|
|
G
|
Mt2
|
metallothionein 2
|
increases expression
|
ISO
|
Astemizole results in increased expression of MT2A mRNA
|
CTD |
PMID:32661532 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709
|
|
G
|
Mtf1
|
metal-regulatory transcription factor 1
|
multiple interactions
|
ISO
|
MTF1 protein affects the reaction [Astemizole results in increased expression of MT1M mRNA]
|
CTD |
PMID:32661532 |
|
NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810
|
|
G
|
Mtus1
|
microtubule associated scaffold protein 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of MTUS1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr16:57,905,991...58,051,466
Ensembl chr16:57,906,128...58,051,474
|
|
G
|
Myh6
|
myosin heavy chain 6
|
increases expression
|
EXP
|
Astemizole results in increased expression of MYH6 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333
|
|
G
|
Ndufs7
|
NADH:ubiquinone oxidoreductase core subunit S7
|
increases expression
|
EXP
|
Astemizole results in increased expression of NDUFS7 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 7:10,103,226...10,110,862
Ensembl chr 7:10,103,227...10,110,691
|
|
G
|
Ndufv2
|
NADH:ubiquinone oxidoreductase core subunit V2
|
increases expression
|
EXP
|
Astemizole results in increased expression of NDUFV2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 9:113,137,305...113,157,571
Ensembl chr 9:113,137,306...113,157,520
|
|
G
|
Necab1
|
N-terminal EF-hand calcium binding protein 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of NECAB1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 5:33,155,078...33,375,707
Ensembl chr 5:33,153,975...33,375,707
|
|
G
|
Nr4a3
|
nuclear receptor subfamily 4, group A, member 3
|
increases expression
|
EXP
|
Astemizole results in increased expression of NR4A3 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:67,157,375...67,198,285
|
|
G
|
Oasl
|
2'-5'-oligoadenylate synthetase-like
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of OASL1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr12:47,343,551...47,356,509
Ensembl chr12:47,343,551...47,356,483
|
|
G
|
Osbpl3
|
oxysterol binding protein-like 3
|
increases expression
|
EXP
|
Astemizole results in increased expression of OSBPL3 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 4:80,677,383...80,854,169
Ensembl chr 4:80,677,390...80,854,169
|
|
G
|
Osgepl1
|
O-sialoglycoprotein endopeptidase-like 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of OSGEPL1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 9:55,707,389...55,725,325
Ensembl chr 9:55,707,392...55,721,346
|
|
G
|
Park7
|
Parkinsonism associated deglycase
|
increases expression
|
EXP
|
Astemizole results in increased expression of PARK7 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825
|
|
G
|
Pcdh17
|
protocadherin 17
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of PCDH17 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr15:66,631,549...66,725,007
Ensembl chr15:66,633,142...66,722,105
|
|
G
|
Peli2
|
pellino E3 ubiquitin protein ligase family member 2
|
increases expression
|
EXP
|
Astemizole results in increased expression of PELI2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr15:23,872,984...24,017,448
Ensembl chr15:23,872,984...24,014,817
|
|
G
|
Prl8a3
|
prolactin family 8, subfamily A, member 3
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of PRL8A3 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr17:37,716,716...37,723,215
|
|
G
|
Psmb5
|
proteasome 20S subunit beta 5
|
increases expression
|
EXP
|
Astemizole results in increased expression of PSMB5 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr15:32,042,784...32,047,379
Ensembl chr15:32,042,787...32,047,379
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of PTGS1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Pycr3
|
pyrroline-5-carboxylate reductase 3
|
increases expression
|
EXP
|
Astemizole results in increased expression of PYCR3 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 7:109,484,263...109,489,554
|
|
G
|
Pygm
|
glycogen phosphorylase, muscle associated
|
increases expression
|
EXP
|
Astemizole results in increased expression of PYGM mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:213,119,805...213,134,622
Ensembl chr 1:213,119,791...213,134,612
|
|
G
|
S100a8
|
S100 calcium binding protein A8
|
increases expression
|
EXP
|
Astemizole results in increased expression of S100A8 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:178,464,702...178,465,221
|
|
G
|
S100b
|
S100 calcium binding protein B
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of S100B mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081
|
|
G
|
Sik1
|
salt-inducible kinase 1
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of SIK1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr20:9,947,104...9,958,729
Ensembl chr20:9,947,105...9,958,698
|
|
G
|
Slc1a1
|
solute carrier family 1 member 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of SLC1A1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:235,963,455...236,043,572
Ensembl chr 1:235,963,437...236,045,469
|
|
G
|
Sod2
|
superoxide dismutase 2
|
increases expression
|
EXP
|
Astemizole results in increased expression of SOD2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sqstm1
|
sequestosome 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of SQSTM1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Tf
|
transferrin
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of TF mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400
|
|
G
|
Tgfb2
|
transforming growth factor, beta 2
|
increases expression
|
EXP
|
Astemizole results in increased expression of TGFB2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856
|
|
G
|
Tlr2
|
toll-like receptor 2
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of TLR2 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194
|
|
G
|
Tlr7
|
toll-like receptor 7
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of TLR7 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr X:30,644,324...30,670,796
Ensembl chr X:30,644,355...30,672,151
|
|
G
|
Tmod1
|
tropomodulin 1
|
increases expression
|
EXP
|
Astemizole results in increased expression of TMOD1 mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 5:65,112,062...65,189,563
Ensembl chr 5:65,134,132...65,189,561
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
ISO
|
Astemizole inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]
|
CTD |
PMID:17517105 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
G
|
Vcan
|
versican
|
decreases expression
|
EXP
|
Astemizole results in decreased expression of VCAN mRNA
|
CTD |
PMID:20221588 |
|
NCBI chr 2:22,497,035...22,595,955
Ensembl chr 2:22,497,035...22,595,955
|
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
[Zinc Sulfate binds to azilsartan] which results in increased expression of BAX protein
|
CTD |
PMID:29408668 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions
|
ISO
|
[Zinc Sulfate binds to azilsartan] which results in decreased expression of BCL2L1 protein
|
CTD |
PMID:29408668 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
[Zinc Sulfate binds to azilsartan] which results in increased expression of CASP9 protein
|
CTD |
PMID:29408668 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
|
G
|
Adam33
|
ADAM metallopeptidase domain 33
|
multiple interactions increases expression
|
ISO
|
ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]
|
CTD |
PMID:27784618 |
|
NCBI chr 3:138,715,428...138,736,392
Ensembl chr 3:138,724,046...138,736,347
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
decreases expression
|
EXP
|
Benomyl results in decreased expression of AKT1 mRNA
|
CTD |
PMID:33930522 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
decreases activity
|
ISO EXP
|
Benomyl metabolite results in decreased activity of ALDH2 protein; Benomyl results in decreased activity of ALDH2 protein
|
CTD |
PMID:9585485 PMID:10513990 PMID:11142365 PMID:15331769 PMID:17010440 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219
|
|
G
|
Aldh5a1
|
aldehyde dehydrogenase 5 family, member A1
|
decreases activity
|
EXP
|
Benomyl results in decreased activity of ALDH5A1 protein
|
CTD |
PMID:17010440 |
|
NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714
|
|
G
|
Ampd3
|
adenosine monophosphate deaminase 3
|
decreases expression
|
EXP
|
Benomyl results in decreased expression of AMPD3 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions
|
ISO
|
Benomyl inhibits the reaction [Dihydrotestosterone affects the localization of and results in increased phosphorylation of AR protein]
|
CTD |
PMID:25324206 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
Benomyl inhibits the reaction [BCL2 protein binds to BAX protein]
|
CTD |
PMID:16903866 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions increases phosphorylation
|
ISO
|
Benomyl inhibits the reaction [BCL2 protein binds to BAX protein] Benomyl results in increased phosphorylation of BCL2 protein
|
CTD |
PMID:16903866 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bub1b
|
BUB1 mitotic checkpoint serine/threonine kinase B
|
increases expression
|
ISO
|
Benomyl results in increased expression of BUB1B protein
|
CTD |
PMID:16903866 |
|
NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796
|
|
G
|
Car2
|
carbonic anhydrase 2
|
increases expression
|
EXP
|
Benomyl results in increased expression of CA2 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064
|
|
G
|
Ccl17
|
C-C motif chemokine ligand 17
|
increases expression multiple interactions
|
ISO
|
Benomyl results in increased expression of CCL17 mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]
|
CTD |
PMID:27784618 |
|
NCBI chr19:10,208,120...10,218,340
Ensembl chr19:10,208,120...10,209,895
|
|
G
|
Ccnb1
|
cyclin B1
|
increases response to substance
|
ISO
|
CCNB1 protein results in increased susceptibility to Benomyl
|
CTD |
PMID:11960377 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccnb2
|
cyclin B2
|
increases response to substance
|
ISO
|
CCNB2 protein results in increased susceptibility to Benomyl
|
CTD |
PMID:11960377 |
|
NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682
|
|
G
|
Cd38
|
CD38 molecule
|
decreases expression
|
EXP
|
Benomyl results in decreased expression of CD38 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505
|
|
G
|
Cyp17a1
|
cytochrome P450, family 17, subfamily a, polypeptide 1
|
decreases expression multiple interactions
|
ISO
|
Benomyl results in decreased expression of CYP17A1 mRNA Benomyl results in decreased expression of and results in decreased activity of CYP17A1 protein
|
CTD |
PMID:25324206 |
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974
|
|
G
|
Cyp19a1
|
cytochrome P450, family 19, subfamily a, polypeptide 1
|
increases activity increases expression
|
ISO
|
Benomyl results in increased activity of CYP19A1 protein Benomyl results in increased expression of CYP19A1 mRNA
|
CTD |
PMID:14691014 PMID:25543211 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions increases expression
|
ISO
|
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]
|
CTD |
PMID:27784618 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
increases expression multiple interactions
|
ISO
|
Benomyl results in increased expression of EIF2AK3 protein Acetylcysteine inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]
|
CTD |
PMID:27784618 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
G
|
Ern1
|
endoplasmic reticulum to nucleus signaling 1
|
multiple interactions increases expression
|
ISO
|
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ERN1 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ERN1 protein]
|
CTD |
PMID:27784618 |
|
NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions affects binding
|
ISO
|
Benomyl binds to and results in increased activity of ESR1 protein; Benomyl inhibits the reaction [Estradiol binds to ESR1 protein] Benomyl binds to ESR1 protein
|
CTD |
PMID:14579009 PMID:16626760 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Fgfr4
|
fibroblast growth factor receptor 4
|
increases expression
|
EXP
|
Benomyl results in increased expression of FGFR4 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr17:9,466,686...9,481,423
Ensembl chr17:9,466,692...9,481,389
|
|
G
|
Gipc1
|
GIPC PDZ domain containing family, member 1
|
increases expression
|
EXP
|
Benomyl results in increased expression of GIPC1 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr19:41,380,125...41,392,078
Ensembl chr19:41,380,125...41,391,725
|
|
G
|
Glyat
|
glycine-N-acyltransferase
|
increases expression
|
EXP
|
Benomyl results in increased expression of GLYAT mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 1:219,128,798...219,149,615
Ensembl chr 1:219,128,811...219,150,774
|
|
G
|
Hdac1
|
histone deacetylase 1
|
decreases activity
|
ISO
|
Benomyl results in decreased activity of HDAC1 protein
|
CTD |
PMID:25543211 |
|
NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression multiple interactions
|
ISO
|
Benomyl results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]
|
CTD |
PMID:27784618 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Hspb1
|
heat shock protein family B (small) member 1
|
increases expression
|
EXP
|
Benomyl results in increased expression of HSPB1 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301
|
|
G
|
Ifnb1
|
interferon beta 1
|
multiple interactions
|
ISO
|
Benomyl inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]
|
CTD |
PMID:18177342 |
|
NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487
|
|
G
|
Itga5
|
integrin subunit alpha 5
|
decreases expression
|
ISO
|
Benomyl results in decreased expression of ITGA5 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr 7:136,358,097...136,381,305
Ensembl chr 7:136,358,097...136,381,305
|
|
G
|
Itgb1
|
integrin subunit beta 1
|
decreases expression
|
ISO
|
Benomyl results in decreased expression of ITGB1 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269
|
|
G
|
Klk1c10
|
kallikrein 1-related peptidase C10
|
multiple interactions
|
ISO
|
Benomyl inhibits the reaction [Dihydrotestosterone results in increased secretion of KLK3 protein]
|
CTD |
PMID:25324206 |
|
NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586
|
|
G
|
Klk1c8
|
kallikrein 1-related peptidase C8
|
decreases expression
|
EXP
|
Benomyl results in decreased expression of KLK1B21 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 1:103,684,293...103,688,155
Ensembl chr 1:103,684,293...103,688,155
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases expression
|
EXP
|
Benomyl results in increased expression of MAPK8 mRNA
|
CTD |
PMID:33930522 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mir21
|
microRNA 21
|
decreases expression
|
EXP
|
Benomyl results in decreased expression of MIR21 mRNA
|
CTD |
PMID:33930522 |
|
NCBI chr10:71,902,600...71,902,691
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases expression multiple interactions increases expression
|
ISO
|
Benomyl results in decreased expression of MMP2 mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]
|
CTD |
PMID:25530041 PMID:27784618 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
decreases expression
|
EXP ISO
|
Benomyl results in decreased expression of MMP9 protein Benomyl results in decreased expression of MMP9 mRNA
|
CTD |
PMID:10026946 PMID:25530041 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mmrn1
|
multimerin 1
|
increases expression
|
EXP
|
Benomyl results in increased expression of MMRN1 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 4:91,205,462...91,280,862
Ensembl chr 4:91,233,240...91,280,861
|
|
G
|
Msmb
|
microseminoprotein, beta
|
increases expression
|
EXP
|
Benomyl results in increased expression of MSMB mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr16:7,372,803...7,393,406
Ensembl chr16:7,372,819...7,393,405
|
|
G
|
Mt2
|
metallothionein 2
|
increases expression
|
EXP
|
Benomyl results in increased expression of MT2A mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
Benomyl inhibits the reaction [Lipopolysaccharides results in increased activity of NFKB1 protein]
|
CTD |
PMID:17015962 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
Benomyl inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Or10al27
|
olfactory receptor family 10 subfamily AL member 27
|
increases expression
|
EXP
|
Benomyl results in increased expression of OR10AL27 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr20:794,490...795,491
Ensembl chr20:743,522...816,076
|
|
G
|
Or13p4
|
olfactory receptor family 13 subfamily P member 4
|
increases expression
|
EXP
|
Benomyl results in increased expression of OR13P4 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 5:137,502,182...137,503,129
Ensembl chr 5:137,502,182...137,503,129
|
|
G
|
Or9s23b
|
olfactory receptor family 9 subfamily S member 23B
|
increases expression
|
EXP
|
Benomyl results in increased expression of OR9S23B mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 9:100,564,786...100,565,757
Ensembl chr 9:100,564,786...100,565,757
|
|
G
|
Ormdl3
|
ORMDL sphingolipid biosynthesis regulator 3
|
multiple interactions increases expression
|
ISO
|
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CXCL8 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]
|
CTD |
PMID:27784618 |
|
NCBI chr10:84,086,317...84,092,673
Ensembl chr10:84,086,317...84,093,548
|
|
G
|
Park7
|
Parkinsonism associated deglycase
|
decreases activity
|
ISO
|
Benomyl results in decreased activity of PARK7 protein
|
CTD |
PMID:36842454 |
|
NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage
|
ISO
|
Benomyl results in increased cleavage of PARP1 protein
|
CTD |
PMID:16903866 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
decreases expression
|
ISO
|
Benomyl results in decreased expression of PLAU mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
increases expression
|
EXP
|
Benomyl results in increased expression of PTEN mRNA
|
CTD |
PMID:33930522 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases expression
|
EXP
|
Benomyl results in increased expression of RELA mRNA
|
CTD |
PMID:33930522 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
decreases expression
|
EXP
|
Benomyl results in decreased expression of SCD1 mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785
|
|
G
|
Serpine2
|
serpin family E member 2
|
increases expression
|
ISO
|
Benomyl results in increased expression of SERPINE2 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202
|
|
G
|
Sh2d4a
|
SH2 domain containing 4A
|
increases expression
|
EXP
|
Benomyl results in increased expression of SH2D4A mRNA
|
CTD |
PMID:15885261 |
|
NCBI chr16:26,106,721...26,176,069
Ensembl chr16:26,106,730...26,175,974
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
increases expression
|
ISO
|
Benomyl results in increased expression of TIMP1 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
increases expression
|
ISO
|
Benomyl results in increased expression of TIMP2 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Tnf
|
tumor necrosis factor
|
decreases expression
|
EXP
|
Benomyl results in decreased expression of TNF mRNA
|
CTD |
PMID:33930522 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
affects activity
|
ISO
|
Benomyl affects the activity of TP53 protein
|
CTD |
PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tslp
|
thymic stromal lymphopoietin
|
increases expression multiple interactions
|
ISO
|
Benomyl results in increased expression of TSLP mRNA ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]
|
CTD |
PMID:27784618 |
|
NCBI chr18:24,723,990...24,728,419
Ensembl chr18:24,720,257...24,728,420
|
|
G
|
Uba1
|
ubiquitin-like modifier activating enzyme 1
|
multiple interactions
|
ISO
|
Benomyl results in increased activity of and results in increased ubiquitination of UBA1 protein
|
CTD |
PMID:25714994 |
|
NCBI chr X:4,062,216...4,084,192
Ensembl chr X:4,062,182...4,084,246
|
|
G
|
Vasp
|
vasodilator-stimulated phosphoprotein
|
multiple interactions
|
EXP
|
Benomyl inhibits the reaction [Nitroglycerin results in increased phosphorylation of VASP protein]; Benomyl inhibits the reaction [Pentaerythritol Tetranitrate results in increased phosphorylation of VASP protein]
|
CTD |
PMID:15331769 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650
|
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
[NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein
|
CTD |
PMID:33728909 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
|
G
|
Ace
|
angiotensin I converting enzyme
|
affects expression
|
EXP
|
candesartan affects the expression of ACE mRNA
|
CTD |
PMID:18796534 |
|
NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942
|
|
G
|
Ace2
|
angiotensin converting enzyme 2
|
decreases expression
|
EXP
|
candesartan results in decreased expression of ACE2 mRNA
|
CTD |
PMID:18796534 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
multiple interactions increases expression decreases expression
|
ISO
|
[candesartan co-treated with Fenofibrate] results in increased expression of ADIPOQ protein; candesartan promotes the reaction [Ramipril results in increased expression of ADIPOQ]; Ramipril promotes the reaction [candesartan results in increased expression of ADIPOQ] candesartan results in increased expression of ADIPOQ; candesartan results in increased expression of ADIPOQ protein candesartan results in decreased expression of ADIPOQ
|
CTD |
PMID:16443859 PMID:17483542 PMID:19059660 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
G
|
Agt
|
angiotensinogen
|
multiple interactions
|
ISO EXP
|
candesartan inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]; candesartan inhibits the reaction [AGT protein results in increased chemical synthesis of Nitric Oxide]; candesartan inhibits the reaction [AGT protein results in increased chemical synthesis of Reactive Oxygen Species] candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; candesartan inhibits the reaction [AGT protein results in increased expression of ENG mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of ENG protein]; candesartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH protein]; candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; candesartan inhibits the reaction [Folic Acid results in increased localization of [AGT protein binds to AGTR1A protein]] candesartan inhibits the reaction [AGT protein modified form results in increased expression of COL1A2 protein]; candesartan inhibits the reaction [AGT results in increased expression of NOS3 protein]; candesartan inhibits the reaction [AGT results in increased expression of PTGS2 protein]; candesartan inhibits the reaction [AGT results in increased expression of VEGFA protein]
|
CTD |
PMID:10525314 PMID:11729239 PMID:12065685 PMID:15539634 PMID:15728788 PMID:18551021 PMID:18679781 PMID:23300732 More...
|
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
multiple interactions decreases expression
|
ISO EXP
|
candesartan binds to and results in decreased activity of AGTR1 protein candesartan inhibits the reaction [Folic Acid results in increased localization of [AGT protein binds to AGTR1A protein]] candesartan results in decreased expression of AGTR1A mRNA
|
CTD |
PMID:15728788 PMID:18796534 PMID:21474964 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Agtr2
|
angiotensin II receptor, type 2
|
multiple interactions decreases expression
|
ISO EXP
|
[PD 123319 binds to and results in decreased activity of AGTR2 protein] inhibits the reaction [candesartan results in increased expression of NOS3 protein] candesartan results in decreased expression of AGTR2 mRNA
|
CTD |
PMID:18551021 PMID:18796534 |
|
NCBI chr X:116,914,320...116,918,504
Ensembl chr X:116,913,656...116,918,745
|
|
G
|
Akap11
|
A-kinase anchoring protein 11
|
increases expression
|
EXP
|
candesartan results in increased expression of AKAP11 mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr15:60,320,839...60,365,480
Ensembl chr15:60,320,839...60,365,335
|
|
G
|
Akr1b1
|
aldo-keto reductase family 1 member B1
|
decreases expression
|
EXP
|
candesartan results in decreased expression of AKR1B1 mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
decreases phosphorylation
|
EXP
|
candesartan results in decreased phosphorylation of AKT1 protein
|
CTD |
PMID:17922026 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Atg5
|
autophagy related 5
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Galactose results in decreased expression of ATG5 mRNA]
|
CTD |
PMID:34906534 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821
|
|
G
|
Atp2a2
|
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 protein]
|
CTD |
PMID:16723803 |
|
NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
EXP
|
candesartan results in increased expression of BAX mRNA; candesartan results in increased expression of BAX protein
|
CTD |
PMID:11409658 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bdkrb2
|
bradykinin receptor B2
|
decreases expression
|
EXP
|
candesartan results in decreased expression of BDKRB2 mRNA
|
CTD |
PMID:18796534 |
|
NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:130,237,255...130,267,209
|
|
G
|
Becn1
|
beclin 1
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Galactose results in decreased expression of BECN1 mRNA]
|
CTD |
PMID:34906534 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Ca1
|
carbonic anhydrase 1
|
decreases activity
|
ISO
|
candesartan results in decreased activity of CA1 protein
|
CTD |
PMID:11196069 |
|
NCBI chr 2:88,550,681...88,593,454
Ensembl chr 2:88,495,475...88,593,454
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]
|
CTD |
PMID:23300732 PMID:30368989 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Galactose results in decreased activity of CAT protein]
|
CTD |
PMID:34906534 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
decreases expression
|
EXP
|
candesartan results in decreased expression of CCN2 mRNA
|
CTD |
PMID:16685210 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
G
|
Cd36
|
CD36 molecule
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
T 0070907 inhibits the reaction [candesartan results in increased expression of CD36 mRNA] candesartan results in decreased expression of CD36 mRNA
|
CTD |
PMID:14871019 PMID:22124178 |
|
NCBI chr 4:18,209,088...18,302,142
|
|
G
|
Cd40lg
|
CD40 ligand
|
multiple interactions decreases expression
|
ISO
|
candesartan promotes the reaction [Fenofibrate results in decreased expression of CD40LG protein]; Fenofibrate promotes the reaction [candesartan results in decreased expression of CD40LG protein]
|
CTD |
PMID:16443859 |
|
NCBI chr X:140,164,341...140,176,057
Ensembl chr X:140,164,302...140,176,475
|
|
G
|
Col1a2
|
collagen type I alpha 2 chain
|
multiple interactions
|
ISO
|
candesartan inhibits the reaction [AGT protein modified form results in increased expression of COL1A2 protein]
|
CTD |
PMID:11729239 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995
|
|
G
|
Crispld2
|
cysteine-rich secretory protein LCCL domain containing 2
|
decreases expression
|
EXP
|
candesartan results in decreased expression of CRISPLD2 mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr19:64,961,764...65,020,099
Ensembl chr19:64,961,771...65,020,349
|
|
G
|
Crp
|
C-reactive protein
|
multiple interactions decreases expression
|
ISO
|
candesartan promotes the reaction [Fenofibrate results in decreased expression of CRP protein]; Fenofibrate promotes the reaction [candesartan results in decreased expression of CRP protein]
|
CTD |
PMID:14620923 PMID:16443859 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514
|
|
G
|
Cxcl1
|
C-X-C motif chemokine ligand 1
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Indomethacin results in increased expression of CXCL1 protein]
|
CTD |
PMID:17763956 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811
|
|
G
|
Cyba
|
cytochrome b-245 alpha chain
|
decreases expression multiple interactions
|
ISO EXP
|
candesartan results in decreased expression of CYBA protein candesartan results in decreased expression of CYBA; candesartan results in decreased expression of CYBA mRNA Amlodipine promotes the reaction [candesartan results in decreased expression of CYBA]; candesartan inhibits the reaction [Streptozocin results in increased expression of CYBA mRNA]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of CYBA]
|
CTD |
PMID:16139267 PMID:16685210 PMID:18551021 PMID:21107329 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214
|
|
G
|
Cybb
|
cytochrome b-245 beta chain
|
multiple interactions decreases expression
|
EXP
|
Amlodipine promotes the reaction [candesartan results in decreased expression of CYBB]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of CYBB] candesartan results in decreased expression of CYBB; candesartan results in decreased expression of CYBB mRNA
|
CTD |
PMID:16685210 PMID:21107329 |
|
NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065
|
|
G
|
Cyp11b3
|
cytochrome P450, family 11, subfamily b, polypeptide 3
|
affects response to substance decreases expression
|
ISO EXP
|
CYP11B2 protein polymorphism affects the susceptibility to candesartan candesartan results in decreased expression of CYP11B2 mRNA
|
CTD |
PMID:12065207 PMID:18796534 |
|
NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921
|
|
G
|
Eng
|
endoglin
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [AGT protein results in increased expression of ENG mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of ENG protein]
|
CTD |
PMID:15539634 |
|
NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:36,326,202...36,370,933
|
|
G
|
Faslg
|
Fas ligand
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Daunorubicin results in increased expression of FASLG protein]
|
CTD |
PMID:16324756 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [[Acetaldehyde co-treated with Cyanamide] results in increased expression of FOS protein]; candesartan inhibits the reaction [Acetaldehyde promotes the reaction [Cyanamide results in increased expression of FOS protein]]
|
CTD |
PMID:26298003 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Foxo1
|
forkhead box O1
|
multiple interactions
|
ISO
|
[GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of FOXO1 protein]; candesartan inhibits the reaction [Palmitic Acid results in decreased phosphorylation of FOXO1 protein]
|
CTD |
PMID:21255808 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
G
|
Gcg
|
glucagon
|
multiple interactions
|
ISO
|
[GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of FOXO1 protein]; [GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of IRS2 protein]
|
CTD |
PMID:21255808 |
|
NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Galactose results in decreased expression of GDNF mRNA]
|
CTD |
PMID:34906534 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Hspe1
|
heat shock protein family E (Hsp10) member 1
|
decreases expression
|
EXP
|
candesartan results in decreased expression of HSPE1 mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]
|
CTD |
PMID:16139267 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Id1
|
inhibitor of DNA binding 1
|
decreases expression
|
EXP
|
candesartan results in decreased expression of ID1 mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of IL1B protein]; candesartan inhibits the reaction [Gentamicins results in increased expression of IL1B protein]
|
CTD |
PMID:30368989 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [AGT protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; candesartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]
|
CTD |
PMID:10525314 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Irs2
|
insulin receptor substrate 2
|
multiple interactions
|
ISO
|
[GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of IRS2 protein]; candesartan inhibits the reaction [Palmitic Acid results in decreased phosphorylation of IRS2 protein]
|
CTD |
PMID:21255808 |
|
NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543
|
|
G
|
Kcnn4
|
potassium calcium-activated channel subfamily N member 4
|
decreases expression
|
ISO
|
candesartan decreases expression of KCNN4 mRNA and protein in CD4-positive, alpha-beta T cell
|
RGD |
PMID:29388859 |
RGD:329955575 |
NCBI chr 1:89,084,306...89,102,279
Ensembl chr 1:89,086,814...89,102,275
|
|
G
|
Klk1
|
kallikrein 1
|
decreases expression
|
EXP
|
candesartan results in decreased expression of KLK1 mRNA
|
CTD |
PMID:18796534 |
|
NCBI chr 1:103,779,152...103,783,270
Ensembl chr 1:103,779,164...103,783,270
|
|
G
|
Lep
|
leptin
|
multiple interactions increases response to substance decreases expression
|
ISO EXP
|
candesartan promotes the reaction [Ramipril results in increased expression of LEP]; Ramipril promotes the reaction [candesartan results in increased expression of LEP] LEP protein results in increased susceptibility to candesartan candesartan results in decreased expression of LEP
|
CTD |
PMID:17483542 PMID:19059660 PMID:21287150 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]
|
CTD |
PMID:23300732 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]
|
CTD |
PMID:23300732 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
ISO
|
candesartan inhibits the reaction [Isoproterenol results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:20562518 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mmp13
|
matrix metallopeptidase 13
|
increases expression
|
EXP
|
candesartan results in increased expression of MMP13 protein
|
CTD |
PMID:19047581 |
|
NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105
|
|
G
|
Mmp15
|
matrix metallopeptidase 15
|
increases expression
|
EXP
|
candesartan results in increased expression of MMP15 mRNA
|
CTD |
PMID:19047581 |
|
NCBI chr19:9,669,506...9,691,000
Ensembl chr19:9,669,506...9,691,000
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
decreases expression
|
EXP
|
candesartan results in decreased expression of MMP9 mRNA; candesartan results in decreased expression of MMP9 protein
|
CTD |
PMID:19047581 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Indomethacin results in increased activity of MPO protein]
|
CTD |
PMID:17763956 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Streptozocin results in increased expression of NOS2 protein]
|
CTD |
PMID:16139267 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions
|
ISO EXP
|
[PD 123319 binds to and results in decreased activity of AGTR2 protein] inhibits the reaction [candesartan results in increased expression of NOS3 protein] candesartan inhibits the reaction [Streptozocin results in increased expression of NOS3 mRNA]; candesartan inhibits the reaction [Streptozocin results in increased expression of NOS3 protein] candesartan inhibits the reaction [AGT results in increased expression of NOS3 protein]
|
CTD |
PMID:12065685 PMID:16139267 PMID:18551021 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Nox1
|
NADPH oxidase 1
|
multiple interactions decreases expression
|
EXP
|
Amlodipine promotes the reaction [candesartan results in decreased expression of NOX1]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of NOX1]
|
CTD |
PMID:21107329 |
|
NCBI chr X:101,572,338...101,625,571
Ensembl chr X:101,572,340...101,595,520
|
|
G
|
Nox4
|
NADPH oxidase 4
|
decreases expression multiple interactions
|
ISO EXP
|
candesartan results in decreased expression of NOX4 protein Amlodipine promotes the reaction [candesartan results in decreased expression of NOX4]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of NOX4]
|
CTD |
PMID:18551021 PMID:21107329 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
G
|
Nppa
|
natriuretic peptide A
|
increases expression increases secretion
|
EXP
|
candesartan results in increased expression of NPPA mRNA; candesartan results in increased expression of NPPA protein candesartan results in increased secretion of NPPA protein
|
CTD |
PMID:14639023 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493
|
|
G
|
Nr3c2
|
nuclear receptor subfamily 3, group C, member 2
|
affects expression
|
EXP
|
candesartan affects the expression of NR3C2 mRNA
|
CTD |
PMID:18796534 |
|
NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078
|
|
G
|
Or4b1d
|
olfactory receptor family 4 subfamily B member 1D
|
increases expression
|
EXP
|
candesartan results in increased expression of OR4B1D mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr 3:96,663,710...96,664,636
Ensembl chr 3:96,663,710...96,664,636
|
|
G
|
Pln
|
phospholamban
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein]
|
CTD |
PMID:16723803 |
|
NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241
|
|
G
|
Pmch
|
pro-melanin-concentrating hormone
|
decreases expression
|
EXP
|
candesartan results in decreased expression of PMCH mRNA
|
CTD |
PMID:21287150 |
|
NCBI chr 7:24,399,404...24,400,720
Ensembl chr 7:24,399,404...24,400,720
|
|
G
|
Ptgis
|
prostaglandin I2 synthase
|
decreases expression
|
EXP
|
candesartan results in decreased expression of PTGIS mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr 3:176,347,589...176,383,251
Ensembl chr 3:176,335,437...176,407,650
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO
|
candesartan inhibits the reaction [AGT results in increased expression of PTGS2 protein]
|
CTD |
PMID:12065685 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Pthlh
|
parathyroid hormone-like hormone
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH protein]
|
CTD |
PMID:15728788 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP
|
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased phosphorylation of RELA protein]; candesartan inhibits the reaction [Gentamicins results in increased phosphorylation of RELA protein]
|
CTD |
PMID:30368989 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ren
|
renin
|
multiple interactions increases expression decreases activity
|
ISO EXP
|
candesartan inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone] candesartan results in increased expression of REN mRNA candesartan results in decreased activity of REN protein
|
CTD |
PMID:18679781 PMID:18796534 PMID:19047581 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
Ryr2
|
ryanodine receptor 2
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Isoproterenol results in increased phosphorylation of RYR2 protein]
|
CTD |
PMID:16723803 |
|
NCBI chr17:63,081,527...63,667,141
Ensembl chr17:63,081,527...63,666,705
|
|
G
|
Slc22a25
|
solute carrier family 22, member 25
|
multiple interactions
|
ISO
|
candesartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]
|
CTD |
PMID:17132213 |
|
NCBI chr 1:214,767,837...214,956,535
Ensembl chr 1:214,767,837...214,862,340
|
|
G
|
Smad3
|
SMAD family member 3
|
multiple interactions
|
EXP
|
[benazepril co-treated with candesartan] results in decreased expression of SMAD3 protein
|
CTD |
PMID:19487956 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP
|
[benazepril co-treated with candesartan] results in decreased expression of TGFB1 protein; candesartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of TGFB1 mRNA]
|
CTD |
PMID:16778335 PMID:19487956 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Thbd
|
thrombomodulin
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein]
|
CTD |
PMID:16778335 |
|
NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:156,306,632...156,320,582
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
decreases expression
|
EXP
|
candesartan results in decreased expression of TIMP2 mRNA
|
CTD |
PMID:19047581 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Timp3
|
TIMP metallopeptidase inhibitor 3
|
decreases expression
|
EXP
|
candesartan results in decreased expression of TIMP3 mRNA
|
CTD |
PMID:19047581 |
|
NCBI chr 7:19,408,539...19,459,558
Ensembl chr 7:19,409,631...19,459,547
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions decreases expression
|
ISO EXP
|
candesartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; candesartan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; T 0070907 inhibits the reaction [candesartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] candesartan results in decreased expression of TNF mRNA [candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of TNF protein]; candesartan inhibits the reaction [Galactose results in increased expression of TNF mRNA]; candesartan inhibits the reaction [Gentamicins results in increased expression of TNF protein]
|
CTD |
PMID:22124178 PMID:30368989 PMID:34906534 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression
|
EXP
|
candesartan results in increased expression of TP53 mRNA; candesartan results in increased expression of TP53 protein
|
CTD |
PMID:11409658 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Ucp2
|
uncoupling protein 2
|
decreases expression multiple interactions
|
EXP ISO
|
candesartan results in decreased expression of UCP2 mRNA candesartan inhibits the reaction [Palmitic Acid results in increased expression of UCP2 mRNA]
|
CTD |
PMID:16685210 PMID:20667613 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
EXP
|
candesartan inhibits the reaction [Streptozocin results in increased expression of VCAM1 protein]
|
CTD |
PMID:16139267 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
decreases expression multiple interactions
|
ISO
|
candesartan results in decreased expression of VEGFA candesartan inhibits the reaction [VEGFA protein results in increased expression of VEGFA mRNA] candesartan inhibits the reaction [AGT results in increased expression of VEGFA protein]
|
CTD |
PMID:12065685 PMID:16202860 PMID:16675585 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Ybx3
|
Y box binding protein 3
|
decreases expression
|
EXP
|
candesartan results in decreased expression of YBX3 mRNA
|
CTD |
PMID:14871019 |
|
NCBI chr 4:166,861,180...166,884,532
Ensembl chr 4:166,861,181...166,884,691
|
|
|
G
|
Abi2
|
abl-interactor 2
|
increases expression
|
EXP
|
carbendazim results in increased expression of ABI2 mRNA
|
CTD |
PMID:22952946 |
|
NCBI chr 9:69,321,072...69,490,630
Ensembl chr 9:69,321,150...69,490,597
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
increases expression
|
ISO
|
carbendazim results in increased expression of ACACA mRNA
|
CTD |
PMID:26071454 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Ache
|
acetylcholinesterase
|
multiple interactions
|
EXP
|
[carbendazim co-treated with mancozeb] results in increased activity of ACHE protein
|
CTD |
PMID:33217513 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
G
|
Agpat2
|
1-acylglycerol-3-phosphate O-acyltransferase 2
|
increases expression
|
ISO
|
carbendazim results in increased expression of AGPAT2 mRNA
|
CTD |
PMID:26071454 |
|
NCBI chr 3:29,814,924...29,826,569
Ensembl chr 3:29,814,924...29,826,581
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions affects localization
|
ISO
|
AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein] carbendazim affects the localization of AHR protein
|
CTD |
PMID:27286660 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Alb
|
albumin
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of ALB protein
|
CTD |
PMID:35437878 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Anxa10
|
annexin A10
|
increases expression
|
ISO
|
carbendazim results in increased expression of ANXA10 mRNA
|
CTD |
PMID:32194361 |
|
NCBI chr16:32,505,025...32,571,961
Ensembl chr16:32,467,126...32,571,961
|
|
G
|
Arg1
|
arginase 1
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of ARG1 mRNA
|
CTD |
PMID:32194361 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Bag1
|
BAG cochaperone 1
|
increases expression
|
EXP
|
carbendazim results in increased expression of BAG1 mRNA
|
CTD |
PMID:22952946 |
|
NCBI chr 5:60,864,476...60,877,059
Ensembl chr 5:60,864,476...60,878,161
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
EXP
|
carbendazim results in increased expression of BAX mRNA; carbendazim results in increased expression of BAX protein
|
CTD |
PMID:35437878 PMID:35513110 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of BCL2 mRNA
|
CTD |
PMID:35437878 PMID:35513110 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l14
|
Bcl2-like 14
|
increases expression
|
EXP
|
carbendazim results in increased expression of BCL2L14 mRNA
|
CTD |
PMID:22952946 |
|
NCBI chr 4:168,948,919...168,989,450
Ensembl chr 4:168,948,946...168,990,079
|
|
G
|
Bub1b
|
BUB1 mitotic checkpoint serine/threonine kinase B
|
increases activity
|
ISO
|
carbendazim results in increased activity of BUB1B protein
|
CTD |
PMID:37506866 |
|
NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796
|
|
G
|
Casp3
|
caspase 3
|
increases activity multiple interactions increases expression
|
ISO EXP
|
carbendazim results in increased activity of CASP3 protein Chitosan inhibits the reaction [carbendazim results in increased expression of CASP3 protein]
|
CTD |
PMID:30851412 PMID:35705592 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cat
|
catalase
|
decreases activity decreases expression multiple interactions
|
EXP
|
carbendazim results in decreased activity of CAT protein carbendazim results in decreased expression of CAT protein [Chlorpyrifos co-treated with carbendazim] results in decreased activity of CAT protein; Chitosan inhibits the reaction [carbendazim results in decreased expression of CAT protein]
|
CTD |
PMID:27268782 PMID:35513110 PMID:35705592 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccnb1
|
cyclin B1
|
increases expression
|
ISO
|
carbendazim results in increased expression of CCNB1 protein
|
CTD |
PMID:37506866 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Clca2
|
chloride channel accessory 2
|
multiple interactions
|
EXP
|
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of CLCA2 mRNA
|
CTD |
PMID:22382377 |
|
NCBI chr 2:236,655,419...236,682,669
Ensembl chr 2:236,639,545...236,685,129
|
|
G
|
Cldn11
|
claudin 11
|
multiple interactions
|
EXP
|
[carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein
|
CTD |
PMID:28576679 |
|
NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539
|
|
G
|
Clu
|
clusterin
|
decreases expression increases expression
|
EXP
|
carbendazim results in decreased expression of CLU mRNA carbendazim results in increased expression of CLU mRNA
|
CTD |
PMID:22952946 PMID:27466211 |
|
NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860
|
|
G
|
Cyp19a1
|
cytochrome P450, family 19, subfamily a, polypeptide 1
|
increases activity increases expression
|
ISO
|
carbendazim results in increased activity of CYP19A1 protein carbendazim results in increased expression of CYP19A1 mRNA
|
CTD |
PMID:14691014 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression multiple interactions
|
ISO EXP
|
carbendazim results in increased expression of CYP1A1 mRNA; carbendazim results in increased expression of CYP1A1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]; AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein]; salicylamide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]
|
CTD |
PMID:10103034 PMID:21784029 PMID:27286660 PMID:32194361 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases expression
|
ISO
|
carbendazim results in increased expression of CYP1A2 mRNA; carbendazim results in increased expression of CYP1A2 protein
|
CTD |
PMID:21784029 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases expression
|
ISO
|
carbendazim results in increased expression of CYP2B6 mRNA
|
CTD |
PMID:22310298 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of CYP2C19 protein
|
CTD |
PMID:32194361 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
decreases activity
|
ISO
|
carbendazim results in decreased activity of CYP2D6 protein
|
CTD |
PMID:20183062 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression
|
ISO
|
carbendazim results in increased expression of CYP3A4 mRNA
|
CTD |
PMID:22310298 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of CYP7A1 mRNA; carbendazim results in decreased expression of CYP7A1 protein
|
CTD |
PMID:32194361 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
increases expression
|
ISO
|
carbendazim results in increased expression of DGAT1 mRNA
|
CTD |
PMID:26071454 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Dgat2
|
diacylglycerol O-acyltransferase 2
|
increases expression
|
ISO
|
carbendazim results in increased expression of DGAT2 mRNA
|
CTD |
PMID:26071454 |
|
NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566
|
|
G
|
Dnaaf11
|
dynein axonemal assembly factor 11
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of DNAAF11 mRNA
|
CTD |
PMID:27466211 |
|
NCBI chr 7:100,033,843...100,134,979
Ensembl chr 7:100,034,202...100,135,179
|
|
G
|
Dpp7
|
dipeptidylpeptidase 7
|
multiple interactions
|
EXP
|
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of DPP7 mRNA
|
CTD |
PMID:22382377 |
|
NCBI chr 3:28,563,240...28,567,492
Ensembl chr 3:28,563,240...28,567,492
|
|
G
|
Esr1
|
estrogen receptor 1
|
decreases expression affects localization
|
EXP ISO
|
carbendazim results in decreased expression of ESR1 mRNA carbendazim affects the localization of ESR1 protein
|
CTD |
PMID:28576679 PMID:37506866 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Esr2
|
estrogen receptor 2
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of ESR2 mRNA
|
CTD |
PMID:28576679 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709
|
|
G
|
Fabp9
|
fatty acid binding protein 9
|
multiple interactions decreases expression
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein] carbendazim results in decreased expression of FABP9 mRNA; carbendazim results in decreased expression of FABP9 protein
|
CTD |
PMID:33965443 |
|
NCBI chr 2:93,499,136...93,503,267
Ensembl chr 2:93,499,134...93,503,260
|
|
G
|
Fank1
|
fibronectin type III and ankyrin repeat domains 1
|
increases expression
|
EXP
|
carbendazim results in increased expression of FANK1 mRNA
|
CTD |
PMID:22952946 |
|
NCBI chr 1:198,007,496...198,114,790
Ensembl chr 1:198,007,547...198,115,561
|
|
G
|
Foxa2
|
forkhead box A2
|
increases expression
|
ISO
|
carbendazim results in increased expression of FOXA2 mRNA
|
CTD |
PMID:26071454 |
|
NCBI chr 3:155,923,305...155,927,508
Ensembl chr 3:155,923,307...155,928,757
|
|
G
|
Fshb
|
follicle stimulating hormone subunit beta
|
decreases expression multiple interactions
|
EXP
|
carbendazim results in decreased expression of FSHB protein Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072
|
|
G
|
G6pc1
|
glucose-6-phosphatase catalytic subunit 1
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of G6PC1 mRNA
|
CTD |
PMID:32194361 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033
|
|
G
|
Gfap
|
glial fibrillary acidic protein
|
increases expression
|
EXP
|
carbendazim results in increased expression of GFAP protein
|
CTD |
PMID:35513110 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
multiple interactions
|
EXP
|
[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein
|
CTD |
PMID:28576679 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
increases secretion multiple interactions
|
EXP
|
carbendazim results in increased secretion of GOT1 protein Chitosan inhibits the reaction [carbendazim results in increased secretion of GOT1 protein]
|
CTD |
PMID:35705592 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
increases expression increases secretion multiple interactions
|
EXP
|
carbendazim results in increased expression of GPT protein carbendazim results in increased secretion of GPT protein Chitosan inhibits the reaction [carbendazim results in increased secretion of GPT protein]
|
CTD |
PMID:35437878 PMID:35705592 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions decreases expression
|
EXP
|
Chitosan inhibits the reaction [carbendazim results in decreased expression of HMOX1 mRNA]
|
CTD |
PMID:35705592 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Ift81
|
intraflagellar transport 81
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of IFT81 mRNA
|
CTD |
PMID:22952946 PMID:27466211 |
|
NCBI chr12:39,618,559...39,697,971
Ensembl chr12:39,618,651...39,697,962
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions decreases expression
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]
|
CTD |
PMID:33965443 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression
|
ISO EXP
|
carbendazim results in increased expression of IL1B mRNA; carbendazim results in increased expression of IL1B protein
|
CTD |
PMID:26071454 PMID:35513110 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
increases expression multiple interactions
|
ISO EXP
|
carbendazim results in increased expression of IL6 mRNA; carbendazim results in increased expression of IL6 protein Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]
|
CTD |
PMID:26071454 PMID:33965443 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Itga5
|
integrin subunit alpha 5
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of ITGA5 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr 7:136,358,097...136,381,305
Ensembl chr 7:136,358,097...136,381,305
|
|
G
|
Itgb1
|
integrin subunit beta 1
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of ITGB1 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
multiple interactions increases expression
|
EXP
|
Chitosan inhibits the reaction [carbendazim results in increased expression of KEAP1 mRNA]
|
CTD |
PMID:35705592 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Lhb
|
luteinizing hormone subunit beta
|
decreases expression multiple interactions
|
EXP
|
carbendazim results in decreased expression of LHB protein Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445
|
|
G
|
Loxl1
|
lysyl oxidase-like 1
|
multiple interactions increases expression
|
EXP
|
2,5-hexanedione promotes the reaction [carbendazim results in increased expression of LOXL1 protein]; [carbendazim co-treated with 2,5-hexanedione] results in decreased expression of LOXL1 mRNA
|
CTD |
PMID:22382377 |
|
NCBI chr 8:67,587,636...67,612,224
Ensembl chr 8:67,587,636...67,612,224
|
|
G
|
Lpl
|
lipoprotein lipase
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of LPL protein
|
CTD |
PMID:30496565 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107
|
|
G
|
Macrod1
|
mono-ADP ribosylhydrolase 1
|
multiple interactions
|
EXP
|
[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of MACROD1 mRNA
|
CTD |
PMID:22382377 |
|
NCBI chr 1:213,675,413...213,831,571
Ensembl chr 1:213,675,406...213,816,348
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
affects localization
|
ISO
|
carbendazim affects the localization of MAPK1 protein modified form
|
CTD |
PMID:37506866 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
affects localization
|
ISO
|
carbendazim affects the localization of MAPK3 protein modified form
|
CTD |
PMID:37506866 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases expression
|
EXP
|
carbendazim results in increased expression of MAPK8 mRNA
|
CTD |
PMID:35513110 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mfap3l
|
microfibril associated protein 3 like
|
increases expression
|
EXP
|
carbendazim results in increased expression of MFAP3L mRNA
|
CTD |
PMID:22952946 |
|
NCBI chr16:34,422,490...34,465,544
Ensembl chr16:34,426,696...34,441,709
|
|
G
|
Mir128-1
|
microRNA 128-1
|
increases expression
|
EXP
|
carbendazim results in increased expression of MIR128-1 mRNA
|
CTD |
PMID:32418910 |
|
NCBI chr13:42,251,884...42,251,965
Ensembl chr13:42,251,884...42,251,965
|
|
G
|
Mir423
|
microRNA 423
|
increases expression
|
EXP
|
carbendazim results in increased expression of MIR423 mRNA
|
CTD |
PMID:32418910 |
|
NCBI chr10:62,412,272...62,412,350
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of MMP2 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of MMP9 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions increases activity
|
EXP
|
[Chlorpyrifos co-treated with carbendazim] results in increased activity of MPO protein carbendazim results in increased activity of MPO protein
|
CTD |
PMID:27268782 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
carbendazim results in increased expression of NFE2L2 protein Chitosan inhibits the reaction [carbendazim results in decreased expression of NFE2L2 mRNA]
|
CTD |
PMID:30851412 PMID:35705592 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Chitosan inhibits the reaction [carbendazim results in increased expression of NOS2 protein]
|
CTD |
PMID:33965443 PMID:35705592 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
carbendazim inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Ocln
|
occludin
|
decreases expression multiple interactions
|
EXP
|
carbendazim results in decreased expression of OCLN protein Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
|
|
G
|
Pim1
|
Pim-1 proto-oncogene, serine/threonine kinase
|
increases expression
|
EXP
|
carbendazim results in increased expression of PIM1 mRNA
|
CTD |
PMID:22952946 |
|
NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
decreases expression
|
ISO
|
carbendazim results in decreased expression of PLAU mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Ptgds
|
prostaglandin D2 synthase
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of PTGDS mRNA
|
CTD |
PMID:22952946 |
|
NCBI chr 3:28,680,044...28,682,978
Ensembl chr 3:28,680,044...28,682,978
|
|
G
|
Pttg1
|
PTTG1 regulator of sister chromatid separation, securin
|
increases expression
|
ISO
|
carbendazim results in increased expression of PTTG1 protein
|
CTD |
PMID:37506866 |
|
NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases expression multiple interactions
|
EXP
|
carbendazim results in increased expression of RELA protein Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Serpine2
|
serpin family E member 2
|
increases expression
|
ISO
|
carbendazim results in increased expression of SERPINE2 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202
|
|
G
|
Shank3
|
SH3 and multiple ankyrin repeat domains 3
|
multiple interactions
|
EXP
|
[carbendazim co-treated with 2,5-hexanedione] affects the expression of SHANK3 mRNA
|
CTD |
PMID:22382377 |
|
NCBI chr 7:122,448,323...122,518,623
Ensembl chr 7:122,448,323...122,510,410
|
|
G
|
Sil1
|
SIL1 nucleotide exchange factor
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of SIL1 mRNA
|
CTD |
PMID:22952946 PMID:27466211 |
|
NCBI chr18:27,146,526...27,378,459
Ensembl chr18:27,146,527...27,307,693
|
|
G
|
Sod3
|
superoxide dismutase 3
|
increases expression
|
EXP
|
carbendazim results in increased expression of SOD3 mRNA
|
CTD |
PMID:27466211 |
|
NCBI chr14:62,822,865...62,828,602
Ensembl chr14:62,811,177...62,829,125
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
increases expression
|
ISO
|
carbendazim results in increased expression of SREBF1 mRNA
|
CTD |
PMID:26071454 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|
G
|
Star
|
steroidogenic acute regulatory protein
|
decreases expression multiple interactions
|
EXP
|
carbendazim results in decreased expression of STAR mRNA; carbendazim results in decreased expression of STAR protein Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]
|
CTD |
PMID:33965443 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447
|
|
G
|
Tbc1d5
|
TBC1 domain family, member 5
|
decreases expression
|
EXP
|
carbendazim results in decreased expression of TBC1D5 mRNA
|
CTD |
PMID:27466211 |
|
NCBI chr 9:3,740,032...4,256,971
Ensembl chr 9:3,750,325...4,253,581
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
increases expression
|
ISO
|
carbendazim results in increased expression of TIMP1 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
increases expression
|
ISO
|
carbendazim results in increased expression of TIMP2 mRNA
|
CTD |
PMID:25530041 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]
|
CTD |
PMID:33965443 PMID:35437878 PMID:35513110 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnp1
|
transition protein 1
|
increases expression
|
EXP
|
carbendazim results in increased expression of TNP1 mRNA
|
CTD |
PMID:28576679 |
|
NCBI chr 9:82,043,669...82,044,278
Ensembl chr 9:82,043,672...82,044,278
|
|
G
|
Tnp2
|
transition protein 2
|
increases expression
|
EXP
|
carbendazim results in increased expression of TNP2 mRNA
|
CTD |
PMID:28576679 |
|
NCBI chr10:5,386,735...5,387,463
Ensembl chr10:5,383,885...5,387,467
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression affects activity
|
EXP ISO
|
carbendazim results in increased expression of TP53 mRNA carbendazim affects the activity of TP53 protein
|
CTD |
PMID:35435491 PMID:35513110 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tshb
|
thyroid stimulating hormone subunit beta
|
increases expression
|
EXP
|
carbendazim results in increased expression of TSHB protein
|
CTD |
PMID:33965443 |
|
NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984
|
|
|
G
|
Adrb1
|
adrenoceptor beta 1
|
multiple interactions affects binding increases activity
|
ISO EXP
|
[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 12177 binds to and results in decreased activity of ADRB1 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB1 protein]; CGP 12177 inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 20712A inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]
|
CTD |
PMID:2462161 PMID:9593075 PMID:10217540 PMID:12535855 PMID:12761341 PMID:14730417 PMID:15060759 PMID:17628611 PMID:21870877 More...
|
|
NCBI chr 1:265,777,103...265,780,114
Ensembl chr 1:265,766,079...265,849,237
|
|
G
|
Adrb2
|
adrenoceptor beta 2
|
multiple interactions affects binding
|
ISO EXP
|
[CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; CGP 12177 binds to and results in decreased activity of ADRB2 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB2 protein] Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]
|
CTD |
PMID:2462161 PMID:9593075 PMID:12535855 PMID:14730417 PMID:17628611 PMID:21870877 More...
|
|
NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803
|
|
G
|
Adrb3
|
adrenoceptor beta 3
|
multiple interactions affects binding increases activity affects response to substance
|
ISO EXP
|
[CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; CGP 12177 binds to and results in increased activity of ADRB3 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB3 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB3 protein] CGP 12177 results in increased activity of ADRB3 protein ADRB3 affects the susceptibility to CGP 12177 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [CGP 12177 results in increased activity of ADRB3 protein]; CGP 12177 binds to and results in increased activity of ADRB3 protein
|
CTD |
PMID:7815362 PMID:8569714 PMID:10217540 PMID:10952688 PMID:11159692 PMID:11753577 PMID:14730417 PMID:15563584 PMID:21870877 More...
|
|
NCBI chr16:71,544,603...71,547,410
Ensembl chr16:71,542,567...71,547,420
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions increases activity
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; Pertussis Toxin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; U 0126 inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; wortmannin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]
|
CTD |
PMID:15563584 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Gh1
|
growth hormone 1
|
multiple interactions
|
EXP
|
GH1 protein promotes the reaction [CGP 12177 results in increased metabolism of Lipids]
|
CTD |
PMID:14981226 |
|
NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859
|
|
G
|
Lpl
|
lipoprotein lipase
|
increases expression
|
EXP
|
CGP 12177 results in increased expression of LPL mRNA
|
CTD |
PMID:9032464 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases activity
|
ISO
|
CGP 12177 results in increased activity of MAPK1 protein
|
CTD |
PMID:15563584 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases activity
|
ISO
|
CGP 12177 results in increased activity of MAPK3 protein
|
CTD |
PMID:15563584 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Usf1
|
upstream transcription factor 1
|
multiple interactions
|
ISO
|
USF1 gene polymorphism promotes the reaction [CGP 12177 results in increased metabolism of Lipids]; USF1 protein affects the reaction [CGP 12177 results in increased metabolism of Lipids]
|
CTD |
PMID:15985485 |
|
NCBI chr13:86,377,679...86,385,523
Ensembl chr13:86,377,717...86,385,522
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
ISO
|
CGP 12177 results in increased expression of VEGFA mRNA
|
CTD |
PMID:10788502 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions
|
ISO
|
chlormidazole inhibits the reaction [Estradiol results in increased activity of ESR1 protein]
|
CTD |
PMID:30818834 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
Esrra
|
estrogen related receptor, alpha
|
multiple interactions
|
ISO
|
chlormidazole inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; chlormidazole inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
|
CTD |
PMID:30818834 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811
|
|
G
|
Idh3a
|
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha
|
decreases expression
|
ISO
|
chlormidazole results in decreased expression of IDH3A mRNA
|
CTD |
PMID:30818834 |
|
NCBI chr 8:63,867,882...63,887,223
Ensembl chr 8:63,867,820...63,887,223
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
increases activity
|
ISO
|
chlormidazole results in increased activity of NFE2L2 protein
|
CTD |
PMID:30818834 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
increases activity
|
ISO
|
chlormidazole results in increased activity of NR1I3 protein
|
CTD |
PMID:30818834 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions
|
ISO
|
chlormidazole inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]
|
CTD |
PMID:30818834 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
ciclobendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
[clemizole co-treated with Cisplatin] results in decreased expression of CAT protein; clemizole inhibits the reaction [Cisplatin results in decreased expression of CAT protein]
|
CTD |
PMID:37102204 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases expression multiple interactions
|
ISO
|
clemizole results in increased expression of CYP2B6 mRNA [clemizole co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; [clemizole co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA
|
CTD |
PMID:31312845 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression multiple interactions
|
ISO
|
clemizole results in increased expression of CYP3A4 mRNA [clemizole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
|
CTD |
PMID:31312845 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
G6pc1
|
glucose-6-phosphatase catalytic subunit 1
|
increases expression
|
ISO
|
clemizole results in increased expression of G6PC1 mRNA
|
CTD |
PMID:31312845 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033
|
|
G
|
Lcn2
|
lipocalin 2
|
multiple interactions
|
EXP
|
[clemizole co-treated with Cisplatin] results in increased expression of LCN2 protein; clemizole inhibits the reaction [Cisplatin results in increased expression of LCN2 protein]
|
CTD |
PMID:37102204 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842
|
|
G
|
Med1
|
mediator complex subunit 1
|
multiple interactions
|
ISO
|
clemizole promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]
|
CTD |
PMID:31312845 |
|
NCBI chr10:83,641,851...83,685,560
Ensembl chr10:83,641,862...83,685,545
|
|
G
|
Ncoa1
|
nuclear receptor coactivator 1
|
multiple interactions
|
ISO
|
clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein alternative form]; clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein]
|
CTD |
PMID:31312845 |
|
NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924
|
|
G
|
Ncoa3
|
nuclear receptor coactivator 3
|
multiple interactions
|
ISO
|
clemizole promotes the reaction [NCOA3 protein binds to NR1I3 protein]
|
CTD |
PMID:31312845 |
|
NCBI chr 3:175,157,824...175,237,831
Ensembl chr 3:175,157,821...175,240,631
|
|
G
|
Nphs1
|
NPHS1 adhesion molecule, nephrin
|
multiple interactions
|
EXP
|
[Cisplatin co-treated with clemizole] results in decreased expression of NPHS1 protein; clemizole inhibits the reaction [Cisplatin results in decreased expression of NPHS1 protein]
|
CTD |
PMID:37102204 |
|
NCBI chr 1:94,848,261...94,876,522
Ensembl chr 1:94,848,261...94,876,521
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions increases activity
|
ISO
|
[clemizole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
|
CTD |
PMID:31312845 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
affects localization affects binding multiple interactions
|
ISO
|
clemizole affects the localization of NR1I3 protein mutant form clemizole binds to NR1I3 protein [clemizole co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; [clemizole co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; clemizole binds to and results in increased activity of NR1I3 protein alternative form; clemizole inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]; clemizole promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]; clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein alternative form]; clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein]; clemizole promotes the reaction [NCOA3 protein binds to NR1I3 protein]
|
CTD |
PMID:31312845 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370
|
|
G
|
Pck1
|
phosphoenolpyruvate carboxykinase 1
|
increases expression
|
ISO
|
clemizole results in increased expression of PCK1 mRNA
|
CTD |
PMID:31312845 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561
|
|
G
|
Rac1
|
Rac family small GTPase 1
|
multiple interactions
|
EXP
|
clemizole inhibits the reaction [Cisplatin results in increased expression of RAC1 protein]
|
CTD |
PMID:37102204 |
|
NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
decreases expression
|
ISO
|
clemizole results in decreased expression of SCD mRNA
|
CTD |
PMID:31312845 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785
|
|
G
|
Synpo
|
synaptopodin
|
multiple interactions
|
EXP
|
[Cisplatin co-treated with clemizole] results in decreased expression of SYNPO protein; clemizole inhibits the reaction [Cisplatin results in decreased expression of SYNPO protein]
|
CTD |
PMID:37102204 |
|
NCBI chr18:56,326,369...56,347,359
Ensembl chr18:56,319,571...56,353,306
|
|
G
|
Thrsp
|
thyroid hormone responsive
|
affects expression
|
ISO
|
clemizole affects the expression of THRSP mRNA
|
CTD |
PMID:31312845 |
|
NCBI chr 1:161,134,640...161,138,964
Ensembl chr 1:161,133,453...161,139,827
|
|
|
G
|
Aif1
|
allograft inflammatory factor 1
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of AIF1 protein
|
CTD |
PMID:27397090 |
|
NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339
|
|
G
|
Aldh1a2
|
aldehyde dehydrogenase 1 family, member A2
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of ALDH1A2 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883
|
|
G
|
Eya1
|
EYA transcriptional coactivator and phosphatase 1
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of EYA1 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614
|
|
G
|
F2
|
coagulation factor II, thrombin
|
decreases activity
|
ISO
|
Dabigatran results in decreased activity of F2 protein
|
CTD |
PMID:17911567 PMID:25138021 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
G
|
Fga
|
fibrinogen alpha chain
|
multiple interactions
|
ISO
|
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]
|
CTD |
PMID:25138021 |
|
NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577
|
|
G
|
Fgb
|
fibrinogen beta chain
|
multiple interactions
|
ISO
|
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]
|
CTD |
PMID:25138021 |
|
NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434
|
|
G
|
Fgf8
|
fibroblast growth factor 8
|
increases expression
|
ISO
|
Dabigatran results in increased expression of FGF8 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605
|
|
G
|
Fgg
|
fibrinogen gamma chain
|
multiple interactions
|
ISO
|
Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]
|
CTD |
PMID:25138021 |
|
NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:170,652,234...170,661,170
|
|
G
|
Foxc2
|
forkhead box C2
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of FOXC2 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of GDNF mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Gfap
|
glial fibrillary acidic protein
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of GFAP protein
|
CTD |
PMID:27397090 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685
|
|
G
|
Hoxb9
|
homeo box B9
|
increases expression
|
ISO
|
Dabigatran results in increased expression of HOXB9 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872
|
|
G
|
Meox1
|
mesenchyme homeobox 1
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of MEOX1 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976
|
|
G
|
Mertk
|
MER proto-oncogene, tyrosine kinase
|
increases expression
|
ISO
|
Dabigatran results in increased expression of MERTK mRNA
|
CTD |
PMID:27397090 |
|
NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192
|
|
G
|
Neurog2
|
neurogenin 2
|
increases expression
|
ISO
|
Dabigatran results in increased expression of NEUROG2 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 2:218,767,205...218,769,772
Ensembl chr 2:218,765,949...218,769,784
|
|
G
|
Nr4a2
|
nuclear receptor subfamily 4, group A, member 2
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of NR4A2 mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769
|
|
G
|
Olig3
|
oligodendrocyte transcription factor 3
|
increases expression
|
ISO
|
Dabigatran results in increased expression of OLIG3 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274
|
|
G
|
Pax3
|
paired box 3
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of PAX3 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141
|
|
G
|
Pax6
|
paired box 6
|
increases expression
|
ISO
|
Dabigatran results in increased expression of PAX6 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763
|
|
G
|
Plp1
|
proteolipid protein 1
|
increases expression
|
ISO
|
Dabigatran results in increased expression of PLP1 mRNA
|
CTD |
PMID:27397090 |
|
NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314
|
|
G
|
Rcor2
|
REST corepressor 2
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of RCOR2 mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 1:213,882,585...213,890,022
Ensembl chr 1:213,878,519...213,890,022
|
|
G
|
Ret
|
ret proto-oncogene
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of RET protein]
|
CTD |
PMID:28585189 |
|
NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556
|
|
G
|
Slc18a2
|
solute carrier family 18 member A2
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231
|
|
G
|
Snca
|
synuclein alpha
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in increased expression of SNCA mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315
|
|
G
|
Tcf15
|
transcription factor 15
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of TCF15 mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr 3:161,099,301...161,105,083
Ensembl chr 3:161,099,301...161,105,083
|
|
G
|
Th
|
tyrosine hydroxylase
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in decreased expression of TH mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP
|
Dabigatran inhibits the reaction [Rotenone results in increased expression of TNF mRNA]
|
CTD |
PMID:28585189 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Uncx
|
UNC homeobox
|
decreases expression
|
ISO
|
Dabigatran results in decreased expression of UNCX mRNA
|
CTD |
PMID:31711903 |
|
NCBI chr12:20,206,604...20,211,125
Ensembl chr12:20,206,609...20,211,125
|
|
|
G
|
Glp1r
|
glucagon-like peptide 1 receptor
|
increases activity multiple interactions
|
ISO
|
danuglipron results in increased activity of GLP1R protein [danuglipron results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
|
CTD |
PMID:39395609 |
|
NCBI chr20:8,973,393...9,011,622
Ensembl chr20:8,973,352...9,011,654
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
increases activity
|
ISO
|
danuglipron results in increased activity of KCNH2 protein
|
CTD |
PMID:39395609 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
|
G
|
Kcnh1
|
potassium voltage-gated channel subfamily H member 1
|
decreases activity
|
ISO
|
desmethylastemizole results in decreased activity of KCNH1 protein
|
CTD |
PMID:16816845 |
|
NCBI chr13:106,253,101...106,555,712
Ensembl chr13:106,253,213...106,555,710
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
multiple interactions
|
ISO
|
desmethylastemizole binds to and results in decreased activity of KCNH2 protein
|
CTD |
PMID:10376921 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
affects response to substance
|
ISO
|
ABCB1 gene SNP affects the susceptibility to Domperidone
|
CTD |
PMID:21063774 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Adra1d
|
adrenoceptor alpha 1D
|
affects response to substance
|
ISO
|
ADRA1D gene SNP affects the susceptibility to Domperidone
|
CTD |
PMID:21063774 |
|
NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331
|
|
G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
multiple interactions
|
ISO
|
Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL2 mRNA]
|
CTD |
PMID:21691039 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
multiple interactions
|
ISO
|
Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA]
|
CTD |
PMID:21691039 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression
|
ISO
|
Domperidone results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:9860486 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases hydroxylation
|
ISO
|
CYP1A2 protein results in increased hydroxylation of Domperidone
|
CTD |
PMID:15327587 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases hydroxylation
|
ISO
|
CYP2B6 protein results in increased hydroxylation of Domperidone
|
CTD |
PMID:15327587 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c79
|
cytochrome P450, family 2, subfamily c, polypeptide 79
|
increases hydroxylation
|
ISO
|
CYP2C8 protein results in increased hydroxylation of Domperidone
|
CTD |
PMID:15327587 |
|
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
increases hydroxylation
|
ISO
|
CYP2D6 protein results in increased hydroxylation of Domperidone
|
CTD |
PMID:15327587 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
multiple interactions
|
ISO
|
CYP3A4 protein results in increased hydroxylation of and results in decreased alkylation of Domperidone
|
CTD |
PMID:15327587 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Drd1
|
dopamine receptor D1
|
multiple interactions affects binding
|
ISO
|
Cyclosporine promotes the reaction [Domperidone binds to DRD1 protein]
|
CTD |
PMID:12673668 |
|
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,545,111...10,567,166
|
|
G
|
Drd2
|
dopamine receptor D2
|
multiple interactions affects binding
|
ISO EXP
|
Cyclosporine promotes the reaction [Domperidone binds to DRD2 protein] Domperidone binds to and results in decreased activity of DRD2 protein
|
CTD |
PMID:2571179 PMID:8103596 PMID:10626749 PMID:12071432 PMID:12130853 PMID:12673668 More...
|
|
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339
|
|
G
|
Il6
|
interleukin 6
|
decreases expression
|
ISO
|
Domperidone results in decreased expression of IL6 protein
|
CTD |
PMID:10568223 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity multiple interactions affects response to substance
|
ISO
|
Domperidone results in decreased activity of KCNH2 protein Domperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium] KCNH2 gene SNP affects the susceptibility to Domperidone
|
CTD |
PMID:15640612 PMID:19583963 PMID:21063774 PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
Domperidone inhibits the reaction [Indomethacin results in increased activity of MPO protein]
|
CTD |
PMID:21691039 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
Domperidone inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]
|
CTD |
PMID:21691039 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Prl
|
prolactin
|
multiple interactions increases expression
|
ISO EXP
|
Domperidone inhibits the reaction [Deoxyepinephrine results in decreased expression of PRL protein]; Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein] Domperidone results in increased expression of PRL protein
|
CTD |
PMID:1304515 PMID:1874184 PMID:6736848 PMID:8532072 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Domperidone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
decreases expression
|
ISO
|
Domperidone results in decreased expression of TGFB1 protein
|
CTD |
PMID:10568223 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Thra
|
thyroid hormone receptor alpha
|
multiple interactions
|
ISO
|
Domperidone binds to and results in decreased activity of THRA protein
|
CTD |
PMID:25752796 |
|
NCBI chr10:84,198,141...84,225,659
Ensembl chr10:84,197,011...84,225,657
|
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity multiple interactions
|
ISO
|
Droperidol results in decreased activity of KCNH2 protein Droperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
|
CTD |
PMID:16757186 PMID:21158687 PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Droperidol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity
|
ISO
|
emedastine results in decreased activity of KCNH2 protein
|
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions increases expression
|
ISO
|
Mycophenolic Acid promotes the reaction [Esomeprazole results in increased expression of CYP1A1 mRNA]
|
CTD |
PMID:25929522 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
|
G
|
Araf
|
A-Raf proto-oncogene, serine/threonine kinase
|
decreases expression
|
ISO
|
Fenbendazole analog results in decreased expression of ARAF protein
|
CTD |
PMID:35569513 |
|
NCBI chr X:3,780,932...3,845,919
Ensembl chr X:3,780,932...3,792,611
|
|
G
|
Aurkb
|
aurora kinase B
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of AURKB protein
|
CTD |
PMID:23411599 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
ISO
|
Fenbendazole analog results in increased expression of BAX protein; Fenbendazole results in increased expression of BAX protein Acetylcysteine inhibits the reaction [Fenbendazole analog results in increased expression of BAX protein]; Acetylcysteine inhibits the reaction [Fenbendazole results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole analog results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole results in increased expression of BAX protein]
|
CTD |
PMID:35569513 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression
|
ISO
|
Fenbendazole analog results in decreased expression of BCL2 protein; Fenbendazole results in decreased expression of BCL2 protein
|
CTD |
PMID:35569513 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Casp3
|
caspase 3
|
increases expression increases cleavage
|
ISO
|
Fenbendazole analog results in increased expression of CASP3 mRNA Fenbendazole analog results in increased cleavage of CASP3 protein; Fenbendazole results in increased cleavage of CASP3 protein
|
CTD |
PMID:35569513 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of CASP8 mRNA; Fenbendazole results in increased expression of CASP8 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases cleavage increases expression
|
ISO
|
Fenbendazole analog results in increased cleavage of CASP9 protein; Fenbendazole results in increased cleavage of CASP9 protein Fenbendazole analog results in increased expression of CASP9 mRNA; Fenbendazole results in increased expression of CASP9 mRNA
|
CTD |
PMID:35569513 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cbx5
|
chromobox 5
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of CBX5 protein
|
CTD |
PMID:23411599 |
|
NCBI chr 7:136,203,827...136,254,575
Ensembl chr 7:136,211,649...136,229,118
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Fenbendazole results in increased expression of CCL2 protein
|
CTD |
PMID:20116850 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of CCND1 mRNA
|
CTD |
PMID:23411599 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccne2
|
cyclin E2
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of CCNE2 mRNA
|
CTD |
PMID:23411599 |
|
NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882
|
|
G
|
Cdh1
|
cadherin 1
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of CDH1 protein; Fenbendazole results in increased expression of CDH1 protein
|
CTD |
PMID:35569513 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
affects expression
|
ISO
|
Fenbendazole affects the expression of CDH2 protein; Fenbendazole analog affects the expression of CDH2 protein
|
CTD |
PMID:35569513 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Cdk1
|
cyclin-dependent kinase 1
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of CDK1 mRNA; Fenbendazole results in increased expression of CDK1 protein
|
CTD |
PMID:23411599 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of CDKN1A mRNA; Fenbendazole results in increased expression of CDKN1A protein
|
CTD |
PMID:23411599 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn2a
|
cyclin-dependent kinase inhibitor 2A
|
increases methylation increases expression decreases expression
|
EXP
|
Fenbendazole results in increased methylation of CDKN2A gene Fenbendazole results in increased expression of CDKN2A protein Fenbendazole results in decreased expression of CDKN2A protein
|
CTD |
PMID:22659510 PMID:23411599 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248
|
|
G
|
Cdkn2b
|
cyclin-dependent kinase inhibitor 2B
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of CDKN2B mRNA
|
CTD |
PMID:23411599 |
|
NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855
|
|
G
|
Cdr2
|
cerebellar degeneration-related protein 2
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of CDR2 mRNA
|
CTD |
PMID:23411599 |
|
NCBI chr 1:184,934,128...184,959,036
Ensembl chr 1:184,934,129...184,968,863
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
decreases activity
|
ISO
|
Fenbendazole results in decreased activity of CYP1A2 protein
|
CTD |
PMID:22048645 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Dnm1l
|
dynamin 1-like
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of DNM1L mRNA; Fenbendazole results in increased expression of DNM1L mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions
|
ISO
|
Fenbendazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]
|
CTD |
PMID:23769903 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of H2AX protein; Fenbendazole results in increased expression of H2AX protein
|
CTD |
PMID:35569513 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hsf1
|
heat shock transcription factor 1
|
increases activity
|
ISO
|
Fenbendazole results in increased activity of HSF1 protein
|
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
G
|
Ifng
|
interferon gamma
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of IFNG mRNA; Fenbendazole results in increased expression of IFNG mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il6
|
interleukin 6
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of IL6 mRNA; Fenbendazole results in increased expression of IL6 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Il6r
|
interleukin 6 receptor
|
increases expression
|
ISO
|
Fenbendazole results in increased expression of IL6R protein modified form
|
CTD |
PMID:20116850 |
|
NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221
|
|
G
|
Incenp
|
inner centromere protein
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of INCENP protein
|
CTD |
PMID:23411599 |
|
NCBI chr 1:215,945,558...216,017,247
Ensembl chr 1:215,948,283...215,977,084
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
decreases expression
|
ISO
|
Fenbendazole results in decreased expression of MAPT protein
|
CTD |
PMID:16930453 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Mdh2
|
malate dehydrogenase 2
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of MDH2 mRNA; Fenbendazole results in increased expression of MDH2 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of MDM2 mRNA
|
CTD |
PMID:23411599 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Mfn2
|
mitofusin 2
|
increases expression
|
ISO
|
Fenbendazole results in increased expression of MFN2 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
increases expression
|
EXP
|
Fenbendazole results in increased expression of MKI67 protein
|
CTD |
PMID:23411599 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases expression
|
ISO
|
Fenbendazole analog results in decreased expression of MMP2 mRNA; Fenbendazole analog results in decreased expression of MMP2 protein
|
CTD |
PMID:35569513 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
affects expression decreases expression
|
ISO
|
Fenbendazole affects the expression of MMP9 protein; Fenbendazole analog affects the expression of MMP9 protein Fenbendazole analog results in decreased expression of MMP9 mRNA; Fenbendazole results in decreased expression of MMP9 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
Fenbendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Opa1
|
OPA1, mitochondrial dynamin like GTPase
|
increases expression
|
ISO
|
Fenbendazole results in increased expression of OPA1 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr11:84,612,943...84,690,025
Ensembl chr11:84,615,340...84,689,955
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
decreases expression
|
ISO
|
Fenbendazole results in decreased expression of PTGS2 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases phosphorylation multiple interactions
|
ISO
|
Fenbendazole analog results in increased phosphorylation of RELA protein; Fenbendazole results in increased phosphorylation of RELA protein Acetylcysteine inhibits the reaction [Fenbendazole analog results in increased phosphorylation of RELA protein]; Acetylcysteine inhibits the reaction [Fenbendazole results in increased phosphorylation of RELA protein]
|
CTD |
PMID:35569513 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Sirt1
|
sirtuin 1
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of SIRT1 mRNA; Fenbendazole results in increased expression of SIRT1 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
G
|
Slc2a1
|
solute carrier family 2 member 1
|
decreases expression
|
ISO
|
Fenbendazole analog results in decreased expression of SLC2A1 mRNA; Fenbendazole results in decreased expression of SLC2A1 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742
|
|
G
|
Slc2a4
|
solute carrier family 2 member 4
|
decreases expression
|
ISO
|
Fenbendazole analog results in decreased expression of SLC2A4 mRNA; Fenbendazole results in decreased expression of SLC2A4 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
G
|
Suclg1
|
succinate-CoA ligase GDP/ADP-forming subunit alpha
|
increases expression
|
ISO
|
Fenbendazole analog results in increased expression of SUCLG1 mRNA; Fenbendazole results in increased expression of SUCLG1 mRNA
|
CTD |
PMID:35569513 |
|
NCBI chr 4:106,866,329...106,895,686
Ensembl chr 4:106,866,114...106,895,689
|
|
G
|
Tmem70
|
transmembrane protein 70
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with Fenbendazole] results in decreased expression of TMEM70 protein
|
CTD |
PMID:27914986 |
|
NCBI chr 5:7,420,396...7,438,023
Ensembl chr 5:7,420,396...7,438,023
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases secretion increases expression multiple interactions
|
ISO
|
Fenbendazole results in increased secretion of TNF protein Fenbendazole analog results in increased expression of TNF mRNA U 0126 inhibits the reaction [Fenbendazole results in increased secretion of TNF protein]
|
CTD |
PMID:20848085 PMID:35569513 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression
|
EXP ISO
|
Fenbendazole results in increased expression of TP53 protein Fenbendazole analog results in increased expression of TP53 protein; Fenbendazole results in increased expression of TP53 protein
|
CTD |
PMID:23411599 PMID:35569513 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Ube2e2
|
ubiquitin-conjugating enzyme E2E 2
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with Fenbendazole] results in decreased expression of UBE2E2 protein
|
CTD |
PMID:27914986 |
|
NCBI chr15:9,411,067...9,688,731
Ensembl chr15:9,411,539...9,712,661
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
ISO
|
Fenbendazole results in increased expression of VEGFA protein
|
CTD |
PMID:20116850 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Wee1
|
WEE1 G2 checkpoint kinase
|
decreases expression
|
EXP
|
Fenbendazole results in decreased expression of WEE1 protein modified form
|
CTD |
PMID:23411599 |
|
NCBI chr 1:173,605,609...173,632,450
Ensembl chr 1:173,608,949...173,632,449
|
|
|
G
|
Arhgef2
|
Rho/Rac guanine nucleotide exchange factor 2
|
decreases expression
|
ISO
|
flubendazole results in decreased expression of ARHGEF2 protein
|
CTD |
PMID:30075109 |
|
NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
increases phosphorylation
|
ISO
|
flubendazole results in increased phosphorylation of BCL2 protein
|
CTD |
PMID:32652169 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
increases phosphorylation
|
ISO
|
flubendazole results in increased phosphorylation of BCL2L1 protein
|
CTD |
PMID:32652169 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage multiple interactions
|
ISO
|
flubendazole results in increased cleavage of CASP3 protein BAY 11-7085 affects the reaction [flubendazole results in increased cleavage of CASP3 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; Cyclosporine inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]
|
CTD |
PMID:32652169 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions
|
ISO
|
flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]
|
CTD |
PMID:30075109 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
multiple interactions
|
ISO
|
flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]
|
CTD |
PMID:30075109 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases activity
|
ISO
|
flubendazole results in increased activity of MAPK8 protein
|
CTD |
PMID:32652169 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mcl1
|
MCL1 apoptosis regulator, BCL2 family member
|
increases phosphorylation
|
ISO
|
flubendazole results in increased phosphorylation of MCL1 protein
|
CTD |
PMID:32652169 |
|
NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782
|
|
G
|
Pmaip1
|
phorbol-12-myristate-13-acetate-induced protein 1
|
increases expression
|
ISO
|
flubendazole results in increased expression of PMAIP1 protein
|
CTD |
PMID:32652169 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382
|
|
G
|
Ptk2
|
protein tyrosine kinase 2
|
decreases expression
|
ISO
|
flubendazole results in decreased expression of PTK2 protein
|
CTD |
PMID:30075109 |
|
NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091
|
|
G
|
Rac1
|
Rac family small GTPase 1
|
decreases expression
|
ISO
|
flubendazole results in decreased expression of RAC1 protein
|
CTD |
PMID:30075109 |
|
NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases activity multiple interactions
|
ISO
|
flubendazole results in increased activity of RELA protein 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine affects the reaction [flubendazole results in increased activity of RELA protein]; BAY 11-7085 affects the reaction [flubendazole results in increased activity of RELA protein]
|
CTD |
PMID:32652169 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rhoa
|
ras homolog family member A
|
decreases expression
|
ISO
|
flubendazole results in decreased expression of RHOA protein
|
CTD |
PMID:30075109 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]; flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]
|
CTD |
PMID:30075109 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tp53
|
tumor protein p53
|
increases activity
|
ISO
|
flubendazole results in increased activity of TP53 protein
|
CTD |
PMID:32652169 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
|
G
|
Abca1
|
ATP binding cassette subfamily A member 1
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of ABCA1 protein Lansoprazole results in increased expression of ABCA1 mRNA; Lansoprazole results in increased expression of ABCA1 protein
|
CTD |
PMID:20060385 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
affects response to substance
|
ISO
|
ABCB1 affects the susceptibility to Lansoprazole
|
CTD |
PMID:19238367 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Apoe
|
apolipoprotein E
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of APOE mRNA; Lansoprazole results in increased expression of APOE protein
|
CTD |
PMID:20060385 |
|
NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855
|
|
G
|
Aqp4
|
aquaporin 4
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of AQP4 mRNA; Lansoprazole results in increased expression of AQP4 protein
|
CTD |
PMID:20437101 |
|
NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in decreased expression of BCL2 mRNA]
|
CTD |
PMID:28412091 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
C1qa
|
complement C1q A chain
|
decreases expression
|
EXP
|
Lansoprazole results in decreased expression of C1QA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732
|
|
G
|
C1qc
|
complement C1q C chain
|
decreases expression
|
EXP
|
Lansoprazole results in decreased expression of C1QC mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468
|
|
G
|
C4bpa
|
complement component 4 binding protein, alpha
|
decreases expression
|
EXP
|
Lansoprazole results in decreased expression of C4BPA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,627,959...44,663,552
Ensembl chr13:44,627,982...44,663,471
|
|
G
|
C4bpb
|
complement component 4 binding protein, beta
|
decreases expression
|
EXP
|
Lansoprazole results in decreased expression of C4BPB mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,673,064...44,683,781
Ensembl chr13:44,673,065...44,683,793
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO EXP
|
Lansoprazole inhibits the reaction [Demecolcine results in increased activity of CASP3 protein] Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of CASP3 mRNA]; Lansoprazole inhibits the reaction [Ethanol results in increased expression of CASP3 protein]
|
CTD |
PMID:12530016 PMID:28412091 PMID:29339218 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of CAT protein]
|
CTD |
PMID:18726076 PMID:29339218 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cfi
|
complement factor I
|
decreases expression
|
EXP
|
Lansoprazole results in decreased expression of CFI mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786
|
|
G
|
Cxcl1
|
C-X-C motif chemokine ligand 1
|
decreases expression multiple interactions
|
EXP
|
Lansoprazole results in decreased expression of CXCL1 mRNA; Lansoprazole results in decreased expression of CXCL1 protein Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA]; Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 protein]
|
CTD |
PMID:15334676 PMID:16328016 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases activity decreases activity increases expression
|
ISO EXP
|
Lansoprazole results in increased activity of CYP1A1 promoter Lansoprazole results in decreased activity of CYP1A1 protein Lansoprazole results in increased expression of CYP1A1 mRNA; Lansoprazole results in increased expression of CYP1A1 protein
|
CTD |
PMID:8169844 PMID:8647108 PMID:8900397 PMID:9041675 PMID:9152597 PMID:9860486 PMID:10859152 PMID:12623754 PMID:14550749 PMID:18502397 PMID:25626140 PMID:33814510 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases expression
|
ISO EXP
|
Lansoprazole results in increased expression of CYP1A2 mRNA; Lansoprazole results in increased expression of CYP1A2 protein
|
CTD |
PMID:8169844 PMID:9152597 PMID:9744552 PMID:12623754 PMID:14550749 PMID:25626140 More...
|
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
increases expression decreases activity
|
ISO
|
Lansoprazole results in increased expression of CYP1B1 mRNA Lansoprazole results in decreased activity of CYP1B1 protein
|
CTD |
PMID:12623754 PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
increases expression
|
EXP
|
Lansoprazole results in increased expression of CYP2B1 protein
|
CTD |
PMID:9152597 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
increases expression
|
EXP
|
Lansoprazole results in increased expression of CYP2B2 protein
|
CTD |
PMID:9152597 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G
|
Cyp2c11
|
cytochrome P450, subfamily 2, polypeptide 11
|
increases hydroxylation
|
ISO
|
CYP2C18 protein results in increased hydroxylation of Lansoprazole
|
CTD |
PMID:7870052 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
affects response to substance increases expression decreases activity increases hydroxylation affects metabolic processing increases metabolic processing decreases metabolic processing multiple interactions
|
ISO EXP
|
CYP2C19 gene affects the susceptibility to Lansoprazole; CYP2C19 gene polymorphism affects the susceptibility to Lansoprazole Lansoprazole results in increased expression of CYP2C6 mRNA; Lansoprazole results in increased expression of CYP2C6 protein Lansoprazole results in decreased activity of CYP2C19 protein CYP2C19 protein results in increased hydroxylation of Lansoprazole CYP2C19 protein affects the metabolism of Lansoprazole CYP2C19 protein results in increased metabolism of Lansoprazole; Lansoprazole results in increased metabolism of CYP2C19 protein CYP2C19 gene polymorphism results in decreased metabolism of Lansoprazole CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]; Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole]; Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]
|
CTD |
PMID:8627562 PMID:8930576 PMID:9152597 PMID:9272410 PMID:11829200 PMID:11929404 PMID:12975331 PMID:14550749 PMID:15010519 PMID:15258107 PMID:15285851 PMID:15963082 PMID:17377957 PMID:19814645 PMID:21212520 PMID:21795468 More...
|
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2c79
|
cytochrome P450, family 2, subfamily c, polypeptide 79
|
affects metabolic processing increases hydroxylation
|
ISO
|
CYP2C8 protein affects the metabolism of Lansoprazole CYP2C8 protein results in increased hydroxylation of Lansoprazole
|
CTD |
PMID:7870052 PMID:8627562 |
|
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
decreases degradation multiple interactions
|
ISO
|
Lansoprazole results in decreased degradation of CYP2E1 protein Lansoprazole results in increased expression of and results in increased activity of CYP2E1 protein
|
CTD |
PMID:36243147 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases metabolic processing increases hydroxylation increases expression affects metabolic processing
|
ISO
|
CYP3A4 protein results in increased metabolism of Lansoprazole CYP3A4 protein results in increased hydroxylation of Lansoprazole Lansoprazole results in increased expression of CYP3A4 mRNA; Lansoprazole results in increased expression of CYP3A4 protein CYP3A4 protein affects the metabolism of Lansoprazole
|
CTD |
PMID:7870052 PMID:8627562 PMID:8930576 PMID:9744552 PMID:10859152 PMID:11829200 PMID:12975331 PMID:15010519 More...
|
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
multiple interactions
|
ISO
|
CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]
|
CTD |
PMID:17377957 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Cyp4a1
|
cytochrome P450, family 4, subfamily a, polypeptide 1
|
increases expression
|
EXP
|
Lansoprazole results in increased expression of CYP4A1 protein
|
CTD |
PMID:9152597 |
|
NCBI chr 5:134,360,096...134,374,233
Ensembl chr 5:134,360,111...134,374,231
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of EGFR protein
|
CTD |
PMID:9881512 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Fas
|
Fas cell surface death receptor
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Ethanol results in increased expression of FAS protein]
|
CTD |
PMID:29339218 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104
|
|
G
|
Faslg
|
Fas ligand
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Ethanol results in increased expression of FASLG protein]
|
CTD |
PMID:29339218 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fgf2
|
fibroblast growth factor 2
|
decreases expression
|
ISO
|
Lansoprazole results in decreased expression of FGF2 protein
|
CTD |
PMID:9881512 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493
|
|
G
|
Fgf21
|
fibroblast growth factor 21
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of FGF21 protein
|
CTD |
PMID:8774986 |
|
NCBI chr 1:105,219,825...105,221,376
Ensembl chr 1:105,219,825...105,232,056
|
|
G
|
Gast
|
gastrin
|
increases expression
|
ISO EXP
|
Lansoprazole results in increased expression of GAST protein
|
CTD |
PMID:7750667 PMID:8792694 PMID:11680587 PMID:11975934 PMID:12189558 PMID:12438555 PMID:20095383 More...
|
|
NCBI chr10:85,765,216...85,767,881
Ensembl chr10:85,765,216...85,767,880
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions
|
ISO
|
Lansoprazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]
|
CTD |
PMID:23769903 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
Hamp
|
hepcidin antimicrobial peptide
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of HAMP mRNA
|
CTD |
PMID:31669099 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases expression increases activity
|
ISO EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; Lansoprazole results in increased activity of and results in increased expression of HMOX1 protein Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein]; U 0126 inhibits the reaction [Lansoprazole results in increased expression of HMOX1 protein] Lansoprazole results in increased expression of HMOX1 mRNA; Lansoprazole results in increased expression of HMOX1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased activity of HMOX1 promoter]
|
CTD |
PMID:16712795 PMID:19628634 PMID:19764090 PMID:28412091 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions decreases expression
|
ISO
|
Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] Lansoprazole results in decreased expression of IFNG mRNA
|
CTD |
PMID:16932910 PMID:19232345 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein]
|
CTD |
PMID:29339218 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il1b
|
interleukin 1 beta
|
decreases expression multiple interactions
|
ISO EXP
|
Lansoprazole results in decreased expression of IL1B mRNA Lansoprazole inhibits the reaction [Ethanol results in increased expression of IL1B protein]
|
CTD |
PMID:16932910 PMID:29339218 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
decreases expression multiple interactions
|
ISO EXP
|
Lansoprazole results in decreased expression of IL6 mRNA Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 mRNA]
|
CTD |
PMID:16932910 PMID:28412091 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
increases oxidation
|
EXP
|
Lansoprazole results in increased oxidation of KEAP1 protein
|
CTD |
PMID:19628634 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Lhb
|
luteinizing hormone subunit beta
|
multiple interactions increases expression
|
EXP
|
Lansoprazole inhibits the reaction [LHB protein results in increased abundance of Testosterone] Lansoprazole results in increased expression of LHB protein
|
CTD |
PMID:7589908 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation
|
EXP
|
Lansoprazole results in increased phosphorylation of MAPK1 protein
|
CTD |
PMID:19628634 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation
|
EXP
|
Lansoprazole results in increased phosphorylation of MAPK3 protein
|
CTD |
PMID:19628634 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
affects binding
|
ISO
|
Lansoprazole binds to MAPT protein alternative form
|
CTD |
PMID:20110603 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MPO protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein]
|
CTD |
PMID:17151854 PMID:17895592 PMID:18726076 PMID:24337826 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions increases expression increases phosphorylation
|
EXP
|
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of NFE2L2 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein] Lansoprazole results in increased expression of NFE2L2 mRNA Lansoprazole results in increased phosphorylation of NFE2L2 protein
|
CTD |
PMID:19628634 PMID:28412091 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:29339218 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nr1h2
|
nuclear receptor subfamily 1, group H, member 2
|
increases activity
|
ISO
|
Lansoprazole results in increased activity of NR1H2 protein
|
CTD |
PMID:20060385 |
|
NCBI chr 1:104,178,483...104,183,863
Ensembl chr 1:104,178,234...104,183,863
|
|
G
|
Nr1h3
|
nuclear receptor subfamily 1, group H, member 3
|
increases activity
|
ISO
|
Lansoprazole results in increased activity of NR1H3 protein
|
CTD |
PMID:20060385 |
|
NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
increases activity
|
ISO
|
Lansoprazole results in increased activity of NR1I2 protein
|
CTD |
PMID:25455453 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Phospho1
|
phosphoethanolamine/phosphocholine phosphatase 1
|
decreases activity
|
ISO
|
Lansoprazole results in decreased activity of PHOSPHO1 protein
|
CTD |
PMID:17227223 |
|
NCBI chr10:81,258,810...81,266,345
Ensembl chr10:81,257,427...81,268,481
|
|
G
|
Pomc
|
proopiomelanocortin
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of POMC protein
|
CTD |
PMID:16524691 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions increases expression
|
EXP
|
AG-041R inhibits the reaction [Lansoprazole results in increased expression of PTGS2 protein]
|
CTD |
PMID:12438555 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of RELA protein]
|
CTD |
PMID:29339218 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Retsat
|
retinol saturase
|
decreases expression
|
EXP
|
Lansoprazole results in decreased expression of RETSAT mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:106,211,436...106,229,552
|
|
G
|
Serping1
|
serpin family G member 1
|
decreases expression
|
EXP
|
Lansoprazole results in decreased expression of SERPING1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:90,249,423...90,258,717
|
|
G
|
Shh
|
sonic hedgehog signaling molecule
|
decreases expression
|
ISO
|
Lansoprazole results in decreased expression of SHH mRNA
|
CTD |
PMID:20437101 |
|
NCBI chr 4:7,687,872...7,697,025
Ensembl chr 4:7,687,846...7,697,901
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Lansoprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Slc22a8
|
solute carrier family 22 member 8
|
multiple interactions
|
ISO
|
[Lansoprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican
|
CTD |
PMID:36243147 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588
|
|
G
|
Tgfa
|
transforming growth factor alpha
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of TGFA protein
|
CTD |
PMID:9881512 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression
|
ISO
|
Lansoprazole results in increased expression of TGFB1 protein
|
CTD |
PMID:36243147 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions decreases expression
|
ISO EXP
|
Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] Lansoprazole inhibits the reaction [Ethanol results in increased expression of TNF protein] Lansoprazole results in decreased expression of TNF mRNA
|
CTD |
PMID:16932910 PMID:19232345 PMID:29339218 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
EXP
|
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of TP53 mRNA]
|
CTD |
PMID:28412091 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression
|
EXP
|
Lansoprazole results in increased expression of UGT1A1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt2b1
|
UDP glucuronosyltransferase 2 family, polypeptide B1
|
increases expression
|
EXP
|
Lansoprazole results in increased expression of UGT2B1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331
|
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
affects binding
|
ISO
|
ledipasvir binds to ABCG2 protein
|
CTD |
PMID:33954893 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Klrc1
|
killer cell lectin like receptor C1
|
decreases expression
|
ISO
|
ledipasvir co-treated with sofosbuvir decreases expression of NCR1 protein in natural killer cells
|
RGD |
PMID:31218578 |
RGD:40400920 |
NCBI chr 4:164,828,163...164,838,446
Ensembl chr 4:164,828,163...164,838,464
|
|
G
|
Ncr1
|
natural cytotoxicity triggering receptor 1
|
affects expression
|
ISO
|
ledipasvir co-treated sofosbuvir with affects expression of NCR1 protein in natural killer cells
|
RGD |
PMID:31218578 |
RGD:40400920 |
NCBI chr 1:78,657,409...78,665,255
Ensembl chr 1:78,659,262...78,703,273
|
|
|
G
|
Cyp26a1
|
cytochrome P450, family 26, subfamily a, polypeptide 1
|
decreases activity multiple interactions
|
ISO
|
liarozole results in decreased activity of CYP26A1 protein [liarozole co-treated with Tretinoin] results in increased expression of CYP26A1 mRNA; liarozole promotes the reaction [Tretinoin results in increased expression of CYP26A1 mRNA]
|
CTD |
PMID:15597402 PMID:16279770 PMID:21428449 PMID:21838328 |
|
NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of ABCB1 mRNA; Mebendazole results in decreased expression of ABCB1 protein
|
CTD |
PMID:28606429 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of ABCC1 mRNA
|
CTD |
PMID:28606429 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
G
|
Ager
|
advanced glycosylation end product-specific receptor
|
increases expression
|
ISO
|
Mebendazole results in increased expression of AGER mRNA
|
CTD |
PMID:24747151 |
|
NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685
|
|
G
|
Arhgef2
|
Rho/Rac guanine nucleotide exchange factor 2
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of ARHGEF2 protein
|
CTD |
PMID:30075109 |
|
NCBI chr 2:176,358,909...176,416,178
Ensembl chr 2:176,358,904...176,417,646
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
[Mebendazole results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]
|
CTD |
PMID:18667591 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
affects response to substance multiple interactions increases phosphorylation
|
ISO
|
BCL2 protein affects the susceptibility to Mebendazole [Mebendazole results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]
|
CTD |
PMID:18667591 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bmp6
|
bone morphogenetic protein 6
|
increases expression
|
ISO
|
Mebendazole results in increased expression of BMP6 mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261
|
|
G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
Mebendazole results in increased activity of CASP3 protein
|
CTD |
PMID:37473966 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp7
|
caspase 7
|
increases activity
|
ISO
|
Mebendazole results in increased activity of CASP7 protein
|
CTD |
PMID:37473966 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Mebendazole results in increased expression of CCL2 protein
|
CTD |
PMID:20116850 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions
|
ISO
|
Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]
|
CTD |
PMID:30075109 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565
|
|
G
|
Cdh2
|
cadherin 2
|
multiple interactions
|
ISO
|
Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]
|
CTD |
PMID:30075109 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression
|
ISO EXP
|
Mebendazole results in increased expression of CYP1A1 mRNA; Mebendazole results in increased expression of CYP1A1 protein
|
CTD |
PMID:9860486 PMID:12841937 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases expression
|
ISO EXP
|
Mebendazole results in increased expression of CYP1A2 protein
|
CTD |
PMID:12841937 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Ereg
|
epiregulin
|
increases expression
|
ISO
|
Mebendazole results in increased expression of EREG mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
Mebendazole results in increased expression of FOS mRNA
|
CTD |
PMID:12730611 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
decreases expression affects binding
|
ISO
|
Mebendazole results in decreased expression of GAPDH mRNA Mebendazole binds to GAPDH protein
|
CTD |
PMID:37473966 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions
|
ISO
|
Mebendazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]
|
CTD |
PMID:23769903 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
Hes1
|
hes family bHLH transcription factor 1
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of HES1 protein
|
CTD |
PMID:32277947 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061
|
|
G
|
Hk1
|
hexokinase 1
|
affects binding decreases expression
|
ISO
|
Mebendazole binds to HK1 protein Mebendazole results in decreased expression of HK1 mRNA
|
CTD |
PMID:37473966 |
|
NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814
|
|
G
|
Il1a
|
interleukin 1 alpha
|
increases expression
|
ISO
|
Mebendazole results in increased expression of IL1A mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression
|
ISO
|
Mebendazole results in increased expression of IL1B mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il24
|
interleukin 24
|
increases expression
|
ISO
|
Mebendazole results in increased expression of IL24 mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr13:44,905,362...44,910,760
Ensembl chr13:44,905,363...44,910,760
|
|
G
|
Il6r
|
interleukin 6 receptor
|
increases expression
|
ISO
|
Mebendazole results in increased expression of IL6R protein modified form
|
CTD |
PMID:20116850 |
|
NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221
|
|
G
|
Ldha
|
lactate dehydrogenase A
|
decreases activity affects binding decreases expression
|
ISO
|
Mebendazole results in decreased activity of LDHA protein Mebendazole binds to LDHA protein Mebendazole results in decreased expression of LDHA mRNA
|
CTD |
PMID:37473966 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation
|
ISO
|
Mebendazole results in increased phosphorylation of MAPK1 protein
|
CTD |
PMID:20848085 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
increases phosphorylation
|
ISO
|
Mebendazole results in increased phosphorylation of MAPK3 protein
|
CTD |
PMID:20848085 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
increases phosphorylation
|
ISO
|
Mebendazole results in increased phosphorylation of MAPK8 protein
|
CTD |
PMID:20848085 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mapk9
|
mitogen-activated protein kinase 9
|
increases phosphorylation
|
ISO
|
Mebendazole results in increased phosphorylation of MAPK9 protein
|
CTD |
PMID:20848085 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of MAPT protein
|
CTD |
PMID:16930453 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Met
|
MET proto-oncogene, receptor tyrosine kinase
|
increases expression
|
ISO
|
Mebendazole results in increased expression of MET mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of MYC mRNA; Mebendazole results in decreased expression of MYC protein
|
CTD |
PMID:31207347 PMID:32277947 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
increases expression
|
ISO
|
Mebendazole results in increased expression of NLRP3 mRNA
|
CTD |
PMID:24747151 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Notch1
|
notch receptor 1
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of NOTCH1 protein
|
CTD |
PMID:32277947 |
|
NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
Mebendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Pid1
|
phosphotyrosine interaction domain containing 1
|
increases expression
|
ISO
|
Mebendazole results in increased expression of PID1 mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression
|
ISO
|
Mebendazole results in increased expression of PTGS2 mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptk2
|
protein tyrosine kinase 2
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of PTK2 protein
|
CTD |
PMID:30075109 |
|
NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091
|
|
G
|
Rac1
|
Rac family small GTPase 1
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of RAC1 protein
|
CTD |
PMID:30075109 |
|
NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109
|
|
G
|
Rhoa
|
ras homolog family member A
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of RHOA protein
|
CTD |
PMID:30075109 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302
|
|
G
|
S100a8
|
S100 calcium binding protein A8
|
increases expression
|
ISO
|
Mebendazole results in increased expression of S100A8 mRNA
|
CTD |
PMID:24747151 |
|
NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:178,464,702...178,465,221
|
|
G
|
S100a9
|
S100 calcium binding protein A9
|
increases expression
|
ISO
|
Mebendazole results in increased expression of S100A9 mRNA
|
CTD |
PMID:24747151 |
|
NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870
|
|
G
|
Slc2a1
|
solute carrier family 2 member 1
|
affects binding decreases expression
|
ISO
|
Mebendazole binds to SLC2A1 protein Mebendazole results in decreased expression of SLC2A1 mRNA
|
CTD |
PMID:37473966 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742
|
|
G
|
Slc47a1
|
solute carrier family 47 member 1
|
decreases expression
|
ISO
|
Mebendazole results in decreased expression of SLC47A1 mRNA
|
CTD |
PMID:28606429 |
|
NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,533,583...46,587,096
|
|
G
|
Slc7a11
|
solute carrier family 7 member 11
|
increases expression
|
ISO
|
Mebendazole results in increased expression of SLC7A11 mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695
|
|
G
|
Slpi
|
secretory leukocyte peptidase inhibitor
|
increases expression
|
ISO
|
Mebendazole results in increased expression of SLPI mRNA
|
CTD |
PMID:32816093 |
|
NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]; Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]
|
CTD |
PMID:30075109 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Thra
|
thyroid hormone receptor alpha
|
multiple interactions
|
ISO
|
Mebendazole binds to and results in decreased activity of THRA protein
|
CTD |
PMID:25752796 |
|
NCBI chr10:84,198,141...84,225,659
Ensembl chr10:84,197,011...84,225,657
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression increases secretion
|
ISO
|
U 0126 inhibits the reaction [Mebendazole results in increased secretion of TNF protein] Mebendazole results in increased expression of TNF mRNA
|
CTD |
PMID:20848085 PMID:24747151 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
ISO
|
Mebendazole results in increased expression of VEGFA protein
|
CTD |
PMID:20116850 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
decreases expression
|
ISO
|
mizolastine results in decreased expression of ICAM1
|
CTD |
PMID:11291777 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity
|
ISO
|
mizolastine results in decreased activity of KCNH2 protein
|
CTD |
PMID:11082114 PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
decreases expression
|
ISO
|
Nocodazole results in decreased expression of ABCC2 mRNA; Nocodazole results in decreased expression of ABCC2 protein
|
CTD |
PMID:10691972 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
increases expression
|
ISO
|
Nocodazole results in increased expression of ABCC3 mRNA
|
CTD |
PMID:10691972 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
increases expression multiple interactions
|
ISO
|
Nocodazole results in increased expression of ACTA2 mRNA 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Nocodazole results in increased expression of ACTA2 mRNA]
|
CTD |
PMID:31170432 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
decreases activity
|
ISO EXP
|
Nocodazole results in decreased activity of AHR protein
|
CTD |
PMID:16611024 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Anapc2
|
anaphase promoting complex subunit 2
|
multiple interactions
|
ISO
|
Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein]
|
CTD |
PMID:21903591 |
|
NCBI chr 3:28,484,590...28,496,338
Ensembl chr 3:28,484,614...28,496,337
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions decreases localization
|
ISO
|
Nocodazole inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein] Nocodazole results in decreased localization of AR protein
|
CTD |
PMID:20807808 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Atm
|
ATM serine/threonine kinase
|
multiple interactions
|
ISO
|
Doxorubicin inhibits the reaction [Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]]; Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]
|
CTD |
PMID:31597699 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629
|
|
G
|
Atp7b
|
ATPase copper transporting beta
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [Copper affects the localization of ATP7B protein]
|
CTD |
PMID:10982773 |
|
NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801
|
|
G
|
Aurka
|
aurora kinase A
|
multiple interactions
|
ISO
|
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased expression of and results in increased phosphorylation of AURKA protein; [bisphenol A analog co-treated with Nocodazole] results in decreased expression of AURKA protein; [bisphenol A co-treated with Nocodazole] results in decreased expression of AURKA protein; MLN8054 inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKA protein]
|
CTD |
PMID:24976383 PMID:35041905 |
|
NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771
|
|
G
|
Aurkb
|
aurora kinase B
|
multiple interactions
|
ISO
|
4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein
|
CTD |
PMID:24976383 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
ISO
|
Nocodazole analog results in increased expression of BAX protein
|
CTD |
PMID:28412508 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
increases phosphorylation decreases expression multiple interactions
|
ISO
|
Nocodazole results in increased phosphorylation of BCL2 protein Nocodazole analog results in decreased expression of BCL2 protein TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein]
|
CTD |
PMID:15907805 PMID:28412508 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
multiple interactions
|
ISO
|
Nocodazole affects the reaction [BIRC5 protein affects the susceptibility to Melphalan]
|
CTD |
PMID:16373717 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Bub1
|
BUB1 mitotic checkpoint serine/threonine kinase
|
multiple interactions increases phosphorylation
|
ISO
|
[Nocodazole co-treated with Caffeine] results in increased expression of BUB1 protein modified form; chromium hexavalent ion inhibits the reaction [Nocodazole results in increased phosphorylation of BUB1 protein]
|
CTD |
PMID:21670593 |
|
NCBI chr 3:135,473,525...135,504,921
Ensembl chr 3:135,472,582...135,504,921
|
|
G
|
Bub3
|
BUB3 mitotic checkpoint protein
|
increases expression
|
ISO
|
Nocodazole results in increased expression of BUB3 protein
|
CTD |
PMID:38851359 |
|
NCBI chr 1:195,760,532...195,771,140
Ensembl chr 1:195,758,105...195,791,028
|
|
G
|
Capza1
|
capping actin protein of muscle Z-line subunit alpha 1
|
multiple interactions
|
ISO
|
[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole
|
CTD |
PMID:22918941 |
|
NCBI chr 2:195,008,035...195,053,100
Ensembl chr 2:195,008,039...195,053,100
|
|
G
|
Capza2
|
capping actin protein of muscle Z-line subunit alpha 2
|
multiple interactions
|
ISO
|
[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole
|
CTD |
PMID:22918941 |
|
NCBI chr 4:46,944,040...46,979,930
Ensembl chr 4:46,895,701...46,979,938
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage multiple interactions decreases expression
|
ISO
|
Nocodazole results in increased cleavage of CASP3 protein [Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; [Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]] Nocodazole analog results in decreased expression of CASP3 protein
|
CTD |
PMID:21903591 PMID:28412508 PMID:31597699 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions increases cleavage
|
ISO
|
Caspase Inhibitors inhibits the reaction [Nocodazole analog results in increased expression of CASP8 protein modified form] Nocodazole analog results in increased cleavage of CASP8 protein
|
CTD |
PMID:28412508 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases cleavage
|
ISO
|
Nocodazole analog results in increased cleavage of CASP9 protein
|
CTD |
PMID:28412508 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Ccar1
|
cell division cycle and apoptosis regulator 1
|
multiple interactions increases expression
|
ISO
|
Nocodazole inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein]; Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein] Nocodazole results in increased expression of CCAR1 protein
|
CTD |
PMID:19073175 PMID:21903591 |
|
NCBI chr20:31,228,624...31,271,233
Ensembl chr20:31,228,624...31,271,227
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Nocodazole results in increased expression of CCL2 protein
|
CTD |
PMID:20116850 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccnb1
|
cyclin B1
|
increases expression
|
ISO
|
Nocodazole analog results in increased expression of CCNB1 protein; Nocodazole results in increased expression of CCNB1 protein
|
CTD |
PMID:21670593 PMID:28412508 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Cdk1
|
cyclin-dependent kinase 1
|
increases expression
|
ISO
|
Nocodazole analog results in increased expression of CDK1 protein
|
CTD |
PMID:28412508 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455
|
|
G
|
Cdt1
|
chromatin licensing and DNA replication factor 1
|
multiple interactions
|
ISO
|
[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of and results in decreased phosphorylation of CDT1 protein
|
CTD |
PMID:21670593 |
|
NCBI chr19:67,529,249...67,534,195
Ensembl chr19:67,529,201...67,534,194
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
affects localization multiple interactions
|
ISO EXP
|
Nocodazole affects the localization of CFTR protein Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]
|
CTD |
PMID:12529251 PMID:15994425 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Chek1
|
checkpoint kinase 1
|
decreases expression
|
ISO
|
Nocodazole results in decreased expression of CHEK1 protein
|
CTD |
PMID:26914363 |
|
NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359
|
|
G
|
Csf2
|
colony stimulating factor 2
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Nocodazole inhibits the reaction [Quercetin results in increased secretion of CSF2 protein]
|
CTD |
PMID:18346843 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
ISO EXP
|
Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of and results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of CYP1A1 mRNA]
|
CTD |
PMID:8190110 PMID:16611024 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Egf
|
epidermal growth factor
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [EGF protein results in increased expression of PSA mRNA]
|
CTD |
PMID:20807808 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
G
|
Faslg
|
Fas ligand
|
multiple interactions
|
ISO
|
[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein
|
CTD |
PMID:15907805 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fbxo5
|
F-box protein 5
|
multiple interactions
|
ISO
|
[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of FBXO5 protein
|
CTD |
PMID:21670593 |
|
NCBI chr 1:44,601,412...44,607,781
Ensembl chr 1:44,601,412...44,607,781
|
|
G
|
Fis1
|
fission, mitochondrial 1
|
increases expression
|
EXP
|
Nocodazole results in increased expression of FIS1 protein
|
CTD |
PMID:26732598 |
|
NCBI chr12:25,345,239...25,360,135
Ensembl chr12:25,345,239...25,349,335
|
|
G
|
Gmnn
|
geminin, DNA replication inhibitor
|
multiple interactions
|
ISO
|
[Nocodazole co-treated with chromium hexavalent ion] results in increased ubiquitination of GMNN protein
|
CTD |
PMID:21670593 |
|
NCBI chr17:40,729,760...40,738,077
Ensembl chr17:40,729,824...40,738,068
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases expression
|
ISO
|
Nocodazole results in increased expression of H2AX protein modified form
|
CTD |
PMID:26914363 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hamp
|
hepcidin antimicrobial peptide
|
decreases expression
|
ISO
|
Nocodazole results in decreased expression of HAMP mRNA
|
CTD |
PMID:25633564 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression
|
EXP
|
Nocodazole results in increased expression of HSPA5 protein
|
CTD |
PMID:26732598 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
|
CTD |
PMID:33377310 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
|
CTD |
PMID:33377310 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Il6r
|
interleukin 6 receptor
|
increases expression
|
ISO
|
Nocodazole results in increased expression of IL6R protein modified form
|
CTD |
PMID:20116850 |
|
NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221
|
|
G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
increases phosphorylation multiple interactions
|
ISO
|
Nocodazole results in increased phosphorylation of JUN protein TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]
|
CTD |
PMID:12221076 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
G
|
Klk1c10
|
kallikrein 1-related peptidase C10
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]
|
CTD |
PMID:20807808 |
|
NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586
|
|
G
|
Lcmt1
|
leucine carboxyl methyltransferase 1
|
decreases response to substance
|
ISO
|
LCMT1 results in decreased susceptibility to Nocodazole
|
CTD |
PMID:17724024 |
|
NCBI chr 1:187,335,173...187,391,195
Ensembl chr 1:187,327,706...187,391,516
|
|
G
|
Lzts1
|
leucine zipper tumor suppressor 1
|
affects response to substance
|
ISO
|
LZTS1 protein affects the susceptibility to Nocodazole
|
CTD |
PMID:17349584 |
|
NCBI chr16:25,309,502...25,364,942
Ensembl chr16:25,309,507...25,364,940
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein] Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]
|
CTD |
PMID:15907805 PMID:17822405 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein] Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]
|
CTD |
PMID:15907805 PMID:17822405 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions increases phosphorylation
|
ISO
|
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:12221076 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
G
|
Mapk9
|
mitogen-activated protein kinase 9
|
increases phosphorylation multiple interactions
|
ISO
|
Nocodazole results in increased phosphorylation of MAPK9 protein TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein]
|
CTD |
PMID:12221076 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
decreases expression
|
ISO
|
Nocodazole results in decreased expression of MAPT protein
|
CTD |
PMID:16930453 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
G
|
Myt1
|
myelin transcription factor 1
|
increases phosphorylation
|
ISO
|
Nocodazole results in increased phosphorylation of MYT1 protein
|
CTD |
PMID:16611024 |
|
NCBI chr 3:189,263,569...189,327,844
Ensembl chr 3:189,263,467...189,327,844
|
|
G
|
Nanog
|
Nanog homeobox
|
decreases expression
|
ISO
|
Nocodazole results in decreased expression of NANOG protein
|
CTD |
PMID:21559451 |
|
NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061
|
|
G
|
Ngf
|
nerve growth factor
|
multiple interactions
|
EXP
|
Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]; Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]
|
CTD |
PMID:17822405 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834
|
|
G
|
Notch1
|
notch receptor 1
|
decreases expression multiple interactions
|
ISO
|
Nocodazole results in decreased expression of NOTCH1 protein BI 2536 inhibits the reaction [Nocodazole results in decreased expression of NOTCH1 protein]; Doxorubicin inhibits the reaction [Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]]; Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]
|
CTD |
PMID:31597699 |
|
NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613
|
|
G
|
Npc1
|
NPC intracellular cholesterol transporter 1
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin]
|
CTD |
PMID:16174794 |
|
NCBI chr18:3,654,237...3,699,853
Ensembl chr18:3,654,237...3,699,800
|
|
G
|
Npm1
|
nucleophosmin 1
|
affects phosphorylation
|
ISO
|
Nocodazole affects the phosphorylation of NPM1 protein
|
CTD |
PMID:15190079 |
|
NCBI chr10:18,245,739...18,255,913
Ensembl chr10:18,245,740...18,256,024 Ensembl chr X:18,245,740...18,256,024
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Ntrk1
|
neurotrophic receptor tyrosine kinase 1
|
multiple interactions
|
EXP
|
Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]
|
CTD |
PMID:17822405 |
|
NCBI chr 2:175,534,844...175,551,664
Ensembl chr 2:175,534,844...175,551,787
|
|
G
|
Optn
|
optineurin
|
affects localization
|
ISO
|
Nocodazole affects the localization of OPTN protein
|
CTD |
PMID:25096716 |
|
NCBI chr17:78,118,847...78,169,543
Ensembl chr17:78,118,866...78,169,543
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO
|
TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein] Nocodazole analog results in increased cleavage of PARP1 protein; Nocodazole results in increased cleavage of PARP1 protein
|
CTD |
PMID:15907805 PMID:21903591 PMID:28412508 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Plk1
|
polo-like kinase 1
|
multiple interactions decreases phosphorylation
|
ISO
|
[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein; Doxorubicin affects the reaction [[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein] Nocodazole results in decreased phosphorylation of PLK1 protein
|
CTD |
PMID:31597699 |
|
NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:186,147,658...186,157,637
|
|
G
|
Pou5f1
|
POU class 5 homeobox 1
|
decreases expression
|
ISO
|
Nocodazole results in decreased expression of POU5F1 protein
|
CTD |
PMID:21559451 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598
|
|
G
|
Ppp2r2a
|
protein phosphatase 2, regulatory subunit B, alpha
|
decreases response to substance
|
ISO
|
PPP2R2A results in decreased susceptibility to Nocodazole
|
CTD |
PMID:17724024 |
|
NCBI chr15:45,380,142...45,439,428
Ensembl chr15:45,379,683...45,439,405
|
|
G
|
Qrich1
|
glutamine-rich 1
|
multiple interactions increases phosphorylation
|
ISO
|
Genistein inhibits the reaction [Nocodazole results in increased phosphorylation of QRICH1 protein]
|
CTD |
PMID:17510977 |
|
NCBI chr 8:118,095,435...118,135,001
Ensembl chr 8:118,095,429...118,134,999
|
|
G
|
Rangap1
|
RAN GTPase activating protein 1
|
multiple interactions
|
ISO
|
Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein]
|
CTD |
PMID:21646468 |
|
NCBI chr 7:115,104,820...115,130,564
Ensembl chr 7:115,104,823...115,130,564
|
|
G
|
Rap1a
|
RAP1A, member of RAS oncogene family
|
multiple interactions
|
EXP
|
Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]
|
CTD |
PMID:17822405 |
|
NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:195,896,971...195,974,808
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]
|
CTD |
PMID:29247640 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Sumo1
|
small ubiquitin-like modifier 1
|
multiple interactions
|
ISO
|
Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein]
|
CTD |
PMID:21646468 |
|
NCBI chr 9:68,572,901...68,602,803
Ensembl chr 9:68,572,911...68,602,890
|
|
G
|
Tf
|
transferrin
|
decreases expression
|
ISO
|
Nocodazole results in decreased expression of TRF protein
|
CTD |
PMID:34089742 |
|
NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
|
CTD |
PMID:33377310 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions increases expression
|
ISO
|
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein] Nocodazole analog results in increased expression of TP53 protein; Nocodazole results in increased expression of TP53 protein
|
CTD |
PMID:12221076 PMID:21559451 PMID:28412508 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tuba1a
|
tubulin, alpha 1A
|
multiple interactions
|
ISO
|
Nocodazole inhibits the reaction [TUBA1A protein binds to TUBA1A protein]
|
CTD |
PMID:19222062 |
|
NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:131,968,770...131,996,035
|
|
G
|
Tymp
|
thymidine phosphorylase
|
multiple interactions
|
ISO
|
[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein]; TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein]
|
CTD |
PMID:15907805 |
|
NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression
|
ISO
|
Nocodazole results in increased expression of VEGFA protein
|
CTD |
PMID:20116850 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]
|
CTD |
PMID:21413024 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Flt1
|
Fms related receptor tyrosine kinase 1
|
multiple interactions
|
ISO
|
NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]; paxilline inhibits the reaction [NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]
|
CTD |
PMID:25371888 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750
|
|
G
|
Kcnma1
|
potassium calcium-activated channel subfamily M alpha 1
|
multiple interactions
|
ISO
|
NS 1619 binds to and results in increased activity of KCNMA1 protein; NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]
|
CTD |
PMID:21413024 |
|
NCBI chr15:351,065...1,057,117
Ensembl chr15:351,659...1,057,117
|
|
G
|
Kcnmb1
|
potassium calcium-activated channel subfamily M regulatory beta subunit 1
|
multiple interactions
|
ISO
|
NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]
|
CTD |
PMID:21413024 |
|
NCBI chr10:19,062,014...19,119,005
Ensembl chr10:19,062,291...19,073,204
|
|
|
G
|
Abca1
|
ATP binding cassette subfamily A member 1
|
increases expression
|
ISO
|
Omeprazole results in increased expression of ABCA1 mRNA
|
CTD |
PMID:20060385 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
decreases activity
|
ISO
|
Omeprazole results in decreased activity of ABCB11 protein
|
CTD |
PMID:20829430 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
affects expression multiple interactions
|
EXP ISO
|
Omeprazole affects the expression of ABCB1A mRNA Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1 protein] Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1A protein]
|
CTD |
PMID:19483382 PMID:30452898 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
decreases expression
|
ISO
|
Omeprazole results in decreased expression of ABCB4 mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
ISO
|
[Omeprazole results in increased susceptibility to Cisplatin] which results in decreased expression of ABCC2 protein
|
CTD |
PMID:35447140 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
increases expression
|
EXP
|
Omeprazole results in increased expression of ABCC3 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Abcc6
|
ATP binding cassette subfamily C member 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABCC6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
increases expression multiple interactions
|
ISO
|
Omeprazole results in increased expression of ABCG2 mRNA alternative form; Omeprazole results in increased expression of ABCG2 protein Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow]
|
CTD |
PMID:20804740 PMID:31348918 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Abcg5
|
ATP binding cassette subfamily G member 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABCG5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376
|
|
G
|
Abhd1
|
abhydrolase domain containing 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABHD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:31,142,476...31,147,464
Ensembl chr 6:31,142,476...31,147,464
|
|
G
|
Abhd14b
|
abhydrolase domain containing 14b
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABHD14B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:115,966,792...115,970,829
Ensembl chr 8:115,965,932...115,970,833
|
|
G
|
Abhd17a
|
abhydrolase domain containing 17A, depalmitoylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of ABHD17A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:9,775,016...9,781,447
|
|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACACA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888
|
|
G
|
Acadl
|
acyl-CoA dehydrogenase, long chain
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACADL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:75,783,689...75,822,077
Ensembl chr 9:75,783,689...75,822,164
|
|
G
|
Ace2
|
angiotensin converting enzyme 2
|
decreases expression
|
EXP ISO
|
Omeprazole results in decreased expression of ACE2 mRNA
|
CTD |
PMID:32808185 |
|
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596
|
|
G
|
Aco1
|
aconitase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:60,055,895...60,111,920
Ensembl chr 5:60,055,866...60,112,600
|
|
G
|
Aco2
|
aconitase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACO2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:115,265,816...115,308,931
Ensembl chr 7:115,265,791...115,308,892
|
|
G
|
Acot12
|
acyl-CoA thioesterase 12
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACOT12 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:24,721,648...24,763,686
Ensembl chr 2:24,721,910...24,765,298
|
|
G
|
Acot4
|
acyl-CoA thioesterase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of ACOT4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138
|
|
G
|
Adam15
|
ADAM metallopeptidase domain 15
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADAM15 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:177,052,363...177,062,879
Ensembl chr 2:177,052,363...177,062,849
|
|
G
|
Add1
|
adducin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:80,333,242...80,401,641
Ensembl chr14:80,333,244...80,391,732
|
|
G
|
Adh1c
|
alcohol dehydrogenase 1C (class I), gamma polypeptide
|
decreases expression
|
ISO
|
Omeprazole results in decreased expression of ADH1C mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291
|
|
G
|
Adh4
|
alcohol dehydrogenase 4 (class II), pi polypeptide
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADH4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:229,622,092...229,640,120
Ensembl chr 2:229,622,095...229,641,879
|
|
G
|
Adtrp
|
androgen-dependent TFPI-regulating protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of ADTRP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:23,113,578...23,199,616
Ensembl chr17:23,135,809...23,216,622
|
|
G
|
Afm
|
afamin
|
affects expression
|
EXP
|
Omeprazole affects the expression of AFM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:17,815,194...17,848,042
Ensembl chr14:17,815,194...17,848,039
|
|
G
|
Agt
|
angiotensinogen
|
affects expression
|
EXP
|
Omeprazole affects the expression of AGT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
affects expression
|
EXP
|
Omeprazole affects the expression of AGTR1A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions decreases activity increases activity increases expression decreases expression affects localization increases response to substance
|
ISO EXP
|
AG-879 inhibits the reaction [Omeprazole results in increased activity of AHR protein]; AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of AHR mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]; Omeprazole binds to and results in increased activity of AHR protein; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; omeprazole sulfide inhibits the reaction [Omeprazole results in increased activity of AHR protein]; Puromycin inhibits the reaction [Omeprazole results in increased expression of AHR protein] Omeprazole results in decreased activity of AHR protein Omeprazole affects the localization of AHR protein AHR protein results in increased susceptibility to Omeprazole [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Omeprazole affects the localization of [ARNT protein co-treated with AHR protein]
|
CTD |
PMID:9139728 PMID:9395520 PMID:14742684 PMID:16109480 PMID:20171196 PMID:21703235 PMID:21861773 PMID:21924250 PMID:22687989 PMID:23850985 PMID:25797602 PMID:25826687 PMID:26187274 PMID:26272953 PMID:31669099 More...
|
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Akr1a1
|
aldo-keto reductase family 1 member A1
|
affects expression
|
EXP
|
Omeprazole affects the expression of AKR1A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035
|
|
G
|
Akr7a2
|
aldo-keto reductase family 7, member A2
|
affects expression
|
EXP
|
Omeprazole affects the expression of AKR7A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:156,835,551...156,844,109
|
|
G
|
Akr7a3
|
aldo-keto reductase family 7 member A3
|
affects expression multiple interactions
|
EXP
|
Omeprazole affects the expression of AKR7A3 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA
|
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153
|
|
G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
affects expression multiple interactions
|
EXP
|
Omeprazole affects the expression of ALDH1A1 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ALDH1A1 mRNA
|
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
G
|
Aldh1a3
|
aldehyde dehydrogenase 1 family, member A3
|
increases expression
|
ISO
|
Omeprazole results in increased expression of ALDH1A3 mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777
|
|
G
|
Aldh1a7
|
aldehyde dehydrogenase family 1, subfamily A7
|
affects expression
|
EXP
|
Omeprazole affects the expression of ALDH1A7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:227,627,977...227,667,877
Ensembl chr 1:227,627,448...227,672,523
|
|
G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
affects expression
|
EXP
|
Omeprazole affects the expression of ALDH2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219
|
|
G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
increases expression
|
ISO
|
Omeprazole results in increased expression of ALDH3A1 mRNA
|
CTD |
PMID:12040753 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
G
|
Alkbh7
|
alkB homolog 7
|
affects expression
|
EXP
|
Omeprazole affects the expression of ALKBH7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:1,925,896...1,928,048
Ensembl chr 9:1,925,743...1,928,048
|
|
G
|
Ap2m1
|
adaptor related protein complex 2 subunit mu 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of AP2M1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:93,859,690...93,868,600
Ensembl chr11:93,859,690...93,868,480
|
|
G
|
Apcs
|
amyloid P component, serum
|
affects expression
|
EXP
|
Omeprazole affects the expression of APCS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:87,905,532...87,906,508
Ensembl chr13:87,905,532...87,928,824
|
|
G
|
Apoa4
|
apolipoprotein A4
|
affects expression
|
EXP
|
Omeprazole affects the expression of APOA4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164
|
|
G
|
Apoh
|
apolipoprotein H
|
affects expression
|
EXP
|
Omeprazole affects the expression of APOH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:93,841,992...93,855,897
Ensembl chr10:93,841,966...93,857,127
|
|
G
|
Apool
|
apolipoprotein O-like
|
affects expression
|
EXP
|
Omeprazole affects the expression of APOOL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:81,569,960...81,635,906
Ensembl chr X:81,570,053...81,640,036
|
|
G
|
Arg1
|
arginase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ARG1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Arl6ip1
|
ARL6 interacting reticulophagy regulator 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ARL6IP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:181,864,717...181,874,232
Ensembl chr 1:181,864,746...181,874,232
|
|
G
|
Arnt
|
aryl hydrocarbon receptor nuclear translocator
|
multiple interactions affects localization
|
ISO EXP
|
Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter] Omeprazole affects the localization of ARNT protein Omeprazole affects the localization of [ARNT protein co-treated with AHR protein]
|
CTD |
PMID:9395520 PMID:21703235 PMID:25826687 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546
|
|
G
|
Asgr2
|
asialoglycoprotein receptor 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ASGR2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:55,320,082...55,333,294
Ensembl chr10:55,320,091...55,333,263
|
|
G
|
Atf5
|
activating transcription factor 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATF5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183
|
|
G
|
Atp5f1e
|
ATP synthase F1 subunit epsilon
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP5F1E mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:183,677,270...183,680,172
Ensembl chr 3:183,677,273...183,680,214
|
|
G
|
Atp6ap2
|
ATPase H+ transporting accessory protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP6AP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:12,856,708...12,883,670
Ensembl chr X:12,855,859...12,905,875
|
|
G
|
Atp6v1a
|
ATPase H+ transporting V1 subunit A
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP6V1A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:70,066,800...70,120,603
Ensembl chr11:70,035,134...70,120,603
|
|
G
|
Atp6v1f
|
ATPase H+ transporting V1 subunit F
|
affects expression
|
EXP
|
Omeprazole affects the expression of ATP6V1F mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:59,033,020...59,035,980
|
|
G
|
Atp7a
|
ATPase copper transporting alpha
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein] Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein]; Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein]
|
CTD |
PMID:25337692 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093
|
|
G
|
Baat
|
bile acid CoA:amino acid N-acyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of BAAT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:68,647,166...68,656,137
Ensembl chr 5:68,646,203...68,656,181
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of BAX protein]
|
CTD |
PMID:30452898 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]
|
CTD |
PMID:30452898 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl6b
|
BCL6B, transcription repressor
|
affects expression
|
EXP
|
Omeprazole affects the expression of BCL6B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:55,439,566...55,444,631
Ensembl chr10:55,432,382...55,444,631
|
|
G
|
Bltp3b
|
bridge-like lipid transfer protein family member 3B
|
affects expression
|
EXP
|
Omeprazole affects the expression of BLTP3B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:26,068,948...26,149,033
Ensembl chr 7:26,068,955...26,149,083
|
|
G
|
Bmf
|
Bcl2 modifying factor
|
affects expression
|
EXP
|
Omeprazole affects the expression of BMF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258
|
|
G
|
Bmx
|
BMX non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]
|
CTD |
PMID:21861773 |
|
NCBI chr X:33,859,128...33,921,876
Ensembl chr X:33,859,129...33,921,874
|
|
G
|
Bnip3
|
BCL2 interacting protein 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of BNIP3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962
|
|
G
|
Btf3
|
basic transcription factor 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of BTF3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:31,394,010...31,401,138
Ensembl chr 2:31,394,011...31,401,125 Ensembl chr13:31,394,011...31,401,125
|
|
G
|
C1qa
|
complement C1q A chain
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of C1QA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732
|
|
G
|
C1qbp
|
complement C1q binding protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of C1QBP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:56,198,534...56,203,185
Ensembl chr10:56,198,540...56,203,235
|
|
G
|
C1qc
|
complement C1q C chain
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of C1QC mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468
|
|
G
|
C1s
|
complement C1s
|
affects expression
|
EXP
|
Omeprazole affects the expression of C1S mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736
|
|
G
|
C2cd2
|
C2 calcium-dependent domain containing 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of C2CD2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016
|
|
G
|
C4bpa
|
complement component 4 binding protein, alpha
|
affects expression decreases expression
|
EXP
|
Omeprazole affects the expression of C4BPA mRNA Omeprazole results in decreased expression of C4BPA mRNA
|
CTD |
PMID:19483382 PMID:25626140 |
|
NCBI chr13:44,627,959...44,663,552
Ensembl chr13:44,627,982...44,663,471
|
|
G
|
C4bpb
|
complement component 4 binding protein, beta
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of C4BPB mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,673,064...44,683,781
Ensembl chr13:44,673,065...44,683,793
|
|
G
|
C7
|
complement C7
|
affects expression
|
EXP
|
Omeprazole affects the expression of C7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:55,815,687...55,892,605
Ensembl chr 2:55,816,807...55,892,672
|
|
G
|
C8b
|
complement C8 beta chain
|
affects expression
|
EXP
|
Omeprazole affects the expression of C8B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:124,763,974...124,801,522
Ensembl chr 5:124,761,790...124,801,516
|
|
G
|
Ca3
|
carbonic anhydrase 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of CAR3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524
|
|
G
|
Cadps2
|
calcium dependent secretion activator 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of CADPS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:52,746,054...53,275,252
Ensembl chr 4:52,746,065...53,275,004
|
|
G
|
Caprin1
|
cell cycle associated protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CAPRIN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:110,606,489...110,685,408
Ensembl chr 3:110,606,489...110,685,562
|
|
G
|
Car2
|
carbonic anhydrase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of CA2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064
|
|
G
|
Casp3
|
caspase 3
|
increases activity multiple interactions affects expression increases cleavage
|
ISO EXP
|
Omeprazole analog results in increased activity of CASP3 protein; Omeprazole results in increased activity of CASP3 protein Omeprazole inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] Omeprazole inhibits the reaction [Ethanol results in increased activity of CASP3 protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of CASP3 mRNA]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of CASP3 protein] Omeprazole affects the expression of CASP3 mRNA Omeprazole results in increased cleavage of CASP3 protein
|
CTD |
PMID:15461867 PMID:18336733 PMID:19251492 PMID:19483382 PMID:25637687 PMID:30452898 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases cleavage
|
ISO
|
Omeprazole analog results in increased cleavage of CASP8 protein
|
CTD |
PMID:18336733 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Cat
|
catalase
|
increases activity multiple interactions
|
EXP ISO
|
Omeprazole results in increased activity of CAT protein Omeprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein] Omeprazole inhibits the reaction [Acetic Acid results in increased activity of CAT protein]
|
CTD |
PMID:18547560 PMID:28849987 PMID:33245926 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Cbr1
|
carbonyl reductase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CBR1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104 Ensembl chr11:46,378,411...46,381,104
|
|
G
|
Cckbr
|
cholecystokinin B receptor
|
multiple interactions
|
ISO
|
[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3
|
CTD |
PMID:17704804 |
|
NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745
|
|
G
|
Ccnd1
|
cyclin D1
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of CCND1 mRNA
|
CTD |
PMID:17202759 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
Omeprazole results in increased expression of CDKN1A protein
|
CTD |
PMID:27358234 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdo1
|
cysteine dioxygenase type 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CDO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:41,619,076...41,633,719
Ensembl chr18:41,619,070...41,633,891
|
|
G
|
Cept1
|
choline/ethanolamine phosphotransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CEPT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:196,682,455...196,724,430
Ensembl chr 2:196,681,681...196,723,812
|
|
G
|
Ces2h
|
carboxylesterase 2H
|
affects expression
|
EXP
|
Omeprazole affects the expression of CES2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752
|
|
G
|
Cfi
|
complement factor I
|
affects expression decreases expression
|
EXP
|
Omeprazole affects the expression of CFI mRNA Omeprazole results in decreased expression of CFI mRNA
|
CTD |
PMID:19483382 PMID:25626140 |
|
NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786
|
|
G
|
Cftr
|
CF transmembrane conductance regulator
|
affects metabolic processing
|
ISO
|
CFTR protein affects the metabolism of Omeprazole
|
CTD |
PMID:15319328 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
G
|
Chp1
|
calcineurin-like EF-hand protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CHP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:126,989,579...127,042,443
|
|
G
|
Cisd1
|
CDGSH iron sulfur domain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CISD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:17,254,462...17,267,843
Ensembl chr20:17,254,187...17,271,042
|
|
G
|
Clcn4
|
chloride voltage-gated channel 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of CLCN4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:27,290,769...27,356,967
Ensembl chr X:27,290,868...27,356,939
|
|
G
|
Clpp
|
caseinolytic mitochondrial matrix peptidase proteolytic subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of CLPP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:1,917,305...1,924,706
Ensembl chr 9:1,918,682...1,924,705
|
|
G
|
Clptm1l
|
CLPTM1-like
|
affects expression
|
EXP
|
Omeprazole affects the expression of CLPTM1L mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:31,496,094...31,512,148
Ensembl chr 1:31,496,094...31,512,077
|
|
G
|
Cmbl
|
carboxymethylenebutenolidase homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of CMBL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880
|
|
G
|
Cmpk1
|
cytidine/uridine monophosphate kinase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CMPK1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:133,717,073...133,744,623
Ensembl chr 5:133,717,086...133,744,596
|
|
G
|
Copg1
|
COPI coat complex subunit gamma 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of COPG1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:121,923,644...121,949,819
Ensembl chr 4:121,923,873...121,949,812
|
|
G
|
Cops4
|
COP9 signalosome subunit 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of COPS4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:9,382,897...9,413,216
Ensembl chr14:9,382,900...9,413,107
|
|
G
|
Coq3
|
coenzyme Q3 methyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of COQ3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:40,226,313...40,257,383
Ensembl chr 5:40,226,368...40,257,617
|
|
G
|
Cox4i1
|
cytochrome c oxidase subunit 4i1
|
affects expression
|
EXP
|
Omeprazole affects the expression of COX4I1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:65,630,383...65,636,623
Ensembl chr19:65,630,432...65,636,624
|
|
G
|
Cpn1
|
carboxypeptidase N subunit 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CPN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:252,793,786...252,822,675
Ensembl chr 1:252,793,423...252,822,664
|
|
G
|
Cpq
|
carboxypeptidase Q
|
affects expression
|
EXP
|
Omeprazole affects the expression of CPQ mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:66,148,973...66,719,189
Ensembl chr 7:66,149,377...66,716,137
|
|
G
|
Crem
|
cAMP responsive element modulator
|
affects expression
|
EXP
|
Omeprazole affects the expression of CREM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160
|
|
G
|
Csnk2b
|
casein kinase 2 beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of CSNK2B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525
|
|
G
|
Csrp1
|
cysteine and glycine-rich protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CSRP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139
|
|
G
|
Ctnna1
|
catenin alpha 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CTNNA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:27,002,330...27,135,009
Ensembl chr18:26,999,820...27,135,007
|
|
G
|
Ctsb
|
cathepsin B
|
decreases activity
|
ISO
|
Omeprazole results in decreased activity of CTSB protein
|
CTD |
PMID:34871754 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478
|
|
G
|
Ctsd
|
cathepsin D
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Cysteamine results in increased expression of CTSD protein]
|
CTD |
PMID:20165931 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821
|
|
G
|
Ctse
|
cathepsin E
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of CTSE
|
CTD |
PMID:7575556 |
|
NCBI chr13:45,644,168...45,666,722
Ensembl chr13:45,644,147...45,666,722
|
|
G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
decreases expression multiple interactions
|
ISO
|
Omeprazole results in decreased expression of CXCR4 mRNA AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]
|
CTD |
PMID:25826687 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases activity multiple interactions decreases activity increases expression
|
ISO EXP
|
Omeprazole results in increased activity of CYP1A1 promoter Omeprazole inhibits the reaction [Oxygen results in increased expression of CYP1A1 protein]; Omeprazole promotes the reaction [Oxygen results in decreased expression of CYP1A1 mRNA] Omeprazole results in decreased activity of CYP1A1 protein Omeprazole results in increased expression of CYP1A1 mRNA; Omeprazole results in increased expression of CYP1A1 protein [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; lavendustin A inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Staurosporine inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA] AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter]
|
CTD |
PMID:8647108 PMID:8900397 PMID:9041675 PMID:9139728 PMID:9152597 PMID:9395520 PMID:9860486 PMID:10103034 PMID:10859152 PMID:11454723 PMID:11849738 PMID:12040753 PMID:12623754 PMID:12841937 PMID:14742684 PMID:14987951 PMID:15681896 PMID:15860653 PMID:17202759 PMID:17954527 PMID:18420780 PMID:18502397 PMID:19118567 PMID:20171196 PMID:21666223 PMID:21703235 PMID:21784029 PMID:22687989 PMID:25626140 PMID:25826687 PMID:26187180 PMID:26272953 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases activity increases expression decreases activity multiple interactions
|
ISO EXP
|
Omeprazole results in increased activity of CYP1A2 promoter; Omeprazole results in increased activity of CYP1A2 protein Omeprazole results in increased expression of CYP1A2 mRNA; Omeprazole results in increased expression of CYP1A2 protein Omeprazole results in decreased activity of CYP1A2 protein [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA [Omeprazole results in increased expression of CYP1A2 protein] which results in decreased alkylation of Phenacetin; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; Omeprazole results in increased expression of and results in increased activity of CYP1A2 protein
|
CTD |
PMID:9152597 PMID:9744552 PMID:12040753 PMID:12623754 PMID:12841937 PMID:15681896 PMID:15802389 PMID:16035375 PMID:17954527 PMID:18332078 PMID:18420780 PMID:18502397 PMID:19118567 PMID:19230594 PMID:20171196 PMID:21784029 PMID:21924250 PMID:22524704 PMID:22687989 PMID:23274770 PMID:23850985 PMID:24752503 PMID:25626140 PMID:26204831 PMID:27794450 PMID:30044681 PMID:31863871 PMID:36288780 More...
|
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
multiple interactions affects expression decreases activity increases expression
|
ISO
|
Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter] Omeprazole affects the expression of CYP1B1 mRNA Omeprazole results in decreased activity of CYP1B1 protein Omeprazole results in increased expression of CYP1B1 mRNA
|
CTD |
PMID:12040753 PMID:12623754 PMID:18420780 PMID:21703235 PMID:25826687 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp2a1
|
cytochrome P450, family 2, subfamily a, polypeptide 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:91,359,278...91,372,554
Ensembl chr 1:91,359,272...91,389,730
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of CYP2B1 mRNA; Omeprazole results in increased expression of CYP2B1 protein
|
CTD |
PMID:9152597 PMID:19118567 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
increases expression affects expression
|
EXP
|
Omeprazole results in increased expression of CYP2B2 protein Omeprazole affects the expression of CYP2B2 mRNA
|
CTD |
PMID:9152597 PMID:19483382 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
affects expression decreases activity increases expression increases activity
|
EXP ISO
|
Omeprazole affects the expression of CYP2B3 mRNA Omeprazole results in decreased activity of CYP2B10 protein Omeprazole results in increased expression of CYP2B6 mRNA Omeprazole results in increased activity of CYP2B6 protein
|
CTD |
PMID:17954527 PMID:18420780 PMID:19118567 PMID:19483382 PMID:22524704 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
decreases metabolic processing decreases activity multiple interactions increases hydroxylation increases metabolic processing affects metabolic processing
|
ISO
|
CYP2C19 gene alternative form results in decreased metabolism of Omeprazole Omeprazole results in decreased activity of CYP2C19 protein [5-bromotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-chlorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [7-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Chloramphenicol results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [indopan results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Tryptamines analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin]; Omeprazole inhibits the reaction [CYP2C19 protein results in decreased methylation of adinazolam]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of auriculasin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of Clopidogrel] CYP2C19 protein results in increased hydroxylation of Omeprazole CYP2C19 protein results in increased metabolism of Omeprazole CYP2C19 protein affects the metabolism of Omeprazole
|
CTD |
PMID:8930576 PMID:9600717 PMID:11752104 PMID:12464242 PMID:12467917 PMID:12485723 PMID:12637241 PMID:14586384 PMID:15258107 PMID:15286053 PMID:15306208 PMID:15626586 PMID:16035375 PMID:17565714 PMID:17702393 PMID:18511451 PMID:18520598 PMID:19812348 PMID:20573087 PMID:21277363 PMID:21795468 PMID:21915887 PMID:22634058 PMID:26599973 PMID:31515991 More...
|
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2d1
|
cytochrome P450, family 2, subfamily d, polypeptide 1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of CYP2D9 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 7:115,789,026...115,793,430
Ensembl chr 7:115,789,023...115,793,479
|
|
G
|
Cyp2d3
|
cytochrome P450, family 2, subfamily d, polypeptide 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2D3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:115,797,785...115,802,142
Ensembl chr 7:115,797,789...115,802,158
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
affects expression decreases activity
|
EXP ISO
|
Omeprazole affects the expression of CYP2D4 mRNA Omeprazole results in decreased activity of CYP2D6 protein
|
CTD |
PMID:18420780 PMID:19483382 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
ISO
|
Omeprazole results in increased expression of and results in increased activity of CYP2E1 protein
|
CTD |
PMID:15802389 PMID:36243147 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp2f4
|
cytochrome P450, family 2, subfamily f, polypeptide 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2F4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553
|
|
G
|
Cyp2j4
|
cytochrome P450, family 2, subfamily j, polypeptide 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2J4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042
|
|
G
|
Cyp2t1
|
cytochrome P450, family 2, subfamily t, polypeptide 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP2T1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:91,573,923...91,579,215
Ensembl chr 1:91,574,572...91,579,215
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
affects metabolic processing increases metabolic processing multiple interactions increases expression
|
ISO
|
CYP3A4 protein affects the metabolism of Omeprazole CYP3A4 protein results in increased metabolism of Omeprazole [Omeprazole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein affects the reaction [Omeprazole results in increased expression of CYP3A4 mRNA]; Omeprazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Omeprazole results in increased expression of and results in increased activity of CYP3A4 protein Omeprazole results in increased expression of CYP3A4 mRNA; Omeprazole results in increased expression of CYP3A4 protein
|
CTD |
PMID:7870052 PMID:8930576 PMID:9744552 PMID:12235278 PMID:12485723 PMID:12695340 PMID:15286053 PMID:15466163 PMID:15626586 PMID:15802389 PMID:17041008 PMID:17565714 PMID:17954527 PMID:19118567 PMID:19299527 PMID:22634058 More...
|
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
affects expression increases expression
|
EXP
|
Omeprazole affects the expression of CYP3A23-3A1 mRNA Omeprazole results in increased expression of CYP3A23-3A1 mRNA
|
CTD |
PMID:19118567 PMID:19483382 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
affects expression increases expression
|
EXP ISO
|
Omeprazole affects the expression of CYP3A9 mRNA Omeprazole results in increased expression of CYP3A5 mRNA
|
CTD |
PMID:19118567 PMID:19483382 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Cyp4a8
|
cytochrome P450, family 4, subfamily a, polypeptide 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP4A8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:133,938,882...133,970,226
Ensembl chr 5:133,938,883...133,970,226
|
|
G
|
Cyp4f6
|
cytochrome P450, family 4, subfamily f, polypeptide 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of CYP4F6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:12,680,799...12,708,378
Ensembl chr 7:12,680,806...12,708,402
|
|
G
|
Dbi
|
diazepam binding inhibitor
|
affects expression
|
EXP
|
Omeprazole affects the expression of DBI mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450
|
|
G
|
Dcaf11
|
DDB1 and CUL4 associated factor 11
|
affects expression
|
EXP
|
Omeprazole affects the expression of DCAF11 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:33,015,370...33,027,407
Ensembl chr15:33,016,762...33,027,672
|
|
G
|
Dcxr
|
dicarbonyl and L-xylulose reductase
|
affects expression
|
EXP
|
Omeprazole affects the expression of DCXR mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:106,504,730...106,506,619
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
Omeprazole results in increased expression of DDIT3 protein
|
CTD |
PMID:27358234 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Decr1
|
2,4-dienoyl-CoA reductase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of DECR1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033
|
|
G
|
Dexi
|
Dexi homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of DEXI mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:5,632,400...5,645,653
Ensembl chr10:5,632,961...5,645,648
|
|
G
|
Dgat1
|
diacylglycerol O-acyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of DGAT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:110,098,906...110,115,016
|
|
G
|
Dhcr24
|
24-dehydrocholesterol reductase
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHCR24 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936
|
|
G
|
Dhrs4
|
dehydrogenase/reductase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHRS4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:32,924,482...32,948,103
Ensembl chr15:32,936,522...32,948,101
|
|
G
|
Dhrs7b
|
dehydrogenase/reductase 7B
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHRS7B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:46,003,845...46,036,498
Ensembl chr10:46,003,845...46,036,499
|
|
G
|
Dhx16
|
DEAH-box helicase 16
|
affects expression
|
EXP
|
Omeprazole affects the expression of DHX16 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:2,866,804...2,879,790
Ensembl chr20:2,866,804...2,879,751
|
|
G
|
Dmac2l
|
distal membrane arm assembly component 2 like
|
affects expression
|
EXP
|
Omeprazole affects the expression of DMAC2L mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:93,941,690...93,960,662
|
|
G
|
Dnajc3
|
DnaJ heat shock protein family (Hsp40) member C3
|
affects expression
|
EXP
|
Omeprazole affects the expression of DNAJC3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:102,432,667...102,475,643
Ensembl chr15:102,432,663...102,475,643
|
|
G
|
Dpp4
|
dipeptidylpeptidase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of DPP4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422
|
|
G
|
Dpyd
|
dihydropyrimidine dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of DPYD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:209,293,929...210,159,778
|
|
G
|
Ears2
|
glutamyl-tRNA synthetase 2, mitochondrial
|
affects expression
|
EXP
|
Omeprazole affects the expression of EARS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:186,025,740...186,057,165
|
|
G
|
Echs1
|
enoyl-CoA hydratase, short chain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ECHS1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506
|
|
G
|
Eci1
|
enoyl-CoA delta isomerase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ECI1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:13,961,250...13,974,595
Ensembl chr10:13,961,218...13,974,773
|
|
G
|
Eci2
|
enoyl-CoA delta isomerase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of ECI2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:30,056,274...30,092,169
Ensembl chr17:30,076,524...30,092,161
|
|
G
|
Eef1g
|
eukaryotic translation elongation factor 1 gamma
|
affects expression
|
EXP
|
Omeprazole affects the expression of EEF1G mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:215,289,815...215,300,421
Ensembl chr 1:215,277,860...215,301,479
|
|
G
|
Egf
|
epidermal growth factor
|
multiple interactions
|
ISO
|
Omeprazole promotes the reaction [Indomethacin results in increased expression of EGF protein]
|
CTD |
PMID:18431645 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
G
|
Ehhadh
|
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of EHHADH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662
|
|
G
|
Eif4a2
|
eukaryotic translation initiation factor 4A2
|
affects expression
|
EXP
|
Omeprazole affects the expression of EIF4A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:91,268,730...91,276,738
Ensembl chr11:91,268,731...91,275,323
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of EIF4EBP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Eif4h
|
eukaryotic translation initiation factor 4H
|
affects expression
|
EXP
|
Omeprazole affects the expression of EIF4H mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:27,719,527...27,736,350
Ensembl chr12:27,719,321...27,736,346
|
|
G
|
Enc1
|
ectodermal-neural cortex 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENC1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721
|
|
G
|
Eno1
|
enolase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:166,002,867...166,014,252
Ensembl chr 3:77,946,261...77,986,003 Ensembl chr 5:77,946,261...77,986,003
|
|
G
|
Enpep
|
glutamyl aminopeptidase
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENPEP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:220,456,258...220,526,218
Ensembl chr 2:220,456,278...220,526,218
|
|
G
|
Enpp1
|
ectonucleotide pyrophosphatase/phosphodiesterase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ENPP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044
|
|
G
|
Ep300
|
E1A binding protein p300
|
multiple interactions
|
ISO
|
Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]
|
CTD |
PMID:21703235 |
|
NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574
|
|
G
|
Epcam
|
epithelial cell adhesion molecule
|
affects expression
|
EXP
|
Omeprazole affects the expression of EPCAM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702
|
|
G
|
Erp29
|
endoplasmic reticulum protein 29
|
affects expression
|
EXP
|
Omeprazole affects the expression of ERP29 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:40,750,177...40,756,607
Ensembl chr12:40,750,314...40,757,010
|
|
G
|
Esd
|
esterase D
|
affects expression
|
EXP
|
Omeprazole affects the expression of ESD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508
|
|
G
|
Etfb
|
electron transfer flavoprotein subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of ETFB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:102,988,499...103,002,663
Ensembl chr 1:102,988,499...103,002,659
|
|
G
|
Faah
|
fatty acid amide hydrolase
|
affects expression
|
EXP
|
Omeprazole affects the expression of FAAH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:134,716,545...134,735,396
Ensembl chr 5:134,716,545...134,735,396
|
|
G
|
Fads2
|
fatty acid desaturase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of FADS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066
|
|
G
|
Fbp1
|
fructose-bisphosphatase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of FBP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:2,212,941...2,235,749
Ensembl chr17:2,213,492...2,235,746
|
|
G
|
Fdft1
|
farnesyl diphosphate farnesyl transferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of FDFT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168
|
|
G
|
Fdps
|
farnesyl diphosphate synthase
|
affects expression
|
EXP
|
Omeprazole affects the expression of FDPS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:176,795,192...176,807,136
|
|
G
|
Fdx2
|
ferredoxin 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of FDX2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:27,881,091...27,886,230
Ensembl chr 8:27,881,091...27,886,015
|
|
G
|
Fmo1
|
flavin containing dimethylaniline monoxygenase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of FMO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874
|
|
G
|
Gamt
|
guanidinoacetate N-methyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GAMT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:10,099,267...10,102,083
Ensembl chr 7:10,098,571...10,102,083
|
|
G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GAPDH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
G
|
Gast
|
gastrin
|
increases expression
|
ISO EXP
|
Omeprazole results in increased expression of GAST protein
|
CTD |
PMID:11422300 PMID:12189558 PMID:12763636 PMID:15223672 PMID:16618411 PMID:17652263 More...
|
|
NCBI chr10:85,765,216...85,767,881
Ensembl chr10:85,765,216...85,767,880
|
|
G
|
Gbe1
|
1,4-alpha-glucan branching enzyme 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GBE1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:22,181,194...22,446,640
Ensembl chr11:22,181,103...22,446,638
|
|
G
|
Gchfr
|
GTP cyclohydrolase I feedback regulator
|
affects expression
|
EXP
|
Omeprazole affects the expression of GCHFR mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926
|
|
G
|
Ggh
|
gamma-glutamyl hydrolase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GGH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:38,326,747...38,349,655
Ensembl chr 5:38,326,594...38,349,647
|
|
G
|
Ggt1
|
gamma-glutamyltransferase 1
|
multiple interactions
|
EXP
|
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GGT1 mRNA
|
CTD |
PMID:22687989 |
|
NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050
|
|
G
|
Gjb1
|
gap junction protein, beta 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GJB1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:70,541,845...70,549,776
Ensembl chr X:70,541,862...70,549,843
|
|
G
|
Gpld1
|
glycosylphosphatidylinositol specific phospholipase D1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GPLD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:40,512,659...40,560,483
Ensembl chr17:40,512,660...40,554,975
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GPX1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions
|
EXP
|
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA
|
CTD |
PMID:22687989 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862
|
|
G
|
Gpx4
|
glutathione peroxidase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of GPX4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
G
|
Grina
|
glutamate ionotropic receptor NMDA type subunit associated protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GRINA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:109,842,870...109,846,048
Ensembl chr 7:109,843,196...109,846,042
|
|
G
|
Grpel1
|
GrpE-like 1, mitochondrial
|
affects expression
|
EXP
|
Omeprazole affects the expression of GRPEL1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:78,517,049...78,522,868
Ensembl chr14:78,517,052...78,522,861
|
|
G
|
Gsta5
|
glutathione S-transferase alpha 5
|
increases expression multiple interactions
|
EXP
|
Omeprazole results in increased expression of GSTA5 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA
|
CTD |
PMID:17202759 PMID:22687989 |
|
NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of GSTP1 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
Gstt1
|
glutathione S-transferase theta 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of GSTT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019
|
|
G
|
Gtf2h5
|
general transcription factor IIH subunit 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of GTF2H5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:49,061,904...49,068,612
Ensembl chr 1:49,061,959...49,070,039
|
|
G
|
Gulo
|
gulonolactone (L-) oxidase
|
affects expression
|
EXP
|
Omeprazole affects the expression of GULO mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:44,381,226...44,403,314
Ensembl chr15:44,381,214...44,403,422
|
|
G
|
Gzma
|
granzyme A
|
affects expression
|
EXP
|
Omeprazole affects the expression of GZMA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:46,473,763...46,485,696
Ensembl chr 2:46,473,763...46,485,696
|
|
G
|
H3f3b
|
H3.3 histone B
|
affects expression
|
EXP
|
Omeprazole affects the expression of H3F3B mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:101,755,404...101,764,616
Ensembl chr10:101,755,404...101,757,636
|
|
G
|
Hal
|
histidine ammonia lyase
|
affects expression
|
EXP
|
Omeprazole affects the expression of HAL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:29,894,495...29,924,744
Ensembl chr 7:29,893,855...29,924,744
|
|
G
|
Hamp
|
hepcidin antimicrobial peptide
|
increases expression multiple interactions increases secretion
|
ISO
|
Omeprazole results in increased expression of HAMP mRNA 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA] Omeprazole results in increased expression of HAMP mRNA; Omeprazole results in increased expression of HAMP protein Omeprazole results in increased secretion of HAMP protein
|
CTD |
PMID:31669099 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
G
|
Hao2
|
hydroxyacid oxidase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HAO2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:188,888,848...188,921,567
Ensembl chr 2:188,889,212...188,913,133
|
|
G
|
Hba-a2
|
hemoglobin alpha, adult chain 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HBA-A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,828,377...15,829,141
|
|
G
|
Hbb
|
hemoglobin subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of HBB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:167,630,245...167,663,873
|
|
G
|
Hdc
|
histidine decarboxylase
|
affects expression increases stability increases expression multiple interactions
|
EXP
|
Omeprazole affects the expression of HDC mRNA Omeprazole results in increased stability of HDC protein Omeprazole results in increased expression of HDC mRNA Omeprazole results in increased expression of and results in increased activity of HDC protein
|
CTD |
PMID:12763636 PMID:19483382 |
|
NCBI chr 3:134,300,628...134,318,704
Ensembl chr 3:134,300,632...134,318,711
|
|
G
|
Hgd
|
homogentisate 1, 2-dioxygenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of HGD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:76,592,202...76,643,776
Ensembl chr11:76,592,204...76,643,767
|
|
G
|
Hmgn1
|
high mobility group nucleosome binding domain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of HMGN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:48,891,813...48,897,732
Ensembl chr11:48,891,814...48,897,771
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases expression
|
ISO
|
Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]; Omeprazole results in increased expression of and results in increased activity of HMOX1 protein Omeprazole results in increased expression of HMOX1 mRNA; Omeprazole results in increased expression of HMOX1 protein
|
CTD |
PMID:16712795 PMID:27725188 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hprt1
|
hypoxanthine phosphoribosyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of HPRT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:137,655,744...137,687,718
Ensembl chr X:137,655,680...137,687,712
|
|
G
|
Hps5
|
HPS5, biogenesis of lysosomal organelles complex 2 subunit 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HPS5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:106,417,902...106,457,220
Ensembl chr 1:106,417,902...106,452,859
|
|
G
|
Hsd17b4
|
hydroxysteroid (17-beta) dehydrogenase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of HSD17B4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467
|
|
G
|
Hsdl2
|
hydroxysteroid dehydrogenase like 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of HSDL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798
|
|
G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
decreases expression multiple interactions
|
EXP
|
Omeprazole results in decreased expression of HSPA1A mRNA; Omeprazole results in decreased expression of HSPA1A protein Zinc Compounds analog inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]
|
CTD |
PMID:15223672 PMID:16945336 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspa1l
|
heat shock protein family A (Hsp70) member 1 like
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA]
|
CTD |
PMID:25637687 |
|
NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877
|
|
G
|
Htra1
|
HtrA serine peptidase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of HTRA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:194,928,069...194,977,619
Ensembl chr 1:194,927,687...194,977,620
|
|
G
|
Ier3
|
immediate early response 3
|
multiple interactions
|
ISO
|
[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3
|
CTD |
PMID:17704804 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]
|
CTD |
PMID:19232345 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
G
|
Igf1
|
insulin-like growth factor 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of IGF1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
G
|
Igfals
|
insulin-like growth factor binding protein, acid labile subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of IGFALS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:14,397,076...14,408,439
Ensembl chr10:14,403,399...14,407,138
|
|
G
|
Igfbp2
|
insulin-like growth factor binding protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of IGFBP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:81,864,783...81,892,171
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
ISO EXP
|
Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein]
|
CTD |
PMID:26970604 PMID:38341112 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il16
|
interleukin 16
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Ethanol results in increased expression of IL16 protein]
|
CTD |
PMID:38341112 |
|
NCBI chr 1:147,026,852...147,127,177
Ensembl chr 1:147,027,097...147,127,023
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
|
CTD |
PMID:32418911 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP ISO
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL6 protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL6 protein] Omeprazole inhibits the reaction [Ethanol results in increased expression of IL6 protein]
|
CTD |
PMID:25637687 PMID:32418911 PMID:38341112 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Impa1
|
inositol monophosphatase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of IMPA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:93,370,200...93,391,474
Ensembl chr 2:93,370,299...93,391,468
|
|
G
|
Inhbe
|
inhibin subunit beta E
|
affects expression
|
EXP
|
Omeprazole affects the expression of INHBE mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519
|
|
G
|
Isyna1
|
inositol-3-phosphate synthase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ISYNA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:18,873,119...18,876,116
Ensembl chr16:18,873,121...18,875,955
|
|
G
|
Itih4
|
inter-alpha-trypsin inhibitor heavy chain 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of ITIH4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:6,086,985...6,102,162
Ensembl chr16:6,086,973...6,102,160
|
|
G
|
Jak1
|
Janus kinase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of JAK1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758
|
|
G
|
Kdelr2
|
KDEL endoplasmic reticulum protein retention receptor 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of KDELR2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:16,252,424...16,270,737
Ensembl chr12:16,252,424...16,270,719
|
|
G
|
Kdr
|
kinase insert domain receptor
|
affects expression multiple interactions
|
EXP ISO
|
Omeprazole affects the expression of KDR mRNA Omeprazole promotes the reaction [Oxygen results in decreased expression of KDR protein]
|
CTD |
PMID:19483382 PMID:26272953 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192
|
|
G
|
Krt8
|
keratin 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of KRT8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403
|
|
G
|
Lcat
|
lecithin cholesterol acyltransferase
|
affects expression
|
EXP
|
Omeprazole affects the expression of LCAT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:50,744,598...50,748,064
Ensembl chr19:50,744,601...50,748,081
|
|
G
|
Lcmt1
|
leucine carboxyl methyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of LCMT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:187,335,173...187,391,195
Ensembl chr 1:187,327,706...187,391,516
|
|
G
|
Lipc
|
lipase C, hepatic type
|
affects expression
|
EXP
|
Omeprazole affects the expression of LIPC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:80,390,471...80,516,285
|
|
G
|
Lox
|
lysyl oxidase
|
affects expression
|
EXP
|
Omeprazole affects the expression of LOX mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:48,162,889...48,175,640
Ensembl chr18:48,165,688...48,239,810
|
|
G
|
Lrp3
|
LDL receptor related protein 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of LRP3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:96,980,762...96,996,157
Ensembl chr 1:96,981,815...96,996,057
|
|
G
|
Man2b1
|
mannosidase, alpha, class 2B, member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of MAN2B1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:39,959,964...39,979,299
Ensembl chr19:39,959,965...39,979,246
|
|
G
|
Map2k2
|
mitogen activated protein kinase kinase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MAP2K2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:9,241,310...9,260,940
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK14 protein]
|
CTD |
PMID:17406807 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
G
|
Masp2
|
MBL associated serine protease 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MASP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:164,319,017...164,332,686
Ensembl chr 5:164,308,991...164,332,705
|
|
G
|
Me1
|
malic enzyme 1
|
affects expression multiple interactions
|
EXP
|
Omeprazole affects the expression of ME1 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ME1 mRNA
|
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275
|
|
G
|
Mmp14
|
matrix metallopeptidase 14
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Indomethacin results in decreased expression of MMP14 protein]
|
CTD |
PMID:16934674 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Hydrogen Peroxide results in decreased activity of MMP2 protein]
|
CTD |
PMID:16934674 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmut
|
methylmalonyl-CoA mutase
|
affects expression
|
EXP
|
Omeprazole affects the expression of MMUT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:27,425,935...27,454,202
Ensembl chr 9:27,425,935...27,454,342
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions decreases activity
|
ISO EXP
|
Omeprazole inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Acids results in increased activity of MPO protein] Omeprazole results in decreased activity of MPO protein Omeprazole inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Cysteamine results in increased expression of MPO protein]; Omeprazole inhibits the reaction [Ethanol results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein]
|
CTD |
PMID:16091555 PMID:17151854 PMID:20165931 PMID:25637687 PMID:27780710 PMID:29770154 PMID:31095933 PMID:33245926 More...
|
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mro
|
maestro
|
affects expression
|
EXP
|
Omeprazole affects the expression of MRO mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:69,723,764...69,742,815
Ensembl chr18:69,725,798...69,743,031
|
|
G
|
Mrpl2
|
mitochondrial ribosomal protein L2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MRPL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:21,830,834...21,834,607
Ensembl chr 9:21,830,835...21,834,641
|
|
G
|
Mrpl9
|
mitochondrial ribosomal protein L9
|
affects expression
|
EXP
|
Omeprazole affects the expression of MRPL9 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:184,768,837...184,775,787
Ensembl chr 2:184,763,529...184,775,777
|
|
G
|
Mug2
|
murinoglobulin 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of PZP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:156,836,140...156,908,972
|
|
G
|
Myadm
|
myeloid-associated differentiation marker
|
affects expression
|
EXP
|
Omeprazole affects the expression of MYADM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:74,779,616...74,796,752
Ensembl chr 1:74,775,698...74,789,710
|
|
G
|
Mycbp2
|
MYC binding protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of MYCBP2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325
|
|
G
|
Myo1d
|
myosin ID
|
affects expression
|
EXP
|
Omeprazole affects the expression of MYO1D mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:65,986,900...66,263,538
Ensembl chr10:65,975,122...66,263,958
|
|
G
|
Naa38
|
N(alpha)-acetyltransferase 38, NatC auxiliary subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of NAA38 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:54,588,304...54,617,715
Ensembl chr10:54,592,990...54,617,715
|
|
G
|
Nap1l1
|
nucleosome assembly protein 1-like 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NAP1L1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:48,819,464...48,844,108
Ensembl chr 7:48,819,477...48,844,104
|
|
G
|
Nat8
|
N-acetyltransferase 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of NAT8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:119,836,986...119,837,764
Ensembl chr 4:119,835,645...119,843,159
|
|
G
|
Ncoa1
|
nuclear receptor coactivator 1
|
multiple interactions
|
ISO
|
Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter]
|
CTD |
PMID:21703235 |
|
NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924
|
|
G
|
Ndrg2
|
NDRG family member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NDRG2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:27,074,481...27,087,376
Ensembl chr15:27,074,481...27,083,125
|
|
G
|
Ndufs5
|
NADH:ubiquinone oxidoreductase subunit S5
|
affects expression
|
EXP
|
Omeprazole affects the expression of NDUFS5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:141,258,828...141,264,552
Ensembl chr 2:184,849,197...185,028,909 Ensembl chr 5:184,849,197...185,028,909 Ensembl chr14:184,849,197...185,028,909
|
|
G
|
Ndufv3
|
NADH:ubiquinone oxidoreductase subunit V3
|
affects expression
|
EXP
|
Omeprazole affects the expression of NDUFV3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:9,613,786...9,622,941
Ensembl chr13:48,468,224...48,488,847 Ensembl chr20:48,468,224...48,488,847
|
|
G
|
Neu2
|
neuraminidase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NEU2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:95,666,338...95,715,209
Ensembl chr 9:95,696,507...95,715,208
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]
|
CTD |
PMID:27725188 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Cisplatin results in decreased expression of NFKBIA protein]
|
CTD |
PMID:32418911 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nfx1
|
nuclear transcription factor, X-box binding 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NFX1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:60,900,140...60,958,889
Ensembl chr 5:60,901,217...60,958,889
|
|
G
|
Nipal2
|
NIPA-like domain containing 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NIPAL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:67,659,628...67,771,105
Ensembl chr 7:67,659,628...67,769,959
|
|
G
|
Nit1
|
nitrilase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NIT1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:86,302,334...86,305,770
Ensembl chr13:86,298,387...86,305,770
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions
|
EXP
|
Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]
|
CTD |
PMID:32418911 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nme2
|
NME/NM23 nucleoside diphosphate kinase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of NME2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:79,394,999...79,400,418
Ensembl chr20:11,179,066...11,179,497 Ensembl chr10:11,179,066...11,179,497
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
increases expression multiple interactions
|
EXP ISO
|
Omeprazole results in increased expression of NQO1 mRNA Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 mRNA]; Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 protein] [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of NQO1 mRNA
|
CTD |
PMID:17202759 PMID:22687989 PMID:26272953 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions increases activity
|
ISO EXP
|
[Omeprazole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein affects the reaction [Omeprazole results in increased expression of CYP3A4 mRNA]
|
CTD |
PMID:12695340 PMID:17041008 PMID:25680588 PMID:26187274 PMID:27732639 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
affects expression decreases metabolic processing increases expression
|
EXP ISO
|
Omeprazole affects the expression of NR1I3 mRNA NR1I3 gene mutant form results in decreased metabolism of Omeprazole Omeprazole results in increased expression of NR1I3 mRNA
|
CTD |
PMID:19118567 PMID:19483382 PMID:27434302 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370
|
|
G
|
Nr3c1
|
nuclear receptor subfamily 3, group C, member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of NR3C1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843
|
|
G
|
Oaf
|
out at first homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of OAF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:52,491,314...52,509,285
Ensembl chr 8:52,491,315...52,509,285
|
|
G
|
Obp3
|
alpha-2u globulin PGCL4
|
affects expression
|
EXP
|
Omeprazole affects the expression of OBP3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:79,637,234...79,640,810
Ensembl chr 5:79,637,234...79,640,675
|
|
G
|
Ogdh
|
oxoglutarate dehydrogenase
|
affects expression
|
EXP
|
Omeprazole affects the expression of OGDH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:85,363,949...85,431,405
Ensembl chr14:85,364,014...85,432,271
|
|
G
|
Olr59
|
olfactory receptor 59
|
affects expression
|
EXP
|
Omeprazole affects the expression of OLR59 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:166,604,972...166,639,634
Ensembl chr 1:166,604,141...166,623,265
|
|
G
|
Ostc
|
oligosaccharyltransferase complex non-catalytic subunit
|
affects expression
|
EXP
|
Omeprazole affects the expression of OSTC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:221,924,727...221,940,253
Ensembl chr 2:221,874,948...221,940,267
|
|
G
|
Otc
|
ornithine transcarbamylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of OTC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:15,126,358...15,202,473
Ensembl chr X:15,126,358...15,239,555
|
|
G
|
Pabpc4
|
poly(A) binding protein, cytoplasmic 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of PABPC4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:140,847,835...140,864,089
Ensembl chr 5:140,848,225...140,864,087
|
|
G
|
Paics
|
phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase
|
affects expression
|
EXP
|
Omeprazole affects the expression of PAICS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr14:31,553,355...31,586,843
Ensembl chr14:31,553,357...31,587,027
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage
|
ISO
|
Omeprazole results in increased cleavage of PARP1 protein
|
CTD |
PMID:15461867 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pc
|
pyruvate carboxylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCX mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:211,228,708...211,327,792
Ensembl chr 1:211,228,731...211,329,940
|
|
G
|
Pccb
|
propionyl-CoA carboxylase subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCCB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:110,470,197...110,520,222
Ensembl chr 8:110,469,934...110,520,187
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
EXP ISO
|
[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; Omeprazole promotes the reaction [Acetic Acid results in increased expression of PCNA protein] Omeprazole inhibits the reaction [Ethanol results in decreased expression of PCNA protein]
|
CTD |
PMID:19251492 PMID:26970604 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pcsk6
|
proprotein convertase subtilisin/kexin type 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCSK6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:128,839,742...129,038,087
Ensembl chr 1:128,839,232...129,052,128
|
|
G
|
Pctp
|
phosphatidylcholine transfer protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of PCTP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:75,305,999...75,351,919
Ensembl chr10:75,305,999...75,326,432
|
|
G
|
Pdcl3
|
phosducin-like 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PDCL3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:48,730,083...48,738,554
Ensembl chr 9:48,723,767...48,739,529
|
|
G
|
Pdia3
|
protein disulfide isomerase family A, member 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PDIA3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:128,841,917...128,867,327
|
|
G
|
Pdia6
|
protein disulfide isomerase family A, member 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PDIA6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:45,791,678...45,810,091
|
|
G
|
Pex19
|
peroxisomal biogenesis factor 19
|
affects expression
|
EXP
|
Omeprazole affects the expression of PEX19 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:87,124,654...87,141,170
Ensembl chr13:87,124,698...87,141,757
|
|
G
|
Pgam1
|
phosphoglycerate mutase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PGAM1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:250,673,049...250,690,203
|
|
G
|
Pgrmc1
|
progesterone receptor membrane component 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PGRMC1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:120,698,610...120,706,805
Ensembl chr X:120,698,610...120,706,805
|
|
G
|
Phyh
|
phytanoyl-CoA 2-hydroxylase
|
affects expression
|
EXP
|
Omeprazole affects the expression of PHYH mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:78,238,747...78,255,645
Ensembl chr17:78,238,747...78,255,645
|
|
G
|
Pigp
|
phosphatidylinositol glycan anchor biosynthesis, class P
|
affects expression
|
EXP
|
Omeprazole affects the expression of PIGP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:47,152,601...47,158,766
Ensembl chr11:47,148,465...47,160,082
|
|
G
|
Pklr
|
pyruvate kinase L/R
|
affects expression
|
EXP
|
Omeprazole affects the expression of PKLR mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:176,840,764...176,849,644
|
|
G
|
Pla2g4a
|
phospholipase A2 group 4A
|
increases phosphorylation multiple interactions
|
ISO
|
Omeprazole results in increased phosphorylation of PLA2G4A protein 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Omeprazole results in increased phosphorylation of PLA2G4A protein]
|
CTD |
PMID:25797602 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641
|
|
G
|
Plbd1
|
phospholipase B domain containing 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PLBD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:171,204,198...171,260,488
Ensembl chr 4:171,204,198...171,260,488
|
|
G
|
Plg
|
plasminogen
|
affects expression
|
EXP
|
Omeprazole affects the expression of PLG mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:50,872,926...50,917,320
|
|
G
|
Pls3
|
plastin 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PLS3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr X:116,401,247...116,495,898
Ensembl chr X:116,401,293...116,495,893
|
|
G
|
Pon2
|
paraoxonase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of PON2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:34,356,270...34,391,684
Ensembl chr 4:34,356,274...34,391,996
|
|
G
|
Pou2f2
|
POU class 2 homeobox 2
|
multiple interactions
|
EXP ISO
|
Omeprazole inhibits the reaction [Cisplatin results in increased expression of POU2F2 protein]
|
CTD |
PMID:30452898 |
|
NCBI chr 1:89,810,153...89,897,560
Ensembl chr 1:89,812,093...89,897,564
|
|
G
|
Ppdpf
|
pancreatic progenitor cell differentiation and proliferation factor
|
affects expression
|
EXP
|
Omeprazole affects the expression of PPDPF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:188,676,821...188,678,599
Ensembl chr 3:188,676,965...188,678,599
|
|
G
|
Prdx2
|
peroxiredoxin 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of PRDX2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006
|
|
G
|
Prdx6
|
peroxiredoxin 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PRDX6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:76,062,082...76,072,631
Ensembl chr13:76,061,554...76,072,657
|
|
G
|
Prl
|
prolactin
|
increases expression
|
ISO
|
Omeprazole results in increased expression of PRL protein
|
CTD |
PMID:20726208 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
G
|
Proc
|
protein C, inactivator of coagulation factors Va and VIIIa
|
affects expression
|
EXP
|
Omeprazole affects the expression of PROC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:24,038,596...24,049,061
Ensembl chr18:24,038,597...24,048,964
|
|
G
|
Prpsap1
|
phosphoribosyl pyrophosphate synthetase-associated protein 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PRPSAP1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:102,199,949...102,221,642
Ensembl chr10:102,199,950...102,221,642
|
|
G
|
Psma6
|
proteasome 20S subunit alpha 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMA6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:78,500,676...78,531,693
Ensembl chr 6:78,500,736...78,531,717
|
|
G
|
Psmb1
|
proteasome 20S subunit beta 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMB1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:65,115,770...65,136,516
Ensembl chr 1:65,114,724...65,136,640
|
|
G
|
Psmb3
|
proteasome 20S subunit beta 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMB3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:83,193,787...83,200,883
Ensembl chr10:83,193,787...83,200,883
|
|
G
|
Psmc1
|
proteasome 26S subunit, ATPase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMC1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:125,122,497...125,134,859
Ensembl chr 6:125,122,490...125,134,858
|
|
G
|
Psmc3
|
proteasome 26S subunit, ATPase 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMC3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:97,487,643...97,493,025
Ensembl chr 3:97,487,632...97,499,176
|
|
G
|
Psmc5
|
proteasome 26S subunit, ATPase 5
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMC5 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:91,687,553...91,693,487
Ensembl chr10:91,686,295...91,695,921
|
|
G
|
Psmd1
|
proteasome 26S subunit, non-ATPase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:94,157,971...94,233,218
Ensembl chr 9:94,157,971...94,233,218
|
|
G
|
Psmd4
|
proteasome 26S subunit ubiquitin receptor, non-ATPase 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of PSMD4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:185,287,941...185,297,238
Ensembl chr 2:185,286,868...185,297,201
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
EXP ISO
|
[Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA; [Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein Omeprazole inhibits the reaction [Ethanol results in increased expression of PTGS2 protein]
|
CTD |
PMID:23038005 PMID:26970604 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Ptms
|
parathymosin
|
affects expression
|
EXP
|
Omeprazole affects the expression of PTMS mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:159,408,647...159,412,837
Ensembl chr 4:159,408,649...159,415,212
|
|
G
|
Ptprf
|
protein tyrosine phosphatase, receptor type, F
|
affects expression
|
EXP
|
Omeprazole affects the expression of PTPRF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426
|
|
G
|
Pttg1ip
|
PTTG1 interacting protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of PTTG1IP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:11,029,608...11,047,395
Ensembl chr20:11,029,608...11,046,909
|
|
G
|
Pygl
|
glycogen phosphorylase L
|
affects expression
|
EXP
|
Omeprazole affects the expression of PYGL mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:94,426,346...94,476,269
|
|
G
|
Rab5if
|
RAB5 interacting factor
|
affects expression
|
EXP
|
Omeprazole affects the expression of RAB5IF mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:165,818,060...165,828,071
Ensembl chr 3:165,816,588...165,828,067
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP ISO
|
[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of RELA protein]; Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] Omeprazole inhibits the reaction [Cisplatin affects the localization of RELA protein]
|
CTD |
PMID:19251492 PMID:30452898 PMID:32418911 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Retsat
|
retinol saturase
|
increases expression
|
EXP
|
Omeprazole results in increased expression of RETSAT mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:106,211,436...106,229,552
|
|
G
|
Rida
|
reactive intermediate imine deaminase A homolog
|
affects expression
|
EXP
|
Omeprazole affects the expression of RIDA mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:67,576,586...67,590,493
Ensembl chr 7:67,576,586...67,590,692
|
|
G
|
Rnase4
|
ribonuclease A family member 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of RNASE4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:26,786,287...26,803,634
Ensembl chr15:26,786,079...26,803,639
|
|
G
|
Rnf103
|
ring finger protein 103
|
affects expression
|
EXP
|
Omeprazole affects the expression of RNF103 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:105,084,762...105,100,839
Ensembl chr 4:105,084,686...105,106,809
|
|
G
|
Rnps1
|
RNA binding protein with serine rich domain 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of RNPS1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:13,950,151...13,960,396
Ensembl chr10:13,950,184...13,960,393
|
|
G
|
Rpl11
|
ribosomal protein L11
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL11 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:153,557,592...153,561,230
Ensembl chr 5:153,557,597...153,561,127
|
|
G
|
Rpl13
|
ribosomal protein L13
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL13 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr19:68,062,442...68,065,065
Ensembl chr19:68,062,493...68,065,059
|
|
G
|
Rpl15
|
ribosomal protein L15
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL15 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr15:9,934,663...9,937,946
Ensembl chr15:9,934,679...9,938,308
|
|
G
|
Rpl17
|
ribosomal protein L17
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL17 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:70,856,275...70,859,388
Ensembl chr 3:111,722,010...111,722,638 Ensembl chr18:111,722,010...111,722,638
|
|
G
|
Rpl23
|
ribosomal protein L23
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL23 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:83,268,223...83,272,184
Ensembl chr10:83,262,592...83,272,214
|
|
G
|
Rpl3
|
ribosomal protein L3
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:113,491,943...113,508,115
Ensembl chr 7:113,501,960...113,507,990
|
|
G
|
Rpl32
|
ribosomal protein L32
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL32 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:150,536,650...150,540,214
Ensembl chr 4:150,536,646...150,540,214
|
|
G
|
Rpl4
|
ribosomal protein L4
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPL4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:73,566,477...73,571,600
Ensembl chr 8:73,566,466...73,571,788
|
|
G
|
Rpn2
|
ribophorin II
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPN2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:166,361,955...166,409,272
Ensembl chr 3:166,362,049...166,409,922
|
|
G
|
Rps14
|
ribosomal protein S14
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS14 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:56,492,010...56,503,092
Ensembl chr18:56,498,245...56,503,091
|
|
G
|
Rps18
|
ribosomal protein S18
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS18 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:4,933,741...4,937,423
Ensembl chr20:4,917,095...4,937,423
|
|
G
|
Rps19
|
ribosomal protein S19
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS19 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:89,608,408...89,614,390
Ensembl chr 7:104,324,520...104,325,132 Ensembl chr 1:104,324,520...104,325,132
|
|
G
|
Rps20
|
ribosomal protein S20
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS20 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:21,616,687...21,618,068
Ensembl chr 3:42,839,965...43,095,621 Ensembl chr 9:42,839,965...43,095,621 Ensembl chr 5:42,839,965...43,095,621
|
|
G
|
Rps3a
|
ribosomal protein S3a
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS3A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:173,822,673...173,827,042
Ensembl chr 2:173,822,488...173,827,043
|
|
G
|
Rps6
|
ribosomal protein S6
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566
|
|
G
|
Rps8
|
ribosomal protein S8
|
affects expression
|
EXP
|
Omeprazole affects the expression of RPS8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:135,866,941...135,869,511
Ensembl chr 5:135,866,941...135,869,548
|
|
G
|
Rras2
|
RAS related 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of RRAS2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:177,668,143...177,737,551
Ensembl chr 1:177,668,144...177,737,551
|
|
G
|
RT1-DMa
|
RT1 class II, locus DMa
|
affects expression
|
ISO
|
Omeprazole affects the expression of HLA-DMA mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,708,933...4,712,335
|
|
G
|
RT1-M3-1
|
RT1 class Ib, locus M3, gene 1
|
affects expression
|
ISO
|
Omeprazole affects the expression of HLA-G mRNA
|
CTD |
PMID:25811541 |
|
NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366
|
|
G
|
RT1-S3
|
RT1 class Ib, locus S3
|
affects expression
|
EXP
|
Omeprazole affects the expression of RT1-S3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:2,675,463...2,680,229
|
|
G
|
S1pr1
|
sphingosine-1-phosphate receptor 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of S1PR1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:206,309,715...206,314,070
Ensembl chr 2:205,900,836...206,328,689
|
|
G
|
Sbspon
|
somatomedin B and thrombospondin, type 1 domain containing
|
affects expression
|
EXP
|
Omeprazole affects the expression of SBSPON mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:8,186,004...8,216,576
Ensembl chr 5:8,185,985...8,218,898
|
|
G
|
Sdc2
|
syndecan 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SDC2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:66,012,405...66,125,101
Ensembl chr 7:66,108,853...66,126,294
|
|
G
|
Sdhc
|
succinate dehydrogenase complex subunit C
|
affects expression
|
EXP
|
Omeprazole affects the expression of SDHC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044
|
|
G
|
Sdhd
|
succinate dehydrogenase complex subunit D
|
affects expression
|
EXP
|
Omeprazole affects the expression of SDHD mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:59,841,090...59,850,641
Ensembl chr 8:59,841,090...59,850,641
|
|
G
|
Sell
|
selectin L
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of SELL protein
|
CTD |
PMID:17652263 |
|
NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600
|
|
G
|
Serinc3
|
serine incorporator 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERINC3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:172,721,208...172,749,853
Ensembl chr 3:172,721,321...172,740,765
|
|
G
|
Serpina1
|
serpin family A member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINA1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:128,631,101...128,653,125
Ensembl chr 6:128,619,382...128,660,703
|
|
G
|
Serpina10
|
serpin family A member 10
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINA10 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:128,520,894...128,529,332
Ensembl chr 6:128,520,896...128,529,332
|
|
G
|
Serpina4
|
serpin family A member 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINA4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:128,764,738...128,773,858
Ensembl chr 6:128,764,769...128,776,028
|
|
G
|
Serpinf2
|
serpin family F member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SERPINF2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:60,770,698...60,778,782
Ensembl chr10:60,770,698...60,778,996
|
|
G
|
Serping1
|
serpin family G member 1
|
decreases expression
|
EXP
|
Omeprazole results in decreased expression of SERPING1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:90,249,423...90,258,717
|
|
G
|
Sfxn1
|
sideroflexin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SFXN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:10,491,315...10,527,793
Ensembl chr17:10,491,344...10,527,456
|
|
G
|
Shmt2
|
serine hydroxymethyltransferase 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SHMT2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:65,244,247...65,249,580
Ensembl chr 7:65,244,247...65,249,567
|
|
G
|
Slc22a1
|
solute carrier family 22 member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC22A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Slc22a5
|
solute carrier family 22 member 5
|
multiple interactions
|
EXP
|
Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]
|
CTD |
PMID:19041296 |
|
NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077
|
|
G
|
Slc22a8
|
solute carrier family 22 member 8
|
multiple interactions
|
ISO
|
[Omeprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican
|
CTD |
PMID:36243147 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588
|
|
G
|
Slc23a1
|
solute carrier family 23 member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC23A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:27,490,549...27,504,563
Ensembl chr18:27,490,374...27,504,702
|
|
G
|
Slc25a13
|
solute carrier family 25 member 13
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC25A13 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:35,145,721...35,328,403
Ensembl chr 4:35,145,721...35,328,360
|
|
G
|
Slc25a3
|
solute carrier family 25 member 3
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC25A3 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:27,499,164...27,506,685
Ensembl chr 7:27,499,165...27,506,309
|
|
G
|
Slc27a2
|
solute carrier family 27 member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC27A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581
|
|
G
|
Slc39a8
|
solute carrier family 39 member 8
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC39A8 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:226,929,644...226,992,667
|
|
G
|
Slc40a1
|
solute carrier family 40 member 1
|
decreases expression
|
ISO
|
Omeprazole results in decreased expression of SLC40A1 protein
|
CTD |
PMID:31669099 |
|
NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460
|
|
G
|
Slc46a1
|
solute carrier family 46 member 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC46A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869
|
|
G
|
Slc66a2
|
solute carrier family 66 member 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC66A2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:75,976,000...76,014,651
Ensembl chr18:75,977,458...76,014,651
|
|
G
|
Slc6a6
|
solute carrier family 6 member 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLC6A6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:125,752,340...125,826,033
Ensembl chr 4:125,752,372...125,826,032
|
|
G
|
Slco1a1
|
solute carrier organic anion transporter family, member 1a1
|
affects expression
|
EXP
|
Omeprazole affects the expression of SLCO1A1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:176,606,924...176,682,027
Ensembl chr 4:176,607,687...176,681,992
|
|
G
|
Slco1a4
|
solute carrier organic anion transporter family, member 1a4
|
increases expression
|
ISO
|
Omeprazole results in increased expression of SLCO1A2 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Ethanol results in decreased activity of SOD1 protein]
|
CTD |
PMID:28849987 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sppl2a
|
signal peptide peptidase-like 2A
|
affects expression
|
EXP
|
Omeprazole affects the expression of SPPL2A mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:134,602,684...134,646,752
Ensembl chr 3:134,605,750...134,646,752
|
|
G
|
Srm
|
spermidine synthase
|
affects expression
|
EXP
|
Omeprazole affects the expression of SRM mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705
|
|
G
|
Srprb
|
SRP receptor subunit beta
|
affects expression
|
EXP
|
Omeprazole affects the expression of SRPRB mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:112,647,577...112,661,524
|
|
G
|
Ssx2ip
|
SSX family member 2 interacting protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of SSX2IP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 2:237,958,286...237,991,026
Ensembl chr 2:237,958,465...237,991,017
|
|
G
|
St3gal6
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of ST3GAL6 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:55,530,120...55,590,950
Ensembl chr11:55,530,248...55,598,720
|
|
G
|
St6gal1
|
ST6 beta-galactoside alpha-2,6-sialyltransferase 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of ST6GAL1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:91,031,481...91,158,111
Ensembl chr11:91,032,450...91,040,415
|
|
G
|
Suclg1
|
succinate-CoA ligase GDP/ADP-forming subunit alpha
|
affects expression
|
EXP
|
Omeprazole affects the expression of SUCLG1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:106,866,329...106,895,686
Ensembl chr 4:106,866,114...106,895,689
|
|
G
|
Surf4
|
surfeit 4
|
affects expression
|
EXP
|
Omeprazole affects the expression of SURF4 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 3:30,646,435...30,659,641
Ensembl chr 3:30,638,299...30,661,390
|
|
G
|
Synj2bp
|
synaptojanin 2 binding protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of SYNJ2BP mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 6:106,920,970...106,958,653
Ensembl chr 6:106,920,970...106,966,543
|
|
G
|
Tacr1
|
tachykinin receptor 1
|
multiple interactions
|
ISO
|
Omeprazole inhibits the reaction [Acids affects the localization of TACR1 protein]
|
CTD |
PMID:16091555 |
|
NCBI chr 4:116,478,617...116,647,492
Ensembl chr 4:116,478,617...116,647,492
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression
|
ISO
|
Omeprazole results in increased expression of TGFB1 protein
|
CTD |
PMID:36243147 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfbi
|
transforming growth factor, beta induced
|
affects expression
|
EXP
|
Omeprazole affects the expression of TGFBI mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471
|
|
G
|
Thnsl2
|
threonine synthase-like 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of THNSL2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 4:104,671,305...104,691,084
Ensembl chr 4:104,670,925...104,691,959
|
|
G
|
Timm21
|
translocase of inner mitochondrial membrane 21
|
affects expression
|
EXP
|
Omeprazole affects the expression of TIMM21 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:80,589,775...80,594,237
Ensembl chr18:80,589,783...80,594,237
|
|
G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
multiple interactions
|
EXP
|
Omeprazole inhibits the reaction [Indomethacin results in increased expression of TIMP2 protein]
|
CTD |
PMID:16934674 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
G
|
Tkfc
|
triokinase and FMN cyclase
|
affects expression
|
EXP
|
Omeprazole affects the expression of TKFC mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:216,664,446...216,677,815
Ensembl chr 1:216,661,477...216,677,928
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
EXP
|
Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]
|
CTD |
PMID:32418911 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tmbim1
|
transmembrane BAX inhibitor motif containing 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMBIM1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 9:83,320,972...83,338,469
Ensembl chr 9:83,320,979...83,338,657
|
|
G
|
Tmbim6
|
transmembrane BAX inhibitor motif containing 6
|
affects expression
|
EXP
|
Omeprazole affects the expression of TEGT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:132,405,217...132,422,492
Ensembl chr 7:132,386,134...132,422,492
|
|
G
|
Tmco1
|
transmembrane and coiled-coil domains 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMCO1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:81,993,172...82,016,496
Ensembl chr13:81,993,097...82,017,201
|
|
G
|
Tmed2
|
transmembrane p24 trafficking protein 2
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMED2 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:37,713,522...37,722,606
Ensembl chr12:37,713,529...37,722,606
|
|
G
|
Tmed7
|
transmembrane p24 trafficking protein 7
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMED7 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:41,505,167...41,512,243
Ensembl chr18:41,478,539...41,512,243
|
|
G
|
Tmem123
|
transmembrane protein 123
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMEM123 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 8:13,206,907...13,237,069
Ensembl chr 8:13,206,403...13,257,427
|
|
G
|
Tmem97
|
transmembrane protein 97
|
affects expression
|
EXP
|
Omeprazole affects the expression of TMEM97 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818
|
|
G
|
Tmprss2
|
transmembrane serine protease 2
|
increases expression
|
EXP
|
Omeprazole results in increased expression of TMPRSS2 mRNA
|
CTD |
PMID:32808185 |
|
NCBI chr11:50,403,707...50,443,224
Ensembl chr11:50,398,349...50,443,114
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of TNF protein] Omeprazole inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of TNF protein]
|
CTD |
PMID:19232345 PMID:25637687 PMID:26970604 PMID:30452898 PMID:32418911 PMID:38341112 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Txn1
|
thioredoxin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TXN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Txnl1
|
thioredoxin-like 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of TXNL1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr18:59,397,275...59,428,072
Ensembl chr18:59,398,535...59,435,518
|
|
G
|
Tyr
|
tyrosinase
|
multiple interactions decreases expression
|
ISO
|
Omeprazole affects the N-linked glycosylation of and results in increased degradation of TYR protein; Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein] Omeprazole results in decreased expression of TYR protein
|
CTD |
PMID:25337692 |
|
NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857
|
|
G
|
Uba52
|
ubiquitin A-52 residue ribosomal protein fusion product 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of UBA52 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr16:18,952,583...18,954,780
|
|
G
|
Ube2n
|
ubiquitin-conjugating enzyme E2N
|
affects expression
|
EXP
|
Omeprazole affects the expression of UBE2N mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:32,041,190...32,071,252
|
|
G
|
Ufd1
|
ubiquitin recognition factor in ER associated degradation 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of UFD1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:95,665,971...95,689,423
Ensembl chr11:95,665,972...95,689,434
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression affects expression
|
ISO EXP
|
Omeprazole results in increased expression of UGT1A1 mRNA Omeprazole affects the expression of UGT1A1 mRNA
|
CTD |
PMID:19118567 PMID:19483382 PMID:25626140 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a2
|
UDP glucuronosyltransferase 1 family, polypeptide A2
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A2 mRNA; Omeprazole results in increased expression of UGT1A3 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a3
|
UDP glycosyltransferase 1 family, polypeptide A3
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A5 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,228,134...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a5
|
UDP glucuronosyltransferase family 1 member A5
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A4 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,210,053...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a6
|
UDP glucuronosyltransferase family 1 member A6
|
increases expression multiple interactions
|
EXP ISO
|
Omeprazole results in increased expression of UGT1A6 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of UGT1A6 mRNA
|
CTD |
PMID:19118567 PMID:22687989 |
|
NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a9
|
UDP glucuronosyltransferase family 1 member A9
|
increases expression
|
ISO
|
Omeprazole results in increased expression of UGT1A9 mRNA
|
CTD |
PMID:19118567 |
|
NCBI chr 9:96,144,786...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt2b1
|
UDP glucuronosyltransferase 2 family, polypeptide B1
|
increases expression
|
EXP
|
Omeprazole results in increased expression of UGT2B1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331
|
|
G
|
Uqcr11
|
ubiquinol-cytochrome c reductase, complex III subunit XI
|
affects expression
|
EXP
|
Omeprazole affects the expression of UQCR11 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 7:9,955,717...9,960,432
Ensembl chr 7:9,955,764...9,959,047
|
|
G
|
Vnn1
|
vanin 1
|
affects expression
|
EXP
|
Omeprazole affects the expression of VNN1 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr 1:23,356,324...23,366,629
Ensembl chr 1:23,356,330...23,366,629
|
|
G
|
Wdr26
|
WD repeat domain 26
|
affects expression
|
EXP
|
Omeprazole affects the expression of WDR26 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr13:95,462,017...95,503,826
Ensembl chr13:95,462,020...95,503,738
|
|
G
|
Ywhag
|
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma
|
affects expression
|
EXP
|
Omeprazole affects the expression of YWHAG mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr12:26,381,106...26,409,466
Ensembl chr12:26,380,816...26,409,465
|
|
G
|
Zdhhc23
|
zinc finger DHHC-type palmitoyltransferase 23
|
affects expression
|
EXP
|
Omeprazole affects the expression of ZDHHC23 mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr11:70,224,581...70,240,971
Ensembl chr11:70,225,045...70,240,102
|
|
G
|
Zwint
|
ZW10 interacting kinetochore protein
|
affects expression
|
EXP
|
Omeprazole affects the expression of ZWINT mRNA
|
CTD |
PMID:19483382 |
|
NCBI chr20:15,502,559...15,953,701
Ensembl chr20:15,937,396...15,953,203
|
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions
|
ISO
|
omeprazole sulfide inhibits the reaction [Methylcholanthrene results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Omeprazole results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] omeprazole sulfide binds to and affects the folding of AHR protein; omeprazole sulfide binds to and results in decreased activity of AHR protein; omeprazole sulfide inhibits the reaction [Methylcholanthrene results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]
|
CTD |
PMID:16109480 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions increases expression
|
ISO
|
omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] omeprazole sulfide results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:16109480 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases metabolic processing
|
ISO
|
CYP3A4 protein results in increased metabolism of omeprazole sulfide
|
CTD |
PMID:16109480 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
decreases activity
|
ISO
|
oxatomide results in decreased activity of CYP2D6 protein
|
CTD |
PMID:15684493 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases metabolic processing decreases activity
|
ISO
|
CYP3A4 protein results in increased metabolism of oxatomide oxatomide results in decreased activity of CYP3A4 protein
|
CTD |
PMID:15684493 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Hexb
|
hexosaminidase subunit beta
|
affects secretion
|
EXP
|
oxatomide affects the secretion of HEXB protein
|
CTD |
PMID:7655991 |
|
NCBI chr 2:30,218,608...30,238,771
Ensembl chr 2:30,218,608...30,238,771
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
oxatomide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
affects transport decreases activity multiple interactions
|
ISO
|
ABCG2 protein affects the transport of oxfendazole oxfendazole results in decreased activity of ABCG2 protein oxfendazole inhibits the reaction [ABCG2 protein affects the transport of Mitoxantrone]
|
CTD |
PMID:15703302 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
Akr7a3
|
aldo-keto reductase family 7 member A3
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of AKR7A3 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of AKR7A3 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of AKR7A3 mRNA]
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153
|
|
G
|
Casp3
|
caspase 3
|
increases cleavage
|
EXP
|
oxfendazole results in increased cleavage of CASP3 protein
|
CTD |
PMID:26558467 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
EXP
|
oxfendazole results in increased expression of CDKN1A protein
|
CTD |
PMID:26558467 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Chek1
|
checkpoint kinase 1
|
affects expression
|
EXP
|
oxfendazole affects the expression of CHEK1 mRNA
|
CTD |
PMID:26558467 |
|
NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 protein; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A1 mRNA]
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A2 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of CYP1A2 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A2 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA]; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA]
|
CTD |
PMID:20033131 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GPX2 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GPX2 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of GPX2 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862
|
|
G
|
Gsta5
|
glutathione S-transferase alpha 5
|
multiple interactions
|
EXP
|
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; [Melatonin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765
|
|
G
|
Gstm1
|
glutathione S-transferase mu 1
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of GSTM1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTM1 mRNA
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569
|
|
G
|
Mad2l1
|
mitotic arrest deficient 2 like 1
|
decreases expression
|
EXP
|
oxfendazole results in decreased expression of MAD2L1 mRNA
|
CTD |
PMID:26558467 |
|
NCBI chr 4:97,236,419...97,247,603
Ensembl chr 4:97,236,503...97,243,222
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
decreases phosphorylation increases expression
|
EXP
|
oxfendazole results in decreased phosphorylation of MDM2 protein oxfendazole results in increased expression of MDM2 mRNA
|
CTD |
PMID:26558467 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Me1
|
malic enzyme 1
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of ME1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA]; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA]
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275
|
|
G
|
Mki67
|
marker of proliferation Ki-67
|
decreases expression
|
EXP
|
oxfendazole results in decreased expression of MKI67 protein
|
CTD |
PMID:26558467 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
EXP
|
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of NQO1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of NQO1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of NQO1 mRNA
|
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
oxfendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
decreases expression
|
EXP
|
oxfendazole results in decreased expression of TOP2A protein
|
CTD |
PMID:26558467 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Tp53
|
tumor protein p53
|
decreases expression
|
EXP
|
oxfendazole results in decreased expression of TP53 mRNA
|
CTD |
PMID:26558467 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
|
G
|
Abca1
|
ATP binding cassette subfamily A member 1
|
increases expression
|
ISO
|
pantoprazole results in increased expression of ABCA1 mRNA
|
CTD |
PMID:20060385 |
|
NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
ISO
|
pantoprazole promotes the reaction [ABCC2 protein affects the transport of estradiol-17 beta-glucuronide]
|
CTD |
PMID:12702717 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
pantoprazole inhibits the reaction [ABCG2 protein affects the transport of 7-hydroxymethotrexate]
|
CTD |
PMID:17032904 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
G
|
C1qa
|
complement C1q A chain
|
decreases expression
|
EXP
|
pantoprazole results in decreased expression of C1QA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732
|
|
G
|
C1qc
|
complement C1q C chain
|
decreases expression
|
EXP
|
pantoprazole results in decreased expression of C1QC mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468
|
|
G
|
C4bpa
|
complement component 4 binding protein, alpha
|
decreases expression
|
EXP
|
pantoprazole results in decreased expression of C4BPA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,627,959...44,663,552
Ensembl chr13:44,627,982...44,663,471
|
|
G
|
C4bpb
|
complement component 4 binding protein, beta
|
decreases expression
|
EXP
|
pantoprazole results in decreased expression of C4BPB mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,673,064...44,683,781
Ensembl chr13:44,673,065...44,683,793
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
pantoprazole inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]
|
CTD |
PMID:18853145 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cebpa
|
CCAAT/enhancer binding protein alpha
|
increases expression
|
ISO
|
Pantoprazole results in increased expression of CEBPA protein
|
CTD |
PMID:39004236 |
|
NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309
|
|
G
|
Cfi
|
complement factor I
|
decreases expression
|
EXP
|
pantoprazole results in decreased expression of CFI mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression decreases expression
|
EXP
|
pantoprazole results in increased expression of CYP1A1 protein pantoprazole results in decreased expression of CYP1A1 mRNA
|
CTD |
PMID:9152597 PMID:25626140 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases expression
|
EXP
|
pantoprazole results in increased expression of CYP1A2 mRNA; pantoprazole results in increased expression of CYP1A2 protein
|
CTD |
PMID:9152597 PMID:25626140 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
increases expression
|
EXP
|
pantoprazole results in increased expression of CYP2B1 protein
|
CTD |
PMID:9152597 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
increases expression
|
EXP
|
pantoprazole results in increased expression of CYP2B2 protein
|
CTD |
PMID:9152597 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
affects response to substance multiple interactions decreases activity increases metabolic processing
|
ISO
|
CYP2C19 gene polymorphism affects the susceptibility to pantoprazole pantoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] pantoprazole results in decreased activity of CYP2C19 protein CYP2C19 protein results in increased metabolism of pantoprazole
|
CTD |
PMID:8930576 PMID:15258107 PMID:20223877 PMID:21795468 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
ISO
|
Pantoprazole results in increased expression of and results in increased activity of CYP2E1 protein
|
CTD |
PMID:36243147 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression multiple interactions increases metabolic processing
|
ISO
|
Pantoprazole results in increased expression of CYP3A4 protein Pantoprazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam] CYP3A4 protein results in increased metabolism of Pantoprazole
|
CTD |
PMID:8930576 PMID:9744552 PMID:15258107 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Fasn
|
fatty acid synthase
|
increases expression
|
ISO
|
Pantoprazole results in increased expression of FASN protein
|
CTD |
PMID:39004236 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
increases activity
|
ISO
|
Pantoprazole results in increased activity of GAPDH protein
|
CTD |
PMID:39004236 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
G
|
Hamp
|
hepcidin antimicrobial peptide
|
increases expression
|
ISO
|
Pantoprazole results in increased expression of HAMP mRNA
|
CTD |
PMID:31669099 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
G
|
Jak2
|
Janus kinase 2
|
multiple interactions
|
ISO
|
pantoprazole decreases expression of JAK2 mRNA and decreases phosphorylation of JAK2 protein in gastrocnemius
|
RGD |
PMID:28489606 |
RGD:127285673 |
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
G
|
Lpl
|
lipoprotein lipase
|
increases expression
|
ISO
|
Pantoprazole results in increased expression of LPL mRNA; Pantoprazole results in increased expression of LPL protein
|
CTD |
PMID:39004236 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
pantoprazole inhibits the reaction [Indomethacin results in increased expression of MPO protein]; pantoprazole inhibits the reaction [Ketoprofen results in increased expression of MPO protein]; pantoprazole inhibits the reaction [Piroxicam results in increased expression of MPO protein]
|
CTD |
PMID:16080005 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions
|
EXP
|
[pantoprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; pantoprazole promotes the reaction [Acetic Acid results in increased expression of PCNA protein]
|
CTD |
PMID:18853145 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
increases expression
|
ISO
|
Pantoprazole results in increased expression of PPARG mRNA
|
CTD |
PMID:39004236 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Retsat
|
retinol saturase
|
increases expression
|
EXP
|
pantoprazole results in increased expression of RETSAT mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:106,211,436...106,229,552
|
|
G
|
Serping1
|
serpin family G member 1
|
decreases expression
|
EXP
|
pantoprazole results in decreased expression of SERPING1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:90,249,423...90,258,717
|
|
G
|
Slc22a8
|
solute carrier family 22 member 8
|
multiple interactions
|
ISO
|
[Pantoprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican
|
CTD |
PMID:36243147 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
increases expression
|
ISO
|
Pantoprazole results in increased expression of SREBF1 mRNA; Pantoprazole results in increased expression of SREBF1 protein
|
CTD |
PMID:39004236 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases expression
|
ISO
|
Pantoprazole results in increased expression of TGFB1 protein
|
CTD |
PMID:36243147 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression
|
EXP
|
pantoprazole results in increased expression of UGT1A1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt2b1
|
UDP glucuronosyltransferase 2 family, polypeptide B1
|
increases expression
|
EXP
|
pantoprazole results in increased expression of UGT2B1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331
|
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
parbendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
decreases methylation
|
ISO
|
CYP1A2 protein results in decreased methylation of pimobendan
|
CTD |
PMID:10611143 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
decreases methylation
|
ISO
|
CYP3A4 protein results in decreased methylation of pimobendan
|
CTD |
PMID:10611143 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions decreases expression
|
ISO
|
pimobendan promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein] pimobendan results in decreased expression of IL1B protein
|
CTD |
PMID:9004165 PMID:10193745 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
decreases expression multiple interactions
|
ISO
|
pimobendan results in decreased expression of IL6 protein pimobendan inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
|
CTD |
PMID:9004165 PMID:10193745 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
multiple interactions
|
EXP
|
pimobendan promotes the reaction [Glucose results in increased secretion of INS1 protein]
|
CTD |
PMID:9492047 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity
|
ISO
|
pimobendan results in decreased activity of KCNH2 protein
|
CTD |
PMID:24052561 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
decreases expression multiple interactions
|
ISO
|
pimobendan results in decreased expression of NOS2 mRNA [pimobendan results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide
|
CTD |
PMID:10193745 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions decreases expression
|
ISO
|
pimobendan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] pimobendan results in decreased expression of TNF protein
|
CTD |
PMID:9004165 PMID:10193745 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression
|
ISO
|
Pimozide results in decreased expression of BCL2 mRNA
|
CTD |
PMID:12130671 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
EXP
|
istradefylline inhibits the reaction [Pimozide results in increased expression of FOS protein]; Tropicamide promotes the reaction [Pimozide results in increased expression of FOS protein]
|
CTD |
PMID:19467297 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Kcna10
|
potassium voltage-gated channel subfamily A member 10
|
multiple interactions
|
ISO
|
Pimozide inhibits the reaction [KCNA10 protein results in increased transport of Potassium]
|
CTD |
PMID:10836990 |
|
NCBI chr 2:197,474,714...197,486,789
Ensembl chr 2:197,474,714...197,486,789
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
multiple interactions decreases activity
|
ISO
|
Pimozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Pimozide results in decreased activity of KCNH2 protein
|
CTD |
PMID:15671647 PMID:19583963 PMID:21158687 PMID:24052561 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Lhb
|
luteinizing hormone subunit beta
|
multiple interactions
|
EXP
|
Pimozide results in decreased secretion of and results in decreased glycosylation of LHB protein
|
CTD |
PMID:3896764 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445
|
|
G
|
Prl
|
prolactin
|
increases expression
|
ISO
|
Pimozide results in increased expression of PRL protein
|
CTD |
PMID:8915564 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
|
G
|
C1qa
|
complement C1q A chain
|
decreases expression
|
EXP
|
Rabeprazole results in decreased expression of C1QA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732
|
|
G
|
C1qc
|
complement C1q C chain
|
decreases expression
|
EXP
|
Rabeprazole results in decreased expression of C1QC mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468
|
|
G
|
C4bpa
|
complement component 4 binding protein, alpha
|
decreases expression
|
EXP
|
Rabeprazole results in decreased expression of C4BPA mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,627,959...44,663,552
Ensembl chr13:44,627,982...44,663,471
|
|
G
|
C4bpb
|
complement component 4 binding protein, beta
|
decreases expression
|
EXP
|
Rabeprazole results in decreased expression of C4BPB mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr13:44,673,064...44,683,781
Ensembl chr13:44,673,065...44,683,793
|
|
G
|
Cfi
|
complement factor I
|
decreases expression
|
EXP
|
Rabeprazole results in decreased expression of CFI mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression decreases activity
|
ISO EXP
|
Rabeprazole results in increased expression of CYP1A1 mRNA; Rabeprazole results in increased expression of CYP1A1 protein Rabeprazole results in decreased activity of CYP1A1 protein
|
CTD |
PMID:9041675 PMID:12623754 PMID:25626140 PMID:33814510 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases expression
|
ISO
|
Rabeprazole results in increased expression of CYP1A2 mRNA
|
CTD |
PMID:12623754 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
decreases activity
|
ISO
|
Rabeprazole results in decreased activity of CYP1B1 protein
|
CTD |
PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
multiple interactions affects response to substance
|
ISO
|
CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole] CYP2C19 gene affects the susceptibility to Rabeprazole
|
CTD |
PMID:15903128 PMID:17377957 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
multiple interactions
|
ISO
|
CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]
|
CTD |
PMID:17377957 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
G
|
Hamp
|
hepcidin antimicrobial peptide
|
increases expression
|
ISO
|
Rabeprazole results in increased expression of HAMP mRNA
|
CTD |
PMID:31669099 |
|
NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297
|
|
G
|
Pomc
|
proopiomelanocortin
|
increases expression
|
ISO
|
Rabeprazole results in increased expression of POMC protein
|
CTD |
PMID:16524691 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173
|
|
G
|
Retsat
|
retinol saturase
|
increases expression
|
EXP
|
Rabeprazole results in increased expression of RETSAT mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:106,211,436...106,229,552
|
|
G
|
Serping1
|
serpin family G member 1
|
decreases expression
|
EXP
|
Rabeprazole results in decreased expression of SERPING1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:90,249,423...90,258,717
|
|
G
|
Slc18a2
|
solute carrier family 18 member A2
|
multiple interactions
|
EXP
|
Rabeprazole promotes the reaction [SLC18A2 protein results in increased secretion of Histamine]
|
CTD |
PMID:14642791 |
|
NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
Rabeprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression
|
EXP
|
Rabeprazole results in increased expression of UGT1A1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt2b1
|
UDP glucuronosyltransferase 2 family, polypeptide B1
|
increases expression
|
EXP
|
Rabeprazole results in increased expression of UGT2B1 mRNA
|
CTD |
PMID:25626140 |
|
NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331
|
|
|
G
|
Bcl2l11
|
Bcl2-like 11
|
increases expression
|
ISO
|
AZD 6244 results in increased expression of BCL2L11 protein
|
CTD |
PMID:22729845 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695
|
|
G
|
Camp
|
cathelicidin antimicrobial peptide
|
multiple interactions
|
ISO
|
AZD 6244 promotes the reaction [Calcitriol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]]; AZD 6244 promotes the reaction [resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]]
|
CTD |
PMID:24039193 |
|
NCBI chr 8:118,720,184...118,721,998
Ensembl chr 8:118,720,184...118,721,998
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage
|
ISO
|
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]] Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP3 protein]
|
CTD |
PMID:17876044 PMID:27222248 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp7
|
caspase 7
|
increases cleavage multiple interactions
|
ISO
|
AZD 6244 results in increased cleavage of CASP7 protein Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP7 protein]
|
CTD |
PMID:17876044 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]
|
CTD |
PMID:27222248 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Ccnb1
|
cyclin B1
|
decreases expression multiple interactions
|
ISO
|
AZD 6244 results in decreased expression of CCNB1 protein Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CCNB1 protein]
|
CTD |
PMID:17876044 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions
|
ISO
|
AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein]
|
CTD |
PMID:17876044 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
multiple interactions decreases expression
|
ISO
|
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK2 protein]
|
CTD |
PMID:17876044 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cdk4
|
cyclin-dependent kinase 4
|
decreases expression multiple interactions
|
ISO
|
AZD 6244 results in decreased expression of CDK4 protein Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK4 protein]
|
CTD |
PMID:17876044 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
AZD 6244 promotes the reaction [decitabine results in increased expression of CDKN1A]
|
CTD |
PMID:19422044 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Chd4
|
chromodomain helicase DNA binding protein 4
|
multiple interactions
|
ISO
|
AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein]
|
CTD |
PMID:27805061 |
|
NCBI chr 4:159,584,623...159,617,867
Ensembl chr 4:159,584,654...159,617,866
|
|
G
|
Creb1
|
cAMP responsive element binding protein 1
|
decreases phosphorylation
|
ISO
|
AZD 6244 results in decreased phosphorylation of CREB1 protein
|
CTD |
PMID:31790661 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
multiple interactions
|
ISO
|
[Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein
|
CTD |
PMID:22415236 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
decreases phosphorylation
|
ISO
|
AZD 6244 results in decreased phosphorylation of FOS protein
|
CTD |
PMID:31790661 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Jak2
|
Janus kinase 2
|
increases phosphorylation
|
ISO
|
selumetinib increases phosphorylation of JAK2 protein in colonic epithelium
|
RGD |
PMID:30706361 |
RGD:127285668 |
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
G
|
Kras
|
KRAS proto-oncogene, GTPase
|
multiple interactions
|
ISO
|
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]
|
CTD |
PMID:27222248 |
|
NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions decreases phosphorylation
|
ISO
|
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein] AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein] AZD 6244 results in decreased phosphorylation of MAPK1 protein
|
CTD |
PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions decreases phosphorylation
|
ISO
|
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein] AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein] AZD 6244 results in decreased phosphorylation of MAPK3 protein
|
CTD |
PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mmp1
|
matrix metallopeptidase 1
|
decreases activity
|
ISO
|
AZD 6244 results in decreased activity of MMP1 protein
|
CTD |
PMID:31790661 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases activity
|
ISO
|
AZD 6244 results in decreased activity of MMP2 protein
|
CTD |
PMID:31790661 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
decreases activity
|
ISO
|
AZD 6244 results in decreased activity of MMP9 protein
|
CTD |
PMID:31790661 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions decreases expression
|
ISO
|
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of MYC protein]
|
CTD |
PMID:17876044 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage multiple interactions
|
ISO
|
AZD 6244 results in increased cleavage of PARP1 protein Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of PARP1 protein] AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]
|
CTD |
PMID:17876044 PMID:27222248 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Rps6ka1
|
ribosomal protein S6 kinase A1
|
multiple interactions decreases phosphorylation
|
ISO
|
Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of RPS6KA1 protein]
|
CTD |
PMID:17876044 |
|
NCBI chr 5:151,362,819...151,402,064
Ensembl chr 5:151,362,819...151,476,044
|
|
G
|
Socs3
|
suppressor of cytokine signaling 3
|
multiple interactions
|
ISO
|
AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 mRNA]; AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 protein]
|
CTD |
PMID:23782265 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
G
|
Ucp1
|
uncoupling protein 1
|
multiple interactions
|
ISO
|
AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]
|
CTD |
PMID:27805061 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
decreases activity
|
ISO
|
AZD 6244 results in decreased activity of UGT1A1 protein
|
CTD |
PMID:38823552 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt1a5
|
UDP glucuronosyltransferase family 1 member A5
|
decreases activity
|
ISO
|
AZD 6244 results in decreased activity of UGT1A4 protein
|
CTD |
PMID:38823552 |
|
NCBI chr 9:96,210,053...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Ugt2b7
|
UDP glucuronosyltransferase family 2 member B7
|
decreases activity
|
ISO
|
AZD 6244 results in decreased activity of UGT2B7 protein
|
CTD |
PMID:38823552 |
|
NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
decreases activity multiple interactions
|
ISO
|
telmisartan results in decreased activity of ABCB11 protein telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
|
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcg1
|
ATP binding cassette subfamily G member 1
|
multiple interactions increases expression
|
ISO
|
PPARG mutant form inhibits the reaction [telmisartan results in increased expression of ABCG1 mRNA]
|
CTD |
PMID:22124178 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563
|
|
G
|
Ace
|
angiotensin I converting enzyme
|
decreases expression multiple interactions
|
EXP
|
Telmisartan results in decreased expression of ACE mRNA; Telmisartan results in decreased expression of ACE protein Telmisartan inhibits the reaction [Pregabalin results in increased expression of ACE protein]
|
CTD |
PMID:19171132 PMID:25973029 PMID:29909460 PMID:31629013 |
|
NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942
|
|
G
|
Ace2
|
angiotensin converting enzyme 2
|
multiple interactions increases expression decreases expression decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein] Telmisartan results in increased expression of ACE2 mRNA; Telmisartan results in increased expression of ACE2 protein Telmisartan results in decreased expression of ACE2 mRNA; Telmisartan results in decreased expression of ACE2 protein Telmisartan inhibits the reaction [Pregabalin results in decreased expression of ACE2 protein] telmisartan decreases expression of mRNA in mandible of rats with periodontal disease
|
CTD RGD |
PMID:21381899 PMID:25973029 PMID:28656296 PMID:29909460 PMID:31629013 PMID:33364953 More...
|
RGD:329956421 |
NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596
|
|
G
|
Ache
|
acetylcholinesterase
|
multiple interactions
|
ISO
|
bisphenol A diglycidyl ether inhibits the reaction [Telmisartan inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Telmisartan inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
|
CTD |
PMID:23060470 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
G
|
Acp5
|
acid phosphatase 5, tartrate resistant
|
decreases activity
|
EXP
|
telmisartan decreases enzyme activity of Trap, Acp5 in serum of rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
increases expression
|
ISO
|
telmisartan results in increased expression of ADIPOQ mRNA telmisartan results in increased expression of ADIPOQ protein
|
CTD |
PMID:19730415 PMID:20555330 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
G
|
Agt
|
angiotensinogen
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein] Telmisartan inhibits the reaction [AGT protein results in decreased expression of PLAU mRNA]; Telmisartan inhibits the reaction [AGT protein results in decreased expression of SYP protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of AGTR1A mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1G mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1H mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of CRH protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of FOS protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of IL1B protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]; Telmisartan inhibits the reaction [AGT protein results in increased ubiquitination of SYP protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of AGT protein]; Telmisartan inhibits the reaction [Diatrizoate results in increased expression of AGT protein]; Telmisartan inhibits the reaction [Iohexol results in increased expression of AGT protein]; Telmisartan inhibits the reaction [Pregabalin results in decreased expression of AGT protein] telmisartan results in decreased expression of AGT mRNA; telmisartan results in decreased expression of AGT protein
|
CTD |
PMID:9533614 PMID:17620961 PMID:18487452 PMID:19171132 PMID:19289654 PMID:19292980 PMID:19452295 PMID:19706694 PMID:31629013 PMID:33872574 PMID:34339004 More...
|
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
affects binding increases expression multiple interactions decreases expression decreases expression
|
EXP ISO
|
telmisartan binds to AGTR1 protein telmisartan results in increased expression of AGTR1 mRNA Telmisartan binds to and results in decreased activity of AGTR1 protein; Telmisartan inhibits the reaction [AGT protein results in increased expression of AGTR1A mRNA]; Telmisartan inhibits the reaction [Daunorubicin results in increased expression of AGTR1A protein]; Telmisartan inhibits the reaction [Pregabalin results in increased expression of AGTR1 protein] telmisartan binds to and results in decreased activity of AGTR1 protein telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; telmisartan inhibits the reaction [Streptozocin results in increased expression of AGTR1A protein] telmisartan results in decreased expression of AGTR1A mRNA telmisartan decreases expression of mRNA in mandible of rats with periodontal disease
|
CTD RGD |
PMID:8220885 PMID:9533614 PMID:9728324 PMID:17620961 PMID:19171132 PMID:19706694 PMID:20888384 PMID:21381899 PMID:21557540 PMID:31629013 PMID:33364953 More...
|
RGD:329956421 |
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Agtr1b
|
angiotensin II receptor, type 1b
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]
|
CTD |
PMID:17620961 |
|
NCBI chr 2:104,774,005...104,849,262
Ensembl chr 2:104,773,930...104,849,310
|
|
G
|
Agtr2
|
angiotensin II receptor, type 2
|
increases expression
|
EXP
|
telmisartan increases expression of mRNA in mandible of rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr X:116,914,320...116,918,504
Ensembl chr X:116,913,656...116,918,745
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
increases activity
|
EXP
|
Telmisartan results in increased activity of AHR protein
|
CTD |
PMID:28728110 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Alb
|
albumin
|
affects expression multiple interactions
|
ISO
|
telmisartan affects the expression of ALB protein modified form Telmisartan affects the reaction [LEPR protein affects the abundance of ALB protein]
|
CTD |
PMID:16671338 PMID:34464088 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
increases activity multiple interactions
|
EXP
|
telmisartan increases enzyme activity of Alpl in serum of rats with periodontal disease Telmisartan inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of ALPL protein]
|
CTD RGD |
PMID:27269004 PMID:33364953 |
RGD:329956421 |
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
G
|
Ang2
|
angiogenin, ribonuclease A family, member 2
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of ANG2 protein]
|
CTD |
PMID:23750309 |
|
NCBI chr15:26,871,842...26,889,421
Ensembl chr15:26,871,838...26,889,421
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BAX mRNA]
|
CTD |
PMID:24831514 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 mRNA]
|
CTD |
PMID:24831514 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bdnf
|
brain-derived neurotrophic factor
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]
|
CTD |
PMID:23747572 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
G
|
Cacna1g
|
calcium voltage-gated channel subunit alpha1 G
|
multiple interactions decreases expression
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [telmisartan results in decreased expression of CACNA1G mRNA]; SB 203580 inhibits the reaction [telmisartan results in decreased expression of CACNA1G mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1G mRNA]
|
CTD |
PMID:19292980 |
|
NCBI chr10:79,851,886...79,919,926
Ensembl chr10:79,851,896...79,919,634
|
|
G
|
Cacna1h
|
calcium voltage-gated channel subunit alpha1 H
|
multiple interactions decreases expression
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [telmisartan results in decreased expression of CACNA1H mRNA]; SB 203580 inhibits the reaction [telmisartan results in decreased expression of CACNA1H mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1H mRNA]
|
CTD |
PMID:19292980 |
|
NCBI chr10:14,894,630...14,952,317
Ensembl chr10:14,894,641...14,952,771
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Pyruvaldehyde results in increased cleavage of CASP3 protein] telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]; telmisartan inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein] Telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]; Telmisartan inhibits the reaction [Diatrizoate results in increased activity of CASP3 protein]; Telmisartan inhibits the reaction [Iohexol results in increased activity of CASP3 protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of CASP3]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of CASP3 protein]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CASP3 mRNA] Telmisartan results in decreased expression of CASP3 protein
|
CTD |
PMID:18565324 PMID:19452295 PMID:21620867 PMID:21819444 PMID:22750630 PMID:24831514 PMID:26439596 PMID:27269004 PMID:29909460 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [arsenite results in decreased activity of CAT protein]; Telmisartan inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]
|
CTD |
PMID:23750309 PMID:26929000 PMID:34339004 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] telmisartan results in decreased expression of CCL2 protein
|
CTD |
PMID:17922026 PMID:22124178 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccl5
|
C-C motif chemokine ligand 5
|
decreases response to substance
|
ISO
|
telmisartan results in decreased susceptibility to CCL5 protein
|
CTD |
PMID:18158351 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884
|
|
G
|
Ccr2
|
C-C motif chemokine receptor 2
|
decreases expression
|
EXP
|
telmisartan results in decreased expression of CCR2 mRNA
|
CTD |
PMID:17922026 |
|
NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059
|
|
G
|
Cd36
|
CD36 molecule
|
increases expression multiple interactions
|
ISO
|
telmisartan results in increased expression of CD36 mRNA PPARG mutant form inhibits the reaction [telmisartan results in increased expression of CD36 mRNA]; T 0070907 inhibits the reaction [telmisartan results in increased expression of CD36 mRNA]
|
CTD |
PMID:22124178 |
|
NCBI chr 4:18,209,088...18,302,142
|
|
G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [TNF protein promotes the reaction [CEBPB protein binds to IL6 promoter]]
|
CTD |
PMID:19289654 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
G
|
Crh
|
corticotropin releasing hormone
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [AGT protein results in increased expression of CRH protein]
|
CTD |
PMID:33872574 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386
|
|
G
|
Crp
|
C-reactive protein
|
decreases expression
|
ISO
|
telmisartan results in decreased expression of CRP protein
|
CTD |
PMID:20555330 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514
|
|
G
|
Ctsk
|
cathepsin K
|
decreases expression
|
EXP
|
telmisartan decreases expression of mRNA in mandible of rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582
|
|
G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
multiple interactions decreases response to substance
|
ISO
|
PPARG protein promotes the reaction [telmisartan inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein]]; telmisartan inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein] telmisartan results in decreased susceptibility to CXCL12 protein
|
CTD |
PMID:18158351 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627
|
|
G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
decreases expression
|
EXP
|
telmisartan decreases expression of protein in mandible of SHR rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
G
|
Cyba
|
cytochrome b-245 alpha chain
|
decreases expression multiple interactions
|
ISO EXP
|
telmisartan results in decreased expression of CYBA mRNA; telmisartan results in decreased expression of CYBA protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of CYBA protein]
|
CTD |
PMID:16141465 PMID:19171132 PMID:21054405 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214
|
|
G
|
Cybb
|
cytochrome b-245 beta chain
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in increased expression of CYBB protein] telmisartan results in decreased expression of CYBB mRNA Telmisartan inhibits the reaction [Glucose results in increased expression of CYBB mRNA]; Telmisartan inhibits the reaction [Glucose results in increased expression of CYBB protein] Telmisartan inhibits the reaction [arsenite results in increased expression of CYBB mRNA]
|
CTD |
PMID:19171132 PMID:21381899 PMID:34339004 PMID:34464088 |
|
NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065
|
|
G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CYCS mRNA]
|
CTD |
PMID:24831514 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
G
|
Cyp2j4
|
cytochrome P450, family 2, subfamily j, polypeptide 4
|
decreases activity
|
ISO
|
Telmisartan results in decreased activity of CYP2J2 protein
|
CTD |
PMID:30965050 |
|
NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
decreases expression
|
EXP
|
telmisartan results in decreased expression of DDIT3 protein
|
CTD |
PMID:19102871 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Edn1
|
endothelin 1
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDN1 protein]
|
CTD |
PMID:20888384 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Ednra
|
endothelin receptor type A
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDNRA protein]
|
CTD |
PMID:20888384 |
|
NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284
|
|
G
|
Ednrb
|
endothelin receptor type B
|
multiple interactions
|
EXP
|
telmisartan promotes the reaction [Daunorubicin results in increased expression of EDNRB protein]
|
CTD |
PMID:20888384 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
G
|
Faslg
|
Fas ligand
|
multiple interactions
|
ISO EXP
|
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of FASL protein] telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of FASLG protein]
|
CTD |
PMID:21620867 PMID:21819444 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
G
|
Fn1
|
fibronectin 1
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 protein]
|
CTD |
PMID:19706694 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137
|
|
G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [AGT protein results in increased expression of FOS protein]
|
CTD |
PMID:33872574 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
multiple interactions
|
ISO
|
Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein]
|
CTD |
PMID:23747572 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Gfap
|
glial fibrillary acidic protein
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein] Telmisartan results in decreased expression of GFAP protein
|
CTD |
PMID:23747572 PMID:29909460 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685
|
|
G
|
Ggt1
|
gamma-glutamyltransferase 1
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of GGT1 protein]
|
CTD |
PMID:23750309 |
|
NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,141...13,088,050
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
multiple interactions
|
ISO
|
Telmisartan inhibits the reaction [Dibutyl Phthalate results in increased expression of GJA1 protein]
|
CTD |
PMID:37356649 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GOT1 protein]
|
CTD |
PMID:27269004 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GPT protein]
|
CTD |
PMID:26929000 PMID:27269004 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
decreases activity multiple interactions
|
EXP
|
Telmisartan results in decreased activity of GSR protein Telmisartan inhibits the reaction [arsenite results in decreased activity of GSR protein]
|
CTD |
PMID:34339004 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
G
|
Hgf
|
hepatocyte growth factor
|
increases expression
|
ISO
|
telmisartan results in increased expression of HGF mRNA
|
CTD |
PMID:21479465 |
|
NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
|
|
G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
decreases expression
|
EXP
|
telmisartan results in decreased expression of HSPA5 protein
|
CTD |
PMID:19102871 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
G
|
Ibsp
|
integrin-binding sialoprotein
|
increases expression
|
EXP
|
telmisartan increases expression of mRNA in mandible of WKY rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr14:5,744,497...5,757,242
Ensembl chr14:5,744,501...5,775,299
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] telmisartan inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA] telmisartan inhibits the reaction [Daunorubicin results in increased expression of ICAM1 protein]
|
CTD |
PMID:17724226 PMID:20888384 PMID:22124178 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions increases expression decreases expression
|
EXP
|
telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL10 protein] Telmisartan results in increased expression of IL10 protein telmisartan decreases expression of protein in mandible of WKY rats with periodontal disease
|
CTD RGD |
PMID:24831514 PMID:29909460 PMID:33364953 |
RGD:329956421 |
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] Telmisartan inhibits the reaction [AGT protein results in increased expression of IL1B protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of IL1B protein] telmisartan decreases expression of protein in mandible of SHR rats with periodontal disease
|
CTD RGD |
PMID:22124178 PMID:33872574 PMID:34339004 PMID:33364953 |
RGD:329956421 |
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; Telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [TNF protein promotes the reaction [CEBPB protein binds to IL6 promoter]]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein] telmisartan results in decreased expression of IL6 mRNA Telmisartan results in decreased expression of IL6 protein
|
CTD |
PMID:19289654 PMID:21479465 PMID:22124178 PMID:29909460 PMID:34339004 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Ins1
|
insulin 1
|
increases expression
|
EXP
|
Telmisartan results in increased expression of INS1 protein
|
CTD |
PMID:19171132 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
G
|
Ins2
|
insulin 2
|
decreases expression
|
ISO
|
telmisartan results in decreased expression of INS protein
|
CTD |
PMID:15892894 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805
|
|
G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
multiple interactions
|
ISO
|
[Atorvastatin co-treated with Telmisartan] results in decreased expression of IRAK1 mRNA
|
CTD |
PMID:20524934 |
|
NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825
|
|
G
|
Kcnn4
|
potassium calcium-activated channel subfamily N member 4
|
decreases expression
|
ISO
|
telmisartan decreases expression of KCNN4 mRNA and protein in CD4-positive alpha-beta T cell
|
RGD |
PMID:26502942 |
RGD:329955577 |
NCBI chr 1:89,084,306...89,102,279
Ensembl chr 1:89,086,814...89,102,275
|
|
G
|
Lepr
|
leptin receptor
|
multiple interactions
|
ISO
|
Telmisartan affects the reaction [LEPR protein affects the abundance of ALB protein]; Telmisartan affects the reaction [LEPR protein affects the expression of OCLN mRNA]
|
CTD |
PMID:34464088 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215
|
|
G
|
Lipe
|
lipase E, hormone sensitive type
|
multiple interactions increases expression
|
ISO
|
PPARD promotes the reaction [telmisartan results in increased expression of LIPE protein]
|
CTD |
PMID:20176998 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:90,093,433...90,112,117
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:22124178 PMID:33872574 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions decreases phosphorylation
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein] telmisartan results in decreased phosphorylation of MAPK14 protein
|
CTD |
PMID:19292980 PMID:22124178 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:22124178 PMID:33872574 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mapkapk2
|
MAPK activated protein kinase 2
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [Streptozocin results in increased expression of MAPKAPK2 protein modified form]
|
CTD |
PMID:21381899 |
|
NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326
|
|
G
|
Mas1
|
MAS1 proto-oncogene, G protein-coupled receptor
|
multiple interactions increases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in decreased expression of MAS1 protein] Telmisartan results in increased expression of MAS1 protein Telmisartan inhibits the reaction [Pregabalin results in decreased expression of MAS1 protein]
|
CTD |
PMID:21381899 PMID:28656296 PMID:31629013 |
|
NCBI chr 1:50,428,064...50,459,537
Ensembl chr 1:50,425,257...50,500,561
|
|
G
|
Mir146a
|
microRNA 146a
|
multiple interactions
|
ISO EXP
|
[Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146A telmisartan inhibits the reaction [ischemia-reperfusion injury increases expression of Mir146a miRNA in kidney]
|
CTD RGD |
PMID:20524934 PMID:27760486 |
RGD:155882556 |
NCBI chr10:28,349,996...28,350,090
|
|
G
|
Mir146b
|
microRNA 146b
|
multiple interactions
|
ISO
|
[Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146B
|
CTD |
PMID:20524934 |
|
NCBI chr 1:255,144,860...255,144,947
Ensembl chr 1:255,144,860...255,144,947
|
|
G
|
Mir320a
|
microRNA 320a
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [ischemia-reperfusion injury increases expression of Mir320a miRNA in kidney]
|
RGD |
PMID:27760486 |
RGD:155882556 |
NCBI chr15:51,926,088...51,926,169
Ensembl chr15:51,926,088...51,926,169
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases expression decreases expression
|
EXP
|
telmisartan results in decreased expression of MMP2 protein telmisartan decreases expression of mRNA in mandible of WKY rats with periodontal disease
|
CTD RGD |
PMID:21054405 PMID:33364953 |
RGD:329956421 |
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
decreases expression
|
EXP
|
telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO EXP
|
bisphenol A diglycidyl ether inhibits the reaction [Telmisartan inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Telmisartan inhibits the reaction [Streptozocin results in increased activity of MPO protein] Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased activity of MPO protein]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
|
CTD |
PMID:23060470 PMID:24831514 PMID:26439596 PMID:26929000 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mylk
|
myosin light chain kinase
|
multiple interactions
|
ISO
|
MYLK protein inhibits the reaction [Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]]; Telmisartan inhibits the reaction [Glucose results in increased expression of MYLK mRNA]; Telmisartan inhibits the reaction [Glucose results in increased expression of MYLK protein]
|
CTD |
PMID:34464088 |
|
NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659
|
|
G
|
Ncf1
|
neutrophil cytosolic factor 1
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in increased expression of NCF1 protein] telmisartan results in decreased expression of NCF1 mRNA; telmisartan results in decreased expression of NCF1 protein Telmisartan results in decreased expression of NCF1 mRNA; Telmisartan results in decreased expression of NCF1 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF1 protein]
|
CTD |
PMID:16141465 PMID:19171132 PMID:21054405 PMID:21381899 |
|
NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079
|
|
G
|
Ncf2
|
neutrophil cytosolic factor 2
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in increased expression of NCF2 protein] telmisartan results in decreased expression of NCF2 mRNA; telmisartan results in decreased expression of NCF2 protein telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF2 protein]
|
CTD |
PMID:16141465 PMID:21054405 PMID:21381899 |
|
NCBI chr13:67,505,492...67,536,015
Ensembl chr13:67,505,375...67,536,149
|
|
G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of NFKB1 protein]
|
CTD |
PMID:21620867 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA]]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA]
|
CTD |
PMID:22124178 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO EXP
|
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of NOS2 protein]; telmisartan inhibits the reaction [sodium arsenite results in increased expression of NOS2 protein] Telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of NOS2 protein]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of NOS2 protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of NOS2]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 mRNA]
|
CTD |
PMID:21620867 PMID:21819444 PMID:22750630 PMID:24831514 PMID:26439596 PMID:26929000 PMID:27269004 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions increases expression increases phosphorylation
|
ISO
|
2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan results in increased expression of NOS3 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan results in increased phosphorylation of NOS3 protein]
|
CTD |
PMID:21156825 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Nox4
|
NADPH oxidase 4
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Daunorubicin results in increased expression of NOX4 protein]
|
CTD |
PMID:21054405 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
G
|
Nphs1
|
NPHS1 adhesion molecule, nephrin
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [Daunorubicin results in decreased expression of NPHS1 protein]
|
CTD |
PMID:20888384 |
|
NCBI chr 1:94,848,261...94,876,522
Ensembl chr 1:94,848,261...94,876,521
|
|
G
|
Nppb
|
natriuretic peptide B
|
affects expression decreases expression multiple interactions
|
ISO EXP
|
telmisartan affects the expression of NPPB protein telmisartan results in decreased expression of NPPB protein Telmisartan inhibits the reaction [Pregabalin results in increased expression of NPPB protein]
|
CTD |
PMID:16671338 PMID:18712048 PMID:31629013 |
|
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310
|
|
G
|
Ocln
|
occludin
|
multiple interactions
|
ISO
|
MYLK protein inhibits the reaction [Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]]; Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]; Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN protein] Telmisartan affects the reaction [LEPR protein affects the expression of OCLN mRNA]
|
CTD |
PMID:34464088 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
|
|
G
|
Olr1
|
oxidized low density lipoprotein receptor 1
|
multiple interactions
|
ISO
|
Telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of OLR1 mRNA]; Telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of OLR1 protein]
|
CTD |
PMID:22124178 |
|
NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598
|
|
G
|
Plau
|
plasminogen activator, urokinase
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [AGT protein results in decreased expression of PLAU mRNA]
|
CTD |
PMID:19706694 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
G
|
Ppard
|
peroxisome proliferator-activated receptor delta
|
increases expression multiple interactions
|
EXP ISO
|
telmisartan results in increased expression of PPARD protein PPARD promotes the reaction [telmisartan results in increased expression of LIPE protein]; PPARD promotes the reaction [telmisartan results in increased expression of UCP1 protein]; PPARD promotes the reaction [telmisartan results in increased expression of UCP2 protein]; PPARD promotes the reaction [telmisartan results in increased expression of UCP3 protein]
|
CTD |
PMID:20176998 |
|
NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions increases activity increases expression
|
ISO EXP
|
PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA]]; PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; PPARG mutant form inhibits the reaction [telmisartan results in increased expression of ABCG1 mRNA]; PPARG mutant form inhibits the reaction [telmisartan results in increased expression of CD36 mRNA]; PPARG protein promotes the reaction [telmisartan inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein]] Telmisartan results in increased activity of PPARG protein telmisartan inhibits the reaction [Streptozocin results in decreased expression of PPARG protein] telmisartan results in increased expression of PPARG protein telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of PPARG mRNA]; telmisartan promotes the reaction [Daunorubicin results in increased expression of PPARG protein]
|
CTD |
PMID:18158351 PMID:20176998 PMID:20888384 PMID:21381899 PMID:22124178 PMID:24831514 PMID:28728110 More...
|
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [Streptozocin results in decreased expression of PPARGC1A protein]
|
CTD |
PMID:21381899 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
G
|
Prkaa2
|
protein kinase AMP-activated catalytic subunit alpha 2
|
multiple interactions
|
ISO
|
Telmisartan inhibits the reaction [Dibutyl Phthalate results in increased expression of PRKAA2 protein]
|
CTD |
PMID:37356649 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324
|
|
G
|
Prkaca
|
protein kinase cAMP-activated catalytic subunit alpha
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [Pregabalin results in decreased expression of PRKACA protein]
|
CTD |
PMID:31629013 |
|
NCBI chr19:41,059,843...41,083,189
Ensembl chr19:41,059,843...41,086,494
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions increases activity
|
ISO EXP
|
telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] [Telmisartan co-treated with Aspirin] inhibits the reaction [Streptozocin results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [arsenite results in increased activity of PTGS2 protein]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [Daunorubicin results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of PTGS2]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 mRNA] telmisartan inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein] Telmisartan results in increased activity of PTGS2 protein
|
CTD |
PMID:20223228 PMID:20888384 PMID:22124178 PMID:22750630 PMID:24831514 PMID:26439596 PMID:26929000 PMID:27269004 PMID:34339004 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Pth1r
|
parathyroid hormone 1 receptor
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of PTH1R protein]
|
CTD |
PMID:23750309 |
|
NCBI chr 8:119,572,295...119,597,405
Ensembl chr 8:119,575,868...119,598,108
|
|
G
|
Pthlh
|
parathyroid hormone-like hormone
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of PTHLH protein]
|
CTD |
PMID:23750309 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP ISO
|
[telmisartan co-treated with Aspirin] inhibits the reaction [Streptozocin results in increased expression of RELA protein]; telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of RELA mRNA]; telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of RELA protein] telmisartan inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]
|
CTD |
PMID:20223228 PMID:22124178 PMID:24831514 PMID:26929000 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Ren
|
renin
|
increases expression
|
EXP
|
telmisartan results in increased expression of REN mRNA; telmisartan results in increased expression of REN protein
|
CTD |
PMID:9533614 |
|
NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543
|
|
G
|
Runx2
|
RUNX family transcription factor 2
|
increases expression
|
EXP
|
telmisartan increases expression of mRNA in mandible of rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
G
|
Scn5a
|
sodium voltage-gated channel alpha subunit 5
|
increases activity
|
ISO
|
telmisartan results in increased activity of SCN5A protein
|
CTD |
PMID:29306026 |
|
NCBI chr 8:128,098,613...128,196,515
Ensembl chr 8:128,098,613...128,196,470
|
|
G
|
Sema3b
|
semaphorin 3B
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [Calcitriol results in increased expression of SEMA3B protein]; telmisartan inhibits the reaction [Progesterone results in increased expression of SEMA3B protein]
|
CTD |
PMID:21933904 |
|
NCBI chr 8:117,150,307...117,161,570
Ensembl chr 8:117,150,589...117,157,658
|
|
G
|
Sema3f
|
semaphorin 3F
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [Calcitriol results in increased expression of SEMA3F protein]; telmisartan inhibits the reaction [Progesterone results in increased expression of SEMA3F protein]
|
CTD |
PMID:21933904 |
|
NCBI chr 8:117,236,269...117,265,206
Ensembl chr 8:117,236,269...117,265,206
|
|
G
|
Serpine1
|
serpin family E member 1
|
multiple interactions
|
ISO EXP
|
telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; telmisartan inhibits the reaction [Hydrogen Peroxide results in increased expression of SERPINE1 mRNA] telmisartan inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]
|
CTD |
PMID:17620961 PMID:19706694 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357
|
|
G
|
Slc18a2
|
solute carrier family 18 member A2
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]
|
CTD |
PMID:23747572 |
|
NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]
|
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
G
|
Slc6a3
|
solute carrier family 6 member 3
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]
|
CTD |
PMID:23747572 |
|
NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:31,537,990...31,578,962
|
|
G
|
Snca
|
synuclein alpha
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]
|
CTD |
PMID:23747572 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315
|
|
G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions
|
EXP
|
Telmisartan inhibits the reaction [Methotrexate results in decreased expression of and results in decreased activity of SOD1 protein]
|
CTD |
PMID:27269004 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Spp1
|
secreted phosphoprotein 1
|
increases expression
|
EXP
|
telmisartan increases expression of mRNA in mandible of WKY rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820
|
|
G
|
Syp
|
synaptophysin
|
multiple interactions
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in decreased expression of SYP protein] telmisartan inhibits the reaction [AGT protein results in decreased expression of SYP protein]; telmisartan inhibits the reaction [AGT protein results in increased ubiquitination of SYP protein]
|
CTD |
PMID:18487452 |
|
NCBI chr X:17,521,348...17,536,449
Ensembl chr X:17,521,348...17,536,984
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein] telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; telmisartan inhibits the reaction [Daunorubicin results in increased expression of TGFB1 protein] telmisartan results in decreased expression of TGFB1 mRNA
|
CTD |
PMID:19171132 PMID:19706694 PMID:20888384 PMID:21381899 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Th
|
tyrosine hydroxylase
|
multiple interactions
|
ISO
|
telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]
|
CTD |
PMID:23747572 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227
|
|
G
|
Tjp1
|
tight junction protein 1
|
multiple interactions affects localization decreases expression
|
ISO
|
2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan affects the localization of TJP1 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan results in decreased expression of TJP1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan results in decreased expression of TJP1 protein]; wortmannin inhibits the reaction [telmisartan affects the localization of TJP1 protein]; wortmannin inhibits the reaction [telmisartan results in decreased expression of TJP1 mRNA]; wortmannin inhibits the reaction [telmisartan results in decreased expression of TJP1 protein] telmisartan results in decreased expression of TJP1 mRNA; telmisartan results in decreased expression of TJP1 protein
|
CTD |
PMID:19252288 |
|
NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158
|
|
G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
ISO
|
[Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 protein
|
CTD |
PMID:20524934 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions decreases expression decreases expression
|
ISO EXP
|
PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; T 0070907 inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; T 0070907 inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; [Telmisartan co-treated with Aspirin] inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of TNF protein]; Telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of TNF]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of TNF]; Telmisartan inhibits the reaction [TNF protein promotes the reaction [CEBPB protein binds to IL6 promoter]]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; telmisartan inhibits the reaction [sodium arsenite results in increased expression of TNF protein]; telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein] Telmisartan results in decreased expression of TNF protein telmisartan decreases expression of protein in mandible of SHR rats with periodontal disease
|
CTD RGD |
PMID:19289654 PMID:20223228 PMID:21620867 PMID:21819444 PMID:22124178 PMID:22750630 PMID:24831514 PMID:26439596 PMID:26929000 PMID:29909460 PMID:34339004 PMID:33364953 More...
|
RGD:329956421 |
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tnfrsf11b
|
TNF receptor superfamily member 11B
|
increases expression
|
EXP
|
telmisartan increases expression of mRNA in mandible of WKY rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075
|
|
G
|
Tnfsf11
|
TNF superfamily member 11
|
decreases expression
|
EXP
|
telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
G
|
Traf6
|
TNF receptor associated factor 6
|
multiple interactions
|
ISO
|
[Atorvastatin co-treated with Telmisartan] results in decreased expression of TRAF6 mRNA
|
CTD |
PMID:20524934 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
|
|
G
|
Ucp1
|
uncoupling protein 1
|
multiple interactions increases expression
|
ISO
|
PPARD promotes the reaction [telmisartan results in increased expression of UCP1 protein]
|
CTD |
PMID:20176998 |
|
NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420
|
|
G
|
Ucp2
|
uncoupling protein 2
|
multiple interactions increases expression
|
ISO
|
PPARD promotes the reaction [telmisartan results in increased expression of UCP2 protein]
|
CTD |
PMID:20176998 |
|
NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743
|
|
G
|
Ucp3
|
uncoupling protein 3
|
multiple interactions increases expression
|
ISO
|
PPARD promotes the reaction [telmisartan results in increased expression of UCP3 protein]
|
CTD |
PMID:20176998 |
|
NCBI chr 1:164,227,910...164,240,893
Ensembl chr 1:164,227,882...164,241,210
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
EXP
|
telmisartan inhibits the reaction [Daunorubicin results in increased expression of VCAM1 protein]
|
CTD |
PMID:20888384 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions decreases expression
|
ISO EXP
|
telmisartan inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA] telmisartan results in decreased expression of VEGFA mRNA telmisartan inhibits the reaction [sodium arsenite results in increased expression of VEGFA]
|
CTD |
PMID:17724226 PMID:19171132 PMID:26439596 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Vtn
|
vitronectin
|
decreases expression
|
EXP
|
telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal disease
|
RGD |
PMID:33364953 |
RGD:329956421 |
NCBI chr10:63,892,782...63,895,862
Ensembl chr10:63,892,766...63,895,860
|
|
|
G
|
1700012B07Rikl
|
RIKEN cDNA 1700012B07 gene like
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of 1700012B07RIKL gene
|
CTD |
PMID:33854195 |
|
NCBI chr10:95,271,034...95,304,337
Ensembl chr10:95,268,422...95,304,315
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
decreases expression
|
ISO
|
Thiabendazole results in decreased expression of ABCB1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of ABCC2 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Acot2
|
acyl-CoA thioesterase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ACOT2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 6:109,341,426...109,352,818
Ensembl chr 6:109,342,646...109,350,502
|
|
G
|
Acot4
|
acyl-CoA thioesterase 4
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACOT4 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138
|
|
G
|
Acy1
|
aminoacylase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACY1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:115,951,068...115,956,471
Ensembl chr 8:115,951,068...115,956,405
|
|
G
|
Adam15
|
ADAM metallopeptidase domain 15
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAM15 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 2:177,052,363...177,062,879
Ensembl chr 2:177,052,363...177,062,849
|
|
G
|
Adamtsl3
|
ADAMTS-like 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAMTSL3 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:145,698,004...146,006,195
Ensembl chr 1:145,698,004...146,006,195
|
|
G
|
Adcy6
|
adenylate cyclase 6
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ADCY6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:131,621,860...131,642,923
Ensembl chr 7:131,621,860...131,642,770
|
|
G
|
Adrm1
|
ADRM1 26S proteasome ubiquitin receptor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ADRM1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:187,643,043...187,647,805
Ensembl chr 3:187,642,654...187,648,483
|
|
G
|
Afp
|
alpha-fetoprotein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AFP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649
|
|
G
|
Agt
|
angiotensinogen
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AGT mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
G
|
Aig1
|
androgen-induced 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of AIG1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:9,866,546...10,089,454
Ensembl chr 1:9,866,548...10,089,155
|
|
G
|
Akap8
|
A-kinase anchoring protein 8
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:11,966,769...11,983,056
Ensembl chr 7:11,966,772...11,982,900
|
|
G
|
Akap8l
|
A-kinase anchoring protein 8 like
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8L mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:11,983,215...12,012,843
Ensembl chr 7:11,982,721...12,012,811
|
|
G
|
Alb
|
albumin
|
decreases expression
|
EXP
|
Thiabendazole results in decreased expression of ALB mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Aldh9a1
|
aldehyde dehydrogenase 9 family, member A1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALDH9A1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr13:82,038,679...82,055,478
Ensembl chr13:82,038,533...82,055,481
|
|
G
|
Alg2
|
ALG2, alpha-1,3/1,6-mannosyltransferase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALG2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:66,564,328...66,568,887
Ensembl chr 5:66,564,330...66,568,887
|
|
G
|
Angptl4
|
angiopoietin-like 4
|
multiple interactions increases expression
|
EXP ISO
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANGPTL4 mRNA Thiabendazole results in increased expression of ANGPTL4 mRNA
|
CTD |
PMID:33854195 PMID:39207506 |
|
NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681
|
|
G
|
Anks3
|
ankyrin repeat and sterile alpha motif domain containing 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ANKS3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:11,121,504...11,142,261
Ensembl chr10:11,121,553...11,142,491
|
|
G
|
Anxa11
|
annexin A11
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANXA11 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr16:1,419,627...1,464,590
Ensembl chr16:1,418,351...1,464,839
|
|
G
|
Aplf
|
aprataxin and PNKP like factor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APLF mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:121,627,800...121,679,980
Ensembl chr 4:121,627,800...121,679,961
|
|
G
|
Apof
|
apolipoprotein F
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APOF mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:1,285,222...1,286,659
Ensembl chr 7:1,285,222...1,286,659
|
|
G
|
Arf2
|
ADP-ribosylation factor 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ARF2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:89,367,843...89,389,644
Ensembl chr10:89,368,044...89,389,651
|
|
G
|
Arpc1a
|
actin related protein 2/3 complex, subunit 1A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ARPC1A gene
|
CTD |
PMID:33854195 |
|
NCBI chr12:14,616,245...14,639,052
Ensembl chr12:14,616,248...14,639,052
|
|
G
|
Asb7
|
ankyrin repeat and SOCS box-containing 7
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ASB7 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:129,621,462...129,677,788
Ensembl chr 1:129,635,330...129,677,505
|
|
G
|
Ass1
|
argininosuccinate synthase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ASS1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627
|
|
G
|
Atosa
|
atos homolog A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ATOSA mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:84,575,360...84,653,103
Ensembl chr 8:84,575,370...84,653,091
|
|
G
|
Atp5mc1
|
ATP synthase membrane subunit c locus 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP5MC1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:81,520,762...81,523,735
Ensembl chr10:81,520,765...81,523,363
|
|
G
|
Atp6v0d1
|
ATPase H+ transporting V0 subunit D1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP6V0D1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:50,313,268...50,357,248
Ensembl chr19:50,313,273...50,357,395
|
|
G
|
Bag3
|
BAG cochaperone 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BAG3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280
|
|
G
|
Banp
|
Btg3 associated nuclear protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BANP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:66,916,417...66,994,286
Ensembl chr19:66,916,267...66,991,317
|
|
G
|
Bcl9
|
BCL9, transcription coactivator
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of BCL9 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:187,449,425...187,475,241
|
|
G
|
Bhmt
|
betaine-homocysteine S-methyltransferase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BHMT mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:26,594,852...26,614,429
Ensembl chr 2:26,594,854...26,614,715
|
|
G
|
C1qc
|
complement C1q C chain
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C1QC mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468
|
|
G
|
C8h11orf54
|
similar to human chromosome 11 open reading frame 54
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C8H11ORF54 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:20,405,240...20,427,811
Ensembl chr 8:20,405,241...20,427,811
|
|
G
|
Camk2g
|
calcium/calmodulin-dependent protein kinase II gamma
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAMK2G mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr15:3,553,238...3,612,310
Ensembl chr15:3,553,294...3,612,310
|
|
G
|
Cap1
|
cyclase associated actin cytoskeleton regulatory protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CAP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:140,427,265...140,507,678
Ensembl chr 5:140,427,269...140,453,470
|
|
G
|
Caps2
|
calcyphosine 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAPS2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:49,467,320...49,525,465
Ensembl chr 7:49,464,885...49,525,465
|
|
G
|
Casp3
|
caspase 3
|
increases activity
|
EXP
|
Thiabendazole results in increased activity of CASP3 protein
|
CTD |
PMID:26748015 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
increases activity
|
EXP
|
Thiabendazole results in increased activity of CASP8 protein
|
CTD |
PMID:26748015 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
increases activity
|
EXP
|
Thiabendazole results in increased activity of CASP9 protein
|
CTD |
PMID:26748015 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Cbs
|
cystathionine beta synthase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CBS mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,709,395...9,734,066
|
|
G
|
Ccdc125
|
coiled-coil domain containing 125
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCDC125 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:33,542,916...33,568,501
Ensembl chr 2:33,543,300...33,568,288
|
|
G
|
Ccnd1
|
cyclin D1
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of CCND1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccnl1
|
cyclin L1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCNL1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:152,495,169...152,508,855
Ensembl chr 2:152,495,172...152,507,468
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions increases expression
|
EXP ISO
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CDKN1A mRNA Thiabendazole results in increased expression of CDKN1A mRNA
|
CTD |
PMID:33854195 PMID:39207506 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cebpd
|
CCAAT/enhancer binding protein delta
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CEBPD mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824
|
|
G
|
Cep85
|
centrosomal protein 85
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CEP85 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:151,640,316...151,687,891
Ensembl chr 5:151,639,282...151,687,860
|
|
G
|
Cerk
|
ceramide kinase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CERK mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:119,105,674...119,149,885
Ensembl chr 7:119,105,674...119,148,570
|
|
G
|
Cfb
|
complement factor B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFB mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,955,776...3,981,740
|
|
G
|
Cfl1
|
cofilin 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFL1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353
|
|
G
|
Chchd10
|
coiled-coil-helix-coiled-coil-helix domain containing 10
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CHCHD10 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:12,725,274...12,730,295
Ensembl chr20:12,725,277...12,745,677
|
|
G
|
Chek2
|
checkpoint kinase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CHEK2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667
|
|
G
|
Chmp5
|
charged multivesicular body protein 5
|
affects expression
|
EXP
|
Thiabendazole affects the expression of CHMP5 mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr 5:60,877,369...60,894,512
Ensembl chr 5:60,877,341...60,894,511
|
|
G
|
Cirbp
|
cold inducible RNA binding protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CIRBP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:10,184,515...10,189,623
|
|
G
|
Clcf1
|
cardiotrophin-like cytokine factor 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLCF1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:210,937,763...210,947,064
Ensembl chr 1:210,937,255...210,947,064
|
|
G
|
Clec2g
|
C-type lectin domain family 2, member G
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLEC2G mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:164,303,865...164,313,737
Ensembl chr 4:164,300,076...164,314,591
|
|
G
|
Clu
|
clusterin
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CLU mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860
|
|
G
|
Cndp2
|
carnosine dipeptidase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CNDP2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr18:80,314,799...80,331,900
Ensembl chr18:80,314,801...80,331,900
|
|
G
|
Cp
|
ceruloplasmin
|
decreases expression
|
ISO
|
Thiabendazole results in decreased expression of CP mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087
|
|
G
|
Cpt2
|
carnitine palmitoyltransferase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CPT2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818
|
|
G
|
Cry1
|
cryptochrome circadian regulator 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CRY1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822
|
|
G
|
Cryab
|
crystallin, alpha B
|
decreases expression
|
ISO
|
Thiabendazole results in decreased expression of CRYAB mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528
|
|
G
|
Cspp1
|
centrosome and spindle pole associated protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSPP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:13,860,072...13,975,299
Ensembl chr 5:13,860,072...13,975,321
|
|
G
|
Csrnp1
|
cysteine and serine rich nuclear protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSRNP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:128,582,364...128,594,163
Ensembl chr 8:128,582,365...128,588,469
|
|
G
|
Cth
|
cystathionine gamma-lyase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of CTH gene
|
CTD |
PMID:33854195 |
|
NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066
|
|
G
|
Ctnnal1
|
catenin alpha-like 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CTNNAL1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:76,309,546...76,375,869
Ensembl chr 5:76,309,546...76,364,637
|
|
G
|
Cux2
|
cut-like homeobox 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CUX2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:40,168,402...40,368,303
Ensembl chr12:40,149,292...40,366,528
|
|
G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions increases expression increases activity
|
EXP ISO
|
herbimycin inhibits the reaction [Thiabendazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Thiabendazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Thiabendazole results in increased expression of CYP1A1 protein] Thiabendazole results in increased expression of CYP1A1 mRNA; Thiabendazole results in increased expression of CYP1A1 protein
|
CTD |
PMID:8900397 PMID:10103034 PMID:11226373 PMID:14987951 PMID:15110098 PMID:39207506 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions increases expression affects metabolic processing decreases activity
|
ISO EXP
|
beta-Naphthoflavone promotes the reaction [CYP1A2 protein affects the metabolism of Thiabendazole] Thiabendazole results in increased expression of CYP1A2 mRNA; Thiabendazole results in increased expression of CYP1A2 protein Thiabendazole results in decreased activity of CYP1A2 protein
|
CTD |
PMID:10936227 PMID:11124226 PMID:12920490 PMID:15110098 PMID:16261361 PMID:18539377 PMID:18570159 More...
|
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of CYP2B1 mRNA; Thiabendazole results in increased expression of CYP2B1 protein
|
CTD |
PMID:15110098 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G
|
Cyp2b2
|
cytochrome P450, family 2, subfamily b, polypeptide 2
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of CYP2B2 mRNA; Thiabendazole results in increased expression of CYP2B2 protein
|
CTD |
PMID:15110098 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of CYP2B6 mRNA
|
CTD |
PMID:18570159 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G
|
Cyp2c22
|
cytochrome P450, family 2, subfamily c, polypeptide 22
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP2C22 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:248,941,143...248,980,767
Ensembl chr 1:248,904,062...248,971,182
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of CYP2C19 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
decreases expression
|
ISO
|
Thiabendazole results in decreased expression of CYP2E1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of CYP3A4 mRNA
|
CTD |
PMID:18570159 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Cyp4a1
|
cytochrome P450, family 4, subfamily a, polypeptide 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4A1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:134,360,096...134,374,233
Ensembl chr 5:134,360,111...134,374,231
|
|
G
|
Cyp4f1
|
cytochrome P450, family 4, subfamily f, polypeptide 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4F1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:12,661,357...12,672,952
Ensembl chr 7:12,661,359...12,672,612
|
|
G
|
Cytip
|
cytohesin 1 interacting protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CYTIP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:63,106,895...63,183,769
Ensembl chr 3:63,107,607...63,134,832
|
|
G
|
Dbp
|
D-box binding PAR bZIP transcription factor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DBP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:105,312,256...105,317,205
Ensembl chr 1:105,312,108...105,317,205
|
|
G
|
Dclre1c
|
DNA cross-link repair 1C
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DCLRE1C mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr17:79,684,988...79,718,399
Ensembl chr17:79,678,698...79,718,734
|
|
G
|
Ddx20
|
DEAD-box helicase 20
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX20 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:195,847,105...195,859,989
Ensembl chr 2:195,847,105...195,855,461
|
|
G
|
Ddx5
|
DEAD-box helicase 5
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX5 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:92,224,393...92,231,928
Ensembl chr10:92,224,395...92,231,300
|
|
G
|
Defb1
|
defensin beta 1
|
decreases expression
|
ISO
|
Thiabendazole results in decreased expression of DEFB1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr16:77,001,326...77,016,068
Ensembl chr16:77,001,326...77,016,068
|
|
G
|
Dffb
|
DNA fragmentation factor subunit beta
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DFFB mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:169,804,873...169,817,157
Ensembl chr 5:169,804,889...169,817,225
|
|
G
|
Dlg2
|
discs large MAGUK scaffold protein 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DLG2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:153,864,545...155,916,238
Ensembl chr 1:153,865,299...155,916,215
|
|
G
|
Dll1
|
delta like canonical Notch ligand 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DLL1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:64,985,161...64,993,274
Ensembl chr 1:64,985,161...64,993,276
|
|
G
|
Dmrt3
|
doublesex and mab-3 related transcription factor 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DMRT3 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:232,670,642...232,690,557
Ensembl chr 1:232,675,059...232,688,833
|
|
G
|
Dnajb1
|
DnaJ heat shock protein family (Hsp40) member B1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416
|
|
G
|
Dnajb9
|
DnaJ heat shock protein family (Hsp40) member B9
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB9 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344
|
|
G
|
Dpp4
|
dipeptidylpeptidase 4
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DPP4 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422
|
|
G
|
Dusp1
|
dual specificity phosphatase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644
|
|
G
|
Dusp5
|
dual specificity phosphatase 5
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DUSP5 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417
|
|
G
|
Dusp6
|
dual specificity phosphatase 6
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833
|
|
G
|
Dzip1l
|
DAZ interacting zinc finger protein 1-like
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DZIP1L gene
|
CTD |
PMID:33854195 |
|
NCBI chr 8:109,067,466...109,108,390
Ensembl chr 8:109,067,775...109,108,393
|
|
G
|
Emilin1
|
elastin microfibril interfacer 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of EMILIN1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:31,175,919...31,183,657
Ensembl chr 6:31,175,919...31,183,657
|
|
G
|
Enpp3
|
ectonucleotide pyrophosphatase/phosphodiesterase 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ENPP3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:22,382,717...22,454,324
Ensembl chr 1:22,382,964...22,454,314
|
|
G
|
Epb41l3
|
erythrocyte membrane protein band 4.1-like 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of EPB41L3 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 9:116,502,864...116,707,274
Ensembl chr 9:116,462,807...116,707,274
|
|
G
|
Epm2aip1
|
EPM2A interacting protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of EPM2AIP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:120,112,265...120,119,613
Ensembl chr 8:120,112,084...120,121,458
|
|
G
|
Erf
|
Ets2 repressor factor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ERF mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:89,957,760...89,966,213
Ensembl chr 1:89,957,760...89,966,213
|
|
G
|
Esd
|
esterase D
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ESD mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508
|
|
G
|
Fam135a
|
family with sequence similarity 135, member A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM135A mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:33,916,449...33,997,140
Ensembl chr 9:33,916,449...33,997,051
|
|
G
|
Fam177a1
|
family with sequence similarity 177, member A1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM177A1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 6:78,367,780...78,382,703
Ensembl chr 6:78,367,780...78,392,836
|
|
G
|
Fam204a
|
family with sequence similarity 204, member A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM204A mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:269,323,473...269,352,772
Ensembl chr 1:269,323,473...269,352,772
|
|
G
|
Fam53a
|
family with sequence similarity 53, member A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM53A gene
|
CTD |
PMID:33854195 |
|
NCBI chr14:81,308,127...81,348,930
Ensembl chr14:81,319,375...81,348,923
|
|
G
|
Ficd
|
FIC domain protein adenylyltransferase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FICD mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:48,549,737...48,554,626
Ensembl chr12:48,549,737...48,554,626
|
|
G
|
Fkbp4
|
FKBP prolyl isomerase 4
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FKBP4 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:163,389,464...163,397,918
Ensembl chr 4:163,389,464...163,397,918
|
|
G
|
Fkbp5
|
FKBP prolyl isomerase 5
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of FKBP5 gene
|
CTD |
PMID:33854195 |
|
NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118
|
|
G
|
Fmn1
|
formin 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FMN1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:120,555,445...120,939,978
Ensembl chr 3:120,555,431...120,933,124
|
|
G
|
Fmo2
|
flavin containing dimethylaniline monoxygenase 2
|
decreases expression
|
ISO
|
Thiabendazole results in decreased expression of FMO2 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr13:77,755,131...77,777,597
Ensembl chr13:77,757,629...77,777,534
|
|
G
|
Frmd4b
|
FERM domain containing 4B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FRMD4B mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:131,452,361...131,778,734
Ensembl chr 4:131,452,365...131,640,287
|
|
G
|
Fzd6
|
frizzled class receptor 6
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FZD6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:71,939,916...71,971,685
Ensembl chr 7:71,939,973...71,971,680
|
|
G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of GADD45A mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
G
|
Gadd45g
|
growth arrest and DNA-damage-inducible, gamma
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GADD45G mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369
|
|
G
|
Gatd3a
|
glutamine amidotransferase class 1 domain containing 3A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GATD3A mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:10,514,459...10,522,556
Ensembl chr20:10,514,443...10,522,555
|
|
G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
increases activity multiple interactions
|
ISO
|
Thiabendazole results in increased activity of GCLC protein [Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein
|
CTD |
PMID:11019651 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
G
|
Gdf15
|
growth differentiation factor 15
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GDF15 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022
|
|
G
|
Ghr
|
growth hormone receptor
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of GHR mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 2:54,269,066...54,532,595
Ensembl chr 2:54,270,206...54,532,331
|
|
G
|
Gin1
|
gypsy retrotransposon integrase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIN1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:105,740,914...105,762,357
Ensembl chr 9:105,742,094...105,762,357
|
|
G
|
Git2
|
GIT ArfGAP 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIT2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:47,490,350...47,531,232
Ensembl chr12:47,490,369...47,533,250
|
|
G
|
Glb1
|
galactosidase, beta 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GLB1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326
|
|
G
|
Gnpda2
|
glucosamine-6-phosphate deaminase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GNPDA2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr14:38,874,611...38,892,688
Ensembl chr14:38,874,647...38,892,683
|
|
G
|
Gprasp3
|
G protein-coupled receptor associated sorting protein family member 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GPRASP3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr X:103,639,366...103,644,561
Ensembl chr X:103,609,243...103,650,463
|
|
G
|
Gramd1a
|
GRAM domain containing 1A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GRAMD1A mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:95,494,378...95,520,730
Ensembl chr 1:95,494,378...95,520,716
|
|
G
|
Gria1
|
glutamate ionotropic receptor AMPA type subunit 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GRIA1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309
|
|
G
|
Grina
|
glutamate ionotropic receptor NMDA type subunit associated protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GRINA mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:109,842,870...109,846,048
Ensembl chr 7:109,843,196...109,846,042
|
|
G
|
Gsdma
|
gasdermin A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GSDMA gene
|
CTD |
PMID:33854195 |
|
NCBI chr10:84,110,590...84,135,804
Ensembl chr10:84,123,314...84,135,804
|
|
G
|
Gstk1
|
glutathione S-transferase kappa 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GSTK1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:72,085,532...72,089,934
Ensembl chr 4:72,085,531...72,089,927
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of GSTP1 mRNA
|
CTD |
PMID:15110098 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705
|
|
G
|
Gstt1
|
glutathione S-transferase theta 1
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of GSTT1 mRNA
|
CTD |
PMID:15110098 |
|
NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019
|
|
G
|
Hapstr2
|
HUWE1 associated protein modifying stress responses 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of HAPSTR2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr X:143,958,364...143,960,399
Ensembl chr X:143,958,032...143,960,240
|
|
G
|
Hars1
|
histidyl-tRNA synthetase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HARS1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr18:28,655,669...28,672,712
Ensembl chr18:28,655,671...28,672,712
|
|
G
|
Havcr1
|
hepatitis A virus cellular receptor 1
|
decreases expression
|
ISO
|
Thiabendazole results in decreased expression of HAVCR1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268
|
|
G
|
Hebp1
|
heme binding protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HEBP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:169,705,665...169,735,199
Ensembl chr 4:169,705,668...169,735,199
|
|
G
|
Hes1
|
hes family bHLH transcription factor 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HES1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of HMOX1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Hs3st3b1
|
heparan sulfate-glucosamine 3-sulfotransferase 3B1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HS3ST3B1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185
|
|
G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD11B2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812
|
|
G
|
Hsd17b10
|
hydroxysteroid (17-beta) dehydrogenase 10
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD17B10 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr X:24,568,551...24,571,012
Ensembl chr X:24,568,551...24,574,681
|
|
G
|
Hsd17b2
|
hydroxysteroid (17-beta) dehydrogenase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HSD17B2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943
|
|
G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPA1B mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
G
|
Hspbp1
|
HSPA (Hsp70) binding protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPBP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:78,194,067...78,217,836
Ensembl chr 1:78,189,305...78,217,835
|
|
G
|
Ier3
|
immediate early response 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IER3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
G
|
Ifna12l
|
interferon alpha 12 like
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IFNA12L gene
|
CTD |
PMID:33854195 |
|
NCBI chr 5:108,592,149...108,593,214
Ensembl chr 5:108,541,882...108,571,940
|
|
G
|
Igfbp1
|
insulin-like growth factor binding protein 1
|
multiple interactions increases expression
|
EXP ISO
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IGFBP1 mRNA Thiabendazole results in increased expression of IGFBP1 mRNA
|
CTD |
PMID:33854195 PMID:39207506 |
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344
|
|
G
|
Igkv2-112l2
|
immunoglobulin kappa variable 2-112 like 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IGKV2-112L2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 4:103,444,658...103,445,307
Ensembl chr 4:103,766,891...103,767,229
|
|
G
|
Inpp5f
|
inositol polyphosphate-5-phosphatase F
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of INPP5F mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:192,620,891...192,700,681
Ensembl chr 1:192,620,891...192,700,681
|
|
G
|
Iqcb1
|
IQ motif containing B1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IQCB1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr11:77,410,986...77,465,540
Ensembl chr11:77,410,314...77,465,478
|
|
G
|
Irf2bp2
|
interferon regulatory factor 2 binding protein 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IRF2BP2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:71,456,689...71,462,368
Ensembl chr19:71,456,689...71,462,368
|
|
G
|
Itprip
|
inositol 1,4,5-trisphosphate receptor interacting protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ITPRIP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:256,704,087...256,727,661
Ensembl chr 1:256,699,832...256,727,644
|
|
G
|
Junb
|
JunB proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of JUNB mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218
|
|
G
|
Katnip
|
katanin interacting protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KATNIP gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:189,700,838...189,867,402
Ensembl chr 1:189,700,775...189,867,402
|
|
G
|
Khdc4
|
KH domain containing 4, pre-mRNA splicing factor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KHDC4 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:176,446,895...176,475,405
Ensembl chr 2:176,446,910...176,475,392
|
|
G
|
Klf10
|
KLF transcription factor 10
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KLF10 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:71,352,612...71,358,680
Ensembl chr 7:71,350,573...71,358,948
|
|
G
|
Klf2
|
KLF transcription factor 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of KLF2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr16:17,555,136...17,557,768
Ensembl chr16:17,555,136...17,557,768
|
|
G
|
Klhl10
|
kelch-like family member 10
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KLHL10 gene
|
CTD |
PMID:33854195 |
|
NCBI chr10:85,876,804...85,893,081
Ensembl chr10:85,876,783...85,893,081
|
|
G
|
Lgalsl
|
galectin-like
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LGALSL mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr14:99,198,340...99,205,846
Ensembl chr14:99,198,339...99,206,487
|
|
G
|
Lhx2
|
LIM homeobox 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of LHX2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645
|
|
G
|
Litaf
|
lipopolysaccharide-induced TNF factor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LITAF mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930
|
|
G
|
Lnx2
|
ligand of numb-protein X 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LNX2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:13,119,139...13,184,401
Ensembl chr12:13,119,139...13,184,401
|
|
G
|
Loxl3
|
lysyl oxidase-like 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LOXL3 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 4:117,098,358...117,114,673
Ensembl chr 4:117,099,635...117,115,046
|
|
G
|
Lpcat1
|
lysophosphatidylcholine acyltransferase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPCAT1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:31,594,621...31,644,946
Ensembl chr 1:31,594,622...31,644,946
|
|
G
|
Lpgat1
|
lysophosphatidylglycerol acyltransferase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPGAT1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr13:105,825,630...105,896,366
Ensembl chr13:105,820,468...105,896,364
|
|
G
|
Lpin3
|
lipin 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LPIN3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:169,953,479...169,978,034
Ensembl chr 3:169,960,522...169,978,031
|
|
G
|
Lta4h
|
leukotriene A4 hydrolase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LTA4H mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:29,856,846...29,888,642
Ensembl chr 7:29,856,802...29,888,641
|
|
G
|
Lurap1l
|
leucine rich adaptor protein 1-like
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LURAP1L gene
|
CTD |
PMID:33854195 |
|
NCBI chr 5:100,402,921...100,455,479
Ensembl chr 5:100,407,483...100,455,478
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of MAP1LC3B protein
|
CTD |
PMID:39207506 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Mapkapk2
|
MAPK activated protein kinase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MAPKAPK2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326
|
|
G
|
Marf1
|
meiosis regulator and mRNA stability factor 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MARF1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:1,395,271...1,439,974
Ensembl chr10:1,395,282...1,439,974
|
|
G
|
Med12l
|
mediator complex subunit 12L
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MED12L mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:145,403,318...145,726,317
Ensembl chr 2:145,404,375...145,723,516
|
|
G
|
Mettl14
|
methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of METTL14 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:214,215,165...214,231,412
Ensembl chr 2:214,215,165...214,231,412
|
|
G
|
Mfap5
|
microfibril associated protein 5
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of MFAP5 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 4:157,399,919...157,422,448
Ensembl chr 4:157,395,597...157,422,448
|
|
G
|
Mif
|
macrophage migration inhibitory factor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIF mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:12,767,138...12,791,222
Ensembl chr 4:134,041,774...134,042,121 Ensembl chr20:134,041,774...134,042,121
|
|
G
|
Mir122
|
microRNA 122
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR122 mRNA
|
CTD |
PMID:34626815 |
|
NCBI chr18:61,028,817...61,028,901
|
|
G
|
Mir130a
|
microRNA 130a
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR130A mRNA
|
CTD |
PMID:34626815 |
|
NCBI chr 3:90,229,228...90,229,315
|
|
G
|
Mir146a
|
microRNA 146a
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR146A mRNA
|
CTD |
PMID:34626815 |
|
NCBI chr10:28,349,996...28,350,090
|
|
G
|
Mir193
|
microRNA 193
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR193 mRNA
|
CTD |
PMID:34626815 |
|
NCBI chr10:65,170,317...65,170,402
|
|
G
|
Mir22
|
microRNA 22
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR22 mRNA
|
CTD |
PMID:34626815 |
|
NCBI chr10:60,805,331...60,805,425
Ensembl chr10:60,805,331...60,805,425
|
|
G
|
Mir32
|
microRNA 32
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR32 mRNA
|
CTD |
PMID:34626815 |
|
NCBI chr 5:76,391,285...76,391,354
|
|
G
|
Mir33
|
microRNA 33
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR33 mRNA
|
CTD |
PMID:34626815 |
|
NCBI chr 7:115,593,952...115,594,020
Ensembl chr 7:115,593,952...115,594,020
|
|
G
|
Mir486
|
microRNA 486
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR486 mRNA
|
CTD |
PMID:34626815 |
|
|
|
G
|
Mlycd
|
malonyl-CoA decarboxylase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MLYCD mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:64,356,582...64,372,447
Ensembl chr19:64,356,223...64,372,446
|
|
G
|
Mocs2
|
molybdenum cofactor synthesis 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:48,237,655...48,249,394
Ensembl chr 2:48,237,655...48,249,394
|
|
G
|
Morc3
|
MORC family CW-type zinc finger 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MORC3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr11:46,621,575...46,664,315
Ensembl chr11:46,621,548...46,664,309
|
|
G
|
Mpo
|
myeloperoxidase
|
increases metabolic processing
|
ISO
|
MPO protein results in increased metabolism of Thiabendazole metabolite
|
CTD |
PMID:21513789 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Mrgbp
|
MRG domain binding protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRGBP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:188,074,695...188,078,162
Ensembl chr 3:188,074,709...188,078,153
|
|
G
|
Mrnip
|
MRN complex interacting protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRNIP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:35,002,440...35,026,555
|
|
G
|
Mrpl44
|
mitochondrial ribosomal protein L44
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPL44 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:88,555,050...88,560,101
Ensembl chr 9:88,555,019...88,561,215
|
|
G
|
Mrps18b
|
mitochondrial ribosomal protein S18B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPS18B mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:2,842,978...2,849,065
Ensembl chr20:2,842,528...2,849,065
|
|
G
|
Mtarc1
|
mitochondrial amidoxime reducing component 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MTARC1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr13:98,854,235...98,894,208
Ensembl chr13:98,871,289...98,894,252
|
|
G
|
Myo10
|
myosin X
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MYO10 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:77,831,532...78,036,137
Ensembl chr 2:77,831,532...78,036,137
|
|
G
|
N4bp2l2
|
NEDD4 binding protein 2-like 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of N4BP2L2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:4,972,967...5,038,027
Ensembl chr12:4,972,990...5,033,405
|
|
G
|
Nae1
|
NEDD8 activating enzyme E1 subunit 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NAE1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:452,462...478,591
Ensembl chr19:452,432...478,831
|
|
G
|
Ndufb11
|
NADH:ubiquinone oxidoreductase subunit B11
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of NDUFB11 gene
|
CTD |
PMID:33854195 |
|
NCBI chr X:4,126,317...4,128,575
Ensembl chr X:4,126,245...4,128,566
|
|
G
|
Nfe2
|
nuclear factor, erythroid 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NFE2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:136,261,234...136,273,850
Ensembl chr 7:136,261,236...136,268,585
|
|
G
|
Nfil3
|
nuclear factor, interleukin 3 regulated
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NFIL3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr17:12,432,376...12,447,605
Ensembl chr17:12,432,198...12,450,826
|
|
G
|
Nppb
|
natriuretic peptide B
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of NPPB mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310
|
|
G
|
Nr0b2
|
nuclear receptor subfamily 0, group B, member 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR0B2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475
|
|
G
|
Nr1d1
|
nuclear receptor subfamily 1, group D, member 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812
|
|
G
|
Nr1d2
|
nuclear receptor subfamily 1, group D, member 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr15:9,955,034...9,981,329
Ensembl chr15:9,954,906...9,981,330
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
increases activity
|
ISO
|
Thiabendazole results in increased activity of NR1I2 protein
|
CTD |
PMID:25455453 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
G
|
Nucks1
|
nuclear casein kinase and cyclin-dependent kinase substrate 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NUCKS1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr13:45,897,275...45,926,491
Ensembl chr13:45,897,248...45,923,101
|
|
G
|
Odc1
|
ornithine decarboxylase 1
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of ODC1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146
|
|
G
|
Olr943
|
olfactory receptor 943
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of OLR943 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 7:4,038,349...4,039,287
Ensembl chr 7:4,038,349...4,039,287
|
|
G
|
Oplah
|
5-oxoprolinase (ATP-hydrolysing)
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of OPLAH mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:109,892,136...109,932,403
Ensembl chr 7:109,891,405...109,915,979
|
|
G
|
Orai3
|
ORAI calcium release-activated calcium modulator 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ORAI3 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:191,811,671...191,816,530
Ensembl chr 1:191,811,424...191,816,530
|
|
G
|
Oxct1
|
3-oxoacid CoA transferase 1
|
affects expression
|
EXP
|
Thiabendazole affects the expression of OXCT1 mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr 2:54,963,964...55,112,303
Ensembl chr 2:54,963,784...55,112,298
|
|
G
|
Pabir1
|
PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PABIR1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:231,541,411...231,542,717
Ensembl chr 1:231,537,357...231,612,411
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage
|
ISO
|
Thiabendazole results in increased cleavage of PARP1 protein
|
CTD |
PMID:39207506 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Parpbp
|
PARP1 binding protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene
|
CTD |
PMID:33854195 |
|
NCBI chr 7:24,398,897...24,468,330
Ensembl chr 7:24,398,897...24,464,744
|
|
G
|
Pdlim1
|
PDZ and LIM domain 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PDLIM1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:248,991,818...249,040,409
Ensembl chr 1:248,991,818...249,047,379
|
|
G
|
Pdp1
|
pyruvate dehydrogenase phosphatase catalytic subunit 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PDP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:30,245,699...30,252,494
Ensembl chr 5:30,242,704...30,253,960
|
|
G
|
Pdzd2
|
PDZ domain containing 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PDZD2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 2:63,111,650...63,497,520
Ensembl chr 2:63,111,650...63,497,478
|
|
G
|
Per1
|
period circadian regulator 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PER1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211
|
|
G
|
Per3
|
period circadian regulator 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PER3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:166,740,914...166,778,243
Ensembl chr 5:166,743,050...166,777,999
|
|
G
|
Pfkfb1
|
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of PFKFB1 mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr X:22,936,038...22,989,691
Ensembl chr X:22,937,494...22,989,704
|
|
G
|
Pgk1
|
phosphoglycerate kinase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PGK1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr X:75,336,988...75,352,962
Ensembl chr X:75,336,687...75,352,959
|
|
G
|
Pias3
|
protein inhibitor of activated STAT, 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIAS3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:186,921,384...186,930,292
Ensembl chr 2:186,921,428...186,936,714
|
|
G
|
Pip4p1
|
phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIP4P1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr15:26,620,399...26,624,369
Ensembl chr15:26,620,401...26,624,246
|
|
G
|
Pirb
|
paired Ig-like receptor B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LILRB3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:74,414,556...74,433,015
Ensembl chr 1:74,331,291...74,422,116
|
|
G
|
Plekhg5
|
pleckstrin homology and RhoGEF domain containing G5
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLEKHG5 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:167,860,730...167,904,229
Ensembl chr 5:167,860,794...167,904,229
|
|
G
|
Plk2
|
polo-like kinase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLK2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296
|
|
G
|
Plpp4
|
phospholipid phosphatase 4
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PLPP4 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:193,260,181...193,389,659
Ensembl chr 1:193,260,434...193,389,675
|
|
G
|
Pmvk
|
phosphomevalonate kinase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PMVK mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:177,174,344...177,184,076
Ensembl chr 2:177,174,335...177,184,080
|
|
G
|
Pnkd
|
PNKD metallo-beta-lactamase domain containing
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNKD mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:83,317,757...83,386,263
Ensembl chr 9:83,317,738...83,386,262
|
|
G
|
Pnrc1
|
proline-rich nuclear receptor coactivator 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNRC1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:52,443,400...52,489,303
Ensembl chr 5:52,443,400...52,446,491
|
|
G
|
Por
|
cytochrome p450 oxidoreductase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of POR gene
|
CTD |
PMID:33854195 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
G
|
Ppard
|
peroxisome proliferator-activated receptor delta
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PPARD mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707
|
|
G
|
Prdm15
|
PR/SET domain 15
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRDM15 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr11:50,633,973...50,691,624
Ensembl chr11:50,633,973...50,691,823
|
|
G
|
Prelid2
|
PRELI domain containing 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELID2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr18:34,120,989...34,212,699
Ensembl chr18:34,125,373...34,212,167
|
|
G
|
Prelp
|
proline and arginine rich end leucine rich repeat protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELP mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr13:47,920,480...47,943,547
Ensembl chr13:47,922,590...47,932,324
|
|
G
|
Prkcb
|
protein kinase C, beta
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of PRKCB mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740
|
|
G
|
Proser2
|
proline and serine rich 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PROSER2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr17:77,061,371...77,096,788
Ensembl chr17:77,077,727...77,095,194
|
|
G
|
Prpf39
|
pre-mRNA processing factor 39
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRPF39 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:88,825,227...88,851,342
Ensembl chr 6:88,825,243...88,851,341
|
|
G
|
Prss3b
|
protease, serine, 3B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PRSS3B gene
|
CTD |
PMID:33854195 |
|
NCBI chr 4:70,838,484...70,842,192
Ensembl chr 4:70,838,471...70,845,283
|
|
G
|
Psmc2
|
proteasome 26S subunit, ATPase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:14,148,080...14,162,390
Ensembl chr 4:14,148,090...14,162,390
|
|
G
|
Psmc4
|
proteasome 26S subunit, ATPase 4
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC4 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:92,476,690...92,485,268
Ensembl chr 1:92,476,690...92,485,060
|
|
G
|
Psmc5
|
proteasome 26S subunit, ATPase 5
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC5 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:91,687,553...91,693,487
Ensembl chr10:91,686,295...91,695,921
|
|
G
|
Ptpa
|
protein phosphatase 2 phosphatase activator
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PTPA mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:34,087,637...34,118,100
Ensembl chr 3:34,087,575...34,162,772
|
|
G
|
Pus10
|
pseudouridine synthase 10
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PUS10 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr14:101,822,525...101,885,187
Ensembl chr14:101,822,458...101,885,190
|
|
G
|
Rabep1
|
rabaptin, RAB GTPase binding effector protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABEP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:56,064,742...56,168,778
Ensembl chr10:56,064,753...56,166,177
|
|
G
|
Rabl2
|
RAB, member of RAS oncogene family like 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABL2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:122,531,787...122,540,500
Ensembl chr 7:122,531,792...122,540,395
|
|
G
|
Ramac
|
RNA guanine-7 methyltransferase activating subunit
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RAMAC gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:145,117,752...145,123,640
Ensembl chr 1:145,117,736...145,124,256
|
|
G
|
Rangap1
|
RAN GTPase activating protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RANGAP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:115,104,820...115,130,564
Ensembl chr 7:115,104,823...115,130,564
|
|
G
|
Rars1
|
arginyl-tRNA synthetase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RARS1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:20,774,804...20,799,251
Ensembl chr10:20,774,805...20,799,251
|
|
G
|
Rbm14
|
RNA binding motif protein 14
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RBM14 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:211,476,298...211,535,077
Ensembl chr 1:211,523,972...211,535,065
|
|
G
|
Rbm3
|
RNA binding motif protein 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RBM3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr X:17,020,863...17,024,341
Ensembl chr X:17,020,864...17,024,841
|
|
G
|
Rbpms
|
RNA binding protein, mRNA processing factor
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RBPMS gene
|
CTD |
PMID:33854195 |
|
NCBI chr16:64,942,159...65,098,504
Ensembl chr16:64,942,530...65,098,503
|
|
G
|
Resf1
|
retroelement silencing factor 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RESF1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:184,057,165...184,093,374
Ensembl chr 4:184,057,010...184,098,429
|
|
G
|
Rev1
|
REV1, DNA directed polymerase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of REV1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:47,773,907...47,847,554
Ensembl chr 9:47,773,907...47,847,332
|
|
G
|
Rfx7
|
regulatory factor X, 7
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RFX7 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:82,134,747...82,219,898
Ensembl chr 8:82,134,747...82,219,898
|
|
G
|
Rgcc
|
regulator of cell cycle
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RGCC gene
|
CTD |
PMID:33854195 |
|
NCBI chr15:61,071,574...61,084,408
Ensembl chr15:61,071,574...61,084,408
|
|
G
|
Rgs16
|
regulator of G-protein signaling 16
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RGS16 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr13:68,421,480...68,443,312
Ensembl chr13:68,438,120...68,443,313
|
|
G
|
Rhobtb3
|
Rho-related BTB domain containing 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RHOBTB3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:7,094,972...7,201,507
Ensembl chr 2:7,095,253...7,150,906
|
|
G
|
Rnase10
|
ribonuclease A family member 10
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RNASE10 gene
|
CTD |
PMID:33854195 |
|
NCBI chr15:26,700,219...26,702,681
Ensembl chr15:26,688,102...26,706,105
|
|
G
|
Rnd3
|
Rho family GTPase 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RND3 gene; [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RND3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:55,981,142...55,998,494
Ensembl chr 3:55,980,355...55,998,536
|
|
G
|
Rorc
|
RAR-related orphan receptor C
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RORC mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566
|
|
G
|
Rxylt1
|
ribitol xylosyltransferase 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RXYLT1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 7:59,656,274...59,668,140
Ensembl chr 7:59,656,276...59,668,050
|
|
G
|
Sall4
|
spalt-like transcription factor 4
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SALL4 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743
|
|
G
|
Sardh
|
sarcosine dehydrogenase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SARDH mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:30,908,621...30,973,409
Ensembl chr 3:30,908,621...30,972,137
|
|
G
|
Scnn1a
|
sodium channel epithelial 1 subunit alpha
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SCNN1A mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405
|
|
G
|
Sdr42e1
|
short chain dehydrogenase/reductase family 42E, member 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SDR42E1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:62,624,130...62,636,652
Ensembl chr19:62,624,150...62,636,756
|
|
G
|
Serpina1
|
serpin family A member 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SERPINA1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:128,631,101...128,653,125
Ensembl chr 6:128,619,382...128,660,703
|
|
G
|
Sesn2
|
sestrin 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SESN2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255
|
|
G
|
Setd6
|
SET domain containing 6, protein lysine methyltransferase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SETD6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:9,349,011...9,356,515
Ensembl chr19:9,353,520...9,356,515
|
|
G
|
Sfrp2
|
secreted frizzled-related protein 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SFRP2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079
|
|
G
|
Sh3bp2
|
SH3-domain binding protein 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SH3BP2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr14:80,400,685...80,437,887
Ensembl chr14:80,400,685...80,437,906
|
|
G
|
Sigirr
|
single Ig and TIR domain containing
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SIGIRR mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:205,625,742...205,637,883
Ensembl chr 1:205,627,708...205,637,802
|
|
G
|
Sik2
|
salt-inducible kinase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SIK2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:60,121,913...60,221,707
Ensembl chr 8:60,121,913...60,221,818
|
|
G
|
Slc12a6
|
solute carrier family 12, member 6
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC12A6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:119,525,521...119,624,655
Ensembl chr 3:119,526,295...119,624,653
|
|
G
|
Slc20a1
|
solute carrier family 20 member 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC20A1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:136,880,360...136,894,255
Ensembl chr 3:136,880,290...136,894,249
|
|
G
|
Slc25a39
|
solute carrier family 25, member 39
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC25A39 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:87,862,630...87,867,626
Ensembl chr10:87,862,631...87,866,973
|
|
G
|
Slc26a6
|
solute carrier family 26 member 6
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC26A6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:118,438,110...118,448,271
Ensembl chr 8:118,438,180...118,448,270
|
|
G
|
Slc37a2
|
solute carrier family 37 member 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC37A2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:45,134,596...45,160,551
Ensembl chr 8:45,134,596...45,277,989
|
|
G
|
Slk
|
STE20-like kinase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SLK gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:256,415,013...256,470,942
Ensembl chr 1:256,415,013...256,467,829
|
|
G
|
Smad7
|
SMAD family member 7
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SMAD7 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
|
|
G
|
Smpx
|
small muscle protein, X-linked
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SMPX gene
|
CTD |
PMID:33854195 |
|
NCBI chr X:41,049,354...41,107,323
Ensembl chr X:41,049,356...41,107,137
|
|
G
|
Snrnp200
|
small nuclear ribonucleoprotein U5 subunit 200
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SNRNP200 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:134,882,173...134,911,512
Ensembl chr 3:134,882,173...134,911,500
|
|
G
|
Snx4
|
sorting nexin 4
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SNX4 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr11:80,965,965...81,023,234
Ensembl chr11:80,965,967...81,028,448
|
|
G
|
Socs3
|
suppressor of cytokine signaling 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SOCS3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
G
|
Sod3
|
superoxide dismutase 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SOD3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr14:62,822,865...62,828,602
Ensembl chr14:62,811,177...62,829,125
|
|
G
|
Sohlh1
|
spermatogenesis and oogenesis specific basic helix-loop-helix 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SOHLH1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 3:29,061,267...29,065,588
Ensembl chr 3:29,061,267...29,065,588
|
|
G
|
Spag1
|
sperm associated antigen 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SPAG1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:69,246,301...69,306,483
Ensembl chr 7:69,246,582...69,306,482
|
|
G
|
Srd5a2
|
steroid 5 alpha-reductase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SRD5A2 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 6:27,178,089...27,217,588
Ensembl chr 6:27,178,079...27,217,588
|
|
G
|
Srrm2
|
serine/arginine repetitive matrix 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRRM2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:13,320,059...13,353,337
Ensembl chr10:13,320,059...13,353,337
|
|
G
|
Srsf5
|
serine and arginine rich splicing factor 5
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRSF5 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:106,333,998...106,341,467
Ensembl chr 6:106,336,756...106,341,931
|
|
G
|
Stard9
|
StAR-related lipid transfer domain containing 9
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of STARD9 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:128,034,866...128,150,493
Ensembl chr 3:128,034,908...128,127,402
|
|
G
|
Susd2
|
sushi domain containing 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SUSD2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:13,016,960...13,024,264
Ensembl chr20:13,016,907...13,024,264
|
|
G
|
Sympk
|
symplekin scaffold protein
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SYMPK mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:87,800,416...87,828,727
Ensembl chr 1:87,799,853...87,828,727
|
|
G
|
Taf9b
|
TATA-box binding protein associated factor 9b
|
affects expression
|
EXP
|
Thiabendazole affects the expression of TAF9B mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr X:75,354,823...75,366,166
Ensembl chr X:75,354,825...75,366,414
|
|
G
|
Tat
|
tyrosine aminotransferase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TAT mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482
|
|
G
|
Tdp2
|
tyrosyl-DNA phosphodiesterase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TDP2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr17:40,656,969...40,668,362
Ensembl chr17:40,656,971...40,668,288
|
|
G
|
Tead2
|
TEA domain transcription factor 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TEAD2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:104,838,795...104,855,635
Ensembl chr 1:104,838,623...104,855,630
|
|
G
|
Tecr
|
trans-2,3-enoyl-CoA reductase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TECR mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr19:41,431,422...41,472,880
Ensembl chr19:41,446,071...41,474,432
|
|
G
|
Tgds
|
TDP-glucose 4,6-dehydratase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TGDS mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr15:101,581,765...101,602,779
Ensembl chr15:101,582,227...101,602,718
|
|
G
|
Tgfbi
|
transforming growth factor, beta induced
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TGFBI mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471
|
|
G
|
Tjap1
|
tight junction associated protein 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TJAP1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:22,198,984...22,223,201
Ensembl chr 9:22,199,676...22,223,201
|
|
G
|
Tkt
|
transketolase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TKT mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr16:5,729,381...5,755,170
Ensembl chr16:5,729,991...5,756,431
|
|
G
|
Tmbim6
|
transmembrane BAX inhibitor motif containing 6
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMBIM6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:132,405,217...132,422,492
Ensembl chr 7:132,386,134...132,422,492
|
|
G
|
Tmem268
|
transmembrane protein 268
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TMEM268 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:81,990,314...82,016,970
Ensembl chr 5:81,991,367...82,016,968
|
|
G
|
Tmt1b
|
thiol methyltransferase 1B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMT1B mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:1,973,334...1,975,980
Ensembl chr 7:1,973,337...1,975,980
|
|
G
|
Tnfaip2
|
TNF alpha induced protein 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TNFAIP2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:136,297,388...136,311,106
Ensembl chr 6:136,298,082...136,311,106
|
|
G
|
Tor3a
|
torsin family 3, member A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TOR3A mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr13:71,324,073...71,348,625
Ensembl chr13:71,324,076...71,348,624
|
|
G
|
Tp53
|
tumor protein p53
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of TP53 mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Traf3ip2
|
Traf3 interacting protein 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAF3IP2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr20:44,565,992...44,609,240
Ensembl chr20:44,517,242...44,609,618
|
|
G
|
Trafd1
|
TRAF type zinc finger domain containing 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAFD1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:40,826,251...40,840,169
Ensembl chr12:40,825,851...40,841,320
|
|
G
|
Trim3
|
tripartite motif-containing 3
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of TRIM3 mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr 1:169,362,751...169,385,430
Ensembl chr 1:169,356,738...169,385,430
|
|
G
|
Trim34
|
tripartite motif-containing 34
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRIM34 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:168,119,043...168,130,544
Ensembl chr 1:168,119,074...168,132,059
|
|
G
|
Tsc22d3
|
TSC22 domain family, member 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TSC22D3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519
|
|
G
|
Uba3
|
ubiquitin-like modifier activating enzyme 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UBA3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:131,346,219...131,367,378
Ensembl chr 4:131,346,224...131,367,277
|
|
G
|
Ubb
|
ubiquitin B
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBB mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:47,746,923...47,748,628
Ensembl chr10:47,727,701...47,750,335
|
|
G
|
Ubc
|
ubiquitin C
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBC mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr12:36,899,673...36,905,275
Ensembl chr12:36,900,127...36,905,275
|
|
G
|
Uckl1
|
uridine-cytidine kinase 1-like 1
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UCKL1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 3:189,052,365...189,064,939
Ensembl chr 3:189,052,365...189,064,967
|
|
G
|
Ugdh
|
UDP-glucose 6-dehydrogenase
|
increases expression
|
EXP
|
Thiabendazole results in increased expression of UGDH mRNA
|
CTD |
PMID:18539377 |
|
NCBI chr14:43,202,480...43,226,002
Ensembl chr14:43,202,356...43,226,629
|
|
G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of UGT1A1 mRNA
|
CTD |
PMID:39207506 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
G
|
Unc45a
|
unc-45 myosin chaperone A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UNC45A mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:143,691,183...143,705,944
Ensembl chr 1:143,691,186...143,707,312
|
|
G
|
Uox
|
urate oxidase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UOX mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:238,147,130...238,183,320
Ensembl chr 2:238,083,686...238,183,370
|
|
G
|
Usp2
|
ubiquitin specific peptidase 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of USP2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:53,308,264...53,336,800
Ensembl chr 8:53,308,303...53,336,794
|
|
G
|
Usp40
|
ubiquitin specific peptidase 40
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of USP40 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:96,055,741...96,126,766
Ensembl chr 9:96,055,741...96,126,721
|
|
G
|
Utrn
|
utrophin
|
increases expression
|
ISO
|
Thiabendazole results in increased expression of UTRN mRNA
|
CTD |
PMID:22028826 |
|
NCBI chr 1:8,541,061...9,044,487
Ensembl chr 1:8,542,798...9,044,487
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of VEGFA mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Vnn3
|
vanin 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VNN3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:23,390,596...23,402,858
Ensembl chr 1:23,390,596...23,402,858
|
|
G
|
Vtn
|
vitronectin
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VTN mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:63,892,782...63,895,862
Ensembl chr10:63,892,766...63,895,860
|
|
G
|
Wdr11
|
WD repeat domain 11
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of WDR11 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 1:193,595,606...193,641,149
Ensembl chr 1:193,595,535...193,641,142
|
|
G
|
Wee1
|
WEE1 G2 checkpoint kinase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of WEE1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 1:173,605,609...173,632,450
Ensembl chr 1:173,608,949...173,632,449
|
|
G
|
Wfdc9
|
WAP four-disulfide core domain 9
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of WFDC9 gene
|
CTD |
PMID:33854195 |
|
NCBI chr 3:173,799,888...173,808,383
Ensembl chr 3:173,799,888...173,803,066
|
|
G
|
Yod1
|
YOD1 deubiquitinase
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of YOD1 gene
|
CTD |
PMID:33854195 |
|
NCBI chr13:44,727,319...44,733,933
|
|
G
|
Zfc3h1
|
zinc finger, C3H1-type containing
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFC3H1 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 7:52,894,417...52,950,755
Ensembl chr 7:52,894,172...52,950,758
|
|
G
|
Zfp280d
|
zinc finger protein 280D
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP280D mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 8:81,872,108...81,961,194
Ensembl chr 8:81,873,335...81,961,201
|
|
G
|
Zfp36l2
|
zinc finger protein 36, C3H type-like 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP36L2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 6:16,242,622...16,246,662
Ensembl chr 6:16,242,610...16,246,653
|
|
G
|
Zfp422
|
zinc finger protein 422
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP422 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 4:151,558,254...151,565,730
Ensembl chr 4:151,556,738...151,566,152
|
|
G
|
Zfp455
|
zinc finger protein 455
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP455 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:86,326,568...86,445,514
Ensembl chr 2:86,426,916...86,441,874
|
|
G
|
Zfp598
|
zinc finger protein 598
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP598 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr10:14,198,763...14,210,773
Ensembl chr10:14,185,611...14,210,772
|
|
G
|
Zmym3
|
zinc finger MYM-type containing 3
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM3 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr X:70,568,573...70,584,221
Ensembl chr X:70,568,573...70,584,768
|
|
G
|
Zmym6
|
zinc finger MYM-type containing 6
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM6 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 5:144,680,819...144,728,805
Ensembl chr 5:144,681,197...144,728,803
|
|
G
|
Zranb2
|
zinc finger RANBP2-type containing 2
|
multiple interactions
|
EXP
|
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZRANB2 mRNA
|
CTD |
PMID:33854195 |
|
NCBI chr 2:249,232,010...249,245,786
Ensembl chr 2:249,232,010...249,245,780
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
increases transport
|
ISO
|
ABCB1 protein results in increased transport of veliparib
|
CTD |
PMID:21436403 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
veliparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:30296409 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Atm
|
ATM serine/threonine kinase
|
multiple interactions increases activity
|
ISO
|
veliparib results in increased phosphorylation of and results in increased activity of ATM protein veliparib results in increased activity of ATM protein
|
CTD |
PMID:21917757 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629
|
|
G
|
Bak1
|
BCL2-antagonist/killer 1
|
multiple interactions
|
ISO
|
BAK1 protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]
|
CTD |
PMID:18376143 |
|
NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
BAX protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]
|
CTD |
PMID:18376143 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions
|
ISO
|
BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]
|
CTD |
PMID:18376143 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Brca1
|
BRCA1, DNA repair associated
|
affects response to substance decreases response to substance
|
ISO
|
BRCA1 affects the susceptibility to veliparib BRCA1 protein results in decreased susceptibility to veliparib
|
CTD |
PMID:21633166 PMID:21707865 |
|
NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763
|
|
G
|
Brca2
|
BRCA2, DNA repair associated
|
affects response to substance
|
ISO
|
BRCA2 affects the susceptibility to veliparib
|
CTD |
PMID:21633166 |
|
NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194
|
|
G
|
Cdk12
|
cyclin-dependent kinase 12
|
affects response to substance
|
ISO
|
CDK12 protein affects the susceptibility to veliparib
|
CTD |
PMID:27880910 |
|
NCBI chr10:83,697,174...83,793,676
Ensembl chr10:83,767,206...83,777,183 Ensembl chr10:83,767,206...83,777,183
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
increases metabolic processing
|
ISO
|
CYP1A2 protein results in increased metabolism of veliparib
|
CTD |
PMID:21436403 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
increases metabolic processing
|
ISO
|
CYP2C19 protein results in increased metabolism of veliparib
|
CTD |
PMID:21436403 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
G
|
Cyp2d4
|
cytochrome P450, family 2, subfamily d, polypeptide 4
|
increases metabolic processing
|
ISO
|
CYP2D6 protein results in increased metabolism of veliparib
|
CTD |
PMID:21436403 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837
|
|
G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases metabolic processing
|
ISO
|
CYP3A4 protein results in increased metabolism of veliparib
|
CTD |
PMID:21436403 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
decreases response to substance affects localization
|
ISO
|
EGFR protein results in decreased susceptibility to veliparib veliparib affects the localization of EGFR protein
|
CTD |
PMID:21719137 PMID:21912620 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
G
|
Ercc1
|
ERCC excision repair 1, endonuclease non-catalytic subunit
|
multiple interactions
|
ISO
|
ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]
|
CTD |
PMID:21227924 |
|
NCBI chr 1:88,099,308...88,135,966
Ensembl chr 1:88,118,891...88,139,120
|
|
G
|
Ercc4
|
ERCC excision repair 4, endonuclease catalytic subunit
|
multiple interactions
|
ISO
|
ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]
|
CTD |
PMID:21227924 |
|
NCBI chr10:2,926,085...2,958,176
Ensembl chr10:2,920,455...2,955,539
|
|
G
|
Ercc6
|
ERCC excision repair 6, chromatin remodeling factor
|
multiple interactions
|
ISO
|
veliparib promotes the reaction [ERCC6 protein affects the susceptibility to potassium bromate]
|
CTD |
PMID:25136123 |
|
NCBI chr16:7,771,311...7,841,895
Ensembl chr16:7,771,581...7,841,895
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions increases expression
|
ISO
|
[veliparib co-treated with Topotecan] results in increased expression of H2AX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein] [veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein modified form
|
CTD |
PMID:17505006 PMID:21227924 PMID:21795476 PMID:21917757 PMID:27694308 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]
|
CTD |
PMID:27444121 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Mpg
|
N-methylpurine-DNA glycosylase
|
multiple interactions
|
ISO
|
MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide]
|
CTD |
PMID:21377995 |
|
NCBI chr10:15,900,697...15,906,981
Ensembl chr10:15,899,635...15,907,052
|
|
G
|
Mre11
|
MRE11 homolog, double strand break repair nuclease
|
decreases response to substance
|
ISO
|
MRE11 protein results in decreased susceptibility to veliparib
|
CTD |
PMID:21300766 |
|
NCBI chr 8:19,900,211...19,961,906
Ensembl chr 8:19,913,772...19,961,904
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO
|
veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]
|
CTD |
PMID:27444121 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions decreases activity increases expression
|
ISO
|
PARP1 protein affects the susceptibility to [Temozolomide co-treated with veliparib]; veliparib binds to and results in decreased activity of PARP1 protein; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form] veliparib results in decreased activity of PARP1 protein [veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of PARP1 protein; veliparib results in increased expression of PARP1 protein mutant form [veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin
|
CTD |
PMID:17505006 PMID:19143569 PMID:19823047 PMID:19825992 PMID:21300766 PMID:21917757 PMID:22041887 PMID:22158865 PMID:27694308 PMID:28001384 More...
|
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Parp10
|
poly (ADP-ribose) polymerase family, member 10
|
affects binding
|
ISO
|
veliparib binds to PARP10 protein
|
CTD |
PMID:28001384 |
|
NCBI chr 7:109,829,721...109,839,054
Ensembl chr 7:109,829,722...109,843,566
|
|
G
|
Parp2
|
poly (ADP-ribose) polymerase 2
|
affects binding multiple interactions decreases activity
|
ISO
|
PARP2 protein binds to veliparib veliparib binds to and results in decreased activity of PARP2 protein veliparib results in decreased activity of PARP2 protein
|
CTD |
PMID:19143569 PMID:20092359 PMID:21917757 PMID:28001384 |
|
NCBI chr15:26,494,722...26,517,893
Ensembl chr15:26,494,731...26,517,891
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
decreases response to substance
|
ISO
|
PTEN protein results in decreased susceptibility to veliparib
|
CTD |
PMID:20530668 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Rpa2
|
replication protein A2
|
multiple interactions
|
ISO
|
veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form]
|
CTD |
PMID:27694308 |
|
NCBI chr 5:150,260,668...150,271,329
Ensembl chr 5:150,260,723...150,271,546
|
|
G
|
S100b
|
S100 calcium binding protein B
|
multiple interactions
|
ISO
|
veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]; veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]
|
CTD |
PMID:27444121 |
|
NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081
|
|
G
|
Tdp1
|
tyrosyl-DNA phosphodiesterase 1
|
multiple interactions
|
ISO
|
TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]
|
CTD |
PMID:21227924 |
|
NCBI chr 6:124,892,821...124,960,646
Ensembl chr 6:124,881,574...124,960,642
|
|
G
|
Xrcc1
|
X-ray repair cross complementing 1
|
multiple interactions
|
ISO
|
veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]
|
CTD |
PMID:35778544 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|